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ABSTRACT 
Alarin is a recently discovered splice variant of the galanin-like peptide (GALP) gene. Alarin is a 
highly conserved 25 amino acid peptide which shares its first 5 amino acids with GALP, but lacks the 
galanin receptor binding domain, suggesting that it mediates its biological effects through alternative 
receptors. Alarin has been detected in the rodent hypothalamus. GALP has a well-characterised role in 
the integration of energy and reproductive homeostasis.  
 
Intracerebroventricular (ICV) alarin increases food intake and plasma luteinising hormone (LH) levels 
in rats. Alarin stimulates the release of the orexigenic neuropeptide Y (NPY) and gonadotrophin 
releasing hormone (GnRH) from hypothalamic explants, and GnRH release from an immortalised 
GnRH releasing cell line. Pre-treatment with a GnRH antagonist blocked the alarin-induced increase 
in plasma LH levels in vivo. These results suggest that ICV alarin activates the HPG axis via 
hypothalamic GnRH release. My data also suggests that alarin does not bind to the known galanin 
receptors.  
 
The ventral tegmental area (VTA) is the origin of the mesolimbic dopamine pathway, which mediates 
the rewarding properties of palatable food. Recent work suggests that the VTA reward pathway is 
regulated by appetite-regulating signals including leptin and ghrelin. I have shown that intra-VTA 
melanocortin receptor agonist administration inhibits food intake and administration of an antagonist 
stimulates food intake in rats, suggesting that the melanocortin system may be involved in hedonic 
regulation of appetite, in addition to its role in homeostatic regulation of appetite. 
 
These studies have elucidated the biological effects of alarin in the regulation of appetite and the HPG 
axis, and identified a role for the melanocortin system in regulating the central reward circuitry 
modulating food intake. Further work is required to determine the receptor by which alarin mediates 
its effect and its precise physiological function, and the physiological importance of the VTA 
melanocortin system. 
  
3 
 
DECLARATION OF CONTRIBUTORS 
The majority of the work described in thesis was performed by the author. Any collaboration and 
assistance is described below.  
All radioimmunoassays were carried out under the supervision of Professor M.A. Ghatei (Division of 
Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London). 
Chapters 2 and 3 - In vivo ICV injection studies were carried out with the assistance of the 
‘hypothalamic group’.  
Chapter 5 - The competent bacteria used for generation of probes was produced by Dr J.V. Gardiner 
(Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College 
London). The GAD67 probe utilised for in situ hybridisation was generated by Dr T. Ambepitiya. In 
vivo iVTA injection studies were carried out with the assistance of Dr J. Cooke and Miss K. Beale. 
Immunocytochemistry and in situ hybridisation was carried out with the guidance of Mr J.A.Tadross. 
  
4 
 
ACKNOWLEDGEMENTS 
I would first like to thank my supervisors:  
 
Dr. Kevin Murphy for his unfailing scientific guidance and support, and for his positivity and sense of 
humour throughout.  
 
Dr. Gavin Bewick for his practical advice and help. 
 
I am grateful to Professor Stephen Bloom for giving me the opportunity to work in his department. 
 
Many thanks to all members of the ‘hypothalamic group’ for help with in vivo studies.  
 
Thanks to all of those in the lab who made my time so enjoyable. 
 
Finally, I would like to thank my family and friends for all their support and ‘enthusiasm’ for my 
work. 
  
5 
 
TABLE OF CONTENTS 
 
ABSTRACT .................................................................................................................................. 2 
 
DECLARATION OF CONTRIBUTORS .................................................................................. 3 
 
ACKNOWLEDGEMENTS ......................................................................................................... 4 
 
ABBREVIATIONS .................................................................................................................... 23 
 
 
	  
CHAPTER 1: GENERAL INTRODUCTION ........................................................................ 27 
1.1 The Neuroendocrine system .............................................................................................. 28 
1.2 The Hypothalamus ............................................................................................................. 29 
1.3. Food Intake ....................................................................................................................... 31 
1.3.1. Hypothalamic control of food intake ......................................................................... 31 
1.3.1.1. Hypothalamic nuclei involved in the control of energy homeostasis ................ 32 
    1.3.1.1.1. Arcuate nucleus  .......................................................................................... 32 
        1.3.1.1.1.1. The melanocortin system ..................................................................... 33 
        1.3.1.1.1.2. Neuropeptide Y .................................................................................... 34 
        1.3.1.1.1.3. Cocaine and amphetamine regulated transcript ................................... 35 
    1.3.1.1.2. Dorsomedial nucleus ................................................................................... 36 
        1.3.1.1.2.1. Cholecystokinin ................................................................................... 36 
    1.3.1.1.3. Ventromedial nucleus ................................................................................. 37 
    1.3.1.1.4. Lateral hypothalamic area ........................................................................... 38 
        1.3.1.1.4.1. Orexins ................................................................................................. 39 
        1.3.1.1.4.2. Melanin concentrating hormone .......................................................... 39 
    1.3.1.1.5. Paraventricular nucleus ............................................................................... 40 
        1.3.1.1.5.1. Corticotrophin releasing hormone ....................................................... 41 
        1.3.1.1.5.1. Glucagon-like peptide 1 ....................................................................... 41 
    1.3.1.1.6. Tuberomammillary nucleus ........................................................................ 42 
1.3.2. Brainstem regulation of energy homeostasis ............................................................. 43 
1.3.3. Peripheral regulators of energy homeostasis ............................................................. 44 
1.3.3.1. Leptin ................................................................................................................. 44 
6 
 
1.3.3.2. Insulin ................................................................................................................ 46 
1.3.3.3. Gut hormones ..................................................................................................... 47 
1.3.3.3.1. Ghrelin ........................................................................................................ 47 
1.3.3.3.2. Cholecystokinin .......................................................................................... 48 
1.3.3.3.3. Peptide YY ................................................................................................. 49 
1.3.3.3.4. Pancreatic polypeptide ................................................................................ 49 
1.3.3.3.5. Preproglucagon products ............................................................................ 50 
1.3.4. Non-homeostatic regulation of feeding ..................................................................... 51 
1.3.4.1. The mesolimbic dopaminergic pathway ............................................................ 51 
1.3.4.2. Dopamine and food intake ................................................................................. 53 
1.4.The Neuroendocrine axes .................................................................................................. 54 
1.4.1. Hypothalamic releasing factors ................................................................................. 54 
1.4.2. The median eminence ................................................................................................ 54 
1.4.3. The pituitary gland .................................................................................................... 55 
1.4.3.1. The posterior pituitary ........................................................................................ 55 
1.4.3.2. The anterior pituitary ......................................................................................... 56 
    1.4.3.2.1. The growth hormone axis  .......................................................................... 57 
        1.4.3.2.1.1. Hypothalamic control of the GH axis .................................................. 57 
        1.4.3.2.1.2. Pituitary control of the GH axis ........................................................... 58 
    1.4.3.2.2. The hypothalamo-pituitary-thyroid axes  .................................................... 59 
        1.4.3.2.2.1. Hypothalamic control of the HPT axis ................................................ 59 
        1.4.3.2.2.2. Pituitary control of the HPT axis ......................................................... 59 
        1.4.3.2.2.3. Thyroid hormones ................................................................................ 60 
    1.4.3.2.3. The hypothalamo-pituitary-adrenal axis  .................................................... 61 
        1.4.3.2.3.1. Hypothalamic control of the HPA axis ................................................ 61 
        1.4.3.2.3.2. Pituitary control of the HPA axis ......................................................... 62 
        1.4.3.2.3.3. Glucocorticoids .................................................................................... 62 
    1.4.3.2.4. The hypothalamo-pituitary-gonadal axis  ................................................... 63 
        1.4.3.2.4.1. Hypothalamic control of the HPG axis ................................................ 63 
        1.4.3.2.4.2. Pituitary control of the HPG axis ......................................................... 65 
        1.4.3.2.3.3. Gonads and control of the HPG axis .................................................... 66 
1.5.The galanin peptide family ................................................................................................ 67 
1.5.1. Galanin message associated peptide .......................................................................... 67 
1.5.2. Galanin ...................................................................................................................... 68 
1.5.2.1. Localisation of galanin ....................................................................................... 69 
7 
 
1.5.2.2. Galanin actions ................................................................................................... 70 
    1.5.2.2.1. Galanin and arousal/sleep regulation .......................................................... 70 
    1.5.2.2.2. Galanin and nociception ............................................................................. 70 
    1.5.2.2.3. Galanin and neuroprotection ....................................................................... 70 
    1.5.2.2.4. Galanin and epilepsy ................................................................................... 70 
    1.5.2.2.5. Galanin and learning/ memory .................................................................... 71 
    1.5.2.2.6. Galanin and anxiety/depression .................................................................. 71 
    1.5.2.2.7. Galanin and addiction ................................................................................. 71 
    1.5.2.2.8. Galanin and water balance .......................................................................... 72 
1.5.2.3. Galanin over-expressing and knockout mice ..................................................... 72 
1.5.3. GALP ......................................................................................................................... 73 
1.5.3.1. GALP mRNA and peptide distribution .............................................................. 74 
1.5.3.2. GALP actions ..................................................................................................... 74 
1.5.4. Alarin ......................................................................................................................... 75 
1.5.4.1. Alarin localisation .............................................................................................. 76 
1.5.4.2. Alarin actions ..................................................................................................... 77 
1.6. Aims .................................................................................................................................. 78 
    
	  
	  
 
CHAPTER 2: ALARIN AND ENERGY HOMEOSTASIS ................................................... 79 
2.1 Introduction ........................................................................................................................ 80 
2.1.1. Galanin and food intake ............................................................................................ 80 
    2.1.1.1. Galanin regulation by leptin and insulin ............................................................ 83 
2.1.2. GALP and energy homeostasis ................................................................................. 84 
2.1.2.1. GALP regulation by insulin ............................................................................... 86 
2.1.2.2. GALP regulation by leptin ................................................................................. 86 
2.1.3. Other galanin related peptides and food intake ......................................................... 87 
2.1.4. Galanin receptor mediating effects on feeding .......................................................... 88 
2.2. Hypothesis ........................................................................................................................ 89 
    2.2.1. Aims………………………………………………………………………………..89 
2.3. Materials and methods ...................................................................................................... 90 
2.3.1. Materials .................................................................................................................... 90 
2.3.2. Animals ..................................................................................................................... 90 
8 
 
2.3.3. In vivo studies ............................................................................................................ 90 
2.3.3.1. Intracerebroventircular cannulation ................................................................... 90 
2.3.3.2. Intracerebroventricular injection ........................................................................ 91 
2.3.3.3. Effect of ICV alarin on food intake in ad-libitum fed male rats before the early dark 
phase ............................................................................................................................... 92 
2.3.3.4. Effect of ICV alarin on food intake in fasted male rats in the early light phase .... 
 ......................................................................................................................................... 92 
2.3.3.5. Effect of ICV alarin on food intake in ad-libitum fed male rats in the early light phase
 ......................................................................................................................................... 92 
2.3.3.6 Effect of ICV alarin on behaviour in ad-libitum fed male rats in the early light phase
 ......................................................................................................................................... 92 
2.3.4. In vitro studies ........................................................................................................... 93 
2.3.4.1. Effect of alarin on neuropeptide release from medial basal hypothalamic explants  
 ......................................................................................................................................... 93 
2.3.4.2. Principles of radioimmunoassay ........................................................................ 94 
2.3.4.2.1. Hypothalamic neuropeptide RIAs .............................................................. 95 
    2.3.4.2.1.1. NPY RIA ............................................................................................. 96 
    2.3.4.2.1.2. αMSH RIA ........................................................................................... 96 
    2.3.4.2.1.3. CART RIA ........................................................................................... 96 
2.3.4.3. The effect of fasting on hypothalamic alarin immunoreactivity ........................ 97 
2.3.4.3.1. Rat hypothalamic tissue .............................................................................. 97 
2.3.4.3.2. Acetic acid extraction ................................................................................. 97 
2.3.4.3.3. Alarin ELISA .............................................................................................. 97 
2.3.5 Statistics ...................................................................................................................... 98 
2.4. Results ............................................................................................................................... 99 
2.4.1. Effect of ICV alarin on food intake in ad-libitum fed male rats before the early dark phase
 ............................................................................................................................................. 99 
2.4.2. Effect of ICV alarin on food intake in fasted male rats in the early light phase ....... 99 
2.4.3. Effect of ICV alarin on food intake in ad-libitum fed male rats in the early light phase 
 ............................................................................................................................................. 99 
2.4.4. Effect of ICV alarin on behaviour in ad-libitum fed male rats in the early light phase  
 ........................................................................................................................................... 102 
2.4.5. Effect of alarin on neuropeptide release from hypothalamic explants in vitro  ...... 105 
2.4.6. The effect of fasting on hypothalamic alarin immunoreactivity  ............................ 106 
2.5. Discussion ....................................................................................................................... 107 
9 
 
CHAPTER 3: ALARIN AND THE NEUROENDOCRINE AXES .................................... 113 
3.1. Introduction ..................................................................................................................... 114 
3.1.1. Galanin peptide family and the neuroendocrine axes ............................................. 114 
3.1.2. Galanin peptide family and the HPG axis ............................................................... 115 
3.1.2.1. Galanin and the HPG axis ................................................................................ 115 
3.1.2.2. GALP and the HPG axis .................................................................................. 116 
3.1.3. Galanin peptide family and the HPT axis ............................................................... 119 
3.1.3.1. Galanin and the HPT axis ................................................................................ 119 
3.1.3.2. GALP and the HPT axis .................................................................................. 119 
3.1.4. Galanin peptide family and the growth hormone axis ............................................ 120 
3.1.4.1. Galanin and the growth hormone axis ............................................................. 120 
3.1.4.2. GALP and the growth hormone axis ............................................................... 121 
3.1.5. Galanin peptide family and prolactin/dopamine ..................................................... 122 
3.1.5.1. Galanin and prolactin/dopamine ...................................................................... 122 
3.1.5.2. GALP and prolactin/dopamine ........................................................................ 123 
3.1.6. Galanin peptide family and the HPA axis ............................................................... 124 
3.1.6.1. Galanin and the HPA axis ................................................................................ 124 
3.1.6.2. GALP and the HPA axis .................................................................................. 125 
3.2. Aims ................................................................................................................................ 127 
3.3. Materials and Methods ................................................................................................... 128 
3.3.1. Materials .................................................................................................................. 128 
3.3.2. Animals ................................................................................................................... 128 
3.3.3. In vivo studies .......................................................................................................... 128 
3.3.3.1. Intracerebroventircular cannulation ................................................................. 128 
3.3.3.2. Intracerebroventricular injection ...................................................................... 128 
3.3.3.3. Effect of ICV alarin administration on plasma hormones in intact male rat 
 ....................................................................................................................................... 129 
.3.4. In vitro studies ....................................................................................................... 129 
3.3.4.1. Effect of alarin on neuropeptide release from medial basal hypothalamic explants 
 ....................................................................................................................................... 129 
3.3.4.2. Hypothalamic factor RIAs ............................................................................... 130 
3.3.4.2.1. GnRH RIA ................................................................................................ 130 
3.3.4.2.2. TRH RIA .................................................................................................. 130 
3.3.4.2.3. CRH RIA .................................................................................................. 130 
3.3.4.3. Effect of alarin on GnRH release from GT1-7 cells ........................................ 131 
10 
 
3.3.4.4. Effect of alarin on pituitary hormone release from pituitary explants ............. 131 
3.3.4.5. Effect of alarin and GALP on LH release from LβT2 cells ............................. 132 
3.3.5. Effect of ICV alarin administration on plasma hormones in intact male rats following 
pretreatment with cetrorelix .............................................................................................. 132 
3.3.6. Plasma hormone RIAs ............................................................................................. 132 
3.3.6.1. LH RIA  ........................................................................................................... 132 
3.3.6.2. FSH, TSH, PRL and GH RIA  ......................................................................... 133 
3.3.6.3. Total testosterone RIA  .................................................................................... 133 
3.3.6.4. ACTH immunoradiometric assay for measurement of ACTH in plasma ........ 134 
3.3.6.5. Corticosterone RIA .......................................................................................... 134 
3.3.7. Regulation of hypothalamic alarin by the oestrus cycle .......................................... 135 
3.3.8. Statistics ................................................................................................................... 136 
3.4. Results ............................................................................................................................. 137 
3.4.1. Effect of ICV alarin administration on plasma hormones in intact male rats ......... 137 
3.4.2. Effect of alarin on neuropeptide release from medial basal hypothalamic explants ..... 
 ........................................................................................................................................... 139 
3.4.3. Effect of alarin on GnRH release from GT1-7 cells ............................................... 140 
3.4.4. Effect of alarin on pituitary hormone release from pituitary explants  ................... 142 
3.4.5. Effect of alarin and GALP on LH release from LβT2 cells .................................... 143 
3.4.6. Effect of ICV alarin administration on plasma hormones in intact male rats following 
pretreatment with cetrorelix ............................................................................................. 145 
3.4.7. Regulation of hypothalamic alarin by the oestrus cycle .......................................... 148 
3.5. Discussion ....................................................................................................................... 149 
 
 
 
 
 
 
 
 
11 
 
CHAPTER 4: INVESTIGATING THE RECEPTOR MEDIATING THE BIOLOGICAL 
EFFECTS OF ALARIN .......................................................................................................... 155 
4.1. Introduction ..................................................................................................................... 156 
4.1.1. Galanin receptors ..................................................................................................... 156 
4.1.1.1. Galanin receptor 1 ............................................................................................ 157 
4.1.1.2. Galanin receptor 2 ............................................................................................ 159 
4.1.1.3. Galanin receptor 3 ............................................................................................ 161 
4.1.2. Galanin receptor agonists and antagonists .............................................................. 162 
4.1.2.1. Non-specific galanin receptor agonists ............................................................ 162 
4.1.2.2. Non-specific galanin receptor anatgonists ....................................................... 162 
4.1.2.3. Subtype selective galanin receptor agonists/antagonists ................................. 163 
4.1.2.3.1. GalR1 ........................................................................................................ 163 
4.1.2.3.1. GalR2 ........................................................................................................ 163 
4.1.2.3.1. GalR3 ........................................................................................................ 163 
4.1.3. A GALP specific receptor? ..................................................................................... 164 
4.2 Aims ................................................................................................................................. 165 
4.3 Materials and Methods .................................................................................................... 166 
4.3.1. Materials .................................................................................................................. 166 
4.3.2. Cell culture of galanin recpeptor expressing cells ................................................... 166 
4.3.3. Confirmation of galanin receptor expression by RT-PCR ...................................... 166 
4.3.3.1. Total RNA extraction ....................................................................................... 166 
4.3.3.2. Denaturing formaldehyde gel to check viability of total RNA ........................ 167 
4.3.3.3. Reverse transcription ....................................................................................... 168 
4.3.3.4. Polymerase chain reaction ............................................................................... 168 
4.3.3.5. Visualisation of PCR products ......................................................................... 169 
4.3.4. Membrane preparations ........................................................................................... 170 
4.3.4.1. Preparation of membranes from galanin receptor expressing cells and GT1-7 cells
 ....................................................................................................................................... 170 
4.3.4.2. Preparation of membranes from rat hypothalamic tissue ................................. 170 
4.3.4.3. Biuret assay to determine protein concentration of membranes ...................... 171 
4.3.5. Iodination of galanin and GLP-1 ............................................................................. 171 
4.3.6. Competitive receptor binding assays ....................................................................... 172 
4.3.6.1. Galanin receptor expressing membranes ......................................................... 172 
4.3.6.2. Hypothalamic membrane ................................................................................. 172 
4.3.6.3. GT1-7 membrane ............................................................................................. 172 
12 
 
4.3.7. Galanin receptor antagonist studies ......................................................................... 173 
4.3.7.1. Competitive receptor binding of C7 to membranes expressing GalR1, GalR2 and 
GalR3 ............................................................................................................................ 173 
4.3.7.2. Effect of galanin on GnRH release from GT1-7 cells ..................................... 173 
4.3.7.3. Effect of C7 on galanin induced GnRH release from GT1-7 cells .................. 173 
4.3.7.4. Effect of galanin and C7 on LH release from LβT2 cells ................................ 173 
4.3.7.5. Effect of C7 on GALP induced LH release from LβT2 cells .......................... 174 
4.3.8. The effect of N terminal truncation on alarin bioactivity ........................................ 175 
4.3.8.1. In vivo studies .................................................................................................. 175 
4.3.8.1.1. ICV cannulation and ICV injection .......................................................... 175 
4.3.8.1.2. Effect of ICV alarin 3-25 on food intake in ad-libitum fed male rats in the early 
light phase ................................................................................................................. 175 
4.3.8.1.3. Effect of ICV alarin 3-25 on plasma LH and corticosterone in intact male rats
 .................................................................................................................................. 175 
4.3.8.2. In vitro studies .................................................................................................. 176 
4.3.8.2.1. Effect of alarin 3-25 and alarin 6-25 on GnRH release from GT1-7 cells176 
4.3.8.2.2. Competitive receptor binding of alarin 3-25 and alarin 6-25 at membranes 
expressing GalR1, GalR2 and GalR3 ....................................................................... 176 
4.3.9. Statistics ................................................................................................................... 176 
4.4 Results .............................................................................................................................. 177 
4.4.1. Confirmation of galanin receptor expression by RT-PCR ...................................... 177 
4.4.2. Competitive receptor binding assays ....................................................................... 178 
4.4.2.1. Galanin receptor expressing membranes ......................................................... 178 
4.3.2.2. Hypothalamic membrane ................................................................................. 178 
4.4.3. Determining galanin receptor expression in GT1-7 and LβT2 cells ....................... 180 
4.4.4. Competitive receptor binding assays at GT1-7 membrane ..................................... 181 
4.4.5 . Galanin receptor antagonist studies ........................................................................ 182 
4.4.5.1. Competitive receptor binding of C7 at membranes expressing GalR1, GalR2 and 
GalR3 ............................................................................................................................ 182 
4.4.5.2. Effect of galanin on GnRH release from GT1-7 cells ..................................... 182 
4.4.5.3. Effect of C7 on galanin induced GnRH release from GT1-7 cells .................. 183 
4.4.5.4. Effect of galanin and C7 on LH release from LβT2 cells ................................ 183 
4.4.5.5. Effect of C7 on GALP induced LH release from LβT2 cells .......................... 184 
4.4.6. The effect of N terminal truncation on alarin bioactivity ........................................ 186 
4.4.6.1. In vivo studies .................................................................................................. 186 
13 
 
4.4.6.1.1. Effect of ICV alarin 3-25 on food intake in ad-libitum fed male rats in the early 
light phase ................................................................................................................. 186 
4.4.6.1.2. Effect of ICV alarin 3-25 on plasma LH in intact male rats ..................... 187 
4.4.6.1.3. Effect of ICV alarin 3-25 on plasma corticosterone in intact male rats ... 187 
4.4.6.2. In vitro studies .................................................................................................. 188 
4.4.6.2.1. Effect of alarin 3-25 and alarin 6-25 on GnRH release from GT1-7 cells188 
4.4.6.2.2. Competitive receptor binding of alarin 3-25 and alarin 6-25 at galanin receptor 
expressing membranes .............................................................................................. 189 
4.5. Discussion ....................................................................................................................... 190 
 
	  
	  
 
CHAPTER 5: THE ROLE OF THE VTA IN THE REGULATION OF FEEDING ........ 194 
5.1. Introduction ..................................................................................................................... 195 
5.1.1. The VTA .................................................................................................................. 195 
5.1.1.1. VTA structure .................................................................................................. 195 
5.1.1.2. VTA projections ............................................................................................... 196 
5.1.2. Dopamine ................................................................................................................ 198 
5.1.2.1. Dopamine synthesis and release ...................................................................... 198 
5.1.2.2. Dopamine signalling ........................................................................................ 198 
5.1.2.3. Dopamine metabolism ..................................................................................... 199 
5.1.3. Role of VTA dopaminergic neurons in drug addiction ........................................... 201 
5.1.4. Role of the VTA in feeding ..................................................................................... 202 
    5.1.4.1. Food reward in fed/fasted states ....................................................................... 204 
5.1.5. Peripheral hormones and food reward ..................................................................... 205 
    5.1.5.1. Leptin ................................................................................................................ 205 
    5.1.5.2. Insulin ............................................................................................................... 206 
    5.1.5.3. Ghrelin .............................................................................................................. 207 
5.1.6. Hypothalamic peptides and food reward ................................................................. 208 
    5.1.6.1. LHA neuropeptides and food reward ............................................................... 208 
5.1.6.1.1. Orexin ....................................................................................................... 208 
5.1.6.1.2. MCH ......................................................................................................... 209 
    5.1.6.2. ARC neuropeptides and food reward ............................................................... 210 
5.1.6.2.1. NPY .......................................................................................................... 210 
14 
 
5.1.6.2.2. CART ........................................................................................................ 211 
5.1.6.2.3. Melanocortins ........................................................................................... 212 
5.2 Aims ................................................................................................................................. 214 
5.3 Materials and Methods .................................................................................................... 215 
5.3.1. Materials .................................................................................................................. 215 
5.3.2. Animals ................................................................................................................... 215 
5.3.3. VTA cannulation ..................................................................................................... 215 
5.3.4. IntraVTA administration of factors involved in energy homeostasis ..................... 215 
5.3.5. Verification of intraVTA cannula location ............................................................. 216 
5.3.5.1. India ink injection and tissue processing ......................................................... 216 
5.3.5.2. Haemotoxylin staining ..................................................................................... 216 
5.3.6. IntraVTA feeding studies ........................................................................................ 217 
5.3.6.1. Effect of iVTA administration of peripheral factors on food intake ................ 217 
5.3.6.1.1. Effect of iVTA insulin on food intake in ad-libitum fed rats during the early light 
phase ......................................................................................................................... 217 
5.3.6.1.2. Effect of iVTA insulin on food intake in ad-libitum fed rats during the early dark 
phase ......................................................................................................................... 217 
5.3.6.2. Effect of iVTA administration of LHA neuropeptides on food intake ............ 218 
5.3.6.2.1. Effect of iVTA orexin and MCH on food intake in ad-libitum fed rats during the 
early light phase ........................................................................................................ 218 
5.3.6.3. Effect of iVTA administration of ARC neuropeptides on food intake ............ 218 
5.3.6.3.1. Effect of iVTA CART(55-102) on food intake in fasted rats during the early light 
phase ......................................................................................................................... 218 
5.3.6.3.2. Effect of iVTA CART (55-102) on food intake in ad-libitum fed rats during the 
early light phase ........................................................................................................ 219 
5.3.6.3.3. Effect of iVTA NDP-MSH on food intake in ad-libitum fed rats during the early 
dark phase ................................................................................................................. 219 
5.3.6.3.4. Effect of iVTA NPY and AgRP on food intake in ad-libitum fed rats during the 
early light  phase ....................................................................................................... 219 
5.3.7. Characterisation of melanocortin receptor expressing neurons in the VTA ........... 220 
5.3.7.1. Production of GAD65 and TH probes ............................................................. 221 
5.3.7.1.1. Reverse transcription and PCR ................................................................. 221 
5.3.7.1.2. Purification of PCR products .................................................................... 221 
5.3.7.1.3. Restriction endonuclease digestion of PCR products and plasmids ......... 222 
5.3.7.1.4. Electroelution of DNA fragments ............................................................. 222 
15 
 
5.3.7.1.5. Ligation of PCR products into plasmids ................................................... 223 
5.3.7.1.6. Preparation of plasmids ............................................................................ 223 
    5.3.7.1.6.1. Production of competent bacteria ...................................................... 223 
    5.3.7.1.6.2. Transformation of competent bacteria ............................................... 224 
    5.3.7.1.6.3. Small scale preparation of plasmid DNA .......................................... 225 
    5.3.7.1.6.4. Large scale preparation of plasmid DNA .......................................... 226 
    5.3.7.1.6.5. Caesium chloride gradient purification of plasmid DNA .................. 227 
    5.3.7.1.6.6. Determination of DNA concentration by spectrophotometry ........... 227 
5.3.7.2. In situ hybridisation for GAD65, GAD67 and TH .......................................... 228 
5.3.7.2.1. Production of DIG-labelled RNA probe for in situ hybridisation - GAD65, 
GAD67 and TH ........................................................................................................ 229 
5.3.7.2.2. In situ hybridisation for TH and GAD65/67 on fresh frozen rat brain sections 
 .................................................................................................................................. 230 
5.3.7.2.3. In situ hybridisation for TH and GAD65/67 on paraffin embedded rat brain 
sections ..................................................................................................................... 232 
    5.3.7.2.3.1. Brain tissue fixation and processing .................................................. 232 
    5.3.7.2.3.2. In situ hybridisation ........................................................................... 233 
5.3.7.3. Immunocytochemistry for melanocortin receptors in the VTA ....................... 235 
5.3.7.3.1. Brain tissue fixation and processing ......................................................... 235 
5.3.7.3.2. Melanocortin receptor ICC ....................................................................... 235 
5.3.7.4. Dual ISH /ICC for GAD65/67 or TH mRNA and MC3R-IR .......................... 236 
5.3.8. Studies investigating the mechanisms by which iVTA melanocortins mediate their effects 
on food intake .................................................................................................................... 237 
5.3.8.1. Effect of iVTA NDP-MSH on food intake in ad-libitum fed rats during the early dark 
phase ............................................................................................................................. 237 
5.3.8.2. Effect of iVTA NDP-MSH (lower doses) on food intake in ad-libitum fed rats during 
the early dark phase ...................................................................................................... 237 
5.3.8.3. Effect of iVTA NDP-MSH on food intake in fasted rats during the early light phase
 ....................................................................................................................................... 237 
5.3.8.4. Effect of iVTA AgRP (low doses) on food intake in ad-libitum fed rats during the 
early light phase ............................................................................................................ 238 
5.3.8.5. Effect of iVTA AgRP on food intake in ad-libitum fed rats during the early light 
phase ............................................................................................................................. 238 
5.3.8.6. Effect of iVTA γMSH on food intake in ad-libitum fed rats during the early dark 
phase ............................................................................................................................. 238 
16 
 
5.3.8.7. Effect of IP pretreatment with the GABA receptor antagonist bicuculline before 
iVTA NDP-MSH on food intake in ad-libitum fed rats during the early dark phase ... 239 
5.3.9. Statistics ................................................................................................................... 239 
5.4 Results .............................................................................................................................. 240 
5.4.1. Confirmation of cannula placement ........................................................................ 240 
5.4.2. IntraVTA administration of factors involved in energy homeostasis ..................... 241 
5.4.2.1. Effect of iVTA administration of peripheral factors on food intake ................ 241 
5.4.2.1.1. Effect of iVTA insulin on food intake in ad-libitum fed rats during the early light 
phase ......................................................................................................................... 241 
5.4.2.1.2. Effect of iVTA insulin on food intake in ad-libitum fed rats during the early dark 
phase ......................................................................................................................... 242 
5.4.2.2. Effect of iVTA administration of LHA neuropeptides on food intake ............ 243 
5.4.2.2.1. Effect of iVTA orexin and MCH on food intake in ad-libitum fed rats during the 
early light phase ........................................................................................................ 243 
5.4.2.3. Effect of iVTA administration of ARC neuropeptides on food intake ............ 244 
5.4.2.3.1. Effect of iVTA CART(55-102) on food intake in fasted rats during the early light 
phase ......................................................................................................................... 244 
5.4.2.3.2. Effect of iVTA CART (55-102) on food intake in ad-libitum fed rats during the 
early light phase ........................................................................................................ 244 
5.4.2.3.3. Effect of iVTA NDP-MSH on food intake in ad-libitum fed rats during the early 
dark phase ................................................................................................................. 247 
5.4.2.3.4. Effect of iVTA NPY and AgRP on food intake in ad-libitum fed rats during the 
early light  phase ....................................................................................................... 247 
5.4.3. Characterisation of melanocortin receptor expressing neurons in the VTA ........... 250 
5.4.3.1. Expression of TH and GAD65/67 mRNA in the rat VTA ............................... 250 
5.4.3.1.1. Production of GAD65 and TH probes ...................................................... 250 
5.4.3.1.2. Expression of TH mRNA on fresh frozen rat brain sections .................... 252 
5.4.3.1.3. Expression of TH mRNA on paraffin embedded rat brain sections ......... 253 
5.4.3.1.4. Expression of GAD65/67 mRNA on fresh frozen rat brain sections ....... 254 
5.4.3.1.5. Expression of GAD65/67 mRNA on paraffin embedded rat brain sections .. 
 .................................................................................................................................. 255 
5.4.3.2. Localisation of melanocortin receptors in the rat brain ................................... 256 
5.4.3.2.1. Localisation of MC3R-IR in the rat brain ................................................ 256 
5.4.3.1.2. Localisation of MC4R-IR in the rat brain ................................................ 256 
5.4.3.3. Dual ISH /ICC for GAD65/67 or TH mRNA and MC3R-IR .......................... 257 
17 
 
5.4.4. Studies investigating the mechanisms by which iVTA melanocortins mediate their effects 
on food intake .................................................................................................................... 258 
5.4.4.1. Effect of iVTA NDP-MSH on food intake in ad-libitum fed rats during the early dark 
phase ............................................................................................................................. 258 
5.4.4.2. Effect of iVTA NDP-MSH (lower doses) on food intake in ad-libitum fed rats during 
the early dark phase ...................................................................................................... 258 
5.4.4.3. Effect of iVTA NDP-MSH on food intake in fasted rats during the early light phase
 ....................................................................................................................................... 261 
5.4.4.4. Effect of iVTA AgRP (lower doses) on food intake in ad-libitum fed rats during the 
early light phase ............................................................................................................ 262 
5.4.4.5. Effect of iVTA AgRP on food intake in ad-libitum fed rats during the early light 
phase ............................................................................................................................. 263 
5.4.4.6. Effect of iVTA γMSH on food intake in ad-libitum fed rats during the early dark 
phase ............................................................................................................................. 264 
5.4.4.7. Effect of IP pretreatment with the GABA receptor antagonist bicuculline before 
iVTA NDP-MSH on food intake in ad-libitum fed rats during the early dark phase ... 265 
5.5. Discussion ....................................................................................................................... 266 
 
 
	  
	    
18 
 
CHAPTER 6: GENERAL DISCUSSION .............................................................................. 273 
6.1 Introduction ...................................................................................................................... 274 
6.2 The role of alarin in the regulation of energy homeostasis and reproduction ................. 274 
6.3 The role of the VTA melanocortin system in the regulation of feeding .......................... 277 
 
 
REFERENCES ......................................................................................................................... 281 
 
 
APPENDICES .......................................................................................................................... 355 
Appendix I: Solutions used in this thesis ............................................................................... 355 
Appendix II: List of suppliers ................................................................................................ 363 
 
 
PUBLICATIONS ..................................................................................................................... 364 
  
19 
 
INDEX OF FIGURES 
 
Figure 1.1: Schematic sagittal diagram of the human hypothalamus .......................................... 30 
Figure 1.2: The mesolimbic and mesocortical dopamine pathways ............................................ 52 
Figure 1.3: Schematic diagram of the HPG axis .......................................................................... 64 
Figure 1.4: Organisation of the preprogalanin gene .................................................................... 68 
Figure 1.5: Organisation of the preproGALP gene…………………………………………..... 76 
Figure 1.6: Amino acid sequences of alarin, GALP and galanin peptides ……………....... …..77 
Figure 2.1: The effect of ICV administration of alarin on food intake in ad-libitum fed adult male rats 
during the early dark phase ........................................................................................................ 100 
Figure 2.2: The effect of ICV administration of alarin on food intake in fasted adult male rats in the 
early light phase ......................................................................................................................... 100 
Figure 2.3: The effect of ICV administration of alarin on food intake in ad-libitum fed adult male rats 
in the early light phase ............................................................................................................... 101 
Figure 2.4: The effect of ICV administration of alarin on behaviour in ad-libitum fed adult male rats 
in the early light phase ............................................................................................................... 102 
Figure 2.5: The effect of ICV administration of alarin on feeding behaviour in ad-libitum fed adult 
male rats in the early light phase. ............................................................................................... 103 
Figure 2.6: The effect of alarin on NPY, αMSh and CART release from hypothalamic explants in 
vitro ............................................................................................................................................ 105 
Figure 2.7: Hypothalamic alarin levels in response to fasting in the male rat ........................... 106 
Figure 3.1: The effect of ICV administration of alarin on plasma hormones in intact adult male rats
 .................................................................................................................................................... 138 
Figure 3.2: The effect of alarin on GnRH release from hypothalamic explants and GT1-7 cells in vitro
 .................................................................................................................................................... 141 
Figure 3.3: The effect of alarin on LH and FSH release from pituitary segments, and LH release from 
LβT2 cells in vitro ............................................................................................................. …….144 
Figure 3.4: The effect of ICV administration of alarin on LH, FSH and testosterone in intact adult 
male rats after injection with a GnRH receptor antagonist ........................................................ 146 
Figure 3.5: Hypothalamic alarin levels at different stages of the oestrus cycle in the female rat
 ............................................................................................................................................ ……148 
Figure 4.1: Galanin receptor subtype signalling pathways ........................................................ 156 
20 
 
Figure 4.2: Galanin receptor expression in GalR1 and GalR2 expressing cell lines ................. 177 
Figure 4.3: Competitive receptor binding assays of alarin competing at the galanin receptors and 
hypothalamic membrane ............................................................................................................ 179 
Figure 4.4: Galanin receptor expression in LβT2 and GT1-7 cells ........................................... 180 
Figure 4.5: Competitive receptor binding assays of galanin competing at GT1-7 membrane .. 181 
Figure 4.6: The effect of galanin and GALP on LH release from LβT2 cells ........................... 185 
Figure 4.7: The effect of ICV administration of alarin3-25 on food intake in ad-libitum fed adult male 
rats .............................................................................................................................................. 186 
Figure 4.8: The effect of ICV administration of alarin3-25 on LH and corticosterone in intact adult 
male rats ..................................................................................................................................... 187 
Figure 5.1: Schematic coronal section of the rat brain highlighting the VTA ........................... 196 
Figure 5.2: Schematic diagram of the mesolimbic dopamine circuitry in the rat brain ............. 197 
Figure 5.3: Schematic diagram of the dopamine synthesis pathway ......................................... 200 
Figure 5.4: Representative coronal section of ink injection into the rat VTA ........................... 240 
Figure 5.5: The effect of iVTA administration of CART (55-102) on food intake in fasted male rats
 .................................................................................................................................................... 245 
Figure 5.6: The effect of iVTA administration of CART (55-102) on food intake in ad-libitum fed 
male rats in the early light phase ................................................................................................ 246 
Figure 5.7: The effect of iVTA administration of NDP-MSH on food intake in ad-libitum fed male 
rats in the early dark phase ......................................................................................................... 248 
Figure 5.8: The effect of iVTA administration of NPY and AgRP on food intake in ad-libitum fed 
male rats in the early light phase ................................................................................................ 249 
Figure 5.9: Generation of a tyrosine hydroxylase probe ............................................................ 250 
Figure 5.10: Generation of a glutamic acid decarboxylase 65 probe ......................................... 251 
Figure 5.11: Expression of TH mRNA in frozen rat brain sections .......................................... 252  
Figure 5.12: Expression of TH mRNA in paraffin embedded rat brain sections ....................... 253 
Figure 5.13: Expression of GAD65/67 mRNA in frozen rat brain sections .............................. 254  
Figure 5.14: Expression of GAD65/67 mRNA in paraffin embedded rat brain sections ................ 
………………………………………………………………………………………................255 
Figure 5.15: Localisation of MC3R-immunoreactivity in the rat brain ..................................... 256  
21 
 
Figure 5.16: Dual in situ hybridisation/ICC for GAD65/67 and MC3R-IR in the rat VTA 
……................................................................................................................................257 
Figure 5.17: The effect of iVTA administration of NDP-MSH on food intake in ad-libitum fed male 
rats in the early dark phase ......................................................................................................... 259 
Figure 5.18: The effect of iVTA administration of low doses of NDP-MSH on food intake in ad-
libitum fed male rats in the early dark phase ............................................................................. 260 
Figure 5.19: The effect of iVTA administration of NDP-MSH on food intake in fasted male rats in the 
early light phase ......................................................................................................................... 261 
Figure 5.20: The effect of iVTA administration of low doses of AgRP on food intake in ad-libitum fed 
male rats in the early light phase ................................................................................................ 262 
Figure 5.21: The effect of iVTA administration of AgRP on food intake in ad-libitum fed male rats in 
the early light phase ................................................................................................................... 263 
Figure 5.22: The effect of iVTA administration of gamma-MSH on food intake in ad-libitum fed male 
rats in the early dark phase ......................................................................................................... 264 
Figure 5.23: The effect of iVTA administration of NDP-MSH on food intake after IP administration 
of GABA receptor antagonist bicuculline in ad-libitum fed male rats in the early dark 
phase…………………………………………………………………………………………265 
  
22 
 
INDEX OF TABLES 
Table 2.1: The effect of ICV administration of alarin on behaviour in ad-libitum fed adult male rats in 
the early light phase ................................................................................................................... 104 
Table 3.1: The effect of ICV administration of alarin on plasma hormones in intact adult male rats.
 .................................................................................................................................................... 137 
Table 3.2: The effect of alarin on GnRH, CRH and TRH release from hypothalamic explants in vitro..
 .................................................................................................................................................... 139 
Table 3.3: The effect of rat alarin and murine alarin on GnRH release from GT1-7 cells in vitro.140 
Table 3.4: The effect of alarin on LH, FSH, TSH and PRL release release from pituitary segments, in 
vitro ............................................................................................................................................ 143 
Table 3.5: The effect of ICV administration of alarin on plasma hormones in intact adult male rats 
after injection with a GnRH receptor antagonist ....................................................................... 147 
Table 4.1: Galanin receptor primer sequences used in PCR ...................................................... 169 
Table 4.2: Competitive receptor binding assays of C7 vs. I125 galanin to the galanin receptors ..... 
 .................................................................................................................................................... 182 
Table 4.3: The effect of galanin on GnRH release from GT1-7 cells in vitro ........................... 182 
Table 4.4: The effect of C7 on galanin-induced GnRH release from GT1-7 cells in vitro ............. 
 .................................................................................................................................................... 183 
Table 4.5: The effect of alarin1-25 and alarin3-25 on GnRH release from GT1-7 cells in vitro188 
Table 4.6: The effect of alarin6-25 on GnRH release from GT1-7 cells in vitro ...................... 189 
Table 4.7: Competitive receptor binding assays of alarin3-25 and alarin6-25 vs. I125 galanin to the 
galanin receptors ........................................................................................................................ 189 
Table 5.1: GAD65, GAD67 and TH primer sequences used in PCR. ....................................... 221 
Table 5.2: The effect of iVTA administration of insulin on food intake in ad-libitum fed adult male 
rats in the early light phase. ....................................................................................................... 241 
Table 5.3: The effect of iVTA administration of insulin on food intake in ad-libitum fed adult male 
rats in the early dark phase ......................................................................................................... 242 
Table 5.4: The effect of iVTA administration of orexin and MCH on food intake in ad-libitum fed 
adult male rats in the early light phase ....................................................................................... 243 
  
23 
 
ABBREVIATIONS  
ACSF – artificial cerebrospinal fluid 
ACTH – adenocorticotrophic hromone 
AgRP – agouti related peptide 
α-MSH – alpha- melanocyte stimulating hormone 
ANOVA – analysis of variance 
ANS – autonomic nervous system 
AP – area postrema 
AQ – aqueduct 
ARC – arcuate nucleus 
AVP – argenine vasopressin 
BBB – blood brain barrier 
BNST – bed nucleus of the stria terminalis 
BSA – bovine serum albumin 
CCK – cholecystokinin  
CGRP – calcitonin gene-related peptide 
CLAMS – comprehensive laboratory animal monitoring system 
CNS – central nervous system 
COMT – catechol-O-methyl transferase 
CPM – counts per minute 
CPP – conditioned place preference 
CRH – corticotrophin releasing hormone 
DA – dopamine  
DIO – diet induced obese  
DMEM – Dulbecco’s modified eagle medium 
DMN – dorsomedial nucleus 
DNA – deoxyribonucleic acid 
DOPAC - 3,4-dihydroxyphenylacetic acid 
DPP-IV – dipeptidyl peptidase IV 
DRN – dorsal raphe nucleus 
24 
 
DVC – dorsal vagal complex 
FCS – fetal calf serum 
fMRI – functional magnetic resonance imaging 
FSH – follicle stimulating hormone 
γ-MSH – gamma-melanocyte stimulating hormone 
GABA – gamma-aminobutyric acid 
GAD – glutmatic acid decarboxylase 
GALP – galanin-like peptide 
GALR1 – galanin receptor 1 
GALR2 – galanin receptor 2 
GALR3 – galanin receptor 3 
GH – growth hormone 
GHRH – growth hormone releasing hormone 
GHS-R – growth hormone secretagogue receptor 
GI – gastrointestinal   
GLP-1 – glucagon-like peptide 1 
GMAP – galanin message associated peptide 
GnRH – gonadotrophin releasing hormone 
GPCR – G-protein coupled receptor 
GR – glucocorticoid receptor  
HPA – hypothalamopituitary adrenal 
HPG – hypothalamopituitary gonadal  
HPLC – high-performance liquid chromatography 
HPT – hypothalamopituitary thyroid 
HVA – homovanillic acid 
ICC – immunocytochemistry 
ICV – intracerebroventricular  
IL – interleukin 
IP – intraperitoneal 
IR – immunoreactivity 
25 
 
ISH – in situ hybridisation 
IV – intravenous  
LC – locus coeruleus 
LH – luteinising hormone 
LHA – lateral hypothalamic area 
LPS – lipopolysaccharide 
LV – lateral ventricle  
MAOA – monoamine oxidase A 
MAOB – monoamine oxidase B 
MCH – melanin concentrating hormone 
MDMA – methamphetamine   
MPOA – medial preoptic area 
MPON – medial pre-optic nucleus  
MR – mineralocorticoid receptor 
mRNA – messenger ribonucleic acids 
NAc – nucleus accumbens 
NDP-MSH – [Nle4,D-Phe7]-α-melanocyte stimulating hormone 
NTS – nucleus of the solitary tract 
OFC – orbitofrontal cortex 
OLETF – Otsuka-Long Evans-Tokushima Fatty (rats) 
PAM – peptidylglycine α-amidating monooxygenase 
PFC – prefrontal cortex 
PNS – peripheral nervous system 
POMC – pro-opiomelanocortin 
PP – pancreatic polypeptide 
PRL – prolactin  
PVN – paraventricular nucleus 
PYY – peptide YY 
RIA – radioimmunoassay 
RT-PCR – reverse transcription polymerase chain reaction 
26 
 
SC – subcutaneous 
SCN – suprachiasmatic nucleus 
SEM – standard error of the mean 
SON – supraoptic nucleus 
TH – tyrosine hydroxylase 
TMN – tuberomammillary nucleus 
TRH – thyrotrophin releasing hormone 
VMN – ventromedial nucleus 
UV – ultraviolet  
VIP – vasoactive intestinal peptide 
VTA – ventral tegmental area 
 
 
  
27 
 
CHAPTER 1 
GENERAL INTRODUCTION 
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1.1 THE NEUROENDOCRINE SYSTEM 
In order for a multicellular organism to survive in variable external environments, it must be able to 
control its body’s internal environment. In mammals, the co-ordinated activity of the autonomic 
nervous system (ANS) and the endocrine system play important roles in this internal regulation. The 
ANS generally responds rapidly to external changes with appropriate and tissue specific responses, 
transmitting information via neural impulses and neurotransmitter release. The endocrine system, in 
contrast, consists of glands which release hormones (internal messenger molecules which are involved 
in regulation and feedback of body systems) directly into the blood where they are transported to act 
at often distant target cells and organs. Due to the nature of transportation of hormones, this system 
tends to be slower and less localised, although its effects are often of a longer duration. There is 
considerable overlap and interaction between the ANS and the endocrine system. Endocrine glands 
are innervated by neural stimuli transmitted via the ANS, and the endocrine system regulates nervous 
system function. Many substances have a role in both of these systems with some factors acting as 
hormones in the periphery and as neurotransmitters in the nervous system. The ANS and the 
endocrine system can therefore be considered as a single neuroendocrine regulatory system, acting in 
a co-ordinated fashion to maintain a stable internal environment and to control, amongst other 
systems, the metabolic activities and reproductive functions of an organism.  
 
Galanin, galanin-like peptide (GALP), galanin message-associated peptide (GMAP) and alarin 
comprise the galanin peptide family (Lang et al, 2007). Members of this family play key roles in 
numerous physiological functions in the central nervous system (CNS) and in the peripheral nervous 
system (PNS) and various organs (Lang et al, 2007). The genes encoding the galanin peptide family 
members are expressed in the CNS and neuroendocrine tissues, and galanin and GALP peptides have 
also been detected in the circulation. The galanin peptide family may therefore act as regulatory 
peptides at various levels of the neuroendocrine system (Lang et al, 2007). 
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1.2 THE HYPOTHALAMUS 
The hypothalamus is an area of neural tissue containing many discrete neuronal populations or nuclei. 
It occupies the ventral half of the diencephalon, extending from the region of the optic chiasm to the 
caudal border of the mammillary bodies. It lies below the thalamus and surrounds the third ventricle, 
directly above the pituitary gland. The hypothalamus controls body homeostasis, including body 
temperature, circadian rhythm and feeding behaviour through its regulation of the autonomic nervous 
system and the endocrine system. It has numerous afferent and efferent neuronal connections and a 
specific blood supply network which allow it to make appropriate regulatory responses following 
integration of nervous and chemical signals.  
The hypothalamus can be divided into three functionally and morphologically distinct longitudinal 
zones: the periventricular, medial and lateral zones (Crosby & Woodburne, 1949). Each zone 
comprises discrete regions or nuclei. Those nuclei expressing receptors of the galanin peptide family 
include the arcuate nucleus (ARC), a major site for the integration of peripheral appetite signals (Cone 
et al, 2001;Depczynski et al, 1998), called the infundibular nucleus in man, the paraventricular 
nucleus (PVN), which is the origin of important hypothalamic outputs in the regulation of both 
pituitary hormone secretion and the autonomic nervous system (Mitchell et al, 1997;Depczynski et al, 
1998;Ulrich-Lai & Herman, 2009), the lateral hypothalamic area (LHA), once known as the ‘hunger 
centre’ of the brain (Mennicken et al, 2002;Anand & Brobeck J.R., 1951), and the tuberomammillary 
nucleus (TMN), the main histamine producing region of the brain which is involved in regulation of 
arousal, sleep and circadian rhythm (Haas & Panula, 2003;Depczynski et al, 1998).   
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FIGURE 1.1 The hypothalamic region of the left cerebral hemisphere viewed from the medial aspect and 
dissected to display the major hypothalamic nuclei. The lateral hypothalamic region is coloured magenta and the 
medial hypothalamic nuclei are coloured yellow. (Gray H, 1980). 
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1.3 FOOD INTAKE 
Obesity is a major public health issue world-wide. In 2005, approximately 1.6 billion adults world-
wide were overweight and more than 400 million adults were obese. These figures are predicted to 
rise (World Health Organisation, 2006). 
 
Increased weight predisposes to and can aggravate many clinical conditions, including cardiovascular 
disease, type II diabetes mellitus, restrictive lung disease, certain cancers and infertility (Kopelman, 
2000). Obesity is a multi-factorial condition where genetic, environmental, behavioural and socio-
economic conditions all contribute to determine body weight, adipose tissue mass and distribution 
(Bray, 1992).  
 
1.3.1 HYPOTHALAMIC CONTROL OF FOOD INTAKE 
Despite wide variation in daily food intake and energy expenditure, most individuals are able to 
maintain a remarkably stable body weight over long periods of time (Leibel, 1990). In order for this to 
occur, food intake and energy expenditure must be constantly modulated and balanced. Studies 
carried out in the 1940s and 50s determined that the hypothalamus is essential for such regulation of 
both appetite and energy balance. Early work by Hetherington and Ranson (Hetherington A.W. & 
Ranson S.W., 1940) and Anand and Brobeck (Anand & Brobeck J.R., 1951) proposed a model 
consisting of a feeding centre within the lateral hypothalamus and a satiety centre within the 
ventromedial hypothalamus. These conclusions were based on lesioning studies in rodents which 
revealed that loss of mediobasal hypothalamic function caused obesity, and loss of lateral 
hypothalamic function decreased food intake. This model has subsequently been considered too 
simplistic. Surgical, electrolytic or chemical destruction of other hypothalamic nuclei including the 
ARC (Olney, 1969), and the PVN (Aravich & Sclafani, 1983) also leads to the development of 
obesity, while lesioning of the dorsomedial nucleus (DMN) causes hypophagia (Bellinger & 
Bernardis, 2002).  
 
Energy homeostasis is now thought to be regulated by specific neuropeptides and classical 
neurotransmitters which transmit signals within neuronal circuits that span multiple brain regions. 
Extra-hypothalamic brain regions which are important in regulating energy homeostasis include the 
nucleus of the tractus solitari (NTS) and the area postrema (AP) in the brainstem, the ventral 
tegmental area (VTA) within the midbrain and the nucleus accumbens (NAc) in the striatum 
(Contreras et al, 1984;Hommel et al, 2006).  
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1.3.1.1 HYPOTHALAMIC NUCLEI INVOLVED IN THE CONTROL OF ENERGY 
HOMEOSTASIS  
 
1.3.1.1.1 ARCUATE NUCLEUS 
The ARC is located at the base of the hypothalamus on either side of the third ventricle. Due to its 
location next to the median eminence, which has an incomplete blood brain barrier (BBB), the ARC is 
able to respond to circulating hormones such as leptin, insulin, gonadal and adrenal steroids (Banks, 
2006;Irwig et al, 2004;Tempel & Leibowitz, 1994). 
 
The ARC has a pivotal role in the integration and interpretation of signals of energy balance. There 
are two neuronal populations within the ARC known to be involved in energy homeostasis (Cone et 
al, 2001). One population, located more medially, expresses the orexigenic peptides neuropeptide Y 
(NPY) and agouti related peptide (AgRP) (Hahn et al, 1998;Broberger et al, 1998a). The second 
population is found more laterally and produces the anorexigenic peptides alpha-melanocyte 
stimulating hormone (α-MSH), cleaved from the pro-opiomelanocortin (POMC) precursor molecule, 
and a peptide encoded by cocaine and amphetamine regulated transcript (CART) (Elias et al, 1998a). 
NPY/AgRP co-expressing neurons project predominantly to the PVN and the DMN within the 
hypothalamus, but also to widespread extra-hypothalamic sites, including the bed nucleus of the stria 
terminalis (BNST), the amygdala, and the VTA (Broberger et al, 1998b). The expression of NPY and 
AgRP mRNA in the ARC is increased by fasting (Hahn et al, 1998), and the activity of these neurons 
is directly inhibited by leptin and insulin (Stephens et al, 1995;Sipols et al, 1995) and stimulated by 
ghrelin (Kohno et al, 2003). Specific destruction of these neurons in adult animals causes severe 
hypophagia and reduced body weight in rodents, highlighting their physiological importance (Luquet 
et al, 2005;Bewick et al, 2005). POMC/CART expressing neurons have wider projections to almost 
all hypothalamic nuclei and numerous extra-hypothalamic sites (Elias et al, 1998a;Elmquist et al, 
1999). The activity of these neurons is also regulated by leptin and insulin (Cheung et al, 
1997;Kristensen et al, 1998;Schwartz et al, 1997), and their selective ablation causes hyperphagia and 
obesity (Xu et al, 2005). In addition, a subpopulation of ARC NPY containing neurons co-express 
GABA and synapse directly onto POMC neurons within the ARC. This means that activation of the 
orexigenic neurons concurrently inhibits the activity of their anorexigenic counterparts (Cowley et al, 
2001). Administration of leptin directly into the ARC inhibits feeding (Satoh et al, 1997) and 
lesioning of the ARC attenuates the anorectic effect of peripheral leptin administration (Tang-
Christensen et al, 1999), suggesting that the ARC is critical in mediating leptin’s effects on energy 
homeostasis. 
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1.3.1.1.1.1 THE MELANOCORTIN SYSTEM 
The melanocortins are peptide products of the POMC polypeptide precursor. POMC is tissue 
specifically processed by prohormone convertase enzymes to generate the four melanocortins: 
adrenocorticotrophic hormone (ACTH) and α, β and γ-melanocyte stimulating hormone (MSH) 
(Bertagna, 1994). POMC mRNA is highly expressed in the anterior pituitary and is detectable in other 
peripheral tissues (Lacaze-Masmonteil et al, 1987). The majority of melanocortin peptides in the 
circulation are derived from the anterior pituitary gland (Gibson et al, 1994). In the CNS, POMC 
mRNA is expressed only in the ARC and the NTS in the brainstem (Smith & Funder, 1988). 
However, POMC-immunoreactivity (IR) is widespread throughout the brain, demonstrating the range 
of brain regions innervated by these discrete POMC neuronal populations (Joseph et al, 1985). 
 
There are five cloned melanocortin receptors. All are G protein coupled receptors (GPCR). They 
differ in their tissue distribution and ligand selectivity. Genetic mutations of the melanocortin 4 
receptor (MC4R) result in hyperphagia and obesity in both rodents and humans (Huszar et al, 
1997;Yeo et al, 1998;Vaisse et al, 1998). This receptor is thus considered to be one of the most 
important regulators of energy homeostasis. The MC4R is highly expressed in the hypothalamic PVN, 
VMN, DMN and LHA, in addition to extra-hypothalamic sites including the VTA and the brainstem 
(Mountjoy et al, 1994). MC3-R knock-out mice do not have altered body weight but do have 
increased adipose mass, and the male knockouts show a reduction in locomotor activity (Butler et al, 
2000). 
 
Alpha-MSH is a 13 amino acid peptide agonist of both the MC4R and MC3R (Adan et al, 1994). 
Alpha-MSH inhibits feeding when injected into the 3rd cerebral ventricle (ICV) to food deprived rats 
(Tsujii & Bray, 1989). Unusually, the MC4R and MC3R also have an endogenous antagonist, agouti 
related peptide (AgRP) (Fong et al, 1997), a 132 (131 in rodents) amino acid peptide (Shutter et al, 
1997;Brown et al, 2001). ICV injection of AgRP increases food intake by blocking the anorectic 
effect of α-MSH at the MC4R (Rossi et al, 1998). Transgenic mice overexpressing AgRP have a 
similar phenotype to MC4R knockout mice (Graham et al, 1997;Huszar et al, 1997;Ollmann et al, 
1997).  
 
Beta-MSH binds to the MC4R with a comparative affinity as α-MSH (Schioth et al, 2002). Rodents 
are β-MSH deficient (Bennett, 1986) and therefore there have been fewer studies determining the role 
of β-MSH in food intake. However, a human loss-of-function mutation of β-MSH is associated with 
childhood obesity, suggesting a role for β-MSH in human body-weight regulation (Biebermann et al, 
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2006). Gamma-MSH binds with high affinity to the MC3-R, but only weakly to the MC4-R 
(Oosterom et al, 1999). Chronic ICV infusion of γ-MSH stimulates food intake in rats, an effect 
possibly mediated by a suppression of hypothalamic POMC expression (Lee et al, 2008). 
 
1.3.1.1.1.2 NEUROPEPTIDE Y 
Neuropeptide Y is a 36 amino acid neuropeptide which belongs to the pancreatic polypeptide (PP) 
fold family of proteins. This family is characterised by the presence of a hair-pin fold motif, a proline 
helix connected to an α-helix by a β turn, which is necessary for receptor binding (Glover et al, 1984). 
The PP fold peptides bind to members of the Y receptor family (Blomqvist & Herzog, 1997). NPY is 
one of the most abundant neuropeptides in the CNS (Allen et al, 1984). In the hypothalamus, NPY is 
synthesised by cell bodies in the ARC and the DMN, and is released from terminals in the PVN, 
DMN and LHA (Bai et al, 1985;Chronwall et al, 1985). ICV injection of NPY induces c-fos 
expression in the ARC, PVN, DMN and LHA of rats (Li et al, 1994;Lambert et al, 1995;Vinuela & 
Larsen, 2001).  
 
NPY is the most potent orexigenic neuropeptide known (Woods et al, 1998). Injection of NPY into 
the third cerebral ventricle, and more specifically into the PVN, increases food intake (Clark et al, 
1984;Stanley & Leibowitz, 1984). Chronic injection of NPY into the hypothalamus of rats results in 
hyperphagia and obesity (Stanley et al, 1986;Zarjevski et al, 1993). ARC and PVN NPY-IR is 
increased in response to fasting, which suggests that NPY plays a physiological role in the regulation 
of feeding (Sahu et al, 1988). Immunoblockade of hypothalamic NPY attenuates fasting induced re-
feeding (Lambert et al, 1993) and blocks nocturnal feeding when administered during the dark phase 
(Dube et al, 1994b). NPY binds preferentially to the Y1 and Y5 receptors, and administration of a Y1 
or Y5 receptor antagonist attenuates nocturnal feeding, fasting-induced re-feeding and NPY induced 
feeding (Kanatani et al, 1996;Criscione et al, 1998). Hypothalamic NPY expression is directly 
stimulated by ghrelin (Kamegai et al, 2001) and inhibited by insulin (Sahu et al, 1995;Schwartz et al, 
1992) and leptin (Stephens et al, 1995). The hyperphagia seen in models of impaired leptin signalling 
(ob/ob and db/db mice) is in part due to increased NPY signalling in the hypothalamus (Wilding et al, 
1993;Stephens et al, 1995;Chua et al, 1991). However, NPY knockout mice are phenotypically 
normal in their food intake and body weight, and respond normally to leptin, suggesting compensation 
by other leptin regulated pathways (Erickson et al, 1996). 
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1.3.1.1.1.3 COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT 
CART codes for a neuropeptide widely distributed throughout the CNS and peripheral tissues. Within 
the hypothalamus, CART is expressed in the ARC, where it co-localises with POMC (Elias et al, 
1998a), the PVN, supraoptic nucleus (SON), DMN and the ventromedial nucleus (VMN) (Douglass et 
al, 1995;Koylu et al, 1998;Kristensen et al, 1998).  
 
ICV injection of the active CART peptide, CART (55-102), reduces both nocturnal feeding and 
fasting-induced re-feeding in rodents (Lambert et al, 1998;Kristensen et al, 1998). ICV injection of 
CART antiserum increases nocturnal feeding, and ARC and DMN CART mRNA expression is 
reduced in response to fasting, suggesting a physiological role for CART peptide in the regulation of 
feeding (Kristensen et al, 1998;Lambert et al, 1998). CART is regulated by leptin. Leptin deficient 
ob/ob mice show reduced ARC CART mRNA expression, and peripheral administration of leptin to 
ob/ob mice stimulates CART mRNA expression (Kristensen et al, 1998). 
 
However, movement associated tremors are also observed following central CART (55-102) injection, 
raising the possibility that the anorectic effects of CART are secondary to behavioural abnormalities 
(Kristensen et al, 1998). Interestingly, direct injection of CART into discrete hypothalamic nuclei, 
including the ARC, VMN, DMN and LHA, stimulates food intake, suggesting CART may play both 
anorectic and orexigenic roles within the hypothalamus (Abbott et al, 2001). 
 
  
36 
 
1.3.1.1.2 THE DORSOMEDIAL NUCLEUS 
The DMN is situated caudal to the VMN in the plane of the dorsal premamillary nucleus. The 
majority of inputs to the DMN arise from within the hypothalamus, particularly from the VMN and 
LHA. However, there are also projections from the telencephalon and brainstem (Thompson & 
Swanson, 1998). DMN neurons have predominantly intrahypothalamic projections, with the PVN the 
most densely innervated nucleus (Thompson et al, 1996).  
 
A role for the DMN in feeding control was demonstrated by lesioning studies in rodents: lesioning the 
DMN resulted in hypophagia and reduced body weight (Bellinger & Bernardis, 2002). Intra-DMN 
injections of neuropeptides and neurotransmitters known to be involved in appetite regulation, 
including NPY, galanin and gamma-aminobutyric acid (GABA), all increase acute food intake 
(Kyrkouli et al, 1990b;Kelly et al, 1979;Stanley et al, 1985). 
 
The DMN expresses NPY mRNA and contains both NPY containing cell bodies and NPY-IR fibres 
(White & Kershaw, 1990;Bai et al, 1985;Chronwall et al, 1985). DMN NPY mRNA and protein 
levels are increased in response to chronic food restriction (Lewis et al, 1993;Bi et al, 2003;White & 
Kershaw, 1990), but DMN mRNA levels are also increased in models of obesity (Kesterson 1997, 
Guan 1998 Bi 2001). Although leptin receptor mRNA is found in the DMN (Schwartz 1996, Elmquist 
1998), it is not co-localised with NPY containing neurons within this nucleus, suggesting that DMN 
NPY neurons are not directly regulated by leptin (Bi et al, 2003). 
 
1.3.1.1.2.1 CHOLECYSTOKININ (CCK) 
CCK is one of the most widely distributed neuropeptides in the CNS. CCK-IR and CCK receptors are 
both abundant in the hypothalamus (Beinfeld et al, 1981;Saito et al, 1980). Hypothalamic CCK 
concentration is higher in fed rats than fasted rats (McLaughlin et al, 1985), CCK is released from the 
hypothalamus in response to food intake in monkeys (Schick et al, 1987), and ICV administration of 
anti-serum against CCK stimulates food intake in rats (Schick, 1986), suggesting a role for central 
CCK as a physiological regulator of appetite. ICV injection of CCK-8 suppresses food intake in rats 
and sheep (la Fera, 1979;Schick, 1986). Administration of CCK into several hypothalamic nuclei 
suppresses food intake in rats, most potently in the DMN (Blevins et al, 2000). It has been suggested 
that central CCK mediates its effects on food intake via regulation of NPY-containing neuronal 
populations in the DMN. CCK-1 receptors are found on NPY DMN neurons (Bi et al, 2004) and 
CCK-1 receptor deficient Otsuka-Long Evans-Tokushima Fatty (OLETF) rats have increased NPY 
expression in the DMN (Bi et al, 2001). Furthermore, iDMN injection of CCK reduces NPY mRNA 
expression in the DMN in rats (Bi et al, 2004). 
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1.3.1.1.3 THE VENTROMEDIAL NUCLEUS 
The VMN is located between the lateral wall of the third ventricle and the fornix. The VMN was 
originally identified as a ‘satiety centre’, as lesions to this area resulted in profound and persistent 
hyperphagia and the development of obesity in rats (Hetherington A.W. & Ranson S.W., 1940). 
However, the VMN has not been found to produce any peptides known to be involved in the 
regulation of food intake (Kalra et al, 1999). It is therefore possible that the effects seen following 
surgical lesioning are due to a disruption of neuronal fibres passing through the VMN rather than 
destruction of neurons originating in this nucleus (Sclafani, 1971). However, selective destruction of 
VMN cell bodies also results in hyperphagia and increased body weight gain (Shimizu et al, 1987b). 
The VMN receives projections from the ARC, including neurons containing peptides involved in the 
regulation of food intake (Everitt & Hokfelt, 1989;Kristensen et al, 1998), and VMN neurons in turn 
project to the DMN and the parvocellular division of the PVN (Bernardis & Bellinger, 1987;Kalra et 
al, 1999;Moga & Saper, 1994). Despite not producing any known appetite regulating peptides, the 
VMN expresses receptors for peptides known to regulate food intake, and microinjection of NPY 
(Stanley et al, 1985) or galanin (Schick et al, 1993) into the VMN stimulates food intake in rats, while 
administration of leptin into the VMN inhibits feeding in rats (Jacob et al, 1997).  
 
NPY is thought to mediate its orexigenic effect in the VMN via inhibition of VMN neurons, an action 
mediated by Y1 receptors. Approximately 80% of VMN neurons expressing leptin receptors are 
sensitive to the inhibitory actions of NPY. These data suggest that NPY inhibits VMN neurons that 
are excited by leptin, arresting the anorexigenic tone exerted by VMN neurons (Chee et al, 2010). 
 
The VMN is also a key hypothalamic glucose sensing area. Destruction of the VMN leads to a 
reduction in the counter regulatory response to hypoglycaemia (Borg et al, 1994). VMN glucosensing 
neurons increase their firing rate in response to peripheral glucose infusion (Silver & Erecinska, 1998) 
and electrical stimulation of the VMN activates the sympatho-adrenal system in a manner similar to 
that seen in the counter regulatory response (Stoddard et al, 1986). Glucopenia specifically in the 
VMN causes the release of counter-regulatory response hormones adrenaline and glucagon (Borg et 
al, 1995), while conversely, glucose infusion into the VMN suppresses release of these hormones 
during systemic hypoglycaemia (Borg et al, 1997). 
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1.3.1.1.4 THE LATERAL HYPOTHALAMIC AREA 
The LHA forms a band dorsal and lateral to the VMN, extending from the midbrain tegmentum to the 
lateral preoptic area. The LHA comprises lateral hypothalamic neurons, a major sagittal pathway 
termed the medial forebrain bundle, and interspersed regions dense with synapses and glial cells (Sipe 
& Moore, 1977). The medial forebrain bundle is a large, diffuse collection of ascending and 
descending axons and is thought to be the major conduit of afferent and efferent connections of the 
LHA (Veening et al, 1982). Neuron density is lower in the LHA compared to other hypothalamic 
nuclei (Palkovits & Van Cuc, 1980), but neurons in the LHA are some of the largest in the 
hypothalamus (Bernardis & Bellinger, 1993).  
 
Early studies revealed that lesions to the LHA caused a transient aphagia and profound reduction in 
body weight in rats leading it to be proposed as the ‘feeding centre’ of the brain (Anand & Brobeck 
J.R., 1951). In support of this hypothesis, electrical stimulation of this area increased food intake and 
body weight in rats (Delgado & Anand, 1953). The LHA contains neuronal populations expressing 
the orexigenic peptides melanin concentrating hormone (MCH) (Skofitsch et al, 1985) and orexins A 
and B (Sakurai et al, 1998;de Lecea, 1998). A subset of MCH expressing neurons in the LHA co-
express CART (Broberger, 1999). Additionally, almost a third of neurons found within the LHA are 
glucose sensitive and respond to a rise in glucose concentration by decreasing their firing rate 
(Oomura et al, 1974). 
 
Recent studies have identified a novel role for neurons of the lateral hypothalamus in energy balance. 
The LHA has abundant and reciprocal connections with critical areas of the limbic system, including 
the VTA in the midbrain and the NAc in the forebrain (Saper et al, 1979). As such, the LHA has been 
implicated in linking hypothalamic homeostatic control of feeding with corticolimbic motivation and 
reward based regulation of feeding (Margules & Olds, 1962). This is thought to be mediated by both 
orexin (Harris et al, 2005;Aston-Jones et al, 2009) and MCH (Georgescu et al, 2005) neurons, and an 
additional neuronal population which expresses the leptin receptor but neither orexin or MCH 
(Leinninger et al, 2009). 
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1.3.1.1.4.1 OREXINS 
Orexin A and orexin B are 33 and 28 amino acid neuropeptides respectively, synthesised in cell 
bodies within the LHA (de Lecea, 1998;Sakurai et al, 1998). Orexin-IR fibres project widely 
throughout the brain to areas including the cerebral cortex, thalamus, hypothalamus, VTA and 
brainstem (Elias et al, 1998b;Date et al, 1999). The orexins bind to the orexin receptors OX-R1 and 
OX-R2; the OX-R1 binds orexin A with greater affinity than orexin B while the OX-R2 binds both 
orexins with equal affinity (Sakurai et al, 1998). ICV injection of either of the orexins stimulates food 
intake in rats, an effect thought to be mediated in part by an increase in ARC NPY expression (Lopez 
et al, 2002), and prepro-orexin mRNA expression is up-regulated in fasted rats (Sakurai et al, 1998). 
Microinjection of orexin A directly into the LHA increases food intake in rats (Dube et al, 1999). The 
orexins are also involved in arousal; orexin deficiency in mice and OX-R2 knockout mice both exhibit 
a phenotype similar to that seen in human narcolepsy (Chemelli et al, 1999;Tokita, 2001), which itself 
is characterised by a deficiency in orexin production (Peyron et al, 2000;Nishino et al, 2000). More 
recently, orexins have also been suggested to modulate pleasure/reward pathways in the brain; 
increased orexin mRNA expression in the LHA correlates with increased intensity of reward seeking 
in rats (Harris et al, 2005;Aston-Jones et al, 2009). 
 
1.3.1.1.4.2 MELANIN CONCENTRATING HORMONE 
MCH is a 19 amino acid peptide (Vaughan et al, 1989) produced by neurons of the LHA and the zona 
incerta. MCH-IR neurons project to other hypothalamic nuclei, and to limbic areas (Bittencourt et al, 
1992). ICV injection of MCH stimulates feeding in rats, and MCH mRNA expression is increased 
with fasting (Qu et al, 1996). Chronic MCH administration results in sustained hyperphagia and the 
development of obesity (la-Zuana, 2002). Transgenic mice overexpressing MCH have an obese 
hyperphagic phenotype (Ludwig et al, 2001) and conversely, targeted deletion of MCH results in a 
hypophagic, lean phenotype in mice (Shimada et al, 1998). MCH binds to the MCH-1R, which is 
widely distributed throughout the rodent brain, and highly expressed in the VMN and DMN (Marsh et 
al, 2002). MCH-1R antagonists suppress feeding and reduce body weight, suggesting MCH plays a 
physiological role in food intake, and are currently being developed as treatments for obesity 
(Takekawa et al, 2002). A second MCH receptor exists in humans (MCH-2R), although its function 
remains relatively obscure since it is absent in rodents (Tan et al, 2002). 
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1.3.1.1.5 THE PARAVENTRICULAR NUCLEUS 
The PVN is situated on either side of the top of the third ventricle and is thought to play an important 
role in the control of appetite, and in neuroendocrine and autonomic function. The structure of the 
PVN can be compartmentalised into two cytologically distinct groups. Magnocellular neurons 
containing oxytocin and vasopressin (AVP) project along the infundibular stalk to the neural or 
posterior lobe of the pituitary from which these hormones are released into the general circulation 
(Hatton et al, 1976). Parvocellular neurons project to other regions of the PVN, to other hypothalamic 
and CNS regions and to the median eminence, which lies adjacent to the hypophyseal portal vessels. 
Parvocellular neurons contain numerous neuropeptides, including those that act as hypothalamic 
releasing factors, such as thyrotrophin releasing hormone (TRH) and corticotrophin releasing 
hormone (CRH) (Ishikawa et al, 1988;Antoni, 1986).  
 
Parvocellular PVN (pPVN) neurons express several neuropeptides known to effect appetite (Hokfelt 
1990). Destruction of the PVN results in hyperphagia and weight gain (Weingarten et al, 1985). The 
importance of the PVN in food intake is illustrated by the stimulation of feeding elicited by 
microinjection of most known orexigenic peptides into the PVN, for example NPY (Stanley & 
Leibowitz, 1985), AgRP (Kim et al, 2000a), galanin (Kyrkouli et al, 1986), galanin-like peptide 
(GALP) (Patterson et al, 2006b) and opioids (Grandison & Guidotti, 1977). In addition, 
microinjection of anorectic signals such as αMSH, CRH and glucagons-like peptide 1 (GLP-1) into 
the PVN reduces fasting induced re-feeding (Kim et al, 2000a;Krahn et al, 1988;McMahon & 
Wellman, 1998). Receptors for most known appetite regulating peptides can be detected in the PVN 
(Mountjoy et al, 1994;Roselli-Rehfuss et al, 1993;Marcus et al, 2001;Kishi et al, 2005;Mitchell et al, 
1997). 
 
The PVN receives projections from both NPY/AgRP and POMC/CART expressing ARC neurons and 
peripheral  administration of leptin induces c-fos expression in the PVN of mice (Woods & Stock, 
1996), suggesting that the PVN plays an important role in mediating the effects of peripheral signals 
on energy homeostasis. The PVN also receives neuronal input from the brainstem via ascending fibres 
(Horst et al, 1989). Major projections relay vagus-mediated signals from the gastrointestinal (GI) tract 
and humoral signals to the PVN from the NTS in the brainstem (Schwartz et al, 2000). 
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1.3.1.1.5.1 CORTICOTROPHIN RELEASING HORMONE  
The role of CRH in energy homeostasis is complex and likely involves multiple neuronal circuits. 
Early studies noticed that adrenalectomy, which promotes the synthesis and release of hypothalamic 
CRH, prevents, attenuates or reverses obesity in models including the ob/ob mouse (Solomon & 
Mayer, 1973) and the fa/fa rat (Bray et al, 1991), although it does not reduce body weight in diet-
induced obese (DIO) mice (Makimura et al, 2003). 
 
The pPVN neurons are the main source of CRH in the brain. ICV and iPVN CRH injection reduces 
nocturnal and fasting-induced re-feeding (Krahn et al, 1988;Morley & Levine, 1982). However, it is 
likely that CRH mediates its anorectic effects via other hypothalamic nuclei, since PVN lesions do not 
prevent CRH induced anorexia (Rivest & Richard, 1990). CRH expression within the PVN is reduced 
in food deprived rats, indicating it may be a physiological regulator of appetite (Brady et al, 1990). 
 
It is proposed that CRH suppresses feeding via the CRH-R2 receptor. CRH-R2 down-regulation 
attenuates CRH induced anorexia (Smagin et al, 1998) and CRH-R2 mRNA expression is reduced in 
food deprived rats (Timofeeva, 1997) and increased by ICV leptin injection (Schwartz et al, 1996b). 
However, CRH-R2 knockout mice have similar food intake and body weight to wild-type littermates, 
and only a small reduction in fasting-induced re-feeding has been reported (Bale et al, 2000). 
 
1.3.1.1.5.2 GLUCAGON-LIKE PEPTIDE-1 
GLP-1 is generated by processing of the proglucagon precursor protein in intestinal L cells, and is part 
of the glucagon family of peptides (Shimizu et al, 1987a;Fehmann et al, 1995). GLP-1 mRNA is also 
synthesised in brainstem neurons which project to the hypothalamus (Kreymann et al, 1989;Larsen et 
al, 1997). The GLP-1 receptor (GLP-1R) is found within the hypothalamus (Shughrue et al, 1996), 
and its localisation correlates with GLP-1 binding sites in the ARC and PVN (Kanse et al, 1988). 
Extensive GLP-1-IR fibres originating from the NTS in the brainstem terminate in the PVN, and ICV 
GLP-1 injection induces c-fos expression in the PVN, suggesting this may be the site of central GLP-1 
action (Larsen et al, 1997;Turton et al, 1996). 
 
ICV, and more specifically, iPVN, injection of GLP-1 inhibits fasting-induced re-feeding. This effect 
can be blocked by concurrent administration of the GLP-1R antagonist exendin9-39 (Turton et al, 
1996;McMahon & Wellman, 1998). Chronic central administration of exendin9-39 increases food 
intake and body weight gain in rats, suggesting that GLP-1 plays a physiological role in energy 
homeostasis (Meeran et al, 1999). 
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1.3.1.1.6 TUBEROMAMMILLARY NUCLEUS 
The TMN is a cluster of magnocellular neurons located dorsolaterally to the ARC, in the posterior 
hypothalamus. The TMN lies either side of the mammillary recess and extends dorsally along the tip 
of the third ventricle between the dorsal premammillary nucleus and the DMN; and ventrally, just 
rostral to the medial mammillary body (Schwartz et al, 1991). 
 
Afferent projections to the TMN are widespread, arising from many different areas, including the 
infralimbic cortex, lateral septum, preoptic nucleus and the brainstem (Ericson, 1991;Ericson et al, 
1989). The TMN is the site of synthesis of all histamine in the brain, and the origin of widely 
distributed histaminergic projections (Panula et al, 1984;Watanabe, 1984). The histaminergic TMN 
system regulates general states of metabolism and consciousness, including hibernation and the 
sedative component of anaesthesia (Haas & Panula, 2003). 
 
In addition to histamine, TMN neurons contain several other neurotransmitters and modulators. The 
GABA synthesizing enzyme, glutamic acid decarboxylase (GAD), and GABA itself are found in most 
TMN neurons (Ericson et al, 1991;Airaksinen et al, 1992). The neuropeptides galanin, TRH, 
proenkephalin-derived peptides and substance P are also found in various populations of histamine-
producing TMN neurons (Airaksinen et al, 1992;Staines et al, 1986). 
 
There is evidence to suggest a link between the histaminergic system and energy homeostasis. Leptin-
induced suppression of feeding is partially attenuated in mice that lack the histamine H1 receptor 
(Masaki et al, 2001), implying that the histaminergic system and H1 receptors are important in the 
central regulation of feeding.  
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1.3.2 BRAINSTEM REGULATION OF ENERGY HOMEOSTASIS 
The brainstem plays an important role in the regulation of energy balance. The afferent vagus nerve 
transduces and transports meal related signals from the gut to nerve terminals in the NTS in the caudal 
brainstem. Vagal afferents are stimulated by signals including gut distension, pH, osmolarity and gut 
hormone signalling (McCann & Rogers, 1992). The NTS is also in close proximity to the AP, a 
circumventricular region of the brain which allows the brainstem to detect circulating signals. The 
NTS receives and integrates inputs related to food-intake from a number of peripheral systems, and it 
has been proposed that the brainstem plays a primary role in controlling meal initiation and 
termination (short term feeding effects), while the hypothalamus responds to changes in metabolic 
state and regulates longer term energy balance (Schwartz, 2006).  
 
The brainstem has numerous reciprocal connections with forebrain regions, especially the 
hypothalamus (Horst et al, 1989). Many gut hormones, including CCK and peptide YY3-36 (PYY3-36), 
are proposed to signal to the CNS at least in part via the vagus nerve and the brainstem.  
 
Leptin receptors (ObR) are detected throughout the dorsal vagal complex (DVC), which includes the 
NTS, AP, and dorsal motor nucleus, in the caudal brainstem (Grill et al, 2002;Mercer et al, 
1998;Elmquist et al, 1998) and 4th ventricle administration of leptin reduces food intake and body 
weight to a similar extent as hypothalamic leptin administration (Grill et al, 2002). Unlike in the 
hypothalamus, where ObRb mRNA levels are increased in leptin deficient ob/ob mice (Mercer et al, 
1997), the levels of ObRb mRNA in the hindbrain are similar in lean and ob/ob mice (Mercer et al, 
1998). This discrepancy suggests that hypothalamic leptin signalling may be more important in the 
regulation of energy homeostasis than hindbrain leptin signalling. The brainstem also expresses 
melanocortin receptors, and DVC administration of the MC3/4R agonist MTII suppresses feeding, 
while iDVC administration of the MC3/4R antagonist SHU-9119 increased food intake in rats 
(Williams et al, 2000). 
 
The brainstem also contains glucose sensitive neurons that appear to be a critical in mediating  the 
sympatho-adrenal and ingestive responses to glucopenia (Ritter et al, 1981;Dallaporta et al, 2000). 
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1.3.3 PERIPHERAL REGULATORS OF ENERGY HOMEOSTASIS 
 
1.3.3.1 LEPTIN 
Leptin is the 16kDa protein product of the ob gene, secreted into the circulation from adipocytes 
(Zhang et al, 1994) in direct proportion to adipose tissue mass in rodents and humans (Considine et al, 
1996). Administration of leptin peripherally or centrally reduces food intake and body weight and 
increases thermogenesis in ob/ob mice (Halaas et al, 1995). Leptin is also present in the cerebrospinal 
fluid (CSF) of humans where it correlates with body mass index (BMI), suggesting that the rate of 
leptin uptake into the CNS is also proportional to body adiposity. The efficiency of uptake is reduced 
with higher leptin levels, suggesting a saturable transport mechanism across the BBB (Schwartz et al, 
1996a).  
 
Rare abnormalities of leptin production or mutations in leptin receptor genes have been observed in 
humans, and result in early onset, morbid obesity (Montague et al, 1997;Clement et al, 1998). 
Peripheral administration of leptin to humans with congenital leptin deficiency reduces food intake 
and body weight (Farooqi et al, 1999). 
 
The leptin receptor gene (db or ObR) encodes a single transmembrane receptor belonging to the 
interleukin-6 family of class I cytokine receptors (Tartaglia et al, 1995). ObR has multiple splice 
variants with differing C-terminal sections. Only the ObRb splice variant is capable of activating 
intracellular signalling pathways. Non-functioning splice variants have only short intracellular 
domains, but the ObRb has a large extracellular domain and intracellular domain. In most tissues, 
ObRb mRNA is expressed at low levels compared to the short isoforms. However, in the 
hypothalamus, ObRb is more abundant, particularly in nuclei associated with the regulation of energy 
homeostasis: the ARC, PVN, VMN and DMN (Schwartz et al, 1996b;Baskin et al, 1999b;Cheung et 
al, 1997;Elmquist et al, 1998). The ObRb is co-localised throughout the hypothalamus with appetite-
regulating neuropeptides (Baskin et al, 1999a). It is thought that leptin mediates its effects on energy 
homeostasis by regulating the action of hypothalamic neuropeptide systems to limit energy intake and 
increase energy expenditure (Friedman & Halaas, 1998). 
 
As fat mass increases, plasma leptin levels rise, resulting in increased leptin receptor signalling in the 
hypothalamus. Leptin receptor activation reduces the activity of orexigenic pathways, including ARC 
NPY/AgRP neurons, and increases the activity of anorexigenic pathways, including ARC 
POMC/CART neurons (Cowley et al, 2001). Obese animals and humans have high levels of leptin. 
This suggests that obese individuals suffer from leptin resistance (Frederich et al, 1995a;Caro & 
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Kolaczynski, 1996). Administration of exogenous leptin to obese rodents and humans has only a 
minor effect on energy homeostasis (Halaas et al, 1997;Heymsfield et al, 1999). Such resistance may 
be due to impaired transport of leptin across the BBB, defective receptor signalling or impaired 
downstream signalling (Myers, Jr. et al, 2008). 
 
Starvation results in reduced circulating leptin levels in rodents and humans (Frederich et al, 
1995b;Kolaczynski et al, 1996). Lack of leptin signalling has profound effects causing a suppression 
of the growth, thyroid and gonadal axes and immune function (Lord et al, 1998) and a stimulation of 
the stress axis. These effects are all seen in ob/ob and db/db mice which are models of impaired leptin 
signalling. Administration of exogenous leptin to these animals corrects these abnormalities to 
varying extents (Lord et al, 1998).  
 
These studies suggest that leptin is a critical component of the afferent signalling pathway 
communicating body adiposity and thus, nutritional status from the periphery to CNS structures to 
regulate energy homeostasis.  
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1.3.3.2 INSULIN 
Insulin is a 51 amino acid peptide hormone essential in the regulation of carbohydrate and fat 
metabolism. The major source of circulating insulin is the pancreatic β cell, where insulin is 
synthesised from the pro-insulin precursor. Circulating insulin levels positively correlate with body 
adiposity (Polonsky et al, 1988) suggesting that insulin, like leptin, may act as a signal of adiposity. 
Like leptin resistance, insulin resistance is associated with diabetes and obesity (Reaven, 1995;Colditz 
et al, 1990). Insulin is secreted acutely in response to an increase in blood glucose e.g. after a meal 
(Polonsky et al, 1988). Insulin has extensive and well-characterised effects on metabolism; it 
primarily stimulates glucose uptake from the blood by peripheral tissues, including the liver and 
muscle, and inhibits the breakdown of fat stores (Fain et al, 1966;Saltiel & Kahn, 2001). The insulin 
receptor is a tyrosine kinase receptor, widely distributed in the brain, with highest concentrations 
found in the olfactory bulb, cerebellum, dentate gyrus, piriform cortex, hippocampus, choroid plexus 
and the ARC of the hypothalamus (Marks et al, 1990).  
 
Peripheral insulin can cross the BBB to enter the CNS via a saturable receptor mediated system 
(Baura et al, 1993). Little or no insulin is synthesised in the CNS (Woods et al, 2003). ICV 
administration of insulin reduces food intake in rats and baboons (Woods et al, 1979;McGowan et al, 
1993;Air et al, 2002). The mechanism by which insulin regulates energy homeostasis is thought to 
involve neurons of the ARC. Both POMC and NPY containing neurons in the ARC express the 
insulin receptor (Benoit et al, 2002;Marks et al, 1992b). ICV administration of insulin to fasted rats 
blocks the fasting-induced increases in NPY mRNA in the ARC and NPY-IR in the PVN (Schwartz et 
al, 1992). ICV administration of insulin also induces ARC POMC mRNA expression, and 
administration of a melanocortin antagonist is able to attenuate the ICV insulin-induced anorexia 
(Benoit et al, 2002). These studies suggest that insulin can affect the regulation of energy homeostasis 
through a mechanism involving both the NPY and melanocortin systems.  
 
Chronic central administration of anti-insulin antibodies increases food intake and body weight 
(McGowan et al, 1992), and mice with a brain-specific insulin receptor deficiency are obese (Bruning 
et al, 2000), suggesting that insulin acts as a physiological satiety signal in the brain. 
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1.3.3.3 GUT HORMONES 
The gut is the largest endocrine organ in the body (Ahlman & Nilsson, 2001). Gut derived peptides 
facilitate gut growth and development, regulate gut secretions and motility, and signal to the brain 
regarding the presence and absorptive status of nutrients (Glass, 1980). These gut hormones form a 
gut-brain axis which ensures effective regulation of nutrient intake, mediated via control of appetite, 
satiety and digestive and absorptive ability. 
 
1.3.3.3.1 GHRELIN 
Ghrelin is a 28 amino acid peptide. It was first identified by Kojima et al as an endogenous ligand for 
the growth hormone secretagogue receptor 1a (GHS-R) (Kojima et al, 1999). Ghrelin exists in the 
circulation in two major forms: acylated at the serine residue at position three, and des-acylated. Des-
acylated ghrelin lacks affinity for the GHS-R (Kojima et al, 1999). Ghrelin is primarily secreted by 
endocrine cells in the stomach (Date et al, 2000) and is the only known circulating factor to increase 
appetite.  
 
Circulating ghrelin levels are increased by fasting and fall following food intake in both rats and 
humans (Tschop et al, 2000;Cummings et al, 2001). Peripheral administration of ghrelin acutely 
stimulates food intake in both rats and humans (Wren et al, 2000;Wren et al, 2001a), and chronic 
administration causes weight gain in rats and in malnourished humans (Wren et al, 2001b;Ashby et al, 
2009). Ghrelin is thought to mediate its orexigenic actions via GHS-R mediated activation of 
NPY/AgRP expressing neurons in the ARC (Nakazato et al, 2001). However, there is also evidence 
that ghrelin mediates its orexigenic effects via the vagus nerve (Date et al, 2002).   
 
GHS-R and ghrelin knockout mice have complex energy homeostasis-related phenotypes. Some, but 
not all, models of disrupted ghrelin signalling show resistance to diet induced obesity when 
maintained on a high fat diet (Wortley et al, 2005;Sun et al, 2008;Zigman et al, 2005). 
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1.3.3.3.2 CHOLECYSTOKININ (CCK) 
CCK was the first gut hormone implicated in the regulation of food intake (Gibbs et al, 1973). CCK 
exists in numerous forms with varying numbers of amino acids from CCK-4 to CCK-58, depending 
on post-translational modification of the CCK gene product, preprocholecystokinin. CCK-8 is the 
most extensively characterised form in the regulation of energy homeostasis. CCK is released from 
the I cells of the small intestine following food intake, and specifically by fat and protein intake 
(Liddle et al, 1985). In addition to its effects on satiety, CCK-8 also inhibits gastric emptying, 
stimulates pancreatic enzyme secretion and gall bladder contraction, all of which contribute to the 
efficient digestion of fats and protein. Peripheral administration of CCK-8 to both rodents and humans 
reduces food intake (Gibbs et al, 1973;Kissileff et al, 1981). 
 
Two CCK receptors have been characterised: CCK-1R and CCK-2R (Wank et al, 1992;Kopin et al, 
1994). The anorectic effects of CCK are thought to be mediated via the CCK-1R as they are abolished 
in CCK-1R knockout mice and unaffected in CCK-2R knockout mice (Kopin et al, 1999). In addition, 
CCK-1R antagonists stimulate food intake in rats and humans (Reidelberger & O'Rourke, 
1989;Beglinger et al, 2001). CCK-1R knockout mice have unaltered food intake and body weight 
compared to wild type controls (Kopin et al, 1999), however OLETF rats, which lack the CCK-1R are 
hyperphagic and obese (Funakoshi et al, 1995). This discrepancy in phenotypes between OLETF rats 
and the CCK-1R knockout mice may be explained by species differences in the CCK system such as 
tissue distribution of receptors. It is also possible that the obesity observed in the OLETF strain may 
be the result of additional, as yet undefined, genetic alterations in these rats.  
 
CCK-1 receptors are found on the vagus nerve and it is likely that the effects of CCK on satiety are 
mediated via the vagus nerve and the brainstem (Moran et al, 1990). Peripheral CCK administration 
induces expression of c-fos in the brainstem (Zittel et al, 1999). Lesioning of the vagus nerve 
abolishes the suppressive effect of CCK on feeding in rats (Smith et al, 1981). Importantly, the 
satiating effect of exogenous CCK administration is present in decerebrate rats where the neural 
connections between the brainstem and the forebrain have been lesioned, suggesting that the 
brainstem is able to mediate alterations in food intake without interaction with the hypothalamus or 
other forebrain areas (Grill & Smith, 1988). 
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1.3.3.3.3 PEPTIDE YY 
PYY is a member of the PP fold peptide family, which also includes pancreatic polypeptide (PP) and 
NPY. This family is characterised by a common tertiary structure (Glover et al, 1984). PYY exists in 
two forms, PYY1-36 and PYY3-36, following cleavage of the first two amino acids by the enzyme 
dipeptidyl peptidase-IV (DPP-IV) (Grandt, 1993). PP-fold peptide family members bind with 
differing affinities to the 5 identified Y receptors (Blomqvist & Herzog, 1997). PYY1-36 binds to Y1R, 
Y2R and Y5R, and PYY3-36 preferentially binds to the Y2R (Dumont et al, 1995).   
 
PYY is released from enteroendocrine cells of the gastrointestinal (GI) tract. PYY-IR is found in 
increasing concentrations distally throughout the GI tract, with highest levels detected in the rectum 
(Adrian et al, 1985). PYY is released post prandially in proportion to caloric load, and levels are 
reduced during fasting, suggesting that PYY may be a physiological circulating satiety signal (Adrian 
et al, 1985). In support of this role, peripheral administration of PYY3-36 to both rodents and humans 
reduces food intake (Batterham et al, 2002;Batterham et al, 2003a). PYY3-36 is thought to mediate its 
effects on feeding via the Y2R, as its anorectic effects are attenuated by iARC Y2R antagonist 
administration in rats (Abbott et al, 2005b) and abolished in Y2R knockout mice (Batterham et al, 
2002). 
 
The Y2R is expressed on vagal afferents and in the brainstem, and vagotomy blocks the satiating 
effect of peripheral PYY3-36 administration (Koda et al, 2005;Abbott et al, 2005a). Midbrain 
transections also blocked PYY3-36-induced anorexia, indicating that signalling from the hindbrain to 
the hypothalamus is critical for PYY3-36 induced satiety (Koda et al, 2005). 
 
1.3.3.3.4 PANCREATIC POLYPEPTIDE (PP) 
PP is another member of the PP-fold peptide family and is synthesised and released by F cells in the 
endocrine pancreas (Adrian et al, 1977). PP binds with the highest affinity to the Y4R and Y5R. Like 
PYY, PP is released post-prandially (Adrian et al, 1977) and peripheral administration of PP reduces 
food intake in both mice and humans (Asakawa et al, 1999;Batterham et al, 2003b). PP 
overexpressing mice have reduced food intake and fat mass but also exhibit delayed gastric emptying 
(Ueno et al, 1999). The Y4R is expressed in the NTS, suggesting that the anorectic effect of PP may 
be mediated via the brainstem (Larsen & Kristensen, 1997). It is also possible that PP mediates some 
of its effects on feeding via the vagus nerve, as PP does not reduce food intake in vagotomised rats 
(Asakawa et al, 2003). It has been suggested that PP reduces food intake by delaying gastric 
emptying, rather than directly acting as a satiety signal in the CNS. However, reports from human 
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studies suggest that PP can inhibit food intake at doses that do not effect gastric emptying (Adrian et 
al, 1981;Schmidt et al, 2005). 
 
1.3.3.3.5 PREPROGLUCAGON PRODUCTS IN THE GI TRACT  
The preproglucagon gene codes for a protein which, in the gastrointestinal tract, is processed into the 
peptides GLP-1, oxyntomodulin, GLP-2 and glicentin (Holst, 2007). GLP-1 is synthesised in, and 
released from, L cells within the small intestine. GLP-1 is released in response to the presence of 
macronutrients in the lumen of the gut (Orskov et al, 1994). GLP-1 is the most potent endogenous 
incretin, stimulating insulin synthesis and secretion (Kreymann et al, 1987), inhibiting glucagon 
secretion (Naslund et al, 1999) and enhancing β-cell survival (Edvell, 1999). Peripheral GLP-1 
administration inhibits food intake in rodents and humans (Abbott et al, 2005a;Flint et al, 2001). The 
exact mechanism by which peripheral GLP-1 mediates its effects on satiety is unclear. However it is 
thought that it acts via pathways involving the brainstem and the hypothalamus since both these areas 
express c-fos following intraperitoneal (IP) GLP-1 injection (Baggio et al, 2004a). The vagus nerve 
may play a role, as the anorectic effect of GLP-1 is blocked in vagotomised rats (Abbott et al, 2005a). 
 
Oxyntomodulin is also released post-prandially in proportion to calories ingested (Le Quellec et al, 
1992), and has known incretin effects as well as reducing gastric motility (Schjoldager et al, 1988). 
Peripheral administration of oxyntomodulin acutely reduces food intake, and chronically results in a 
sustained reduction in calorie intake and weight loss in both rats and humans (Dakin et al, 
2004;Wynne et al, 2005;Cohen et al, 2003).  
 
No specific oxyntomodulin receptor has been identified. Oxyntomodulin does bind to the GLP-1R, 
though with a much lower affinity than GLP-1 (Fehmann et al, 1994). The anorectic effects of 
oxyntomodulin are lost in GLP-1R knockout mice and are also inhibited by co-administration of the 
GLP-1 receptor antagonist exendin9-39 (Dakin et al, 2001;Baggio et al, 2004b). However, other studies 
have suggested a novel receptor mediates the effect of oxyntomodulin on feeding (Baggio et al, 
2004b;Chaudhri et al, 2006). The GLP-1R knockout mouse has normal food intake and body weight 
(Scrocchi et al, 1994), suggesting that GLP-1 signalling does not play a physiological role in energy 
homeostasis, or that there is developmental compensation sufficient to overcome this deficit. 
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1.3.4 NON-HOMEOSTATIC REGULATION OF FEEDING  
Non-homeostatic or hedonic regulation of feeding is an important component of appetite regulation 
(Finlayson et al, 2007). There are links between homeostatic and hedonic regulation. In energy 
negative states, the hedonic response to energy providing foods is enhanced, and in energy positive 
states, the hedonic effect of these foods is reduced (Cabanac, 1989). However, the concept of reward 
as a consequence of meeting nutritional demands is insufficient to explain the lack of compensation 
seen with over or under consumption. It has been proposed that in our obesogenic society, the hedonic 
drive to eat overrides the homeostatic regulation of appetite (Berthoud, 2002). Many studies have 
focussed on distinct neuromediators and separate neural circuits for homeostatic and hedonic systems. 
However, anatomically there are abundant and reciprocal connections between hypothalamic nuclei 
and regions involved in reward circuitry such as the VTA and the NAc. A growing body of evidence 
suggests that these two systems interact, and several signalling molecules have been shown to regulate 
both homeostatic and hedonic neural pathways (Abizaid et al, 2006;Fulton et al, 2006;Hommel et al, 
2006). 
 
1.3.4.1 THE MESOLIMBIC DOPAMINERGIC PATHWAY  
The mesolimbic pathway is one of the dopaminergic pathways originating in the VTA in the midbrain 
and projects to limbic structures in the forebrain, including the NAc, amygdala, hippocampus and 
medial prefrontal cortex. This pathway modulates behavioural responses to rewarding stimuli and 
motivation to work for rewards through the neurotransmitter dopamine (DA) (Koob, 1996). The VTA 
receives inputs from abundant and diverse brain regions, including hypothalamic nuclei (LHA and 
VMN), forebrain and hindbrain structures (Geisler & Zahm, 2005). These inputs regulate the activity 
of both dopaminergic neurons and a smaller population of GABA synthesising neurons within the 
VTA. GABAergic neurons are primarily implicated in the local inhibitory control of VTA DA neuron 
activity. Under normal conditions, VTA DA neurons fire in a slow and irregular manner, resulting in a 
tonic release of DA in the NAc (Bunney et al, 1973). When they are excited in response to 
environmental stimuli such as administration of drugs of abuse like cocaine, opiates or amphetamines, 
they fire bursts of action potentials which increase DA release in the NAc (Overton & Clark, 1997). 
This DA release mediates the rewarding and psychomotor effects of drugs of abuse. Food and water, 
or even cues related to them such as smell and sight of food also promote rapid firing by DA neurons 
and this is manifested in behaviours directed towards attaining food (Bassareo & Di Chiara, 
1999;Schultz, 2006). Drug addiction is a result of permanent functional changes in the mesolimbic 
DA system originating from repetitive DA stimulation (Pierce & Kumaresan, 2006). It is possible that 
chronic overindulgence of food may also functionally alter the reward circuitry (Berridge et al, ). 
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FIGURE 1.2 Human (left) and rat (right) brains, showing the mesolimbic and mesocortical dopamine (DA) 
pathways, which originate in the ventral tegmental area (VTA) and send ascending projections to the nucleus 
accumbens (NAc) and prefrontal cortex (PFC), respectively. There is also a reciprocal connection between the 
VTA and the tegmental pedunculopontine nucleus (TPP), a brain region that is involved in non-DA-mediated 
reward signalling. Taken from (Laviolette & van der Kooy, 2004). 
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1.3.4.1.1 DOPAMINE AND FOOD INTAKE 
Dopamine has long been implicated in the regulation of energy homeostasis. DA release appears to 
have site-specific actions on appetite. In hypothalamic nuclei, including the perifornical area, DA 
inhibits feeding via suppression of hypothalamic NPY and stimulation of ARC POMC expression  
(Tong & Pelletier, 1992;Gillard et al, 1993). In the NAc, DA release is associated with the reinforcing 
effects of food (Bassareo & Di Chiara, 1997). Global DA deficiency in rodents markedly suppresses 
food intake and body weight (Ungerstedt, 1971;Szczypka et al, 1999;Zigmond & Stricker, 1972;Zhou 
& Palmiter, 1995).  
 
There are five subtypes of DA receptors organised into D1-like (D1, D5) and D2-like (D2, D3 and 
D4) classes. Both classes of DA receptors are GPCRs and both are thought to play a role in the 
regulation of feeding behaviour (Terry et al, 1995). However, the D2 receptor has been most heavily 
implicated in appetite regulation (Johnson & Kenny, 2010). IP administration of a D2 receptor agonist 
reduces body weight in rats and humans, due to increased energy expenditure mediated via actions at 
the hypothalamus. Conversely, IP administration of the D2 receptor antagonist, sulpiride increases 
food intake and body weight in rats and humans (Baptista et al, 1987;Doknic et al, 2002). 
Interestingly, human genetic studies have shown a higher prevalence for the Taq I A allele, which is 
linked with lower levels of D2 receptors in obese individuals (Spitz et al, 2000). 
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1.4 THE NEUROENDOCRINE AXES 
 
1.4.1 HYPOTHALAMIC RELEASING FACTORS 
Numerous parvocellular neurons of the PVN project to the external median eminence where they 
comprise a large proportion of the neuronal input to this region (Wiegand, 1980). These neurons 
contain many different neuropeptides, including the hypothalamic releasing factors CRH, TRH and 
somatostatin (Lennard et al, 1993;Fliers et al, 1994;Alonso et al, 1992;Merchenthaler & Liposits, 
1994). Galanin, DA and vasoactive intestinal peptide (VIP) are also expressed within these neurons 
(Ceccatelli et al, 1989). 
 
Hypothalamic releasing factors are also expressed in the ARC (Wiegand, 1980). Growth hormone 
releasing hormone (GHRH)-containing cell bodies are located in the lateral ARC (Bloch et al, 1983), 
and a few of the somatostatin releasing nerve terminals in the median eminence originate in the dorsal 
ARC (Makara et al, 1983). DA containing neurons also project from the ARC to the median eminence 
(Ajika & Hokfelt, 1973). 
 
There is also a neuronal population that originates in the medial septal diagonal band (MSDB) and the 
adjacent medial preoptic area (mPOA), which projects to the external median eminence. These 
neurons express and release gonadotrophin releasing hormone (GnRH) (Silverman et al, 1987).  
 
1.4.2 THE MEDIAN EMINENCE 
Anatomically, the median eminence lies immediately below the third cerebral ventricle, posterior to 
the optic chiasm and rostral to the neural stalk connecting the hypothalamus to the posterior pituitary 
gland (Gray H, 1980). The median eminence comprises two zones, an internal and an external zone. 
The internal zone contains the axons of magnocellular neurosecretory neurons originating from the 
hypothalamic PVN and SON and terminating in the posterior pituitary. The external zone contains 
nerve terminals of neuroendocrine neurons and the blood vessels of the hypophyseal-pituitary portal 
system. The nerve terminals are of fibres projecting from the PVN, ARC, periventricular area and the 
POA as described above. They are in close contact with the portal network, allowing transportation of 
hypothalamic releasing factors to the anterior pituitary gland (Knigge & Scott, 1970). 
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1.4.3 THE PITUITARY GLAND 
The pituitary gland (hypophysis) is situated directly below the hypothalamus and lies in the 
hypophyseal fossa of the sphenoid bone. It is continuous with the apex of the infundibulum (Gray H, 
1980). The pituitary gland is divided into two distinct lobes: the anterior pituitary (adenohypophysis) 
and the posterior pituitary (neurohypophysis). In rats, a third intermediate region is found between 
these two lobes (Kurosumi et al, 1961).  
 
1.4.3.1 THE POSTERIOR PITUITARY 
The posterior pituitary is composed of glial cells and the axonal terminals of magnocellular neurons 
originating from cell bodies in the SON and PVN. These glial cells, also known as pituicytes, have 
extensive filamentous processes that surround the nerve terminals and maintain the electrolyte 
composition of the extracellular fluid. Hormones are synthesised within hypothalamic nuclei and 
transported along the nerve fibres which make up the neurosecretory hypothalamo-hypophyseal tract 
to the posterior pituitary from where they are released into the general circulation. These hormones 
include oxytocin and AVP (Dierickx & Vandesande, 1979). Oxytocin promotes contraction of uterine 
and mammary muscle while AVP controls water reabsorption by the kidney (Swaab et al, 
1975;Nielsen et al, 1995;Dale, 1906) 
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1.4.3.2 THE ANTERIOR PITUITARY  
The anterior pituitary is divided into the pars distalis and the pars tuberalis, which extends dorsally 
from the pars distalis and surrounds the infundibular stalk. The anterior pituitary is a highly 
vascularised structure supplied by the superior hypophyseal artery. It also receives venous blood from 
the hypophyseal portal system which drains into the sinusoidal vessels of the anterior pituitary (Gray 
H, 1980). 
 
The pars distalis is comprised of epithelial cells which can be classified either histologically, or by the 
hormone they synthesise and release into the periphery. Histological classification divides these cells 
into acidophils, which stain with acid dyes, basophils, which stain with basic dyes, and chromophobes 
which manifest only pale staining. Classification of these cells by hormone production divides them 
into somatotrophs, which synthesise growth hormone (GH), thyrotrophs which synthesise thyroid-
stimulating hormone (TSH), lactotrophs which synthesise prolactin (PRL), corticotrophs which 
synthesise adrenocorticotropic hormone (ACTH) and gonadotrophs which synthesise luteinising 
hormone (LH) and follicle-stimulating hormone (FSH). Anterior pituitary hormones are stored in 
secretory vesicles, and are released by calcium-dependent exocytosis following an increase in 
intracellular calcium. The distinct hormone-producing cell types are not distributed heterogeneously 
throughout the anterior pituitary. Somatotrophs make up approximately half of all the hormone 
secreting cells and are distributed laterally. Thyrotrophs are also concentrated laterally and these make 
up a tenth of epithelial cells. Corticotrophs are found more medially and comprise 15-20% of 
hormone producing cells. Lactotrophs and gonadotrophs are both randomly distributed and make up 
25 and 10% of hormone-producing cells respectively (Nussey & Whitehead, 2001). 
 
The main function of the anterior pituitary is the regulation of peripheral endocrine organ function 
through the secretion of circulating hormones. The secretion of these hormones is mediated by CNS 
inputs, predominantly those from the hypothalamus, and peripheral inputs from target endocrine 
organs(Nussey & Whitehead, 2001).  
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1.4.3.2.1 THE GROWTH HORMONE AXIS 
 
1.4.3.2.1.1 HYPOTHALAMIC CONTROL OF THE GH AXIS 
GHRH is a 44 (43 in rats) amino acid peptide primarily synthesised in the ARC, and released by nerve 
terminals at the median eminence into the hypophyseal portal circulation. It is transported to the 
anterior pituitary gland where it binds to the GHRH receptor on somatotrophs, acting to maintain 
somatotroph structure and stimulate GH secretion. Ligand binding to the GHRH receptor results in a 
change in intracellular voltage and an increase in intracellular calcium which stimulates vesicle fusion 
and GH release. The GHRH receptor is primarily expressed in the anterior pituitary, but GHRH 
mRNA has also been detected in the ARC, VMN, PVN and suprachiasmatic nucleus (SCN) of the 
hypothalamus (Takahashi et al, 1995), in the brainstem and cerebral cortex, and in peripheral tissues 
including the kidney (Yokote et al, 1998).  
 
 GHRH also stimulates food intake, alters locomotor activity and has a role in the regulation of 
circadian rhythm in the SCN (Vaccarino et al, 1985;Nistic, 1987). GHRH release from the median 
eminence is pulsatile and is inhibited by GHRH itself in a short negative feedback loop, and by 
somatostatin (Bertherat et al, 1992). There is also evidence to suggest that GH itself participates in the 
regulation of its own secretion through feedback at the hypothalamus. Hypothalamic somatostatin 
neurons express the GH receptor; however, few ARC GHRH neurons express the GH receptor 
(Burton, 1992). NPY neurons in the ARC express the GH receptor and are also thought to play a 
physiological role in the feedback of regulation of GH secretion (Minami et al, 1999;Chan et al, 
1996a). Somatostatin and GHRH are secreted alternately, driving the pulsatile secretion of GH. 
 
Somatostatin has two active forms: a 14 and a 28 amino acid molecule. Somatostatin is released from 
neurosecretory nerve terminals of axons originating in the periventricular nucleus of the 
hypothalamus, and is transported in the hypophyseal portal circulation to the anterior pituitary where 
it inhibits GH secretion from somatotrophs and TSH release from thyrotrophs (Makara et al, 
1983;Merchenthaler et al, 1989). Somatostatin release is stimulated by increased levels of circulating 
GH levels. 
 
Somatostatin containing neurons are present in the ARC, the hippocampus and the NTS. Somatostatin 
is also involved in central regulation of motor activity, arousal, cognition and behaviour, and in the 
periphery suppresses the release of several gut hormones from the GI tract. There are five identified 
somatostatin receptors and all are GPCRs. The distribution of these receptors overlaps in the anterior 
pituitary, brain, pancreas and GI tract (Strowski & Blake, 2008;Miller et al, 1995).  
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1.4.3.2.1.2 PITUITARY CONTROL OF THE GROWTH HORMONE AXIS 
GH is a 191 amino acid polypeptide (Niall, 1971) essential for growth and general cell reproduction 
and regeneration. GH is an anabolic hormone which stimulates increased protein synthesis, promotes 
lipolysis and gluconeogenesis and increases bone mineralisation (Davidson, 1987). GH also 
stimulates the immune system and the production of insulin-like growth factor IGF-1 by the liver, 
which itself has widespread and important roles in cell growth and repair, and numerous anabolic 
effects (Clemmons & Underwood, 1991;Hartman et al, 1993). 
 
 Several shorter forms of GH circulate in the plasma (Sinha & Jacobsen, 1994). The majority of 
circulating GH is bound to the GH-binding protein (Baumann, 2001). The pulsatile release of GH is 
regulated by hypothalamic GHRH and somatostatin; however, GH secretion is also stimulated by sex 
steroids (Chowen et al, 2004), exercise (Roth et al, 1963), and sleep (Hunter et al, 1966), and is 
inhibited by glucocorticoids (Tonshoff & Mehls, 1997). GH release is also regulated by ghrelin via 
the growth hormone secretagogue receptor-1a (Kojima et al, 1999). 
 
The GH receptor (GH-R) is a member of the cytokine receptor family with a single transmembrane 
domain. Binding of GH to the GH-R leads to receptor dimerisation and the activation of multiple 
intracellular signalling pathways (Lanning & Carter-Su, 2006). 
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1.4.3.2.2 THE HYPOTHALAMO-PITUITARY-THYROID AXIS 
 
1.4.3.2.2.1 HYPOTHALAMIC CONTROL OF THE HPT AXIS 
TRH is a tripeptide and the smallest known peptide releasing hormone. TRH is released from nerve 
terminals in the median eminence and is transported to the anterior pituitary where it maintains 
thyrotroph structure and function and stimulates the release of TSH (Butler, 1969). The precursor 
proTRH also gives rise to other peptides which have been shown to induce TSH gene expression 
(Pekary, 1998). TRH also stimulates prolactin synthesis and release (Malarkey, 1976;Lancranjan et al, 
1980).  Whilst the majority of TRH released into the median eminence originates from TRH neurons 
in the PVN, this only accounts for a third of all TRH found in the CNS (Winokur & Utiger, 1974). 
TRH also has central actions on arousal, motor activity, thermoregulation and blood pressure (Nillni 
& Sevarino, 1999;Heuer et al, 1999). 
 
Two TRH receptors have been characterised: TRH-R1 and TRH-R2. The binding properties and 
intracellular signalling pathways are the same for both receptors. TRH-R1 is found in the 
hypothalamus and the anterior pituitary (Heuer et al, 1999) while TRH-R2 is expressed in the spino-
thalamic tract and the spinal cord (Heuer et al, 2000). 
 
TRH release from the median eminence is primarily regulated via negative feedback by circulating 
thyroid hormones acting at the level of the hypothalamus (Segerson et al, 1987). However, TRH 
synthesis and release is also regulated by a number of other signals, including catecholamines (Grimm 
& Reichlin, 1973), NPY (Fekete, 2001), leptin (Legradi et al, 1997) and glucocorticoids (Luo et al, 
1995), and the regulation of TRH by circulating thyroid hormones may in part be mediated indirectly 
by these signals (Chiamolera & Wondisford, 2009). 
 
1.4.3.2.2.2 PITUITARY CONTROL OF THE HPT AXIS 
TSH is a glycoprotein hormone comprised of a heterodimer of two non-covalently linked α and β 
subunits. The α subunit is common to the two other pituitary glycoprotein hormones, LH and FSH, 
while the β subunit is specific to TSH (Shupnik et al, 1989). TSH synthesis and release is stimulated 
by TRH originating from the hypothalamus, and inhibited by DA and somatostatin (Harris et al, 
1978). Circulating thyroid hormones also feedback to reduce the synthesis and release of TSH from 
the anterior pituitary (Shupnik et al, 1985). 
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TSH released into the circulation stimulates the release of thyroxine (T4) and triiodothyronine (T3) 
from the thyroid gland via the TSH receptor, a GPCR expressed on the surface of thyroid follicular 
cells (Szkudlinski et al, 2002). 
 
1.4.3.2.2.3 THYROID HORMONES 
The thyroid hormones T4 and T3 are iodinated derivatives of tyrosine. T4 is the main secretory 
product of the thyroid gland and plasma T4 levels are usually 40-fold higher than T3 levels. The 
majority of thyroid hormone in the circulation is bound to plasma proteins including thyroxine 
binding globulin and albumin (Larsen et al, 1981). Approximately 0.03% of total plasma T4 and 0.3% 
of total plasma T3 is present in unbound form. Only free thyroid hormone can enter target cells and 
elicit a biological response. T3 is more biologically active than T4, with a much higher affinity for the 
thyroid hormone receptors (Larsen et al, 1981). Once thyroid hormones are inside the cell, the 
iodothyronine deiodinase enzymes, D1, D2, and D3, regulate the activity of thyroid hormone via 
removal of specific iodine moieties from T4. D2 generates the active form of thyroid hormone T3 via 
deiodination of T4 so the cytoplasmic pool of T3 includes both T3 from the plasma and T3 generated 
by D2. D3 inactivates T3 and, to a lesser extent, prevents T4 from being activated to decrease local T3 
concentrations (Oppenheimer, 1979).  
 
Thyroid hormones are required for the normal functioning of all tissues and play a critical role in 
development, growth, reproduction and metabolism, specifically in the regulation of oxygen 
consumption and metabolic rate (Yen, 2001). Reduced exposure to thyroid hormones during 
development leads to severe mental retardation, and neurological and skeletal abnormalities. Thyroid 
hormones enter target cells by passive diffusion and active transport across plasma membranes 
(Mooradian et al, 1985;Samson et al, 1993). The thyroid hormone receptors (TRα1 and TRβ1, TRβ2 
and TRβ3) are nuclear receptors that are ubiquitously expressed, although with tissue specific 
isoforms. T3 and T4 mediate their effects by binding to these receptors and regulating expression of 
target genes. 
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1.4.3.2.3 THE HYPOTHALAMO-PITUITARY ADRENAL AXIS 
An organism’s ability to respond to stress is dependent on the functioning of the hypothalamo-
pituitary-adrenal (HPA) axis. This axis regulates stress related processes such as metabolism, energy 
expenditure, the immune system, mood and emotions (Selye, 1936). Its importance is reflected in its 
high level of conservation between species (Yao & Denver, 2008). The hypothalamus processes 
information from higher cortical centres in addition to detecting immune insult and alterations to 
whole-body homeostasis (Herman et al, 1996). Such signals result in activation of the sympathetic 
nervous system and release of the HPA axis hormones CRH, ACTH and glucocorticoids. 
Dysregulation of the HPA axis can result in Addison’s disease (Addison, 1855), i.e. adrenal 
insufficiency leading to low cortisol, or Cushing’s syndrome, characterised by excess cortisol 
(Cushing, 1932).  
 
1.4.3.2.3.1 HYPOTHALAMIC CONTROL OF THE HPA AXIS 
CRH is a 41 amino acid peptide synthesised by neurons in the pPVN and released by nerve terminals 
in the median eminence into the hypophyseal portal system (Vale et al, 1983). CRH is transported to 
the anterior pituitary where it stimulates the release of ACTH and maintains the structure of 
corticotrophs (Vale et al, 1981). AVP, a nonapeptide also synthesised in the pPVN is a potent 
synergistic factor with CRH in the stimulation of ACTH secretion (Antoni, 1993); however, AVP has 
little ACTH secretagogue activity alone (Lamberts et al, 1984). There is a reciprocal positive 
interaction between CRH and AVP at the level of the hypothalamus whereby each neuropeptide 
induces release of the other. In the absence of stress, CRH and AVP are secreted in a circadian, 
pulsatile manner. In humans, the largest pulses are in the early morning, resulting in peak circulating 
ACTH and cortisol levels at this time (Horrocks et al, 1990). Acute stress, including inflammatory 
mediators, increases the amplitude and frequency of CRH and AVP secretory pulses in the portal 
circulation (Tsigos & Chrousos, 1994). CRH and AVP release are regulated by glucocorticoids acting 
directly at the hypothalamus (Beyer et al, 1988).  
Two GPCR CRH receptors have been identified: CRH-R1 and CRH-R2 (Turnbull & Rivier, 1997). 
CRH-R1 is more abundant and expressed in the anterior pituitary and widely throughout the brain 
(Wong et al, 1994). CRH-R2 is expressed in the brain and in peripheral tissues.  
 
In addition to its effect on the release of ACTH, other central CRH pathways are involved in the 
behavioural, autonomic and endocrine responses to stress (Fisher, 1993), including regulation of 
energy homeostasis. CRH also suppresses the reproductive, thyroid and growth axes (Tsigos & 
Chrousos, 2002). 
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1.4.3.2.3.2 PITUITARY CONTROL OF THE HPA AXIS 
ACTH is a 39 amino acid anterior pituitary peptide hormone formed by post-translational processing 
of the POMC precursor molecule. Pulsatile ACTH secretion is stimulated by CRH binding to the 
CRH-R1 receptor on pituitary corticotrophs and subsequent stimulation of intracellular adenylate 
cyclase and cyclic adenosine monophosphate (cAMP) dependent protein kinase (Aguilera et al, 
1986). CRH-induced secretion of ACTH is attenuated by elevated circulating glucocorticoid 
concentrations and enhanced by a reduction in circulating glucocorticoid levels (McEwen, 1979). 
ACTH release is also stimulated by inflammatory cytokines including IL-6 acting via the IL-6 
receptor at the anterior pituitary (Gautron et al, 2003). ACTH released into the general circulation 
binds to the MC2-R on the adrenal gland and stimulates the synthesis and release of glucocorticoids 
(Simpson & Waterman, 1988).  
 
1.4.3.2.3.3 GLUCOCORTICOIDS 
Glucocorticoids are the final effectors of the HPA axis and participate in the regulation of whole body 
homeostasis and an organism’s response to stress. Glucocorticoids are steroid hormones synthesised 
and secreted in response to circulating ACTH from cells in the zona fasciculata of the adrenal cortex. 
The major human glucocorticoid is cortisol. The major rat glucocorticoid is corticosterone. 
Glucocorticoids up-regulate expression of anti-inflammatory proteins and down-regulate expression 
of pro-inflammatory proteins. Glucocorticoids inhibit the HPA axis in a negative feedback loop at the 
pituitary, hypothalamus and higher centres of the brain, including limbic structures such as the 
hippocampus (Keller-Wood & Dallman, 1984). Metabolically, glucocorticoids increase protein 
catabolism, hepatic glycogenolysis and gluconeogenesis and lipolysis. These actions result in the 
mobilisation of energy stores which allow an organism to deal with stress. 
Glucocorticoids mediate their effects via the ubiquitous glucocorticoid receptor (GR), to which they 
bind with low affinity, and the mineralocorticoid receptor (MR), expressed in the kidney, colon, heart, 
CNS, brown adipose tissue and sweat glands, to which they bind with much higher affinity (Nussey & 
Whitehead, 2001). Both the GR and the MR are nuclear receptors. Glucocorticoids circulate at 100-
1000 fold higher concentrations than mineralocorticoids and yet bind with similar affinity to the MR 
(Nussey & Whitehead, 2001). To prevent unwanted activation of the MR by circulating 
glucocorticoids, certain tissues including the kidney express 11-β-dehydrogenase isoenzyme 2 
(11βHSD2), an enzyme which oxidises the glucocorticoid cortisol to the inactive metabolite cortisone 
(Albiston et al, 1994). 
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1.4.3.2.4 THE HYPOTHALAMO-PITUITARY-GONADAL AXIS 
The release of reproductive hormones, and thus control of puberty and reproductive behaviour in 
mammals, is mediated by the pulsatile release of GnRH from specific neurons of the hypothalamus. 
GnRH is released into the hypophyseal portal system from where it can access the anterior pituitary 
gland. Here it acts on gonadotrophs, stimulating the release of the gonadotrophins, LH and FSH into 
the general circulation. LH and FSH act on the ovaries in females and the testes in males to control 
the release of sex steroids, and to stimulate spermatogenesis in males and menstrual cycling in 
females. The HPG axis is regulated by negative feedback effects of both the gonadal sex steroids and 
the pituitary gonadotrophins acting at the level of the pituitary and hypothalamus (Figure 1.3). 
 
1.4.3.2.4.1 HYPOTHALAMIC CONTROL OF THE HPG AXIS 
GnRH is a decapeptide first isolated from porcine hypothalamus (Amoss et al, 1971). The amino acid 
sequence is identical across almost all mammalian species examined (Jimenez-Linan et al, 1997). 
GnRH-releasing neurons are found dispersed throughout the anterior hypothalamic nuclei, including a 
large proportion in the preoptic area, and the medial basal areas (Silverman et al, 1987). There are 
only a small number of GnRH neurons in most mammals, approximately 800-2000 (Hoffman G.E. et 
al, 1992). GnRH is generated from a precursor polypeptide by enzymatic processing and packaged 
into storage granules that are transported down axons to the external zone of the median eminence 
(Silverman et al, 1994). The hormone is then released in synchronised pulses from the nerve endings 
into the hypophyseal portal system every 30-120 minutes to stimulate the biosynthesis and secretion 
of LH and FSH from pituitary gonadotrophs (Fink, 1988).  
 
The mechanism underlying GnRH pulsatility is unclear. It has been observed that cultured GnRH 
neurons release GnRH in a pulsatile manner in the absence of glial cells or other neuronal types, 
suggesting an inherent ‘pulse generator’ within the GnRH cells themselves (Wetsel et al, 1992). The 
pulsatility of GnRH release is critical for the correct functioning of the HPG axis (Knobil, 1990).  
Gonadal feedback, stress and nutrition also influence GnRH neuron activity (Clarke & Pompolo, 
2005). Many neuropeptides and hormones have been shown to effect GnRH secretion and the 
reproductive axis and may mediate the effects of these influences on GnRH neurons. These include 
kisspeptin (Thompson et al, 2004), leptin (Barash et al, 1996), products of the POMC gene (Stanley et 
al, 2003), galanin (Sahu et al, 1987) and GALP (Matsumoto et al, 2001) (section 3.1.2).  
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FIGURE 1.3 Schematic diagram of the hypothalamo-pituitary-gonadal (HPG) axis in males and females. 
Gonadotrophin releasing hormone (GnRH) stimulates the release of luteinising hormone (LH) and follicle 
stimulating hormone (FSH) from the pituitary. LH and FSH then stimulate the release of sex steroids from the 
gonads. In males testosterone negatively feeds back at both the hypothalamus and pituitary level. In females, 
depending on the phase of the oestrus cycle, oestrogen and progesterone feed back on the hypothalamus and 
pituitary in either a stimulatory or inhibitory manner. In both sexes, LH and FSH also feed back negatively on 
the hypothalamus to inhibit GnRH release.  
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1.4.3.2.4.2 PITUITARY GLAND CONTROL OF HPG AXIS 
The primary function of GnRH is regulation of the release of gonadotrophins from pituitary 
gonadotrophs. Gonadotroph cells are found in the anterior lobe of the pituitary and are usually located 
adjacent to lactotrophs (Ooi et al, 2004). They are the site of synthesis, storage and release of the 
gonadotrophins LH and FSH. Hypothalamic GnRH binds to and activates GnRH receptors on 
gonadotrophs to stimulate LH and FSH release (Karges et al, 2003). The GnRH receptor is a GPCR 
which is highly homologous between species (Kakar et al, 2004).  
 
The importance of GnRH in gonadotrophin release is illustrated by the reduction of both LH and FSH 
mRNA and serum levels observed in response to experimental disruption of the GnRH/GnRH 
receptor system caused by endogenous GnRH immunoneutralisation, surgical hypothalamus-pituitary 
disconnection or antagonist mediated GnRH receptor blockade (Hamernik & Nett, 1988;Wierman et 
al, 1989). The release of LH and FSH is also regulated by gonadal steroids and members of the TGFβ 
family, activin and inhibin, which enhance and down-regulate FSH synthesis and release respectively 
(Carroll et al, 1991). 
 
LH and FSH belong to a family of structurally related glycoprotein hormones which also includes 
TSH (Stockell & Renwick, 1992). These hormones consist of two distinct glycosylated subunits, a 
common α- and a specific β-subunit which confers biological activity (Pierce & Parsons, 1981). LH 
and FSH are generally expressed within the same cells, although monohormonal gonadotrophs do 
exist (Childs, 1997). Both LH and FSH are synthesised and intermittently secreted from gonadotrophs 
in response to the pulsatile release of GnRH. However, different GnRH pulse frequencies may favour 
different intracellular signal transduction mechanisms which stimulate the synthesis of particular 
gonadotrophin subunits (Burger et al, 2004). 
 
The pulse amplitude and frequency of LH release is sexually dimorphic, and depends on the stage of 
pubertal development, circadian rhythms, and in the female, the stage of the menstrual/oestrus cycle 
(Matsumoto & Bremner, 1984). LH acts via the GPC LH receptor (LH-R) and FSH binds to and 
activates the GPC FSH receptors FSH-R (McFarland et al, 1989). Gonadal steroids feedback to 
regulate LH and FSH synthesis and release (McNeilly et al, 2003). 
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1.4.3.2.4.3 GONADS AND CONTROL OF THE HPG AXIS 
LH-R expression is limited in males to the Leydig cells of the testes (Bhalla et al, 1992). Here, LH 
regulates the synthesis and secretion of androgens, primarily testosterone, and thus maintains the 
endocrine (extra testicular) and paracrine (sperm production) effects of androgens. LH is also required 
for the maintenance of Leydig cell structure and function. Hypophysectomy or inhibition of LH 
secretion causes Leydig cells to atrophy and lose their ability to secrete testosterone (Russell et al, 
1992). In female ovaries, the LH-R is expressed in theca, interstitial, differentiated granulosa and 
luteal cells (Bukovsky et al, 1993). LH stimulates secretion of testosterone from theca cells which is 
then converted into estrogens by neighbouring granulosa cells. LH also triggers ovulation and 
maintains progesterone production of the corpus luteum (Huhtaniemi, 2000). 
 
In males, FSH is an important trophic hormone which regulates Sertoli cell proliferation and function 
(Almiron & Chemes, 1988), initiates spermatogenesis during pubertal development (Russell et al, 
1987) and supports normal spermatogenesis in adults (Matsumoto et al, 1986). In the female, FSH 
stimulates follicular maturation and oestrogen production by granulosa cells in the ovary (Huhtaniemi, 
2000). 
 
The gonadal steroids exert negative feedback actions on the hypothalamo-pituitary axis. GnRH 
secretion is increased following orchidectomy or ovariectomy (Damassa et al, 1976;Clayton, 
1993;Goodman & Daniel, 1985). Gonadal steroids predominantly suppress LH secretion by acting at 
the hypothalamus (Tilbrook & Clarke, 2001) but also have direct effects at the pituitary. Both 
androgen and estrogen receptors are expressed in the hypothalamus (Apostolinas et al, 1999;Shughrue 
et al, 1997). However, it has been reported that endogenous GnRH neurons do not express either of 
these receptors, suggesting that sex steroids act on other neurons to indirectly regulate GnRH release 
(Tilbrook & Clarke, 2001). 
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1.5 THE GALANIN PEPTIDE FAMILY 
The galanin peptide family consists of galanin and galanin-message-associated peptide (GMAP) 
(derived from the same peptide precursor gene product as galanin), galanin-like peptide (GALP) 
(encoded by a distinct gene) and alarin, which is encoded by a recently discovered splice variant of 
the GALP gene. 
 
The galanin receptor family currently consists of three known members, GalR1, GalR2 and GalR3 
which are all GPCRs. Evidence suggests that other, as yet uncharacterised members of this receptor 
family may exist (Branchek et al, 2000).  
 
1.5.1 GALANIN MESSAGE ASSOCIATED PEPTIDE 
GMAP, the 59 amino acid C-terminal fragment of galanin precursor protein (Rokaeus & Brownstein, 
1986) is highly conserved across species. Its physiological role is unclear. GMAP is present in dorsal 
root ganglion cells, dorsal roots and the dorsal horn and is upregulated in sensory afferent neurons 
following peripheral nerve injury (Xu et al, 1995b). Intrathecal administration of GMAP has been 
shown to inhibit spinal nociception, although the effect of GMAP on spinal cord excitability is 
variable depending on the intact or severed status of neurons (Andell-Jonsson et al, 1997;Xu et al, 
1995a;Hao et al, 1999). It is interesting that while GMAP acts similarly to galanin in some 
pharmacological functions, including spinal nociception, it also appears to have some distinct 
functions, suggesting that it may have its own specific receptor (Xu et al, 1995a). GMAP is only 
weakly able to displace I125galanin from binding sites on rat spinal cord membrane (Andell-Jonsson et 
al, 1997) and does not bind to GalR2 or GalR3 expressing membranes in vitro (Wang et al, 1997c). 
However, a specific GMAP receptor has not yet been identified. 
 
More recently, GMAP has been described as having antimicrobial properties. It inhibits the growth of 
the fungus Candida Albicans and suppresses the transition from budded to hyphal form, reducing its 
pathogenicity (Rauch et al, 2007). This suggests a novel role for galanin-related peptides in the innate 
immune response.  
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FIGURE 1.4 Organisation of the preprogalanin gene. Exon 1 encodes only the 5’ untranslated region. Exon 2 
starts with the translation initiation codon of the signal peptide and terminates before the proteolytic site 
preceding the mature galanin peptide. The first 13 amino acids of galanin are encoded by exon 3; the remaining 
16 amino acids and most of GMAP by exons 4 and 5. The remaining portion of GMAP and the polyadenylation 
site are located in exon 6. Arrows indicate endopeptidase cleavage sites. Adapted from (Kofler et al, 1996). 
 
1.5.2 GALANIN  
Galanin is generated by proteolytic processing of a 123-(porcine, human) or 124-(murine) amino acid 
precursor pro-peptide (Rokaeus & Brownstein, 1986). GMAP is also generated by processing of this 
precursor (section 1.5.1). This preprogalanin is encoded by a single-copy gene organised into 6 exons 
spanning about 6Kb of genomic DNA (Kofler et al, 1996) (Figure 1.4). 
 
Galanin is a 29 amino acid (30 in humans) neuropeptide originally isolated from porcine intestine. It 
is so called due to its N-terminal glycine residue and C terminal alanine (Tatemoto et al, 1983). The 
first 15 N-terminal amino acids, which retain the biological activity of the full-length peptide in vivo 
and in vitro, and are known as the galanin receptor binding domain, are highly conserved across 
species. The C terminal portion displays greater variability (Wynick et al, 1998b). Human galanin 
lacks the C-terminal amidation present in all other species examined due to the presence of a serine 
residue at position 30 (Evans & Shine, 1991;Schmidt et al, 1991). The galanin sequence in other 
species is flanked by Gly-Lys-Arg at the C terminus, serving as amide donor (glycine) and dibasic 
proteolytic processing site (Lys-Arg) (Schmidt et al, 1991). 
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1.5.2.1 LOCALISATION OF GALANIN 
Galanin mRNA and galanin-IR have been detected in the CNS of all species examined, including the 
rat (Melander et al, 1986a), mouse (Cheung et al, 2001), primate (Kordower et al, 1992) and human 
(Gentleman et al, 1989). In the CNS, galanin mRNA is most abundant in the hypothalamus and 
brainstem of the rat (Jacobowitz et al, 2004;Ryan & Gundlach, 1996) and mouse (Cheung et al, 
2001). Specifically, there are very high levels in the preoptic, periventricular and dorsomedial 
hypothalamic nuclei, and in the bed nucleus of the stria terminalis (BNST), and NTS. High levels of 
galanin-IR are also found in the external median eminence suggesting a role for galanin as a 
hypophysiotropic hormone (Lopez et al, 1991). 
 
In addition to the CNS, galanin is also found in the periphery. Galanin is found in neuronal fibres of 
the gastrointestinal tract (Melander et al, 1985), in both the endocrine and exocrine pancreas 
(Dunning et al, 1986), in the skin, where it is detected both in nerves (Tainio et al, 1987) and also 
extra-neuronally (Ji et al, 1995), in nerves and other cells of bone and joint tissue (McDonald et al, 
2003), in the adrenal medulla, genitourinary tract and respiratory tract, and in numerous other 
peripheral organ systems (Kaplan et al, 1988c).  
 
Within the hypothalamus, galanin has been reported to co-localise with GHRH and tyrosine 
hydroxylase (Meister & Hokfelt, 1988), GnRH (Coen et al, 1990), oxytocin (Gaymann & Martin, 
1989), CRH and AVP (Ceccatelli et al, 1989) and noradrenaline (Melander et al, 1986b) amongst 
others, suggesting a role for galanin in the regulation of neurosecretory function. In addition, galanin 
is coexpressed with neuropeptides known to be involved in the regulation of energy homeostasis, 
including CCK in the PVN (Meister et al, 1990b) and histamine-synthesizing cells in the TMN 
(Sherin et al, 1998). Galanin is also expressed in specific populations of GABAergic, serotonergic and 
catecholaminergic neurons throughout the CNS (Melander et al, 1986b). 
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1.5.2.2 GALANIN ACTIONS 
Reflective of its widespread distribution and co-localisation with many other neuropeptides and 
neurotransmitters, galanin is thought to regulate numerous and diverse physiological actions in the 
nervous system. The roles of galanin in energy homeostasis and neuroendocrine regulation will be 
discussed in chapters 2 and 3 respectively. Other important actions of galanin are briefly described 
below.  
 
1.5.2.2.1 GALANIN AND AROUSAL/SLEEP REGULATION 
Neuroanatomical studies have revealed the presence of a population of galanin-expressing neurons 
originating in the ventrolateral preoptic nucleus and synapsing on neurons in the TMN, the major 
source of histamine in the brain important in the regulation of sleep and wakefulness (Haas & Panula, 
2003). Galanin-expressing sleep-active neurons of the ventrolateral preoptic nucleus are proposed to 
provide inhibitory inputs to the cell bodies of histamine synthesising neurons of the TMN and other 
components of the ascending monoaminergic arousal system (Sherin et al, 1998).  
 
1.5.2.2.2 GALANIN AND NOCICEPTION 
The presence of galanin in the dorsal spinal cord gave rise to the proposal of a physiological role for 
galanin in spinal pain modulation. Spinal administration (intrathecal) of galanin produces a biphasic 
effect on spinal nociception through activation of GalR1 (inhibitory) or GalR2 (excitatory) receptors. 
Furthermore, galanin mRNA expression is increased in sensory neurons following peripheral nerve 
injury (Villar et al, 1989).  
 
1.5.2.2.3 GALANIN AND NEUROPROTECTION 
Galanin gene expression and peptide levels are potently and persistently elevated following 
experimental nerve injury in numerous different models (Hokfelt et al, 1987;Corts, 1990). This 
elevation in galanin-IR in dorsal root ganglion cells is associated with successful or attempted neural 
repair processes suggesting a trophic role for galanin. In accord with this, galanin has been 
demonstrated to act as a survival (Elliott-Hunt et al, 2004) and growth promoting factor (Holmes et 
al, 2000) for CNS and PNS neurons. 
 
1.5.2.2.4 GALANIN AND EPILEPSY 
Galanin is able to inhibit glutamate but not GABA release in the hippocampus (Zini et al, 1993). This 
suggests that galanin may suppress excitatory tone without affecting inhibitory tone and may therefore 
possess anticonvulsant activity. Indeed, the GalR1 knockout mouse exhibits spontaneous seizure 
activity suggesting this receptor subtype may mediate such actions (Jacoby et al, 2002), while the 
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galanin overexpressing mouse has a higher threshold for seizure development (Kokaia et al, 2001). 
There is therefore great interest in developing selective galanin receptor agonists as antiepileptic 
agents (Robertson et al, 2010). 
 
1.5.2.2.5 GALANIN AND LEARNING/MEMORY 
ICV injection of galanin impairs the performance of rodents in various cognitive tasks. This may be 
due to impairment of both learning and memory, mediated by an inhibition of acetylcholine release in 
the hippocampus (Fisone et al, 1987). Galanin receptor antagonists have been proposed as putative 
cognitive enhancers, and it has been suggested they may be of particular use in Alzheimer’s disease, 
which is characterised by degeneration of cholinergic/galaninergic neurons and a pathological, 
compensatory increase in activity of surviving galanin neurons (Chan-Palay, 1988). In post-mortem 
brains from Alzheimer’s patients, hippocampal galanin binding sites are significantly increased 
(Rodriguez-Puertas et al, 1997).  
 
1.5.2.2.6 GALANIN AND ANXIETY/DEPRESSION 
Galanin is co-expressed in almost all noradrenaline-containing neurons of the locus coruleus (LC) and 
in approximately 70% of serotonergic neurons in the dorsal raphe nucleus (DRN). These nuclei are 
important in the regulation of mood. Overactivity of LC Noradrenergic neurons leads to suppression 
of DRN serotonergic neurons and the development of depression (Sulser, 1979). Serotonin and 
noradrenaline re-uptake inhibitors are effective therapeutic agents in the treatment of depression 
(Nelson, 1996). The use of these drugs is associated with an increase in galanin mRNA and GalR2 
binding in the DRN, thought to be due to inhibition of the noradrenergic suppression of serotonin 
neurons (Lu et al, 2005a). In addition, studies have revealed that administration of selective GalR3 
antagonists has antidepressant-like activity in animal models of depression (Swanson et al, 2005;Barr 
et al, 2006).   
 
1.5.2.2.7 GALANIN AND ADDICTION 
Galanin activity in the amygdala appears to be associated with addictive behaviour such as alcohol 
intake. Animal behavioural studies suggest that central galanin administration increases ethanol intake 
(Lewis et al, 2004) and human genetic studies propose a link between galanin, the GalR3 and 
alcoholism (Belfer et al, 2006;Belfer et al, 2007). 
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1.5.2.2.8 GALANIN AND WATER BALANCE 
Galanin is co-expressed with AVP in magnocellular neurons of the PVN and SON (Skofitsch et al, 
1989;Melander et al, 1986b;Rokaeus et al, 1988;Gaymann & Martin, 1989). These nuclei also have 
galanin binding sites (Melander et al, 1988;Skofitsch et al, 1986), suggesting an involvement of 
galanin in osmotic regulation. Indeed, dehydration or salt loading increases galanin mRNA in 
hypothalamic magnocellular neurons (suggesting increased synthetic activity) and reduces galanin 
peptide levels in the SON, PVN and posterior pituitary gland (suggesting increased release) (Skofitsch 
et al, 1989;Meister et al, 1990a). The same pattern of expression is seen in the chronically 
hyperosmolar, AVP deficient Brattleboro rat (Rokaeus et al, 1988).  
 
Systemic galanin administration causes only a mild diuresis and a small increase in blood pressure in 
rats (Skofitsch et al, 1989). Salt loading and dehydration increase both AVP release and galanin 
mRNA expression in the hypothalamus and reduce galanin-IR in the posterior pituitary (Skofitsch et 
al, 1989). Galanin is then thought to act as a negative feedback modulator of AVP release via GalR1 
activation in an autocrine/paracrine manner (Kondo et al, 1993a;Kondo et al, 1993b;Landry et al, 
1995;Molnar et al, 2005). Magnocellular AVP neurons in PVN and SON express GalR1, and GalR1 
mRNA levels in these hypothalamic nuclei are increased by osmotic challenge and in the Brattleboro 
rat (Landry et al, 1998;Landry et al, 1999).  
 
ICV galanin also dose dependently reduces water consumption in water deprived rats (Brewer et al, 
2005) and in vitro studies suggest a role for galanin in regulating activity of neurons in the sub 
fornical organ (SFO); a circumventricular structure important in the control of water intake. These 
data suggest that galanin may suppress water intake by inhibiting SFO neurons via the GalR1 (Kai et 
al, 2006). 
 
1.5.2.3 GALANIN OVER-EXPRESSING AND KNOCKOUT MICE 
Galanin knockout mice are viable, grow normally, and can reproduce. The two main phenotypic 
abnormalities are a reduction in prolactin, associated with an inability to lactate, and an impaired 
response of sensory neurons to injury (Wynick et al, 1998b). Galanin over-expressing mice are 
healthy and normal when assessed using a variety of physiological and behavioural measures. The 
most apparent difference between these mutant mice and their wild-type littermates is a reduction in 
seizure susceptibility and reduced anxiety. There have been reports of deficits in learning and memory 
in galanin over-expressing mice (Crawley et al, 2002). Subtle differences in the energy homeostatic 
and neuroendocrine phenotypes of galanin knockout and galanin over-expressing mice will be 
discussed in chapters 2 and 3 respectively. 
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1.5.3 GALP  
GALP is a 60 amino acid peptide originally discovered as an endogenous ligand for galanin receptors 
present in the porcine hypothalamus and gastrointestinal tract (Ohtaki et al, 1999). The GALP gene 
comprises 6 exons and has a similar structural organisation to galanin. GALP (1-60) is processed from 
the 115-120 amino acid GALP precursor protein, preproGALP (Figure 1.5). The amino acid sequence 
of GALP (1-60) is highly conserved between humans, primates, rats, mice and pigs. (Ohtaki et al, 
1999;Cunningham et al, 2002;Cunningham et al, 2002;Jureus et al, 2001). The amino acid sequence 
of GALP (9-21) is completely identical to that of galanin (1-13) and is known as the galanin receptor 
binding domain. There are two other significantly conserved regions of GALP which may be 
important mediators of its bioactivity: residues 1-8 and 38-54.  
 
Despite being identified as an endogenous ligand for the GalR2, GALP (1-60) has the highest affinity 
for GalR3, followed by GalR2 and then GalR1. However the physiological consequences of GALP 
binding to GalR3 are unclear (Lang et al, 2005). Studies have reported that while GALP binds to the 
GalR3 with nanomolar affinity in membrane preparations, it is unable to activate intracellular 
signalling pathways. These findings may be artefacts of the low receptor density achieved following 
transfection of cell lines with GalR3 (Berger et al, 2004;Ohtaki et al, 1999).  
 
It has also been suggested that GALP may act via an as yet unknown receptor to mediate some of its 
biological effects (Krasnow et al, 2004). GALP and galanin activate c-fos expression in different 
neuronal populations (Fraley et al, 2003;Lawrence et al, 2003) and have different biological effects in 
vivo (Fraley et al, 2004b). 
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1.5.3.1 GALP MRNA AND PEPTIDE DISTRIBUTION 
GALP mRNA has a much more restricted distribution in the CNS than galanin, and is only detected in 
the ARC of the rat, mouse and macaque hypothalami. GALP-IR cell bodies have been localised to the 
medial and caudal region of the ARC close to the third ventricle (Jureus et al, 2000;Takatsu et al, 
2001). Similar expression patterns have also been shown in the mouse and the macaque (Jureus et al, 
2001;Cunningham et al, 2002). ARC GALP cells send GALP-positive projections to several areas of 
the basal forebrain, including the anterior pPVN, the LHA, the mPOA, the BNST and the lateral 
septal nucleus (Takatsu et al, 2001).  
 
Additionally, GALP mRNA and GALP-IR cell bodies have been detected in the median eminence, 
the infundibular stalk and in pituicytes of the posterior pituitary gland (Fujiwara et al, 2002;Takatsu et 
al, 2001;Shen et al, 2001;Jureus et al, 2000). GALP is absent from other hypothalamic nuclei and 
brain loci. Outside of the CNS, GALP mRNA has also been detected in the GI tract (Ohtaki et al, 
1999;Berger et al, 2003) and the testes (unpublished observation Shen et al, 2002). 
 
1.5.3.2 GALP ACTIONS 
The role of GALP in the regulation of feeding and reproduction has been relatively well-characterised 
and will be discussed in detail in chapters 2 and 3 respectively. GALP has also been implicated in 
regulating other neuroendocrine axes and water homeostasis (Lang et al, 2007). GALP is also able to 
inhibit inflammatory oedema formation in the skin by vasoconstriction and inhibition of blood flow 
(Schmidhuber et al, 2007). Interestingly, the GALP knockout mouse is for the most part 
phenotypically normal, although it does exhibit subtle differences in its response to alterations in 
nutritional status compared to wild-type littermates (Dungan Lemko et al, 2008). 
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1.5.4 ALARIN 
Alternative splicing of mRNA allows many gene products with different functions to be produced 
from a single coding sequence. This is proposed as a mechanism by which greater biological diversity 
is generated (Brett et al, 2002), in addition to being an essential method for the control of tissue 
specific expression of related proteins. Although uncommon within regulatory peptide systems, one 
example is the calcitonin gene-related peptide (CGRP) which is alternatively spliced to form 
calcitonin or CGRP (Amara et al, 1982). Recently, the expression of a splice variant of GALP mRNA 
was observed in gangliocytes of human neuroblastic tumours (neuroendocrine neoplasms). This splice 
variant results in an exclusion of exon 3 and a frame shift after the signal peptide sequence of GALP, 
generating a peptide of 25 amino acids (Santic et al, 2006).   
 
The presence of this splice variant of GALP in murine tissue has been confirmed using reverse-
transcription polymerase-chain-reaction (RT-PCR) analysis using sets of primers spanning exons 1-6. 
Exclusion of exon 3 was predicted to result in a precursor protein which contains the signal sequence 
of preproGALP and the first 5 amino acids of the GALP peptide, followed by 20 amino acids which 
show no homology to any other known murine protein. The proteolytic cleavage site of GALP is 
encoded within exon 2 and thus is maintained in this splice variant, allowing the generation of a 25 
amino acid neuropeptide (Santic et al, 2007), named alarin because of its N-terminal alanine and C-
terminal serine.  
 
Comparing the alarin splice variant between different species, a similar frame shift is predicted to 
occur in rats, macaques and humans, and alarin appears to be reasonably conserved between species. 
The alarin peptide lacks the galanin receptor binding domain, suggesting that it mediates its biological 
effects through alternative receptors. In support of this hypothesis, it has been reported that alarin (1-
25) does not bind to membrane preparations of either human GalR1 or GalR2-expressing 
neuroblastoma cells (Santic et al, 2007). 
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FIGURE 1.5 Organisation of the preproGALP gene. Exon 1 is noncoding. PreproGALP is encoded by exons 
2-6 and the segment with galanin homology [GALP(9-21)] is contained in exon 3. The mature GALP (1-60) is 
encoded by exons 2-5. Post-transcriptional splicing leads to exclusion of exon 3 resulting in a frame shift and a 
novel precursor protein. This protein harbours the signal sequence of preproGALP and the first 5 amino acids of 
the mature GALP peptide followed by another 20 amino acids and proteolytic cleavage leads to alarin (1-25). 
Arrows indicate potential endopeptidase cleavage sites. Adapted from (Lang et al, 2007). 
 
1.5.4.1 ALARIN LOCALISATION 
Alarin-IR was initially detected specifically in cytoplasmic granules in ganglia of human 
ganglioneuromas and ganglioneuroblastomas, as well as in differentiated tumour cells of 
neuroblastoma tissues. Undifferentiated neuroblasts of these tumour tissues did not show alarin-IR or 
alarin-specific mRNA, suggesting alarin expression is a feature of ganglionic differentiation in 
neuroblastic tumour tissues (Santic et al, 2006). 
 
Alarin mRNA has subsequently been detected in murine brain, skin and thymus by RT-PCR (Santic et 
al, 2007). Alarin-IR has been more specifically observed within the rat brain; mainly within the basal 
ganglia, but also in the amygdala and piriform cortex, in the CA1 region and the stratum lacunosum 
molecular of the hippocampus (Eberhard et al, 2007). Interestingly, relatively dense staining has also 
been observed in the hypothalamic TMN. Within the adult female murine brain, alarin-IR has been 
observed in cells of the mitral layer of the olfactory bulb, the dorsolateral cortex, the anterior olfactory 
nucleus (lateral), the piriform cortex, the pyramidal cell layer of the hippocampus, the LC, the facial 
nucleus, Purkinje cells of the cerebellum and the epithelial layer of the choroid plexus (Eberhard et al, 
2008). 
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1.5.4.2 ALARIN ACTIONS 
Galanin and GALP can inhibit substance P- and CGRP-induced oedema formation in the skin (Green 
et al, 1992;Schmidhuber et al, 2007). Alarin-IR has been detected in pericytes surrounding 
microvascular arterioles and venules in the dermis and in layers of smooth muscle cells. Alarin, 
GALP and galanin all demonstrate a similarly profound inhibitory effect on substance P- and CGRP-
induced oedema formation. Alarin is able to inhibit the inflammatory oedema formation in a dose-
dependent manner when co-injected locally into the cutaneous microvasculature at picomolar doses. 
Furthermore, it appears that this anti-inflammatory effect of alarin is mediated via a reduction of 
blood flow in the skin, suggesting potential vasoconstrictor properties of alarin (Santic et al, 2007). 
 
 
FIGURE 1.6 Amino acid sequences of alarin, galanin-like peptide (GALP) and galanin peptides. Amino acids 
conserved between species are highlighted in grey. The 13 conserved residues between galanin and GALP 
which contains the galanin receptor binding domain are in red. The 5 amino acids common to both alarin and 
GALP are in blue. (Cunningham, 2004;Lundkvist et al, 1995;Santic et al, 2007;Schmidt et al, 1991;Tatemoto et 
al, 1983;Vrontakis et al, 1987). 
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1.6 AIMS 
1) To investigate the in vivo effects of ICV alarin on food intake and behaviour, and to 
determine whether alarin is an endogenous regulator of food intake.  
2) To investigate the effect of alarin in vivo and in vitro on the hypothalamo-pituitary axes. 
3) To determine whether alarin binds to the three known galanin receptors 
4) To investigate the effect of VTA administration of appetite regulating peptides 
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CHAPTER 2 
ALARIN AND ENERGY HOMEOSTASIS 
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2.1 INTRODUCTION 
The galanin peptide family have long been implicated in the regulation of energy homeostasis. High 
concentrations of galanin and galanin receptors are present in hypothalamic nuclei known to be 
involved in food intake, and soon after the discovery of galanin, initial experiments were carried out 
to test the effect of ICV administration of galanin on feeding (Kyrkouli et al, 1986). The subsequent 
discovery of GALP (Ohtaki et al, 1999), with its restricted distribution in the ARC of the 
hypothalamus, reignited interest in this family of peptides, and has increased the complexity of the 
role of the galanin family of peptides in energy homeostasis.  
 
2.1.1 GALANIN AND FOOD INTAKE 
Galanin has consistently been reported to acutely increase food intake in satiated and fasted rats 
following ICV injection (Kyrkouli et al, 1986;Kyrkouli et al, 1990b;Kyrkouli et al, 2006;Crawley et 
al, 1990;Barton et al, 1995;Barton et al, 1996;Schick et al, 1993;Tempel et al, 1988). Galanin has 
also been reported to stimulate feeding following central injection in mice (Hohmann et al, 2003), 
goldfish (de Pedro, 1995), squirrels (Boswell et al, 1993) and chicks (Tachibana et al, 2008).  
 
Specific orexigenic effects are seen following microinjection of galanin into the rat PVN, LHA, 
DMN, VMN and amygdala (Corwin et al, 1993;Kyrkouli et al, 1986;Kyrkouli et al, 1990b;Schick et 
al, 1993). Lesioning the PVN abolishes the orexigenic effects of third ventricular galanin 
administration, suggesting that the PVN is necessary to mediate galanin’s stimulatory effects on 
feeding (Kyrkouli et al, 1989). Fourth ventricle administration and iNTS microinjection of galanin 
also stimulate feeding in rats, suggesting that galanin can act in the hindbrain to stimulate appetite. 
These effects are attenuated by iNTS or fourth ventricle administration of the non-specific GalR1 and 
GalR2 antagonist M40 (Koegler & Ritter, 1996). The effects of hindbrain injection of galanin on food 
intake are weak compared to those observed following ICV injection, suggesting that hindbrain 
galanin receptors may have a lesser role than hypothalamic receptors in the orexigenic effect of 
galanin. However, M40 is more effective at reducing fasting-induced re-feeding when injected into 
hindbrain sites compared to ICV administration, supporting a physiological role for hindbrain galanin 
signalling in satiety (Koegler et al, 1999). Interestingly, occlusion of the cerebral aqueduct does not 
effect the feeding response seen following either third or fourth ventricle galanin administration, 
suggesting that galanin can act in both the hypothalamus and the hindbrain to influence food intake 
(Koegler & Ritter, 1997). However, lesioning of the PVN enhances iNTS galanin-induced feeding in 
rats, suggesting there may be some interaction between these two sites of galanin action (Koegler & 
Ritter, 1998).  
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Infusion of galanin antisense oligonucleotides into the rat PVN inhibits feeding, suggesting a 
physiological role for galanin in the regulation of feeding (Akabayashi et al, 1994). Reports are 
contradictory regarding the effect of iPVN galanin receptor antagonist administration on food intake. 
Some studies report a reduction in food intake, and in particular fat ingestion (Adams et al, 2008), 
while others report no effect of a galanin receptor antagonist on food intake (Corwin et al, 1995). 
Chronic central administration of galanin to mice for six days significantly increases food intake and 
body weight (Hohmann et al, 2003). However a study administering lower doses of galanin for a two 
week period reported no significant change in body weight in rats, probably due to tachyphylaxis 
(Smith et al, 1994).  
 
The mechanisms by which galanin increases food intake are unclear. NPY-IR nerve terminals synapse 
onto galanin-IR cell bodies and dendrites in the rat ARC and PVN (Horvath et al, 1996), suggesting 
that galanin may have a role in mediating NPY-induced feeding.  
 
Galanin co-localises with noradrenaline in the PVN (Melander et al, 1986a) and hypothalamic 
administration of noradrenaline stimulates feeding (Grossman, 1962). Inhibition of noradrenaline 
synthesis, or pretreatment with an α2-adrenergic receptor antagonist, blocks galanin induced food 
intake in rats (Kyrkouli et al, 1990a), and iPVN administration of galanin to rats increases 
extracellular noradrenaline levels in the hypothalamus (Kyrkouli et al, 1992).  
 
Galanin-IR fibres synapse onto β-endorphin containing (POMC mRNA expressing) neurons in the 
ARC (Horvath et al, 1995), and ARC POMC/CART neurons express both GalR1 and GalR2 mRNA 
(Bouret et al, 2000). Galanin may stimulate release of β-endorphin, which itself stimulates feeding via 
activation of the µ-opioid receptor (Morley, 1987). Galanin-stimulated feeding in satiated rats is 
reduced by co-administration of a µ-opioid receptor antagonist (Dube et al, 1994a;Barton et al, 
1995;Barton et al, 1996). Studies examining the diurnal variation in galanin observed that the 
increases in hypothalamic galanin mRNA levels in the rat hypothalamus between 1100 and 1500 h 
coincide with increases in hypothalamic POMC expression, but lag slightly behind those in NPY 
expression. It has therefore been suggested that there is a hypothalamic NPY-galanin-β-endorphin 
pathway that stimulates feeding in the rat (Xu et al, 1999). 
 
Early studies using pure macronutrient choice tests suggested that central administration of galanin 
preferentially increases fat consumption (Tempel et al, 1988). Galanin gene expression, peptide 
production and release from the pPVN and the external zone of the median eminence are specifically 
increased in response to fat ingestion, but not ingestion of carbohydrate or protein (Leibowitz et al, 
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1998). However, the hypothesis that galanin production is regulated by signals related to fatty acid 
metabolism remains debatable, and subsequent studies have shown that galanin administration also 
induces large increases in the consumption of mixed nutrient diets (Smith et al, 1997a). It has been 
proposed that the nutrient preference driven by galanin administration is dependent on the circadian 
cycle (Tempel & Leibowitz, 1990). 
 
Transgenic mice lacking or over-expressing galanin in the brain do not display any noticeable 
alterations in feeding pattern or body weight (Steiner et al, 2001;Wynick et al, 1998b). These data 
suggest that while galanin administration may acutely regulate food intake, it does not regulate daily 
feeding or body weight. However, following more detailed phenotypic analysis, it has been suggested 
that the galanin knockout mouse is more sensitive to leptin administration (Hohmann et al, 2003) and 
more glucose intolerant than wild-type littermates (Ahren et al, 2004). Developmental compensation 
may mask more profound effects of the lack of galanin on energy homeostasis. However, linkage 
studies in humans have not revealed a role for the galanin gene in obesity (Schauble et al, 2005). 
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2.1.1.1 GALANIN REGULATION BY LEPTIN AND INSULIN 
The hypothalamic galanin system has been shown to interact with peripheral signals such as leptin 
and insulin. The leptin receptor is expressed on galanin-containing cell bodies within the ARC 
(Hakansson et al, 1998) and central administration of leptin decreases hypothalamic galanin mRNA 
expression (Sahu, 1998a). Central administration of insulin decreases galanin mRNA expression and 
galanin-IR in the anterior PVN (Wang & Leibowitz, 1997) and plasma insulin levels are inversely 
associated with galanin-IR and mRNA expression in the PVN of normal and diabetic rats 
(Akabayashi et al, 1994). 
 
The reported effects of food deprivation (fasting) and food restriction on galanin gene expression are 
inconsistent. In Sprague-Dawley and Wistar rats, food deprivation has no effect on galanin mRNA 
levels in the ARC (Brady et al, 1990;Schwartz et al, 1993;O'Shea & Gundlach, 1991) or DMN 
(Schwartz et al, 1993;O'Shea & Gundlach, 1991), whereas chronic food restriction to 30% below ad-
libitum for two weeks, reduces galanin mRNA expression in the ARC (Brady et al, 1990). In the 
Zucker rat, most groups report that acute food deprivation has no effect on galanin peptide levels in 
specific hypothalamic nuclei examined. However, the concentration of galanin in the pPVN and ARC 
of obese Zucker rats is much greater than in lean Zucker rats, while concentrations in the median 
eminence are much lower (Beck et al, 1993;Mercer et al, 1996;Jhanwar-Uniyal & Chua, 1993). Food 
deprivation in obese Zucker rats induces hypothalamic expression of galanin mRNA (Jhanwar-Uniyal 
& Chua, 1993). Interestingly, high fat feeding of Zucker rats has no effect on galanin gene expression 
in lean animals but significantly reduces galanin mRNA levels in diet induced obese Zucker rats 
(Mercer et al, 1996).  
 
Clinical studies have reported that plasma galanin levels are higher in women with moderate obesity 
than in normal weight controls and that they correlate with leptin levels in these individuals 
(Baranowska et al, 1997;Baranowska et al, 2000). However, a study carried out by another group 
using similar methods reported no differences in plasma galanin levels (Invitti et al, 1995). The source 
of circulating galanin is unknown. It is not currently known whether alterations in circulating galanin 
concentrations contribute to the development of obesity or are a consequence of increased body 
weight. However, peripheral administration of galanin has no effect on food intake in rats, suggesting 
that circulating galanin does not influence food intake (Kyrkouli et al, 1986). 
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2.1.2 GALP AND ENERGY HOMEOSTASIS 
ICV administration of GALP to male rats causes a dose-dependent increase in food intake. The 
orexigenic effect of GALP is ten-fold more potent than that of galanin (Matsumoto et al, 2002) and is 
acute, lasting for only one hour. The orexigenic effect of GALP is exaggerated in diet induced obese 
rats fed on a high fat diet (Lawrence et al, 2002;Krasnow et al, 2003;Lawrence et al, 2003;Tan et al, 
2005). The specific hypothalamic nuclei involved in the orexigenic action of GALP are unclear. 
Several groups report that microinjection of GALP into the PVN and MPOA potently stimulates food 
intake, while injection into the ARC, DMN or LHA has no effect on food intake (Patterson et al, 
2006b;Seth et al, 2003;Taylor et al, 2009). However, one group suggests that while iDMN GALP 
stimulates feeding, injection into the PVN, LHA or ARC/VMH has no effect (Kuramochi et al, 2006). 
These discrepancies may be due to the slightly different co-ordinates used for intranuclear injection, 
or the different strains of rats used. It appears likely that GALP mediates its effect on food intake 
through multiple hypothalamic circuits. 
 
Within the rat ARC, both NPY and orexin containing axons are in close apposition with GALP-
containing cell bodies (Takenoya et al, 2002;Takenoya et al, 2003). Approximately 10% of GALP 
neurons in the rat ARC express the orexin-1 receptor, and in macaques, 42% express the NPY Y1 
receptor (Takenoya et al, 2003;Cunningham, 2004). GALP-IR terminals are in direct contact with 
orexin and MCH containing neurons in the LHA (Takenoya et al, 2003;Takenoya et al, 2005). 
Kuramochi et al suggested that NPY containing neurons in the DMN may mediate the stimulatory 
effects of GALP on food intake, as the orexigenic effects of ICV GALP are attenuated in DMN 
lesioned rats and ICV GALP activates fos expression in NPY-containing neurons of the DMN. 
Furthermore, ICV anti-NPY IgG and NPY Y1 receptor antagonists block the increase in feeding 
observed following ICV GALP administration (Kuramochi et al, 2006). It has also been reported that 
GALP stimulates NPY release from static hypothalamic explants (Seth et al, 2003). Similar 
experiments suggest that orexin neurons within the LHA may also play a role in mediating the 
orexigenic effect of GALP. Again, Fos-IR was expressed in orexin neurons in the LHA following 
ICV GALP, and anti-orexin IgGs markedly inhibited GALP induced hyperphagia (Kageyama et al, 
2006). It is possible that both of these mechanisms contribute to the acute orexigenic effect of central 
GALP administration. 
 
Dopamine containing neurons of the MPOA have also been implicated in mediating the orexigenic 
effect of central GALP administration (Patterson et al, 2006b;Taylor et al, 2009). Specific elimination 
of dopaminergic neuronal inputs to the MPOA attenuates the effect of ICV GALP on food intake 
(Taylor et al, 2009).  
85 
 
 
Central GALP has also been reported to influence feeding in mice. However, in mice, GALP appears 
to inhibit food intake, albeit inconsistently, and reduce body weight (Hansen et al, 2003;Krasnow et 
al, 2003;Krasnow et al, 2004;Man & Lawrence, 2008a). Administration of GALP to mice was carried 
out under anaesthesia in these studies which may disguise any acute orexigenic effect of GALP. 
However, these anorectic effects may also be attributable to the impaired motor behaviour observed 
following administration of GALP to mice (Krasnow et al, 2003;Kauffman et al, 2005). Acute ICV 
administration of GALP to ob/ob mice induces a prolonged decrease in food intake and body weight 
lasting 4 days post-injection, while chronic ICV administration produces a sustained decrease in body 
weight (Hansen et al, 2003). A significant reduction in 24 hour food intake and body weight 
following ICV GALP administration has also been reported in rats (Krasnow et al, 2003;Lawrence et 
al, 2002;Taylor et al, 2009), although this has not been consistently observed (Kuramochi et al, 
2006;Lawrence et al, 2003). It seems possible that the reported anorectic effects of GALP are 
secondary to non-specific behavioural effects, which may mask any orexigenic effect. 
 
ICV GALP administration also causes a prolonged rise in core body temperature, mediated by 
prostaglandins in both rats and mice (Lawrence et al, 2002;Hansen et al, 2003;Man & Lawrence, 
2008b). This effect is associated in ob/ob mice with an increase in uncoupling protein 1 mRNA and 
protein in brown adipose tissue compared to pair-fed control animals, suggesting an effect on 
thermogenesis (Hansen et al, 2003). An increase in metabolic rate as shown by increased oxygen 
consumption has also been reported in rats following GALP infusion (Rich et al, 2007). 
 
The anorectic and febrile effects seen following central GALP administration in rodents have been 
likened to the responses seen in infection and inflammation; the prostaglandin mediated increase in 
core body temperature and anorexia induced by GALP are similar in intensity and timing to those 
produced by the cytokine interleukin-1 (IL-1). Man et al recently demonstrated that central GALP 
administration to rodents induces IL-1α and IL-1β expression in periventricular microglia, and that the 
anorectic and febrile effects of GALP are mediated by IL-1 acting via the IL-1 receptor 1 in the brain 
(Man & Lawrence, 2008a). The physiological or pathological relevance of these effects of GALP 
remain to be determined. 
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2.1.2.1 GALP REGULATION BY INSULIN 
The distribution of GALP containing neurons in the hypothalamus overlaps with the distribution of 
neurons expressing the insulin receptor and insulin receptor substrate-1, although no studies have 
specifically localised insulin receptors on GALP neurons. GALP may be regulated by insulin. 
Streptozotocin-induced diabetic rats, which have low circulating insulin, and diabetic fa/fa rats, which 
are insulin resistant, have reduced GALP mRNA expression in the ARC, and treatment with 
peripheral insulin restores GALP mRNA levels to those of controls (Fraley et al, 2004a;Saito et al, 
2004). Food deprivation and treatment with 2-deoxy-D-glucose, an anti-metabolite which mimics a 
state of glucose deprivation, reduces GALP mRNA expression in the ARC of rats, an effect reversible 
by administration of insulin (Fraley et al, 2004a;Fraley, 2006). Circulating GALP-IR is also reduced 
by fasting in mice, in conjunction with a reduction in transport of GALP across the BBB. 
Administration of glucose increases GALP entry across the BBB consistent with an important role for 
GALP in regulating food intake (Kastin et al, 2001).  
 
2.1.2.2 GALP REGULATION BY LEPTIN 
The distribution of GALP mRNA in the ARC overlaps with the distribution of leptin receptor mRNA, 
and co-localisation studies have revealed that approximately 85% of rat and 98% of macaque ARC 
GALP neurons express the leptin receptor (ObRb) (Cunningham et al, 2002;Jureus et al, 
2000;Takatsu et al, 2001). Acute food deprivation and chronic food restriction induce a decrease in 
hypothalamic GALP mRNA in rats and macaques, which has been shown to be reversible by 
peripheral or central leptin administration in rats (Jureus et al, 2000;Cunningham et al, 2004b;Fraley 
et al, 2004a;Johansson et al, 2008). Furthermore, leptin deficient ob/ob mice have 70% less GALP 
mRNA expression in the hypothalamus compared to wild-type animals, and central (lateral ventricle) 
injection of leptin increases GALP mRNA content in the ARC five-fold in these animals (Jureus et al, 
2001). This suggests that GALP mRNA expression is induced by leptin through a direct action on the 
brain. Obese fa/fa rats and db/db mice, which both have a dysfunctional leptin receptor, also have 
decreased hypothalamic GALP mRNA and peptide concentration, and fewer GALP positive cells in 
the ARC (Kumano et al, 2003;Shen & Gundlach, 2004;Saito et al, 2004). In another model of 
impaired leptin signalling, hypoleptinaemic (and hypoinsulinaemic) streptozotocin-induced diabetic 
rats also have reduced ARC GALP mRNA levels (Shen & Gundlach, 2004;Fraley et al, 2004a). In 
vitro studies reveal that leptin stimulates GALP release from male hypothalamic explants (Seth et al, 
2004). 
 
GALP may therefore be regulated by leptin. However, the effects of leptin on GALP appear counter-
intuitive if GALP is orexigenic as experiments in rats suggest (Matsumoto et al, 2002). It is possible 
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that the regulation of GALP by leptin is related to a role for GALP in the reproductive axis, rather 
then in feeding. This aspect of GALP action will be discussed in detail in chapter 3. Alternatively, it is 
possible the reported anorectic effects of GALP discussed above reflect a physiological role in 
mediating the suppressive effects of leptin on appetite.  
 
 
2.1.3 OTHER GALANIN RELATED PEPTIDES AND FOOD INTAKE 
There have been no studies carried out investigating the role of central GMAP in energy homeostasis. 
At a time when the role of galanin in energy homeostasis was being explored, GMAP was not 
commercially available and is difficult to produce by solid phase peptide synthesis as it is such a large 
peptide (Xu et al, 1996).  
 
While these studies were being conducted, there was no published data regarding the effects of alarin 
on energy homeostasis. 
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2.1.4 GALANIN RECEPTOR MEDIATING EFFECTS ON FEEDING 
The galanin receptor or receptors responsible for mediating the effects of galanin and GALP on food 
intake are unknown. GalR1 and GalR2 knockout mice have not been reported to display any marked 
energy homeostasis-related phenotype (Jacoby et al, 2002;Krasnow et al, 2004), but it has been 
suggested that GalR1-knockout mice are unable to adjust food intake in response to acute changes in 
dietary fat (Zorrilla et al, 2007). In addition, levels of GalR1 mRNA are increased in the PVN 
following glucose and fat deprivation (Gorbatyuk & Hokfelt, 1998a). Thus GalR1 may oppose 
positive energy balance or help to maintain neutral energy balance, although further studies are 
required to determine a mechanism for this effect of GalR1 signalling. 
 
Central administration of the GalR2/3 agonist AR-M1896, or the GalR2 preferring ligand galanin 2–
29, has no effect on food intake in rats (Man & Lawrence, 2008b;Seth et al, 2003;Wang et al, 1998a), 
suggesting that the GalR1 or an unknown receptor is most likely to mediate the orexigenic effects of 
galanin and GALP.  
 
GALP is ten times more potent than galanin for the stimulation of food intake (Lawrence et al, 2002). 
The affinity of galanin to the GalR1 receptor is about 40-fold higher than that of GALP; therefore, it 
is unlikely that the GalR1 mediates the effect of GALP on food intake. Since GALP has a high 
affinity for the GalR2 receptor, the GalR2 receptor could mediate GALP-induced feeding behaviour. 
However, the affinities of galanin and GALP to the GalR2 receptor are almost equal. Assuming that 
GalR2 mediates the effect of GALP, this does not explain the difference of potency in feeding 
between galanin and GALP. Additionally, although both galanin and GALP have an acute stimulatory 
effect on food intake in the rat, only GALP has a suppressive effect on feeding and body weight after 
24 h (Lawrence et al, 2002) suggesting activation of different pathways by galanin and GALP. 
 
These results suggest the possible existence of unknown receptors that mediate feeding by GALP 
and/or galanin. 
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2.2 HYPOTHESIS 
I propose that alarin functions as a hypothalamic neurotransmitter which regulates appetite and 
reproductive function.  
 
2.2.1 AIMS  
Alarin, like other members of the galanin-family of peptides may influence energy homeostasis. Both 
galanin and GALP have orexigenic actions when administered centrally in rats. The mechanisms by 
which galanin and GALP are thought to stimulate feeding differ considerably. The effect of ICV 
administration of alarin on food intake has not been investigated. I hypothesise that central 
administration of alarin will influence food intake in rats. To test this hypothesis I will 
 
1) Determine the effects of central administration of alarin on food intake in rats 
2) Determine the effects of central administration of alarin on behaviour in rats 
3) Investigate the mechanisms by which alarin mediates its effect on feeding in rats 
4) Investigate whether alarin is a physiological regulator of appetite in the rat 
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2.3 MATERIALS AND METHODS 
 
2.3.1 MATERIALS 
Rat alarin (used in all studies unless specified otherwise) was synthesised by BioMol International LP 
(Exeter, UK). The peptide was synthesised on a TentaGel® resin, using an Fmoc/t-butyl-based solid-
phase synthesis strategy. The product was purified by reversed-phase preparative high performance 
liquid chromatography (HPLC) followed by lyophilisation. Analysis of the purified product by 
reverse-phase HPLC and by mass spectrometry showed above 90% purity (molecular weight 2820.8). 
The peptide was not C-terminally amidated. Angiotensin II, GALP, Neuromedin U (NMU), NPY and 
[Nle4,D-Phe7]-α-MSH (NDP-MSH) were purchased from Bachem UK Ltd. (Merseyside, UK). 
Cannulation materials were purchased from PlasticsOne, Inc. (Roanoke, VA). Reagents for explant 
experiments were purchased from BDH (Poole, UK) and Invitrogen Ltd (Paisley, UK). Alarin ELISA 
kit was purchased from Peninsula Laboratories, LLC. (Bachem Group, San Carlos, CA).  
 
2.3.2 ANIMALS 
Adult male Wistar rats (Charles River, Bicester, UK) were maintained in individual cages under 
controlled temperature (21-23°C) and light (12 hours light, 12 hours dark, lights on at 7am) with ad-
libitum access to food (pelleted rat chow, RM1 diet (SDS, UK Ltd, Witham, UK) and water. All 
animal procedures performed were approved by the British Home Office Animals (Scientific 
Procedures) Act 1986 (Project licence number 70/6402). For all studies rats were randomised into 
groups of approximately equal mean body-weight (within 1g). Body-weight and food intake were 
measured daily. Food was weighed on balances accurate to 0.01g (Adam Equipment, Milton Keynes, 
UK). Animals which were considered unwell, or had reduced bodyweight or low food intake were 
excluded from studies. 
 
2.3.3 IN VIVO STUDIES 
 
2.3.3.1 INTRACEREBROVENTRICULAR CANNULATION  
Animals were anaesthetised using injectable anaesthetic drugs. Animals were given an intraperitoneal 
(IP) injection of xylazine (Rompun 12mg/kg, Bayer UK Ltd, Bury St Edmonds, UK) and ketamine 
(Ketalar 60mg/kg, Parke-Davis, Pontypool, UK) in a 2:5 ratio.  
Prophylactic antibiotics were administered to prevent post-operative infection. An intraperitoneal 
injection of amoxycillin sodium (37.5 mg/kg) and flucloxacillin (37.5 mg/kg) was given prior to 
surgery. Animals were then placed in a Kopf stereotaxic frame (David Kopf instruments, supplied by 
Clark Electromedical Instruments, Kent, UK) with the incisor bar set at 3mm below the interaural 
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line. The head was cleaned with 10% w/v povidone/iodine solution (Betadine, Seton Scholl 
Healthcare, UK). A 1.5cm incision was made in the scalp and the skull surface exposed by removal of 
the periosteum. A hole was drilled 0.8mm posterior to the bregma using a handheld electric drill 
(David Kopf Instruments) and a permanent 22-gauge stainless steel cannula (Plastics One Inc) was 
stereotaxically implanted 6.5mm below the skull into the third cerebral ventricle. Three stainless steel 
jewellers’ screws were secured into the skull in three additional drill holes to anchor the dental cement 
(Associated Dental Products Ltd) used to seal the wound and hold the cannula in position. The rats 
were rehydrated by an i.p. injection of 0.9% saline (5 ml/rat). Animals received a single subcutaneous 
injection of buprenophrine (45 mg/kg, Schering-Plough Corp, Welwyn Garden City, UK) for 
analgesia post-operatively. A plastic-topped wire cap (Plastics One Inc.) was then inserted into the 
cannula to prevent blockage.  
Following a seven day recovery period, the animals were handled daily for one week to minimise the 
stress response following injection. Correct cannula placement was confirmed by a positive 
dipsogenic response to the administration of angiotensin II (50 ng per animal) (Epstein et al, 1970).  
 
2.3.3.2 INTRACEREBROVENTRICULAR INJECTION 
In all ICV feeding studies, peptides were administered in a volume of 5 µl at a rate of 120 µl per hour 
to conscious, freely moving animals via a stainless steel injector projecting 1 mm beyond the tip of 
the cannula. The injector was connected by polythene tubing to a Hamilton syringe (Fisher Scientific, 
Leicestershire, UK) in a Harvard infusion pump (Harvard Apparatus, Massachusetts, USA). The 
tubing was filled with water and an air bubble drawn up to separate the experimental compound from 
the water. Each experimental group was injected by a single individual. This minimises cross-
contamination of peptides between injections and allows all animals to be injected within a relatively 
short time period (< 1 hour), resulting in daily fluctuations in food intake having little effect. Each 
individual would typically inject up to 20 animals. Following injection, animals were returned to their 
home cages with a pre-weighed amount of chow and free access to water.  The remaining food was 
reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body-weight was measured at 0 hour and 24 hours 
post-injection.  
Cannulated animals were used in multiple experiments, receiving a maximum of 10 injections. The 
minimum washout period between injections was 72 hours.  
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2.3.3.3 EFFECT OF ICV ALARIN ON FOOD INTAKE IN AD-LIBITUM FED MALE RATS 
BEFORE THE EARLY DARK PHASE  
To observe whether alarin effects food intake during the natural feeding period of the rat, ad-libitum 
fed male Wistar rats were injected ICV with 0.9% saline, alarin (3, 10, 30 or 90 nmol), or 3 nmol 
[Nle4,D-Phe7]-α-MSH (NDP-MSH) (positive control) (Brown et al, 1998) before the onset of the 
dark phase (1900h) (n = 9-10 saline and alarin, n = 5 NDP-MSH).  
 
2.3.3.4 EFFECT OF ICV ALARIN ON FOOD INTAKE IN FASTED MALE RATS DURING 
THE EARLY LIGHT PHASE 
Overnight fasted male Wistar rats received a single ICV injection of either 0.9% saline, alarin (3, 10, 
30 or 90 nmol), or 3 nmol NDP-MSH (positive control) between 0900 and 1000h (n = 7-9 saline and 
alarin, n = 4 NDP-MSH). 
 
2.3.3.5 EFFECT OF ICV ALARIN ON FOOD INTAKE IN AD-LIBITUM FED MALE RATS 
DURING THE EARLY LIGHT PHASE 
Groups of ad-libitum fed male Wistar rats were ICV injected with either 0.9% saline, alarin (3, 6, or 
30 nmol), or 2.4 nmol NPY (positive control) (Levine & Morley, 1984) during the early light phase 
between 0900 and 1000h (n = 8-10 saline or alarin, n = 5 NPY).   
 
2.3.3.6 EFFECT OF ICV ALARIN ON BEHAVIOUR IN AD-LIBITUM FED MALE RATS IN 
THE EARLY LIGHT PHASE 
Ad-libitum fed male Wistar rats received a single ICV injection of 0.9% saline, 30 nmol alarin, 1 nmol 
GALP or 3 nmol neuromedin U (NMU) (positive control) (Wren et al, 2002) (n = 10 saline, alarin and 
GALP, n = 5 NMU) in the early light phase (0900-1000h). The dose of alarin was chosen based on 
data from the feeding studies described in sections 2.3.3.3-2.3.3.5. Behavioural patterns were 
monitored continuously for 120 minutes after injection by observers blinded to the experimental 
treatment. Behaviour was classified into ten different categories: feeding, drinking, grooming, 
burrowing, rearing (defined as stationary with front paws elevated), locomotion (defined as moving 
around the cage with all four paws moving), head down, pica (defined as eating of non-food 
substances), tremor and sleeping, using a method adapted from (Fray et al, 1980). During the analysis, 
each rat was observed for 15 seconds every 5 minutes. This 15 second period was subdivided into 
three 5 second periods, and the behavior of the rat during each time period was noted. Each rat had a 
total of 36 behaviours recorded per hour. These methods have previously been used to detect 
abnormal behavior following central nervous system administration of appetite-effecting 
neuropeptides (Wren et al, 2002;Abbott et al, 2001).  
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2.3.4 IN VITRO STUDIES  
 
2.3.4.1 EFFECT OF ALARIN ON NEUROPEPTIDE RELEASE FROM MEDIAL BASAL 
HYPOTHALAMIC EXPLANTS 
Hypothalamic explants were used to determine the effect of alarin on hypothalamic neuropeptide 
release using an established method (Beak et al, 1998). Adult male Wistar rats were maintained in 
cages of five under standard conditions as described in section 2.3.2. 
Rats were killed by decapitation. The brain was rapidly dissected and mounted, ventral side 
uppermost, onto a platform using superglue (Loctite). This was then placed in a vibrating microtome 
(Campden Instruments, Loughborough, UK) where the brain was bathed at 4°C in oxygenated 
artificial cerebrospinal fluid (aCSF) (appendix). A 1.9mm slice was taken from the base of the brain 
to include the PVN and the POA. The hypothalamic tissue was then dissected free, bordered 
anteriorly by the POAs, laterally by the hypothalamic fissures and at the posterior by the mammillary 
bodies, and transferred to a 12 x 75mm polypropylene tube containing 1ml aCSF equilibrated with 
95% O2 and 5% CO2 and maintained on a static platform in a water bath at 22°C until all explants had 
been dissected. At the start of the experiment, the temperature of the water bath was increased to 
37°C. The hypothalami were then pre-incubated for 120 minutes, with the aCSF replaced after 60 
minutes. Tissues were then exposed to the test substance or to aCSF (basal period) for 45 minutes in 
600 µl aCSF. Treatment was then reversed so tissues having received the test substance then 
underwent a basal period and vice versa for a further 45 minutes. Finally, the viability of the tissue 
was verified by a 45 minutes exposure to aCSF containing 56 mM KCl; isotonicity was maintained by 
substituting K+ for Na+. The aCSF was removed at the end of each incubation period and frozen at -
80°C until determination of release of NPY, αMSH, and CART by radioimmunoassay as described in 
section 2.3.5.1. Explants not showing an increase in peptide release following 56 mM KCl treatment 
were excluded from the analysis.  
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2.3.4.2 PRINCIPLES OF RADIOIMMUNOASSAY 
Radioimmunoassay (RIA) is a technique used for the measurement of a wide range of materials 
including hormones. The basic principle of the assay is based on competition between unlabelled and 
radioactively labelled antigen (peptide) for an antibody binding site. Specificity is dependent on the 
ability of the antibody to recognize subtle structural features of the antigen molecule. The most 
commonly used radiolabel is 125Iodine (125I), and antibodies are often obtained by immunising rabbits 
with antigen (often a peptide) plus adjuvant (though polyclonal antibodies from other species and 
monoclonal antibodies can be used). In the RIA both the labelled peptide and antibody are at specific 
concentrations. The concentration of antibody is limiting so antigen binding will be finite. The 
unlabelled peptide in a sample will compete with labelled peptide for antibody binding. Thus the 
amount of radiolabelled antigen bound to the antibody is inversely proportional to the amount of 
unlabelled antigen in the sample being examined, allowing the amount of unlabelled peptide in a 
sample to be determined. A ‘standard curve’ is determined using known concentrations of pure 
peptide to calculate the percentage of labelled peptide bound for each concentration of unlabelled pure 
peptide. Separation of the unbound radiolabelled antigen from the radiolabelled antigen-antibody 
complex and counting of the proportion of radiolabel present in the two fractions allows direct 
measurement of the amount of unlabelled antigen that has bound to the antibody. By reference to the 
standard curve, the unknown concentrations of peptide in the sample can be obtained by interpolation 
(Thorell & Larson, 1978). 
Various techniques exist which enable antibody-bound antigen to be distinguished from free antigen, 
allowing the distribution of the radioactive antigen between the two fractions to be determined. The 
two methods used in this work are separation by adsorption with charcoal (free radiolabelled antigen 
is contained in the charcoal pellet following centrifugation), or using a primary antibody/secondary 
antibody complex (free label is contained in the supernatant following centrifugation).  
For charcoal separation, dextran is added to a charcoal suspension (appendix) to block the larger holes 
in the porous charcoal. Suspension containing 4mg of charcoal/tube (250 µl) is then added to each 
RIA tube, where it traps the free radiolabelled antigen. The tubes are then centrifuged for 20 minutes 
at 1500g and the supernatant (containing antibody-bound complex) and carbon pellet (free 
radiolabelled antigen) are separated by aspiration, and the bound and free label counted in a gamma 
(γ) counter (model NE1600, Thermo Electron Corporation). Peptide concentrations in the samples 
were calculated using a non-linear plot (RIA Software, Thermo Electron Corporation) and results 
calculated in terms of the NIDDK standard preparations.  
With the secondary antibody separation method, the secondary antibody is derived from an animal 
species different from that used to generate primary antibody. For example, the LH primary antibody 
is raised in a rabbit, and separation is achieved using a sheep anti-rabbit secondary antibody. For all 
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the assays described in this report, the secondary antibody used is sheep anti-rabbit solid phase second 
antibody (Pharmacia Diagnostics, Uppsala, Sweden). The samples were pre-incubated for 60 minutes 
with 100 µl of secondary antibody. Immediately prior to centrifugation, 500 µl of 0.01% Triton-X-
100 solution, and 100 µl of 10% polyethylene glycol (appendix) was added to each tube. The samples 
were then centrifuged at 1500g at 4°C for 20 minutes. Bound and free label were then separated using 
a Pasteur pipette and both the pellet and supernatant counted for 180 seconds in a γ counter as 
described above. 
Each RIA has optimum conditions regarding type of buffer used, assay volume, antibody titre, 
incubation time, temperature and separation method used. The in-house departmental assays used are 
usually incubated at 4°C for 3-5 days.  
All samples were assayed in duplicate. Non-specific binding tubes which do not contain antibody 
were included at the beginning of the assay. Tubes containing half and twice the standard volume of 
added labeled antigen were also included to confirm the quality of the radiolabel. To measure and 
correct for baseline drift, tubes with no sample (zero tubes) were placed at regular intervals 
throughout the assay and standard curves set up at both the beginning and the end of each assay. The 
analytical sensitivity of each assay was determined by the smallest change in hormonal concentration 
that can be reliably detected, essentially governed by the drop in the standard curve and the error of a 
given known value on the curve. The analytical sensitivity was calculated as the smallest standard 
curve value measured which is 2 standard deviations from the zero standard, which contains no 
unlabelled peptide (95% confidence limits) (Thorell & Larson, 1978). 
 
2.3.4.2.1 HYPOTHALAMIC NEUROPEPTIDE RIAS 
The peptides used were purchased from Phoenix Pharmaceuticals or Bachem. All other reagents and 
materials were supplied by Sigma (Poole, Dorset, UK) or BDH (Poole, Dorset, UK). Standard curves 
prepared for each assay used synthetic peptide made up to varying concentrations in assay buffer and 
added in duplicate at volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100 µl. 
Peptides were iodinated using the iodogen method and purified by Prof. M. Ghatei  (Owji et al, 1995). 
Reaction products were purified by high performance liquid chromatography (HPLC) (Gilson 321-
H1) using a C18 column (Waters, Milford, CT, USA). Fractions were tested by RIA and used at 1500 
counts per minute/tube (cpm/tube). 
Antisera were raised in rabbits immunized with each peptide conjugated to Freund’s adjuvant as 
described previously (White, 1963). 
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2.3.4.2.1.1 NPY RIA 
NPY peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the NPY assay 
were made up to 1 pmol/ml in assay buffer. The assay was carried out in 0.06 M phosphate buffer 
with 1% BSA and 0.02% Tween 20. Sample volume of hypothalamic aCSF was 20 µl and samples 
were assayed in duplicate in a total volume of 350 µl, containing a rabbit anti-NPY antibody at a final 
dilution of 1:120,000 and 1500cpm/tube of iodinated NPY. The antiserum showed full cross reactivity 
to synthetic NPY. The assays were incubated at 4°C for 72 hours, before free and antibody bound 
peptide were separated using a secondary antibody. The intra- and interassay variation was 7% and 
8% respectively. 
 
2.3.4.2.1.2 α-MSH RIA 
Alpha-MSH peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the α-MSH 
assay were made up to 0.2 pmol/ml in assay buffer. The assay was carried out in 0.06 M phosphate 
buffer containing 0.3% BSA. Sample volume of hypothalamic aCSF was 100 µl and samples were 
assayed in duplicate in a total volume of 400 µl, containing a rabbit anti-α-MSH antibody at a final 
dilution of 1:20000 and 1500cpm/tube of iodinated α-MSH. The antiserum showed full cross 
reactivity to synthetic α-MSH but no cross reactivity to any other POMC product. The assays were 
incubated at 4°C for 72 hours, before free and antibody bound peptide were separated by charcoal 
adsorption of the free fraction. The sensitivity of the assay was 1 fmol/ml. The intra- and interassay 
variation was 7% and 8% respectively. 
 
2.3.4.2.1.3 CART RIA 
CART peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the CART assay 
were made up to 1 pmol/ml in assay buffer. The assay was carried out in 0.06 M phosphate buffer 
containing 0.3% BSA and 0.02% Tween 20. Sample volume of hypothalamic aCSF was 20 µl and 
samples were assayed in duplicate in a total volume of 350 µl, containing a rabbit anti-CART 
antibody at a final dilution of 1:80000 and 1500cpm/tube of iodinated CART. The assays were 
incubated at 4°C for 72 hours, before free and antibody bound peptide were separated by charcoal 
adsorption of the free fraction. The sensitivity of the assay was 1.25 fmol/tube. The intra- and 
interassay variation was 8% and 9% respectively. 
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2.3.4.3 THE EFFECT OF FASTING ON HYPOTHALAMIC ALARIN 
IMMUNOREACTIVITY 
 
2.3.4.3.1 RAT HYPOTHALAMIC TISSUE 
Adult male Wistar rats were maintained in cages of five under standard conditions as described in 
section 2.3.2. Rats were either fasted for 24 hours, or ad-libitum fed prior to decapitation in the early 
light phase (n = 12-15 per group). The hypothalamus was rapidly dissected out, weighed and 
immediately snap frozen in liquid nitrogen and stored at -80°C until extraction. 
 
2.3.4.3.2 ACETIC ACID EXTRACTION 
Extraction of peptides is carried out under acidic conditions as a number of proteolytic enzymes are 
inactivated at low pH. This method of extraction has been shown to give the highest yield of 
neuropeptides including NPY and VIP (El-Karim et al, 2003). Hypothalami were extracted by boiling 
for 15 minutes in 500 µl of 0.5M acetic acid (appendix). Extracts were stored at -80°C until assay for 
alarin. 
 
2.3.4.3.3 ALARIN ELISA 
Alarin ELISA was used according to the manufacturer’s instructions. Varying concentrations of 
human alarin standard (0.04-25 ng/ml) (50 µl) or rat hypothalamic acetic acid extract (50 µl) was 
added to wells of an immunoplate, and antiserum to human alarin added to each well. Following one 
hour incubation at room temperature, a set concentration of biotinylated tracer was added to each well 
to compete for binding specifically to the antiserum, and samples were incubated for a further two 
hours. The immunoplate was then washed five times using an ELISA buffer before streptavidin-
conjugated horseradish peroxidase (SA-HRP) was added to each well and samples were incubated for 
an hour. SA-HRP binds captured biotinylated tracer. After a further washing step with buffer, 
3,3’,5,5’-tetramethyl benzidine dihydrochloride (TMB) was added to each well and the plate was 
incubated for 30 minutes. Addition of TMB produces a soluble coloured product. The reaction was 
terminated by addition of 2 N HCl. Absorbance was read at 450 nm within ten minutes using a plate 
reader (Labsystems Multiskan MS, Cambridge, UK). The concentration of alarin-like 
immunoreactivity in hypothalamic extract samples was determined using the standard curve. Cross 
reaction of peptide in this ELISA was 100% with alarin and 0% with GALP (human). 
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2.3.5 STATISTICS 
All data is presented as mean ± standard error of the mean (SEM). Data from the feeding studies were 
analysed using a one-way ANOVA (analysis of variance) with post-hoc Dunnett’s multiple 
comparison test (GraphPad Prism 5). As behavioural observation data were not normally distributed, 
Kruskal-Wallis one-way ANOVA on ranks was used for comparisons between treatment groups 
(Systat 11, San Jose, CA). Data from the hypothalamic explant studies were compared by paired 
Student t-test between the basal and the test period. For NPY, these data were pooled from three 
separate experiments in order to generate an n number of approximately 24 per group. In each 
individual experiment, explants act as their own control. In all cases, P<0.05 was considered to be 
statistically significant. 
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2.4 RESULTS 
 
2.4.1 EFFECT OF ICV ALARIN ON FOOD INTAKE IN AD-LIBITUM FED MALE RATS 
BEFORE THE EARLY DARK PHASE  
There was no significant effect of ICV alarin (3, 10, 30 or 90 nmol) administered before the onset of 
the dark phase on food intake 0-1 h post-injection in rats. NDP-MSH (3 nmol) significantly reduced 
0-1h and 0-24h food intake. (0-1 h food intake/g: saline 2.2 ± 0.3, NDP-MSH (3 nmol) 0.3 ± 0.1 
P<0.05. 0-24 h food intake/g: saline 23.0 ± 1.8, NDP-MSH (3 nmol) 8.5 ± 0.6 P<0.001, n = 9-10 
saline and alarin, n = 5 NDP-MSH) (Figure 2.1A and B). There was no significant effect of alarin on 
food intake at any other dose or time point studied. There was no significant effect of alarin on body 
weight at 24h. The highest dose of alarin (90 nmol) caused several of the animals within this group to 
appear unwell immediately following the injection. 
 
2.4.2 EFFECT OF ICV ALARIN ON FOOD INTAKE IN FASTED MALE RATS DURING 
THE EARLY LIGHT PHASE 
There was no significant effect of ICV alarin (3, 10, 30 or 90 nmol) on food intake 0-1 h post-
injection in fasted rats. NDP-MSH (3 nmol) significantly reduced food intake. (0-1 h food intake/g: 
saline 4.9 ± 0.4, NDP-MSH 3 nmol 2.7 ± 0.1 P<0.05, n = 7-9 saline and alarin, n = 4 NDP-MSH) 
(Figure 2.2A). ICV alarin (90 nmol) significantly reduced food intake between 0-24 h post-injection 
(0-24 h food intake/g: saline 32.8 ± 1.8, alarin 90 nmol 23.8 ± 2.2 P<0.05, n = 7-9 saline and alarin, n 
= 4 NDP-MSH) (Figure 2.2B). There was no significant effect of alarin on food intake at any other 
dose or time point studied. There was no significant effect of alarin on body weight at 24 h. The 
highest dose of alarin (90 nmol) caused several of the animals within this group to appear unwell 
immediately following the injection. 
 
2.4.3 EFFECT OF ICV ALARIN ON FOOD INTAKE IN AD-LIBITUM FED MALE RATS 
DURING THE EARLY LIGHT PHASE 
ICV administration of alarin (30 nmol) and NPY (2.4 nmol) to ad-libitum fed male Wistar rats in the 
early light phase significantly increased food intake 0-1 h post injection compared to saline (0-1 h 
food intake/g: saline 0.6 ± 0.3, alarin (30 nmol) 3.1 ± 0.6 P<0.01, NPY 2.4 nmol 3.6 ± 1.1 P<0.01, n 
= 8-10 saline and alarin, n = 5 NPY) (Figure 2.3A). There was no significant effect of alarin on food 
intake at any other dose or time point studied (Figure 2.3B-F). There was no significant effect of 
alarin on body weight at 24 h. Alarin (30 nmol) was considered to be the most effective dose without 
any obvious adverse behavioural effects. 
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FIGURE 2.1 The effect of ICV injection of saline, alarin (3, 10, 30 or 90 nmol) (n = 9-10) or [Nle4,D-Phe7]-
α-melanocyte stimulating hormone (NDP-MSH) (3 nmol) (positive control) (n = 5 NDP-MSH) on 0-1h (A) and 
0-24h (B), food intake in ad-libitum fed male rats before the onset of the dark phase. *, P<0.05; ***, P<0.001 
vs. saline. Results are mean ± SEM.  
 
 
 
FIGURE 2.2 The effect of ICV injection of saline, alarin (3, 10, 30 or 90 nmol) (n = 7-9) or [Nle4,D-Phe7]-α-
melanocyte stimulating hormone (NDP-MSH) (3 nmol) (positive control) (n = 4 NDP-MSH) on 0-1h (A) and 0-
24h (B), food intake in fasted male rats in the early light phase. *, P<0.05 vs. saline. Results are mean ± SEM.  
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FIGURE 2.3 The effect of ICV injection of saline, alarin (3, 6, or 30 nmol) (n = 8-10 per group) or 
neuropeptide Y (NPY) (2.4 nmol) (positive control) (n = 5) on 0-1h (A), 1-2h (B), 2-4h (C), 4-8h (D), 8-24h 
(E), and 0-24h (F) food intake in ad-libitum fed male rats in the early light phase. ***, P<0.001 vs. saline. 
Results are mean ± SEM.  
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2.4.4 EFFECT OF ICV ALARIN ON BEHAVIOUR IN AD-LIBITUM FED MALE RATS IN 
THE EARLY LIGHT PHASE 
ICV administration of 30 nmol alarin had no significant effect on behaviours observed over a 2 hour 
period in ad-libitum fed male Wistar rats when injected in the early light phase compared to saline 
controls (n = 10 saline, alarin and GALP, n = 5 NMU) (Figure 2.4 and Table 2.1).  
Animals injected with 1 nmol GALP showed a significant reduction in grooming compared to saline 
injected animals in the 0-1 hour time period. NMU 3 nmol was used as a positive control. Animals 
that received NMU showed significant increases in grooming, locomotion and drinking and a 
significant decrease in rearing and sleeping compared to saline injected animals in the 0-1 hour time 
period (n = 10 saline, alarin and GALP, n = 5 NMU) (Table 2.1). 
Animals injected with alarin showed a significant increase in grooming, rearing and locomotive 
behaviour compared to GALP injected animals in the 0-1hour time period (Table 2.1).  
To estimate the time at which ICV alarin stimulates food intake within the first hour post-injection, 
the frequency of feeding behaviour observed following ICV administration of saline, alarin (30 nmol) 
and GALP (1 nmol) was analysed in 10 minute time bins. ICV alarin administration was associated 
with an increase in the frequency of feeding behaviour observed 20-30 and 30-40 minutes post-
injection compared to saline injected rats (Figure 2.5). 
   
 
 
FIGURE 2.4 The effect of ICV administration of saline (A) or alarin (30 nmol) (B) to ad-libitum fed male rats 
in the early light phase (n = 10 per group) on behaviour between 0-1h post injection. Animals were observed for 
15 seconds every 5 minutes and this 15-second period was subdivided into three. The behaviour of the rat during 
each time period was scored. Data are presented as % of total behaviours observed.  
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FIGURE 2.5 The effect of ICV administration of saline, alarin (30 nmol), or galanin like peptide (GALP) (1 
nmol) to ad-libitum fed male rats in the early light phase (n = 10 per group) on the frequency of feeding 
behaviour observed in each 10 minute time period between 0-1h post injection. Animals were observed for 15 
seconds every 5 minutes and this 15-second period was subdivided into three. The behaviour of the rat during 
each time period was scored. Data are presented as % of total behaviours observed.  
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TABLE 2.1 The effect of ICV administration of saline, 30 nmol alarin, 1 nmol galanin-like peptide (GALP), 
or 3 nmol neuromedin U (NMU) to ad-libitum fed male rats in the early light phase (n = 5-10 per group) on 
behaviour. Animals were observed for 15 seconds every 5 minutes and this 15-second period was subdivided 
into three. The behaviour of the rat during each time period was scored. Data are presented as median 
(interquartile range). a P < 0.05 vs. saline aa  P < 0.01 vs. saline aaa P < 0.001 vs. saline b P < 0.05 vs. GALP.  
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2.4.5 EFFECT OF ALARIN ON NEUROPEPTIDE RELEASE FROM HYPOTHALAMIC 
EXPLANTS IN VITRO   
Treatment with 100 nM alarin significantly increased NPY release from adult male rat hypothalamic 
explants in vitro compared with basal release (NPY: basal 100 ± 7.4%, 100 nM alarin 129.8 ± 10.2%, 
P<0.05, n = 16-24). At a lower dose (10 nM), or a higher dose (1000 nM), alarin did not significantly 
influence NPY release. Data are presented as a percentage of basal release. These data are pooled 
from three separate experiments (Figure 2.6A). Alarin had no statistically significant effect on αMSH 
or CART release from hypothalamic explants at any dose examined (Figure 2.6B and C). 
 
 
 
FIGURE 2.6 The effect of alarin (10, 100 or 1000 nM) on Neuropeptide Y (NPY) (n = 16-24) (A), alpha-
melanocyte stimulating hormone (αMSH) (n = 12-24) (B), or cocaine and amphetamine regulated transcript 
(CART) (n = 12-24) (C) release from hypothalamic explants from adult male rats. Data are presented as 
percentage of basal release, and are pooled from three separate experiments. *, P<0.05 Results are mean ± SEM. 
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2.4.6 THE EFFECT OF FASTING ON HYPOTHALAMIC ALARIN IMMUNOREACTIVITY 
There was no statistically significant difference between the levels of alarin-like IR in hypothalamic 
extracts from fed or fasted rats (hypothalamic alarin fmol/hypothalamus: fed 32.8 ± 5.2, fasted 33.5 ± 
4.9, n = 12-15 per group) (Figure 2.7). 
 
 
FIGURE 2.7 Alarin-like immunoreactivity in hypothalami taken from ad-libitum fed or 24 hour fasted male 
Wistar rats (n = 12-15 per group). Results are mean ± SEM.  
107 
 
2.5 DISCUSSION 
 
Alarin stimulates food intake in ad-libitum fed male rats following ICV administration in the early 
light phase. This is in accord with the orexigenic effect observed following ICV injection of other 
members of the galanin peptide family to rats (Matsumoto et al, 2002;Kyrkouli et al, 1986). 
 
While all doses of alarin administered to ad-libitum fed rats in the early light phase increased food 
intake at one hour post-injection, only the effect of the highest dose of 30 nmol of alarin reached 
statistical significance, with a mean food intake five fold greater than saline injected animals. Since 
rats are nocturnal, the light phase is not the natural feeding period and thus any stimulation of hunger 
circuits will be more apparent at this time. The orexigenic effect of alarin appears to be  relatively 
weak compared to well characterised hypothalamic orexigenic neuropeptides such as NPY and 
GALP, which potently stimulate food intake at doses of 0.5 nmol and 0.3 nmol respectively (Levine 
& Morley, 1984;Matsumoto et al, 2002). Indeed, the orexigenic effect of alarin is not observed in 
experimental paradigms where rats have a natural drive to eat, such as at the onset of the dark phase 
(the normal feeding period of the rat), or following an overnight fast. ICV GALP administration (1.5 
nmol) stimulates food intake in fasted rats, highlighting its more potent effect on food intake 
compared to alarin (Lawrence et al, 2002). 
 
The high dose of alarin required to stimulate food intake may be due to the lack of a target receptor in 
the immediate region surrounding the third ventricle. It is also possible that alarin acts only as a weak 
ligand at the receptor which mediates its effect on food intake. However, the endogenous receptor for 
alarin is currently unknown, and it is therefore impossible to ascertain whether this is the correct 
explanation. GALP is a more potent stimulator of appetite than galanin (Lawrence et al, 
2002;Matsumoto et al, 2002). GALP is reported to bind to all three galanin receptors with a lower 
affinity to the GalR1 and GalR2 than galanin, and a higher affinity than galanin for the GalR3 (Lang 
et al, 2005;Ohtaki et al, 1999;Smith et al, 1998). Evidence suggests that GALP also binds to one or 
more additional unknown receptors (Fraley et al, 2003;Lawrence et al, 2003;Seth et al, 2004). It is 
possible that alarin mediates its orexigenic effect via binding to the same unknown receptor as GALP. 
Therefore the discrepancy between the potency of GALP and alarin may be due to GALP binding at 
many receptors to mediate its effect on food intake, while alarin binds to only one receptor. I have 
carried out receptor binding studies determining whether alarin binds to the galanin receptors in 
chapter 4.  
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During the course of my studies, a paper was published reporting an orexigenic effect of lateral 
ventricle (LV) administration of alarin (Van Der Kolk et al, 2010a). In this study, LV administration 
of 1 and 5 nmol alarin significantly stimulated food intake between 0-30 minutes post-injection. At 2, 
3 and 4 hours, all doses of alarin (0.1, 0.5, 1 and 5 nmol) significantly increased cumulative food 
intake compared to vehicle, although not dose dependently. The doses of alarin used in this study 
were much lower than the doses that my studies required for an orexigenic effect. It is possible that 
the lateral ventricle is anatomically closer than the third ventricle to the brain region(s) mediating the 
effect of alarin on food intake, and therefore lower doses of alarin are sufficient to elicit an orexigenic 
effect. Alternatively, the use of C-terminally amidated synthetic alarin in these studies may account 
for the difference in potency of alarin between this study and my data. Amidation of a synthetic 
peptide enhances its biological activity by increasing resistance to breakdown by aminopeptidases, 
blocking against synthetase activity, and increasing permeability of cells compared to non-amidated 
synthetic peptides. The importance of amidation for biological activity is highlighted by the 
observation that more than half of known mammalian peptide hormones are amidated (Eipper & 
Mains, 1988). However, there is no reason that endogenous alarin would be amidated. The C-terminal 
residue of alarin is a serine. Endogenous amidation is catalysed by the bifunctional enzyme, 
peptidylglycine α-amidating monooxygenase (PAM), which converts peptides with the structure -X-
Gly to the form -X-NH2 (Eipper & Mains, 1988;Bradbury et al, 1982).  
 
My studies suggest that alarin increases food intake between 0-1 hour post injection, with no 
difference in food intake at any later time points studied. This is similar to the time course of food 
intake seen following ICV GALP injection, which has its maximal orexigenic effect at 30 – 60 
minutes post-injection (Tan et al, 2005). Interestingly, a closer examination of the behavioural 
analysis shows evidence of a doubling in the frequency of feeding behaviour in alarin injected animals 
between 30 to 60 minutes post-injection compared to the frequency observed in saline injected 
animals. More specifically, alarin injected animals have a much greater incidence of feeding 
behaviour between 30-40 minutes post injection, suggesting that there may be a 30 minute delay 
before alarin stimulates feeding. There is little difference in the frequency of feeding behaviour 
between saline and alarin injected animals up to 30 minutes. This effect of alarin on food intake is 
rapid and suggests a site of action local to the point of administration (third cerebral ventricle). In 
support of a hypothalamic site of action for the orexigenic effect of alarin, LV alarin administration 
induces Fos-IR in hypothalamic nuclei known to be involved in energy homeostasis (Van Der Kolk et 
al, 2010a). Fos-IR cells were observed in the PVN, DMN, LHA and ARC of alarin (1 nmol) injected 
rats. This dose of alarin elicited a significant increase in food intake in this study. The acute 
orexigenic effect of alarin provides another reason why the orexigenic effect of alarin may not be 
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apparent in feeding studies where rats already have a drive to eat. Fasted rats or rats at the onset of the 
dark phase presented with food have a very high food intake for the first hour, which might mask any 
orexigenic effects of alarin.  
 
My studies suggest that ICV alarin has no effect on cumulative food intake or body weight 24 hours 
after injection. This is in contrast to what has been reported regarding the effect of GALP, and more 
recently alarin, on body weight. LV alarin administration at a dose of 1 nmol, but not at any other 
dose, significantly increased body weight between 0-24 hours (Van Der Kolk et al, 2010a). The 
discrepancy between this study and my data may be due to differences in the route of administration 
of alarin, or the use of an amidated form of alarin used in these studies, as described above. Several 
studies have observed a significant reduction in 24 hour food intake, and almost all report a reduction 
in body weight following ICV GALP administration in rats (Krasnow et al, 2003;Lawrence et al, 
2002;Taylor et al, 2009). It is possible that the reduction in body weight observed following ICV 
GALP administration is due to activation of a receptor at which alarin does not bind. However, ICV 
galanin has no effect on body weight at 24 hours, and it is therefore unlikely to be any of the known 
galanin receptors which mediate this effect of GALP (Lawrence et al, 2002). Recent data reports c-
Fos protein expression in astrocytes surrounding the ventricles and periventricular regions following 
ICV GALP, a response not observed following ICV galanin (Lawrence et al, 2003). Astrocytes are 
involved in inflammatory responses to infection and injury in the brain and release cytokines such as 
interleukin-1 (IL-1) (Dong & Benveniste, 2001). Furthermore, ICV GALP (and galanin) 
administration has been associated with a prostaglandin mediated rise in core body temperature 
(Lawrence et al, 2002). ICV GALP administration induces IL-1 protein expression in the rat brain, 
and co-infusion of GALP with an IL-1 receptor antagonist partially reverses the reduction in food 
intake and body weight at 24 hours observed following ICV GALP administration to rats. 
Importantly, the IL-1 receptor antagonist had no effect on the acute orexigenic effect of GALP (Man 
& Lawrence, 2008a). These data suggest that the acute orexigenic effects and chronic catabolic effects 
of GALP are mediated by different mechanisms and that the chronic catabolic effects may reflect the 
activation by GALP of inflammatory pathways. It would be interesting to determine whether alarin 
has an effect on core body temperature and IL-1 release. 
 
Due to the lack of subtype specific galanin receptor agonists and antagonists, the receptor(s) which 
mediate galanin and GALP’s effects on feeding are still unknown. The orexigenic potency of GALP 
is ten times that of galanin. The affinity of galanin to the GalR1 receptor is about 40-fold higher than 
that of GALP. It is therefore unlikely that the GalR1 mediates the effect of GALP on food intake. The 
affinities of galanin and GALP to the GalR2 receptor are almost equal. Assuming that GalR2 
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mediates the effect of GALP, this does not explain the difference of potency in feeding between 
galanin and GALP. Additionally, Wang et al. reported that galanin (1–16), a GalR1 and GalR2 
selective ligand, has less potency than galanin for stimulating food intake, and ICV injection of 
galanin (2–29), which has a high affinity for GalR2 and GalR3, did not stimulate feeding behaviour. 
These results suggest the possible existence of as yet unidentified receptors that mediate feeding by 
GALP and/or galanin. However, it is also possible the in vitro pharmacodynamics of the galanin 
receptors do not reflect their in vivo activity. It is also possible that there are differences in the tissue 
availability of GALP and galanin following ICV administration.  
 
Substances can suppress feeding by producing adverse physiological effects such as pain, or nausea, 
or may increase food intake as a secondary effect of increased arousal (Nachman & Ashe, 1973;Ida et 
al, 1999). Analysis of behaviour is often used to investigate the specificity of feeding effects. For 
example, an increase in grooming is often associated with the activation of central stress pathways 
(Dunn et al, 1987), and an increase in locomotor activity and a decrease in sleep is associated with 
arousal (Jones et al, 2001). Orexigenic effects may reflect the activation of arousal pathways, rather 
than specific feeding circuits (Sakurai, 2007). My studies demonstrate that ICV alarin at the effective 
dose administered in the feeding studies (30 nmol) does not significantly affect locomotive or 
sleeping behaviours. This suggests a direct effect of alarin on feeding rather than a secondary effect. 
ICV GALP administration did cause behavioural effects; significant decreases in rearing and 
grooming were observed compared to saline injected control animals. GALP administration has 
previously been associated with a reduction in locomotor activity, though this has only been reported 
in mice (Kauffman et al, 2005), and seems at odds with the stimulatory effect of GALP on the 
sympathetic nervous system (Hansen et al, 2003). Furthermore, unpublished data from within our 
group has shown a reduction in locomotor activity following ICV GALP administration to rats using 
data obtained by the Comprehensive Laboratory Animal Monitoring System (CLAMS) (Personal 
communication from Dr Nina Semjonous). However, behaviour analysis following alarin 
administration did not reveal any reduction in locomotive behaviours compared to saline injected 
animals; in fact there was significantly more rearing and locomotive behaviours following alarin 
administration compared to GALP administration. This suggests that there are differences in the 
effects of these two related peptides, which may reflect differences in receptor activation or in vivo 
pharmacokinetics. 
 
I have shown that alarin (100 nM) stimulates NPY release from hypothalamic explants. Alarin had no 
significant effect on the release of other hypothalamic peptides known to be involved in the regulation 
of appetite α-MSH and CART. The orexigenic effect of alarin may therefore be mediated, at least in 
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part, by an increase in hypothalamic NPY release. It may be expected that an increase in NPY release 
would be accompanied by a decrease in αMSH release (Hahn et al, 1998). However alarin had no 
significant effect on αMSH release from hypothalamic explants. NPY is released from many nuclei of 
the hypothalamus, not all of which will inhibit αMSH. In a study of GALP-treated rat hypothalamic 
explants, GALP increased NPY release and also decreased CART release. In the same study GALP 
had no effect on α-MSH or AgRP release (Seth et al, 2003). It is interesting to note the discrepancies 
between alarin and GALP in the release of hypothalamic neuropeptides, as this may explain the 
difference in magnitude of their orexigenic effects. 
My data comparing alarin-IR in the hypothalami of fed and fasted rats suggests that alarin peptide 
levels are not altered by acute food restriction. A 24 hour fast will increase plasma leptin levels in rats 
(Vuagnat et al, 1998), and thus, this study suggests that leptin may not regulate hypothalamic alarin 
levels. However, isolating the whole hypothalamus and examining peptide levels in this brain region 
is not the most accurate method of investigating alterations in expression. A much more precise way 
to do this would be to take punch biopsies of different hypothalamic nuclei (Palkovits, 1986), as 
antagonistic changes in alarin in different areas would not be masked and potential nuclear specific 
changes would be measured at their magnitude. It would also be interesting to investigate the effect of 
fasting on alarin mRNA in addition to peptide expression as there is often a lack of correlation 
between mRNA and peptide expression (Gygi et al, 1999). The effect of fasting on alarin mRNA 
expression in specific hypothalamic nuclei could be investigated semi-quantitatively using in situ 
hybridisation of brain slices from fed and fasted rats. 
 
The levels of alarin-IR observed in the hypothalami from fed and fasted rats are much lower than 
reported levels of hypothalamic GALP and galanin IR (Kumano et al, 2003). The method of 
extraction used to determine hypothalamic galanin and GALP is different to the extraction method 
used to determine hypothalamic alarin levels, and it is possible that the method of extraction used in 
my studies results in a lower yield of all peptides. It would be necessary to determine levels of galanin 
and GALP using the extraction protocol used in these studies to directly compare relative 
hypothalamic peptide levels.  
 
The lack of alteration in hypothalamic alarin levels in response to fasting is in contrast to changes 
observed in GALP message. Acute food deprivation and chronic food restriction both induce a 
decrease in hypothalamic GALP mRNA in rats and macaques, which is reversible by either peripheral 
or central leptin administration in rats, demonstrating that leptin positively regulates hypothalamic 
GALP expression (Jureus et al, 2000;Cunningham et al, 2004b;Fraley et al, 2004a;Johansson et al, 
2008). It is not known whether fasting also decreases hypothalamic GALP peptide levels. It is unusual 
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that leptin positively regulates GALP, an orexigenic peptide. It is possible that leptin-responsive 
GALP neurons regulate functions other than food intake for example, neuroendocrine functions 
(Matsumoto et al, 2001). 
 
To determine whether alarin is a physiological regulator of feeding, it would be useful to examine the 
effect of ICV administration of alarin IgG. If a reduction in endogenous alarin signalling reduces food 
intake, this would suggest a physiological role for alarin in feeding. If the receptor at which alarin 
mediates its effects on feeding could be isolated, administration of an antagonist at this receptor could 
also be used to investigate the physiological role of alarin in the regulation of food intake. 
These data suggest that alarin, like other members of the galanin peptide family, stimulates food 
intake acutely following ICV injection. It is possible that alarin mediates its orexigenic effect via an 
increase in hypothalamic NPY. Given that the hypothalamus may be the site of action of the 
stimulatory effect of alarin on food intake, it would be interesting to investigate whether alarin has 
any effects on the neuroendocrine axes. Other members of the galanin peptide family are heavily 
implicated in the regulation of the hypothalamo-pituitary axes. 
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CHAPTER 3 
ALARIN AND THE NEUROENDOCRINE AXES 
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3.1 INTRODUCTION  
 
3.1.1 GALANIN PEPTIDE FAMILY AND THE NEUROENDOCRINE AXES 
There is extensive evidence suggesting that the galanin family of peptides regulate neuroendocrine 
function. Galanin has been implicated in the regulation of the HPG, HPA, HPT and growth axes, and 
in the neuroendocrine control of prolactin secretion (Merchenthaler, 2008). GALP has a relatively 
well-characterised role in the regulation of the HPG axis, while its roles in other neuroendocrine axes 
are not so well understood. The presence of galanin-IR in the hypothalamus and median eminence, 
and its co-localisation with known hypophysiotrophic hormones, suggests that galanin may regulate 
anterior pituitary function. The discrete distribution of GALP-IR in the ARC, median eminence and 
posterior lobe of the pituitary is suggestive of a role for GALP in the regulation of neuroendocrine 
axes. GALP and galanin expression is directly regulated by leptin (Jureus et al, 2000;Hakansson et al, 
1998;Sahu, 1998b), suggesting that these neuropeptides may have an intermediary function, coupling 
the action of leptin to various endocrine control systems. There are currently no studies implicating 
alarin in the regulation of neuroendocrine function. 
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3.1.2 GALANIN PEPTIDE FAMILY AND THE HPG AXIS 
The neuropeptides regulating hypothalamic GnRH are not well-characterised. Many peptides 
reportedly regulate hypothalamic GnRH release including some of those involved in energy 
homeostasis. The activity of the reproductive axis is sensitive to the adequacy of nutrition and the 
stores of metabolic reserves. The adipocyte-derived hormone leptin is thought to reflect the state of 
nutrition and energy reserves and serve as a metabolic gate to the reproductive system. Leptin is 
believed to regulate this effect indirectly via altered release of hypothalamic neuropeptides. These 
neuropeptides may include members of the galanin peptide family. 
 
3.1.2.1 GALANIN AND THE HPG AXIS 
Within the preoptic area of the rat hypothalamus, subpopulations of GnRH neurons co-express 
galanin mRNA (Rossmanith et al, 1996;Marks et al, 1992a) and immunoreactivity (Coen et al, 
1990;Merchenthaler et al, 1990). Hypothalamic galanin expression is sexually dimorphic in rodents, 
and galanin-IR is positively regulated by oestrogen (Gabriel et al, 1990). More GnRH neurons co-
express galanin in mature females than in mature males (Rajendren et al, 2000). The degree of this co-
expression is oestrogen-dependent, with highest levels observed during the proestrus stage of the 
oestrus cycle in intact female rats (Marks et al, 1993;Marks et al, 1993;Merchenthaler et al, 1991). 
Galanin is released into the hypophyseal portal system in a pulsatile manner. The regulation of this 
release appears to be dependent on the stage of the oestrus cycle. The highest concentrations of 
galanin in the median eminence are seen during diestrus and proestrus when oestrogen levels are low, 
and the lowest concentrations of galanin are observed at oestrus when oestrogen levels are highest. 
Galanin pulses also coincide with GnRH release from the same vesicles in nerve terminals in the 
median eminence (Lopez et al, 1991;Liposits et al, 1995). 
 
MPOA GnRH neurons express the GalR1 (Mitchell et al, 1999b), and galanin-IR nerve terminals are 
reported to be in close proximity to cell bodies of GnRH neurons in the mPOA and the diagonal band 
of Broca, suggesting a role for galanin in the regulation of hypothalamic GnRH (Merchenthaler et al, 
1990;Rajendren & Li, 2001). Galanin stimulates GnRH release from incubated ARC-median 
eminence (ME) explants in vitro (Lopez & Negro-Vilar, 1990), and ICV administration of galanin 
stimulates the HPG axis (Sahu et al, 1987;Fraley et al, 2004b;Matsumoto et al, 2001;Seth et al, 2004). 
Administration of the non-specific  galanin receptor antagonist galantide inhibits galanin-induced 
GnRH release from ARC-ME explants (Sahu et al, 1994). The physiological importance of galanin in 
reproduction is demonstrated by studies showing that ICV administration of galanin antagonists or IV 
administration of antisera against galanin can blunt the LH surge and ovulation in rats (Sahu et al, 
1994;Lopez et al, 1993).  
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It has been proposed that in the rat, galanin contributes to the generation of GnRH, and subsequent 
LH, surges initiated by oestrogen via a positive feedback mechanism. However, rather than the 
galanin mRNA levels in GnRH neurons increasing before the LH surge, galanin expression in these 
neurons does not begin to rise until the time of the LH surge, peaking 8-12h later (Finn et al, 1998). 
This may reflect either the need to replenish galanin stores depleted during the preceding LH surge or 
the prolonged production of galanin required to serve physiological events occurring on the day of 
oestrus or thereafter.  
 
In addition to galanin/GnRH interactions at the hypothalamic level, galanin is also synthesized locally 
in the rat anterior pituitary gland (Kaplan et al, 1988a;Marks et al, 1993). Galanin expression in the 
rat anterior pituitary is regulated by circulating levels of oestrogen, with highest levels seen at oestrus 
when oestrogen levels are highest (Kaplan et al, 1988b;Gabriel et al, 1990). Galanin is able to directly 
stimulate LH release from cultured rat anterior pituitary cells and potentiates GnRH-induced LH 
release in vitro (Leiva & Croxatto, 1994;Lopez et al, 1991;Peters et al, 2009). GalR2 and GalR3 are 
expressed in the rat anterior pituitary suggesting that galanin may directly control pituitary LH 
secretion via an endocrine or paracrine mechanism (Waters & Krause, 2000). Galanin-IR is detected 
in human fetal gonadotrophs, but in adults is found only in corticotrophs within the anterior pituitary 
(Reyes et al, 2008). 
 
 
3.1.2.2 GALP AND THE HPG AXIS 
GALP-IR fibres are abundant in the medial pre-optic nucleus (MPON) of the hypothalamus (a 
nucleus located within the preoptic area), and GALP-IR nerve terminals have been shown to be in 
close contact with BST and MPON GnRH-IR fibres (Takenoya et al, 2006). Central GALP injection 
induces Fos-IR in MPON neurons in rats (Fraley et al, 2003;Lawrence et al, 2003;Taylor et al, 2009). 
While it is estimated that only 6% of GnRH neurons in the MPON receive contacts from GALP 
containing neurons (Takatsu et al, 2001), 30% of GnRH neurons in the MPOA express c-fos 
following ICV GALP administration, suggesting both direct and indirect effects of GALP on GnRH 
neurons (Matsumoto et al, 2001). 
 
Intraventricular administration of GALP stimulates LH secretion in male and female rats and mice, 
and in male macaques (Matsumoto et al, 2001;Uenoyama et al, 2008;Krasnow et al, 2003;Krasnow et 
al, 2004;Kauffman et al, 2005;Cunningham et al, 2004b). This effect is attenuated by administration 
of a GnRH antagonist, suggesting a hypothalamic rather than pituitary effect. Indeed, direct GALP 
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treatment of dispersed anterior pituitaries has no effect on LH or FSH release (Matsumoto et al, 
2001), but GALP stimulates GnRH release from hypothalamic explants (Seth et al, 2004). GALP 
antiserum is able to block the stimulatory action of leptin on GnRH release from hypothalamic 
explants, suggesting GALP may mediate the effects of leptin on the HPG axis (Seth et al, 2004). 
Chronic GALP administration increases circulating LH and sexual behaviours in diabetic rats, which 
show reduced reproductive function. Insulin and leptin administration reverses the effect of diabetes 
on LH and sexual behaviour. This normalisation can be attenuated by administration of a GALP 
antibody, providing further evidence that GALP modulates the effects of leptin, and suggesting it may 
also mediate the effects of insulin, on reproductive function (Stoyanovitch et al, 2005). GALP has 
been suggested to provide a link between nutritional status and fertility (Seth et al, 2004).  
GALP may act to integrate energy and reproductive homeostasis. The brain has the ability to sense the 
status of metabolic fuel reserves and also governs the activity of the reproductive system. It appears to 
activate the HPG axis only when fuel stores are sufficient to support the energetic demands of 
reproduction. The ARC is the hub for this physiological interaction (Cone et al, 2001). It has been 
suggested that metabolically sensitive GALP neurons may be part of a circuit which relays 
information about fuel reserves to GnRH positive neurons and thereby regulates the activity of the 
reproductive axis (Gottsch et al, 2004).  
 
The effects of GALP on LH release are sexually dimorphic and dependent on both sex hormone 
milieu and stage of sexual maturation. The increase in LH observed in female rats administered 
GALP ICV  is dependent on the presence of oestrogen (Uenoyama et al, 2008). Pubertal rats, which 
express lower levels of GALP mRNA, are more sensitive to the stimulatory effect of GALP on LH 
release than adult animals (Castellano et al, 2006;Rich et al, 2007).  
 
Whilst the pharmacological effects of GALP on the HPG axis have been extensively demonstrated, 
the physiological relevance of this action of GALP is less well understood. Immunoblockade of 
endogenous GALP reduces circulating levels of LH (Stoyanovitch et al, 2005). However, 
hypothalamic GALP mRNA expression in the rat is unchanged by sex steroid hormone manipulations 
such as castration and orchidectomy (Cunningham et al, 2004a), and levels do not vary across the 
oestrus cycle in the female macaque (Cunningham et al, 2004b). In addition, GALP knockout mice 
have a reproductive phenotype indistinguishable from wild-type littermate controls (Dungan Lemko et 
al, 2008). 
 
Despite the reduced basal LH levels observed in fasted rats, fasting enhances the LH response to ICV 
GALP administration (Castellano et al, 2006). It is possible that this is secondary to a decrease in 
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endogenous GALP, caused by reduced leptin in response to fasting, or alternatively, it may represent 
alterations in pituitary sensitivity to GnRH following food deprivation.  
 
In addition to activating the HPG axis, GALP has been reported to regulate sexual behaviour in 
rodents. Administration of GALP to both gonadally-intact and castrated male rats increases the 
occurrence of sexual behaviours (mounts, intromissions and ejaculations) and decreases the latency 
time for these behaviours to take place (Fraley et al, 2004b). In male rats, DA activity in the mPOA 
has been shown to facilitate the control of sexual behaviour (Hull et al, 1986), and lesions of DA 
neurons in the mPOA prevent ICV GALP from stimulating male sex behaviour (Taylor et al, 2009). 
Immunoblockade of endogenous GALP abolishes sexual behaviours in adult male rats, suggesting this 
is a physiological effect (Stoyanovitch et al, 2005). In mice, ICV GALP suppresses sexual behaviour 
in both males and females although this may be attributable to the acutely impaired locomotor activity 
reported following GALP administration to mice (Kauffman et al, 2005).  
 
The receptor mediating the effects of GALP on the HPG axis is as yet unknown. GALP elicits a 
similar LH response in GalR1 knockout mice, GalR2 knockout mice and wild-type controls, 
suggesting that neither GalR1 or GalR2 is essential for mediating these effects of GALP (Krasnow et 
al, 2004). Interestingly, none of the cloned galanin receptors have been shown to be expressed on 
GT1-7 cells, an immortalised GnRH releasing cell line from which GALP stimulates the release of 
GnRH. Galantide, a potent non-subtype selective galanin receptor antagonist, is unable to attenuate 
this effect (Seth et al, 2004). These data suggest that an as yet unknown receptor which can be 
activated by GALP is responsible. 
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3.1.3 GALANIN PEPTIDE FAMILY AND THE HPT AXIS 
During fasting, thyroid hormone levels fall mainly due to an inhibition of TRH gene expression in 
PVN neurons, an effect mediated by reduced circulating leptin levels (Legradi et al, 1997). Leptin is 
believed to regulate this effect indirectly via altered release of arcuate neuropeptides. These 
neuropeptides may include members of the galanin peptide family. 
 
3.1.3.1 GALANIN AND THE HPT AXIS 
ICV injection of galanin decreases plasma TSH, while ICV injection of galanin anti-serum causes an 
increase in plasma TSH in rats (Ottlecz et al, 1988). Galanin-IR axons densely innervate proTRH 
neurons in the pPVN, and the synapses of galanin-containing nerve terminals on TRH neurons are 
symmetric, suggesting an inhibitory role for galanin in the regulation of the HPT axis (Wittmann et al, 
2004). These galaninergic axons innervating TRH neurons in the PVN are likely to arise from cell 
bodies in the DMN and the ARC, as well as extra-hypothalamic regions (Levin et al, 1987). Galanin 
administration directly into the PVN reduces circulating TSH and energy expenditure (Seth et al, 
2003;Menndez, 1992), and incubation of hypothalamic explants with galanin in vitro reduces TRH 
release (Seth et al, 2003). These data suggest galanin may regulate the thyroid axis through the tonic 
inhibition of TRH release from neurons in the PVN. Galanin is present in pituitary thyrotrophs of 
male rats (Cimini, 2003) and monkeys (Niimi et al, 1993). Galanin alone has no effect on TSH release 
from anterior pituitary explants in vitro, but may potentiate TRH-induced TSH release from 
thyrotrophs (Ottlecz et al, 1988).  
 
3.1.3.2 GALP AND THE HPT AXIS 
As a neuropeptide produced in the ARC and regulated by leptin, it is possible that GALP is involved 
in the regulation of the HPT axis. ICV GALP has been reported not to effect circulating TSH levels in 
rats (Matsumoto et al, 2001), but GALP injected directly into the PVN of rats reduces circulating 
TSH levels and GALP treatment of in vitro hypothalamic explants suppresses TRH release (Seth et al, 
2003). GALP has no effect on TSH release from dispersed anterior pituitary explants (Matsumoto et 
al, 2001). Anatomically, GALP containing neurons in the PVN synapse onto only a small number of 
TRH neurons, thus any regulation of TRH secretion by GALP is likely to be an indirect effect 
(Wittmann et al, 2004). Thyroidectomy in rats reduces ARC GALP mRNA expression and is restored 
by thyroxine replacement, suggesting GALP may play a physiological role in the HPT axis 
(Cunningham et al, 2004a).  
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3.1.4 GALANIN PEPTIDE FAMILY AND THE GROWTH HORMONE AXIS 
 
3.1.4.1 GALANIN AND THE GROWTH HORMONE AXIS 
Galanin increases plasma GH levels following peripheral and central injection in rats and peripheral 
infusion in humans (Ottlecz et al, 1986;Bauer et al, 1986;Ottlecz et al, 1988). Co-infusion of galanin 
to humans potentiates the stimulatory effect of GHRH on GH release (Davis et al, 1987). ICV 
injection of galanin antiserum dramatically reduces plasma GH levels in rats and alters GH pulsatility 
by reducing pulse amplitude and increasing pulse frequency, suggesting an important physiological 
role for galanin in the regulation of GH release (Ottlecz et al, 1988;Maiter et al, 1990). The co-
expression of galanin mRNA in ARC GHRH neurons varies with the state of the somatotrophic axis. 
Galanin mRNA levels in ARC GHRH neurons are reduced in GH deficient dwarf rats and in 
hypophysectomised rats, and  administration of GH can increase galanin levels back to those observed 
in intact controls (Chan et al, 1996b). However, while transgenic mice over-expressing galanin 
exhibit increased secretion of growth hormone (Perumal & Vrontakis, 2003), galanin knockout mice 
have normal growth rates and normal GH content in the pituitary (Wynick et al, 1998b). 
 
The stimulatory action of galanin on GH is thought to be mediated by activation of the hypothalamic 
GHRH system and inhibition of the hypothalamic somatostatin system. Galanin is co-expressed with 
GHRH in a population of ARC neurons which project to the median eminence (Niimi et al, 1990), 
and administration of GHRH antisera significantly inhibits the galanin-induced increase in plasma GH 
(Murakami et al, 1987). Somatostatin neurons in the periventricular nucleus express galanin receptors 
and are innervated by galanin-IR nerve terminals (Liposits et al, 1993;Chan et al, 1996b). Galanin is 
able to stimulate the release of both GHRH and somatostatin from median eminence explants in vitro, 
although this is an effect seen with high doses of galanin, and may not reflect endogenous galanin 
activity (Aguila et al, 1992). 
Studies investigating a direct effect of galanin on GH release from the pituitary report either no effect 
or an increase in GH release. The differences observed may be due to the different techniques used in 
these studies. (Ottlecz et al, 1986;Ottlecz et al, 1988;Gabriel et al, 1988;Sato et al, 1991). 
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3.1.4.2 GALP AND THE GROWTH HORMONE AXIS  
There is little evidence to suggest that GALP has a physiological role in the regulation of GH 
secretion in rodents. GH deficient dwarf rats have similar GALP mRNA levels as controls and GH 
administration to dwarf rats has no effect on GALP mRNA expression (Cunningham et al, 2004a). 
ICV injection of GALP has no effect on plasma GH levels in rats (Matsumoto et al, 2001). In 
addition, GALP knockout mice exhibit normal growth rates when compared to wild-type control 
animals (Dungan Lemko et al, 2008). However, administration of GALP to prepubertal rat pups has 
been reported to increase plasma GH levels. GH secretion usually increases at the onset of puberty 
and so the GALP-induced GH increase may represent a secondary effect of GALP as opposed to 
direct regulation (Rich et al, 2007). Electrophysiological studies suggest GALP can directly influence 
the behaviour of ARC GHRH neurons in adult rats (Kuramochi et al, 2005). ICV administration of 
GALP to male rhesus monkeys has also been reported to acutely stimulate GH release (Shahab et al, 
2005). 
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3.1.5 GALANIN PEPTIDE FAMILY AND PROLACTIN/DOPAMINE 
 
3.1.5.1 GALANIN AND PROLACTIN/DOPAMINE 
ICV administration of galanin stimulates prolactin release in the male rat (Koshiyama et al, 
1987;Melander et al, 1987;Ottlecz et al, 1988). It is likely that multiple mechanisms mediate this 
effect. Central galanin administration is associated with a reduction in hypothalamic dopamine 
synthesis and secretion (Melander et al, 1987). Galanin co-localises with tyrosine hydroxlyase (TH) in 
the ARC (Meister & Hokfelt, 1988), galanin-containing axons synapse onto ARC TH-IR neurons 
(Hrabovszky & Liposits, 1994) and ICV galanin decreases tuberoinfundibular dopaminergic neurone 
activity, although only under activated conditions (Gopalan et al, 1993).  
 
ICV galanin increases vasoactive intestinal peptide (VIP)-IR in the CSF, suggesting a role for VIP in 
mediating the effects of galanin (Inoue et al, 1988). Galanin dose-dependently stimulates VIP release 
from rat hypothalamic fragments in vitro (Inoue et al, 1988), and immunoneutralisation with specific 
antiserum against VIP suppresses the stimulatory effect of galanin on plasma prolactin (Koshiyama et 
al, 1987). The stimulatory effect of central galanin on prolactin release is also partially blocked by 
administration of alpha-adrenergic antagonists (Koshiyama et al, 1990b), opioid antagonists 
(Koshiyama et al, 1990b) or non-selective 5-HT1 and 5-HT2 receptor antagonists (Koshiyama et al, 
1990a). 
The effect of peripheral galanin on prolactin release is contentious. Studies report either no effect 
(Koshiyama et al, 1987;Ghigo et al, 1992;Giustina et al, 1992;Murakami et al, 1993;Arvat et al, 
1995;Grottoli et al, 1996), or an increase in plasma prolactin levels following IV infusion of galanin 
in rats and humans (Invitti et al, 1993;Todd et al, 2000;Bauer et al, 1986;Carey, 1993). Galanin 
reportedly enhances arginine and TRH induced prolactin secretion in humans (Ghigo et al, 
1992;Grottoli et al, 1996), and stimulates exaggerated prolactin release in anorexia nervosa patients 
(De Marinis et al, 2000) and patients with Cushing’s disease (Invitti et al, 1993).  
 
There is anatomical evidence to suggest that galanin may directly regulate prolactin release from the 
pituitary. Galanin mRNA and galanin-IR are present in a subpopulation of lactotrophs, and galanin 
mRNA in lactotrophs is dramatically upregulated by oestrogen treatment (Hsu et al, 1990). 
Furthermore, within lactrotrophs galanin co-localises in the same secretory granules as prolactin 
following oestrogen administration (Hyde et al, 1991). Functional evidence of a role for galanin in the 
regulation of pituitary prolactin release is inconsistent. Studies have reported that galanin has no direct 
effect on prolactin release from anterior pituitary dispersed cells or explants in vitro (Inoue et al, 
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1988;Ottlecz et al, 1988;Xu, 1995), but galanin does stimulate prolactin release from a cultured 
lactrotroph cell line in vitro (Hammond et al, 1996).  
 
Data suggests that galanin also has an autocrine/paracrine role in the regulation of lactotroph function. 
Oestrogen stimulates anterior pituitary galanin mRNA expression, which leads to an increase in 
prolactin release and increased lactotroph growth. These effects are completely abolished by treatment 
with galanin antiserum. (Wynick et al, 1993a;Cai et al, 1998). Specific over-expression of galanin in 
lactotrophs also stimulates prolactin synthesis and secretion, and acts as a growth factor in an 
oestrogen-dependent manner (Cai et al, 1999;Perumal & Vrontakis, 2003). Circulating prolactin then 
negatively feeds back at the level of the anterior pituitary and suppresses galanin gene expression 
(Hammond et al, 1997).  
Galanin knockout mice exhibit reduced pituitary prolactin mRNA and peptide, and female mutant 
mice fail to lactate after pregnancy. Furthermore, oestrogen administration to wildtype mice 
stimulates lactotroph proliferation and prolactin release, but these effects are absent in galanin 
knockout mice (Wynick et al, 1998a). 
 
3.1.5.2 GALP AND PROLACTIN/DOPAMINE 
The role of GALP in the regulation of prolactin is less well-characterised than that of galanin. 
Anatomically, GALP-IR nerve fibres make direct contact on TH-containing neurons in the ARC of 
the rat, suggesting that GALP may regulate dopaminergic neurons (Kageyama et al, 2008). 
Interestingly, there may be species specific effects of GALP administration on prolactin release as 
ICV GALP suppresses prolactin release in monkeys, but not in rats (Matsumoto et al, 
2001;Cunningham et al, 2004b). However, neuroendocrine regulation of pituitary function is different 
in many respects between rodents and primate species (Wheeler & Styne, 1988).  
 
GALP mRNA expression in the ARC is not different between rats in diestrus and lactating rats 
(Cunningham et al, 2004a), though the number of GALP cells in the posterior pituitary of rats is 
increased during lactation (Cunningham et al, 2004a). Further studies are required to clarify the 
effects of GALP on prolactin secretion. 
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3.1.6 GALANIN PEPTIDE FAMILY AND THE HPA AXIS 
 
3.1.6.1 GALANIN AND THE HPA AXIS 
Galanin is co-expressed with AVP and CRH in the hypothalamus PVN (Ceccatelli et al, 1989). 
Galanin nerve terminals contact CRH/AVP neurons in the PVN, galanin receptors are expressed in rat 
magnocellular and parvocellular PVN neurons (Mitchell et al, 1997;Mitchell et al, 1999a), and  
GalR1 mRNA co-localises with AVP in the rat PVN (Landry et al, 1998). ICV galanin administration 
to rodents increases Fos-IR in brain regions implicated in the stress response, including the PVN and 
the locus coruleus (Fraley et al, 2003;Bergonzelli, 2001).  
 
The regulation of AVP release by galanin is well characterised and discussed in chapter 1, section 
1.5.2.2.8. However, the data on the role of galanin in the regulation of hypothalamic CRH is more 
controversial. Galanin reportedly enhances CRH release from fetal rat hypothalamic neurons 
(Bergonzelli et al, 2001), suggesting stimulatory activity of galanin at the hypothalamic level of the 
HPA axis. However, under pathophysiological conditions, intraPVN administration of galanin to rats, 
and ICV administration of galanin to mice, attenuates stress-induced rises in plasma ACTH (Hooi et 
al, 1990a). In addition, ICV galanin antiserum administration to rats increases plasma ACTH 
concentration (Hooi et al, 1990b). This galanin-induced suppression of ACTH release is not seen 
following ICV injection of galanin to GalR1 knockout mice, suggesting that this receptor is critical 
for the regulation of the HPA axis by galanin. However, GalR1 knockout mice have basal plasma 
ACTH and corticosterone concentrations indistinguishable from wild-type littermates (Vrontakis, 
1990). 
 
Galanin mRNA and peptide are expressed in the pituitary corticotrophs of male and female humans 
and male rats (Vrontakis et al, 1990;Cimini et al, 1993;Cimini, 1996;Hsu et al, 1991). GalR2 and 
GalR3 mRNA, but not GalR1 mRNA, are expressed in the rat anterior pituitary (Waters & Krause, 
2000). Galanin inhibits ACTH release from rat pituitary corticotrophs in vitro, and this effect is 
abolished by the immunoneutralisation of galanin (Cimini, 1996). Intravenous administration of 
galanin has been reported to reduce plasma ACTH and cortisol levels, and to blunt the ACTH 
response to CRH in humans (Giustina et al, 1994). However, another study reports a rise in plasma 
ACTH and corticosterone following acute subcutaneous (SC) injection of galanin to unstressed rats 
(Malendowicz et al, 1994). 
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3.1.6.2 GALP AND THE HPA AXIS 
GALP may play a role in the HPA axis. ICV injection of GALP induces c-fos expression in 
hypothalamic nuclei known to be involved in stress responses (ARC and DMN) (Fraley et al, 
2003;Lawrence et al, 2003) and increases plasma levels of ACTH in rats (Onaka et al, 2005). 
However, Matsumoto et al report that ICV GALP has no effect on plasma ACTH (Matsumoto et al, 
2001). It is likely that GALP mediates any stimulatory effect it has on ACTH release at the level of 
the hypothalamus, as GALP has no effect on ACTH release directly from the pituitary (Matsumoto et 
al, 2001). Whether this is a physiological action of GALP is unknown. Adrenalectomy has no effect 
on GALP expression in the ARC of rats (Cunningham et al, 2004a). 
 
However GALP expression does appear to be regulated to some extent by stress. ARC GALP-IR 
neurons express Fos protein following an acute electric foot shock stressor (Onaka et al, 2005). 
Lipopolysaccharide (LPS) is a major component of the outer membrane of gram-negative bacteria and 
as such, is an endotoxin which induces a profound acute immune response. Peripheral LPS injection 
dramatically increases GALP gene expression in the ARC and the posterior pituitary. This effect is 
attenuated by pre-treatment with a prostaglandin inhibitor, suggesting that prostaglandins may induce 
posterior pituitary GALP expression (Saito et al, 2003;Saito et al, 2005). Other LPS-induced 
cytokines such as interleukin (IL)-1β and IL-6 may also be involved in the up-regulation of GALP 
expression. The acute inflammation induced by LPS injection increases plasma leptin levels 
(Mastronardi et al, 2001) and it is possible that the increase in leptin may cause the increased 
expression of GALP mRNA in the ARC. However, plasma GALP levels are not altered by LPS 
administration (Saito et al, 2005). 
 
Stress appears to differentially regulate GALP mRNA expression in the ARC and in the posterior 
pituitary. Adjuvant arthritis, used as a model of chronic inflammatory stress, has no effect on GALP 
expression in the ARC, but significantly induces GALP mRNA expression in posterior pituicytes 
(Saito et al, 2003;Saito et al, 2005). Nociceptive stimuli (formalin) also induces GALP expression in 
the posterior pituitary (Saito et al, 2003;Kawasaki et al, 2007). Acute osmotic (hypertonic saline) and 
chronic osmotic (dehydration and salt loading) stimuli induce GALP mRNA expression only in the 
posterior pituitary, but have no effect on ARC GALP mRNA expression (Saito et al, 2003;Shen et al, 
2001). 
 
The galanin family of peptides play important roles in the regulation of the neuroendocrine axes. 
However, the exact physiological role of these peptides and the receptors mediating their effects has 
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not been determined. There have been no studies reporting a role for alarin on neuroendocrine 
function.  
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3.2 AIMS 
Members of the galanin peptide family are heavily implicated in the regulation of neuroendocrine 
axes, and particularly the reproductive axis. The effect of ICV administration of alarin on circulating 
hormone levels has not been investigated. I aim to investigate 
 
1) The effects of central administration of alarin on circulating hormone concentrations in rats in 
vivo 
2) The effect of alarin on neuropeptide release from hypothalamic explants and immortalised 
GnRH releasing GT1-7 cells in vitro 
3) The effect of alarin on pituitary hormone release from anterior pituitary explants and 
immortalised LH releasing LβT2 cells in vitro 
4) Whether alarin is a physiological regulator of reproductive hormones in the female rat 
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3.3 MATERIALS AND METHODS 
 
3.3.1 MATERIALS 
Rat alarin (used in all studies unless specified otherwise) was synthesised by BioMol International LP 
(Exeter, UK). Murine alarin was purchased from Phoenix Pharmaceuticals Inc. Kisspeptin-10 was 
purchased from Peptide Institute Inc. (Osaka, Japan). All other peptides were purchased from Bachem 
(Merseyside,UK). Cannulation materials were purchased from PlasticsOne, Inc. (Roanoke, VA). 
Reagents for explant experiments were purchased from BDH (Poole, UK) and Invitrogen Ltd 
(Paisley, UK). Alarin ELISA was from Peninsula Laboratories, LLC. (Bachem Group, San Carlos, 
CA).  
 
3.3.2 ANIMALS 
Adult male Wistar rats and female Sprague Dawley rats (Charles River, Bicester, UK) were 
maintained as described in section 2.3.2. For all studies rats were randomised into groups of 
approximately equal mean body-weight (within 1g). Body-weight and food intake were measured 
daily. Animals which were considered unwell, or had reduced bodyweight or low food intake were 
excluded from studies 
 
 
3.3.3 IN VIVO STUDIES 
 
3.3.3.1 INTRACEREBROVENTRICULAR CANNULATION  
Cannulation was performed using the same anaesthetic regime and equipment as described previously 
(section 2.3.3.1).  
 
3.3.3.2 INTRACEREBROVENTRICULAR INJECTION 
Substances were administered to freely moving rats using a stainless steel injector projecting 1 mm 
below the cannula tip. Injections were carried out in a total volume of 5 µl and performed as 
previously described (section 2.3.3.2).  
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3.3.3.3 EFFECT OF ICV ALARIN ADMINISTRATION ON PLASMA HORMONES IN 
INTACT MALE RATS IN VIVO 
Adult male ad-libitum fed rats received a single ICV injection of either saline, 6 nmol alarin or 2 nmol 
kisspeptin-10 (positive control) (Thompson et al, 2004) in the early light phase (0900-1200 h). Rats 
were returned to their home cage without food and decapitated either 30 (n = 9-10 saline and alarin, n 
= 5 kisspeptin) or 60 minutes (n = 5 for each group) after injection. Trunk blood was collected in both 
lithium heparin tubes containing 4200 kallikrein inhibitor units aprotinin (Bayer Corp., Haywards 
Heath, UK), and tubes containing potassium EDTA (final concentration of 1.2-2mg EDTA/ml blood) 
(Starstedt). Plasma was separated by centrifugation at 2000g for 10 minutes, snap frozen on dry ice, 
and stored at -20°C until measurement of plasma hormones by RIA. 
 
 
3.3.4 IN VITRO STUDIES 
 
3.3.4.1 EFFECT OF ALARIN ON NEUROPEPTIDE RELEASE FROM MEDIAL BASAL 
HYPOTHALAMIC EXPLANTS 
The static hypothalamic explants incubation system was used as described previously (section 
2.3.4.1). GnRH, CRH, and TRH levels in the aCSF were measured by RIA.  
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3.3.4.2 HYPOTHALAMIC FACTOR RIAS 
3.3.4.2.1 GNRH RIA 
GnRH was purchased from Bachem (UK) Ltd. Standard curves prepared for the GnRH assay used 
synthetic GnRH made up to 1 pmol/ml in assay buffer and GnRH concentrations in aCSF/cell 
medium were determined by RIA using a rabbit anti-GnRH antibody donated by H.M. Fraser and 
used at a final dilution of 1:6000. The assay was carried out in 0.06 M phosphate buffer containing 
0.3% bovine serum albumin (BSA). Sample volume of explant media was 150 µl and cell media was 
200 µl. Samples were assayed in duplicate in a total volume of 350 µl for explants and 700 µl for cell 
study samples, each tube containing 1500cpm/tube of iodinated GnRH. The assays were incubated at 
4°C for 72 hours, before free and antibody bound peptide were separated by charcoal adsorption as 
described in section 2.3.4.2. 
 
3.3.4.2.2 TRH RIA 
TRH peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the TRH assay 
were made up to 1.25 pmol/ml in assay buffer. TRH concentrations in aCSF were determined by RIA 
using a rabbit anti-TRH antibody used at a final dilution of 1:25000. The assay was carried out in 0.06 
M phosphate buffer containing 0.3% BSA. Sample volume of hypothalamic explant media was 150 µl 
and samples were assayed in duplicate in a total volume of 350 µl, containing 1500cpm/tube of 
iodinated TRH. The assays were separated by charcoal adsorption of the free fraction as described in 
section 2.3.4.2. 
 
3.3.4.2.3 CRH RIA 
CRH peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the CRH assay 
were made up to 2 pmol/ml in assay buffer. CRH concentrations in aCSF were determined by RIA 
using a rabbit anti-CRH antibody used at a final dilution of 1:21000. The assay was carried out in 0.06 
M phosphate buffer containing 0.3% BSA and 0.02% Tween 20. Sample volume of explant media 
was 10 µl and samples were assayed in duplicate in a total volume of 350 µl, containing 
1500cpm/tube of iodinated CRH. The assays were incubated at 4°C for 72 hours, before free and 
antibody bound peptide were separated using a secondary antibody as described in section 2.3.4.2. 
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3.3.4.3 EFFECT OF ALARIN ON GNRH RELEASE FROM GT1-7 CELLS 
Immortalised murine hypothalamic GnRH-producing neurons, GT1-7 cells (Mellon et al, 1990) were 
grown in Dulbecco’s modified eagle medium (DMEM) containing 4 mM L-glutamine (Invitrogen 
Ltd.), 25 mM glucose and 1 mM sodium pyruvate, supplemented with 10% (v/v) fetal calf serum 
(FCS) (Invitrogen Ltd.), penicillin (100 IU/ml) and streptomycin (100 µg/ml) (Invitrogen Ltd.) and 
maintained at 37°C in 5% CO2. GT1-7 cells were plated on poly-L-lysine coated 24 well plates (Nunc 
International, Roskilde, Denmark), and incubated for 24 hours before secretion experiments were 
performed, as described previously (Patel et al, 2008). For GnRH secretion experiments, cells were 
pre-incubated for 120 minutes in serum-free medium. Thereafter, the medium was discarded and the 
cells were incubated for 240 minutes in 0.5 ml serum-free medium (basal), serum-free medium 
containing alarin (1,10, 100, 1000 or 10000 nM), serum-free medium containing GALP (0.1, 1, 10, 
100 or 1000 nM) or serum-free medium containing GLP-1 (100 nM) (positive control) (Beak et al, 
1998) (n = 14-30).  
In a separate experiment, cells were incubated in 0.5 ml serum-free medium (basal), 0.5 ml serum-free 
medium containing murine alarin (10, 100 or 1000 nM) or serum-free medium containing GLP-1 (100 
nM) (positive control) (n = 20-24 per group). This was to determine whether there is a difference in 
potency between mouse and rat alarin, since GT1-7s are a cell line of murine origin. The cells were 
incubated at 37°C with the test substance for 240 min after which the medium was removed and 
stored at -20°C until measurement of GnRH by RIA. 
 
3.3.4.4 EFFECT OF ALARIN ON PITUITARY HORMONE RELEASE FROM PITUITARY 
EXPLANTS  
The pituitary explant system was used as described previously (Stanley et al, 2004). Group housed 
male rats (200-250g) were decapitated and the anterior pituitary gland removed immediately and 
divided into four pieces of approximately equal size. Single quarters were placed in the wells of a 48 
well tissue plate (Nunc International) and incubated in 0.5 ml aCSF. They were maintained at 37°C in 
a humidified environment saturated with 95% O2 and 5% CO2 for 120 minute, with the medium 
changed each 60 minute. The segments were then incubated in 0.5 ml of aCSF alone (basal), aCSF 
containing alarin (10, 100 or 1000 nM), or aCSF containing GnRH (100 nM) (positive control) for 
240 minute (n = 10-12). The aCSF was then collected and stored at -20°C until RIA for LH, FSH, 
TSH and PRL. 
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3.3.4.5 EFFECT OF ALARIN ON LH RELEASE FROM LβT2 CELLS 
Immortalized murine pituitary LH releasing LβT2 cells (Alarid et al, 1996;Thomas et al, 1996) were 
cultured and plated as the GT1-7 cells described above (section 3.3.4.1). Cells were incubated in 0.5 
ml serum-free medium (basal), serum-free medium containing alarin (1, 10, 100, 1000 or 10000 nM), 
or serum-free medium containing GnRH (100 nM) (positive control) (n = 8-24) (Turgeon et al, 1996). 
Cells were incubated at 37°C with the test substance for 240 minutes after which the medium was 
removed and stored at -20°C until measurement of LH by RIA. 
 
3.3.5 EFFECT OF ICV ALARIN ON PLASMA HORMONES IN INTACT MALE RATS 
FOLLOWING PRETREATMENT WITH CETRORELIX 
Adult male ad-libitum fed rats received a SC injection of either saline or 200 nmol cetrorelix (GnRH 
receptor antagonist) (Bokser et al, 1990). Animals had been SC injected with saline twice in the week 
prior to the study to acclimatize them to the procedure. Thirty minutes later, animals were ICV 
injected with either saline, 30 nmol alarin or 2 nmol kisspeptin-10 (positive control) (n = 9-11 saline 
and alarin, n = 5 kisspeptin) (Thompson et al, 2004). Rats were returned to their home cage and 
decapitated 30 min after ICV injection and trunk blood collected and stored as previously described 
(section 3.3.3.3). 
  
3.3.6 PLASMA HORMONE RIAS 
3.3.6.1 LH RIA 
The measurement of LH in aCSF and plasma was by RIA using a rabbit anti-LH antibody donated by 
H.M Fraser (Medical Research Centre Reproductive Biology Unit, Edinburgh, UK) and used at a final 
dilution of 1:800,000. Materials and methods provided by the NIDDK and the National Hormone and 
Pituitary Program (Dr. A. Parlow, Harbor University of California, Los Angeles Medical Centre). LH 
was iodinated using the Chloramine T method (Wood et al, 1981).  
LH assays were carried out in Kemteck buffer (0.06 M phosphate EDTA, pH7.4) (appendix). 
Standards were serially diluted to construct a standard curve ranging from 0.05-25 ng/ml. Samples 
were assayed in duplicate in a total volume of 400 µl, containing antibody and 1200 cpm/tube of 
iodinated LH. Plasma sample volumes were 150 µl and pituitary explant samples were 10 µl of a 1:10 
dilution. The assays were incubated at 4°C for 72 hours. Free and antibody-bound LH were separated 
using a goat anti-rabbit secondary antibody as described in section 2.3.4.2.  
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3.3.6.2 FSH, TSH, PRL AND GH RIAS 
FSH, TSH, PRL and GH were assayed using a similar protocol as LH. All pituitary hormones were 
iodinated using the Chloramine T method, carried out in Kemteck buffer, incubated at 4°C for 72 
hours and separated using secondary antibody. The sample plasma volumes for FSH, TSH, PRL and 
GH RIA were 150, 200, 50 and 25 µl respectively. The sample volumes from pituitary explant studies 
were 10 µl of a 1:10 dilution.  
 
3.3.6.3 TOTAL TESTOSTERONE RIA 
Plasma total testosterone concentrations were measured using commercially available ‘Coat-A-Count’ 
solid-phase RIA kits (Siemens Medical Solutions Diagnostics) following the manufacturer’s 
instructions. Solid phase RIA relies on an antigen specific antibody immobilized to the wall of a 
polypropylene tube. The antibody is then incubated with 125I-labelled antigen and unlabelled antigen 
from the standard preparation or sample for a short-fixed time. The bound and free fractions are 
separated by decanting and the bound fraction is counted in a γ counter. The non-linear calibration 
curve is determined and the amount of testosterone in samples calculated in terms of the standard 
preparation.  
The calibrators and 125I labelled antigen were supplied ready to use in liquid form. Both calibrators 
and plasma samples were added to the total testosterone antibody coated tubes in 50 µl volumes. The 
125I labelled total testosterone was added to each tube in 1 ml volumes. The tubes were then vortexed 
and incubated at 37°C for 180 minutes. Free and antibody bound 125I-labelled antigen were separated 
by decanting and the remaining radioactivity in the tubes counted for 60 seconds. The mean cpm were 
calculated for standard and samples and the mean cpm was then plotted against the total testosterone 
standards to construct a standard curve. The standard curve was used to determine the total 
testosterone concentrations for the unknown plasma samples 
 
  
134 
 
3.3.6.4 ACTH IMMUNORADIOMETRIC ASSAY FOR MEASUREMENT OF ACTH IN 
PLASMA 
A solid phase immunoradiometric assay (IRMA) (Euro-Diagnostica) was used for determination of 
levels of ACTH in plasma. Two polyclonal antibodies are used which recognize ACTH at two 
different binding sites. The first is a purified radio-labelled (125I) sheep IgG recognizing the amino-
terminal of ACTH whereas the second antibody recognizes and binds non-competitively to the C-
terminal of the molecule. The second antibody is immobilized and coupled to sheep anti-rabbit 
antibody coating the polypropylene tubes. Both antibodies react with the ACTH molecule and the 
resulting complex is bound to the tube wall. Following a short incubation, the remaining 125I labeled 
sheep anti-ACTH is decanted. The bound radioactivity in the tubes is proportional to the 
concentration of ACTH in the sample or standard. 
The calibrators, reference controls and 125I ACTH-antibody were supplied lysophilised and were 
reconstituted in GDW 30 minutes prior to use. Standard solutions, reference controls and samples 
were added in 200 µl (in duplicate) to numbered tubes followed by addition of 200 µl 125I ACTH-
antibody. The tubes were vortexed gently and incubated overnight at room temperature. All tubes 
apart from the total counts tubes, were washed by addition of 2 ml wash solution into each tube and 
then decanted. This step was then repeated. Each tube was counted for 60 seconds in a γ counter. The 
mean cpm were calculated for standard, reference controls and samples and the mean cpm then 
plotted against the ACTH calibrators to construct a standard curve. The standard curve was used to 
interpolate the ACTH concentrations for the reference preparations and the unknown plasma samples. 
 
3.3.6.5 CORTICOSTERONE RIA 
Corticosterone levels in plasma were determined by a commercial RIA kit (MP Biomedicals Inc.). 
Calibrators, buffer and reference preparations were supplied in liquid form, ready to use. The assay 
was performed in a phosphosaline gelatine buffer (pH 7) containing rabbit gamma globulins in a total 
volume of 500 µl. Samples were diluted 1:200 in buffer and diluted samples, calibrators and reference 
preparations were added at a volume of 100 µl to numbered tubes. Labeled 125I-corticosterone (200 µl, 
50,000 cpm) was then added to all tubes followed by 200 µl of specific corticosterone antibody. All 
tubes were vortexed and incubated at room temperature for 120 minutes. The free and bound fractions 
were then separated by addition of 500 µl precipitant solution (goat anti-rabbit in TRIS buffer) 
followed by centrifugation at 1000g for 15 minutes. The pellet and supernatant were counted for 60 
seconds in a γ counter. Peptide concentrations in the samples were then calculated using a non-linear 
plot and results calculated in terms of the standard preparations.  
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3.3.7 REGULATION OF HYPOTHALAMIC ALARIN BY THE OESTRUS CYCLE  
Fifty female Sprague-Dawley rats weighing 200–250 g were group housed as described in section 
2.3.2. Stages of the oestrous cycle were determined by vaginal smearing (Hubscher et al, 2005). Rats 
were smeared daily for 14 consecutive days. Vaginal smears were taken once each day, between 
0900h and 1200h. To obtain a sample, the tip of a 1 ml syringe was filled with approximately 100 µl 
of sterile water and inserted approximately 3–5 mm into the rat's vagina. Care was exercised not to 
insert the dropper too deeply, because inadvertent cervix stimulation can initiate pseudopregnancy 
(Freeman, 1994). Sterile water was quickly released from the dropper, then immediately drawn back 
into it. The sample containing cells was placed on an untreated glass microscope slide and viewed 
while still wet under a light microscope at 50× magnification (Nikon, Eclipse 50i).  
The cyclic differences in vaginal cytology occur in response to the morphological changes of the 
vaginal epithelium as cells desquamate. The 12–14 h proestrus stage is characterized by round 
nucleated cells of uniform size (Freeman, 1994;Long & Evans, 1922). The next stage, estrus, lasts 25–
27 h, and is distinguished by the appearance of irregularly shaped, un-nucleated cornified cells 
(Freeman, 1994;Long & Evans, 1922). During diestrus, which lasts 55–57 h, more than half of the 
cycle (Freeman, 1994), both leukocytes and nucleated cells are present. 
Regularity of oestrus cycling was confirmed by two consecutive regular cycles. Females not cycling 
regularly were excluded from the study (<25%). On the study day, females were smeared to determine 
their stage of the oestrus cycle and then decapitated and hypothalami rapidly dissected out, weighed 
and snap frozen in liquid nitrogen (n= 6-17 per stage). Trunk blood was collected as previously 
described (section 3.3.3.3) for assay of plasma LH and FSH levels. This was used to confirm stage of 
cycle. Hypothalami were acetic acid extracted as described in section 2.3.4.3.2 before hypothalamic 
alarin levels were measured using an alarin ELISA (Peninsula Laboratories) as described in section 
2.3.4.3.3.  
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3.3.8 STATISTICS 
All data is presented as mean ± SEM. Data from in vivo neuroendocrine axis studies were analysed 
using a one-way ANOVA with post-hoc Tukey’s multiple comparison test (GraphPad Prism 5). Data 
from the pituitary explants study and cell studies were analysed using a one-way ANOVA with post-
hoc Dunnett’s multiple comparison test (GraphPad Prism 5). The data from cell studies were pooled 
from separate experiments (as stated) in order to generate an n number of approximately 24 per group. 
Data from the hypothalamic explant studies were compared by paired Student t-test between the basal 
and the test period. For GnRH, these data were pooled from separate experiments (as stated) in order 
to generate an n number of approximately 24 per group. In each individual experiment, explants act as 
their own control. In all cases, P<0.05 was considered to be statistically significant. Data from the 
alarin ELISA was analysed using a one-way ANOVA with post-hoc Tukey’s multiple comparison test 
(GraphPad Prism 5). 
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3.4 RESULTS 
 
3.4.1 EFFECT OF ICV ALARIN ADMINISTRATION ON PLASMA HORMONES IN 
INTACT MALE RATS IN VIVO 
ICV administration of alarin (6 nmol) significantly increased plasma LH by almost 50% in ad-libitum 
fed male Wistar rats 30 minutes after ICV injection (plasma LH ng/ml; saline 0.7 ± 0.1, 6 nmol alarin 
1.0 ± 0.1, P<0.05, n = 9-10 saline and alarin, n = 5 kisspeptin) (Table 3.1 and Figure 3.1A). Alarin 
had no significant effect on FSH or testosterone at either 30 or 60 min after injection. ICV kisspeptin-
10 (2 nmol) was used as a positive control and resulted in a significant increase in plasma LH, FSH 
and testosterone at 30 min after injection (Figure 3.1B and C and Table 3.1). 
Alarin increased plasma ACTH at 30 min after injection, although this effect did not achieve 
statistical significance (Alarin 6 nmol, P=0.08 vs. saline) and alarin also increased plasma 
corticosterone at 30 min post injection although again, this was not statistically significant (Alarin 6 
nmol, P=0.08 vs. saline) (n = 9-10 saline and alarin, n = 5 kisspeptin) (Table 3.1 and Figure 3.1D and 
E). 
Alarin had no significant effect on plasma prolactin, TSH or GH levels at either time point (Table 
3.1).  
 
 
30 minutes 60 minutes 
 
Saline Alarin (6nmol) 
Kisspeptin 
(2nmol) Saline 
Alarin 
(6nmol) 
LH (ng/ml) 0.7 ± 0.1 1.0 ± 0.1* 7.7 ± 1.8*** 0.5 ± 0.2 1.0 ± 0.5 
FSH (ng/ml) 10.3 ± 0.8 11.5 ± 0.9 17.3 ± 2.3*** 14.3 ± 1.2 11.6 ± 2.2 
Testosterone (nmol/L) 4.6 ± 0.9 4.7 ± 0.9 12.3 ± 1.2** 11.0 ± 4.2 14.9 ± 7.0 
ACTH (pg/ml) 25.8 ± 4.5 91.8 ± 34.1 22.1 ± 4.2 20.3 ± 1.6 17.7 ± 6.0 
Corticosterone 
(ng/ml) 95.6 ± 25.7 244.1 ± 69.3 93.8 ± 39.7 98.9 ± 37.7 149.1 ± 68.0 
TSH (ng/ml) 2.3 ± 0.3 2.3 ± 0.3 2.5 ± 0.2 1.8 ± 0.3 2.0 ± 0.3 
GH (ng/ml) 25.7 ± 8.1 46.3 ± 15.7 31.4 ± 12.2 15.4 ± 4.6 15.2 ± 4.0 
PRL (ng/ml) 7.1 ± 1.6 5.3 ± 1.2 5.5 ± 1.1 4.9 ± 1.6 3.8 ± 1.3 
 
TABLE 3.1 The effect of ICV administration of saline, alarin (6 nmol), or kisspeptin (2 nmol) to ad-libitum 
fed intact male rats on plasma luteinising hormone (LH), follicle stimulating hormone (FSH), testosterone, 
adenocorticotrophic hormone (ACTH), corticosterone, thyroid stimulating hormone (TSH), growth hormone 
(GH), and prolactin (PRL)  (n = 9-10 saline and alarin, n=5 kisspeptin). *, P<0.05 vs. saline;  **, P<0.01 vs. 
saline; ***, P<0.001 vs. saline. Results are mean ± SEM. 
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FIGURE 3.1 The effect of ICV injection of saline, alarin (6 nmol) (n = 9-10 per group), or kisspeptin-10 (2 
nmol) (positive control) (n = 5) on plasma luteinising hormone (LH) (A), follicle stimulating hormone (FSH) 
(B), testosterone (C), adenocorticotrophic hormone (ACTH) (D), and corticosterone (E) levels 30 and 60 min 
after administration in ad libitum fed intact male rats. *, P<0.05; ***, P<0.001 vs. saline (30 min). Results are 
mean ± SEM.  
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3.4.2 EFFECT OF ALARIN ON NEUROPEPTIDE RELEASE FROM MEDIAL BASAL 
HYPOTHALAMIC EXPLANTS 
Treatment with 100 nM alarin significantly increased GnRH release from adult male rat hypothalamic 
explants in vitro compared with basal release (GnRH basal 100 ± 10.6%, 100 nM alarin 135.4 ± 
12.6%; P<0.01, (n = 24). At a lower dose (10 nM), or a higher dose (1000 nM), alarin did not 
significantly influence GnRH release. Data are presented as a percentage of basal release. These data 
are pooled from three separate experiments (Table 3.2 and Figure 3.2A).  
Hypothalamic explants incubated with increasing concentrations of alarin showed a dose dependent 
reduction in TRH release. However, this effect did not achieve statistical significance (alarin 1000 nM 
P=0.07 vs basal, n = 7-9 per group). Data are presented as a percentage of basal release (Table 3.2).  
Hypothalamic explants incubated with increasing concentrations of alarin showed an increase in CRH 
release, however this did not achieve statistical significance (alarin 100 nM P=0.08 vs. basal, n = 6-7 
per group). Data are presented as a percentage of basal release (Table 3.2).  
 
 
Basal Alarin 10nM Alarin 100nM Alarin 1000nM 
GnRH (% of basal) 100.0 ± 10.6 93.0 ± 8.2 135.4 ± 12.6** 100.3 ± 6.4 
CRH (% of basal) 100.0 ± 15.5 106.9 ± 13.1 144.9 ± 19.1 135.0 ± 20.1 
TRH (% of basal) 100.0 ± 14.0 114.7 ± 26.1 90.4 ± 18.4 67.1 ± 16.9 
 
TABLE 3.2 The effect of artificial cerebrospinal fluid (aCSF) (basal) or aCSF containing alarin (10, 100 or 
1000 nM) on the release of gonadotrophin releasing hormone (GnRH), corticotrophin releasing hormone (CRH), 
and thyrotrophin releasing hormone (TRH) from hypothalamic explants from adult male rats (n = 24 per group 
for GnRH, n = 7-9 per group for TRH, n = 6-7 per group for CRH). Data are presented as percentage of basal 
release. **, P<0.01 vs. basal. Results are mean ± SEM. 
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3.4.3 EFFECT OF ALARIN ON GNRH RELEASE FROM GT1-7 CELLS  
Treatment with 1000 nM and 10000 nM alarin significantly increased GnRH release from GT1-7 cells 
60 and 75% above basal respectively, after 240 minute incubation (fmol/ml: basal 75.8 ± 6.9, 1000 
nM alarin 109.9 ± 11.8, 10000 nM alarin 121.1 ± 16.5 P<0.05, n = 38 basal, n = 31 1000 nM alarin,  n 
= 14 10000 nM alarin). GALP 1000 nM also significantly increased GnRH release (fmol/ml: basal 
75.8 ± 6.9, 1000 nM GALP 114.7 ± 16.5 P<0.05, n = 38 basal, n = 27 1000 nM GALP). GLP-1 100 
nM,  used as a positive control (Beak et al, 1998), significantly increased GnRH release to 270% of 
basal (fmol/ml: basal 75.8 ± 6.9, 100 nM GLP-1 187.6 ± 22.1 P<0.001, n = 38 basal, n = 39 100 nM 
GLP-1) These data are pooled from three separate experiments (Figure 3.2B).  
There was no difference in the potency of rat and mouse alarin on GnRH release from GT1-7 cells. 
Murine alarin significantly increased GnRH release from GT1-7 cells at a concentration of 1000 nM, 
but lower concentrations had no significant effect (n = 20-24 per group) (Table 3.3). 
 
Treatment and dose % of basal 
Basal 100.0 ± 12.2 
Rat alarin 1-25 10 nM 108.9 ± 12.3 
Rat alarin 1-25 100 nM 125.3 ± 9.9 
Rat alarin 1-25 1000 nM 159.5 ± 10.8* 
Murine alarin 1-25 10 nM 131.1 ± 14.8 
Murine alarin 1-25 100 nM 127.5 ±12.2 
Murine alarin 1-25 1000 nM 175.7 ± 11.7* 
Glucagon-like peptide-1 100 nM 272.3 ± 11.8*** 
  
TABLE 3.3 The effect of serum-free medium (basal), serum-free medium containing rat alarin (10, 100 or 
1000 nM), serum-free medium containing murine alarin (10, 100 or 1000 nM) or serum-free medium containing 
glucagon-like peptide-1 (100 nM) on GnRH release from GT1-7 cells after a 240 minute incubation (n = 20-24 
per group). Results are mean ± SEM. Data are presented as percentage of basal release and are pooled from 
three separate experiments. *, P<0.05 vs. basal release. ***, P<0.001 vs. basal release.  
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FIGURE 3.2 A) The effect of artificial cerebrospinal fluid (aCSF) (basal) or aCSF containing alarin (10, 100 
or 1000 nM) on GnRH release from hypothalamic explants from adult male rats (n = 24 per group). Data are 
presented as percentage of basal release, and are pooled from three separate experiments. B) The effect on 
GnRH release from GT1-7 cells of a 240 minute incubation with serum-free medium (basal), serum-free 
medium containing alarin (1, 10, 100, 1000, 10000 nM), serum-free medium containing galanin-like peptide 
(GALP) (0.1, 1, 10, 100, 1000 nM) or serum-free medium containing glucagon-like peptide-1 (GLP-1) (100 
nM) (positive control) (n = 14-30 per group). *, P<0.05; **, P<0.01; ***, P<0.001 vs. basal release. Results are 
mean ± SEM.  
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3.4.4 EFFECT OF ALARIN ON HORMONE RELEASE FROM PITUITARY EXPLANTS  
There were no significant changes in LH release from anterior pituitary explants from adult male rats 
following treatment with alarin. GnRH 100 nM, the positive control, significantly stimulated LH 
release from pituitary explants (LH ng/ml: aCSF 182.3 ± 13.3, 100 nM GnRH 491.7 ± 51.2. P<0.001, 
n = 30 per group) (Table 3.4 and Figure 3.3A). Treatment of anterior pituitaries with GALP also had 
no effect on LH release and again GnRH 100 nM, the positive control, significantly stimulated LH 
release (LH ng/ml: aCSF 248.2 ± 23.5, 100 nM GnRH 625.7 ± 101.1 P<0.001, n = 10-12 per group) 
(Table 3.4). 
There was no effect of alarin or GALP on FSH release from anterior pituitary explants from adult 
male rats. Artificial CSF containing GnRH, the positive control, significantly increased FSH release 
compared to aCSF alone. (FSH ng/ml: aCSF 7.2 ± 1.9, 100 nM GnRH 16.3 ± 4.1 P<0.05, n = 10-12 
per group) (Table 3.4 and Figure 3.3B). 
There was no significant effect of alarin on PRL release from anterior pituitary explants from adult 
male rats. GnRH the positive control (Denef & Andries, 1983), significantly stimulated prolactin 
release compared to basal treated controls (Prolactin ng/ml: aCSF 77.5 ± 13.3, 100 nM GnRH 235.3 ± 
26.5 P<0.001, n = 10-12 per group). GALP 1000 nM significantly stimulated prolactin release 
compared to basal (Prolactin ng/ml: aCSF 133.9 ± 15.5, 1000 nM GALP 339.4 ± 71.6 P<0.01, 100 
nM GnRH 342.2 ± 45.0 P<0.01, n = 10-12 per group). 
There was no effect of alarin at any dose on TSH release from anterior pituitary explants (Table 3.4). 
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Basal Alarin 10nM 
Alarin 
100nM 
Alarin 
1000nM GnRH 100nM 
LH (ng/ml) 182.3 ± 13.3 214.8 ± 28.0 216.5 ± 19.3 217.4 ± 17.2 491.7 ± 51.2*** 
FSH (ng/ml) 7.2 ± 1.9 7.1 ± 1.2 8.7 ± 2.6 5.4 ± 1.3 16.3 ± 4.1* 
TSH (ng/ml) 3.1 ± 0.3 - 2.8 ± 0.3 3.3 ± 0.3 2.9 ± 0.2 
PRL (ng/ml) 77.5 ± 13.3 130.3 ± 47.9 148.5 ± 22.6 164.7 ± 23.6 235.3 ± 26.5*** 
 
Basal GALP 10nM 
GALP 
100nM 
GALP 
1000nM GnRH 100nM 
LH (ng/ml) 248.2 ± 23.5 287.9 ± 34.9 293.3 ± 35.9 290.5 ± 45.0 625.7 ± 101.1*** 
FSH (ng/ml) 7.2 ± 1.9 5.0 ± 0.7 4.9 ± 1.0 5.5 ± 1.0 16.3 ± 4.1* 
PRL (ng/ml) 133.9 ± 15.5 210.4 ± 20.7 152.6 ± 26.5 339.4 ± 71.6** 342.2 ± 45.0** 
 
TABLE 3.4 The effect of artificial cerebrospinal fluid (aCSF) (basal), aCSF containing alarin (10, 100 or 1000 
nM), aCSF containing galanin-like peptide (GALP) (10, 100 or 1000 nM) and aCSF containing gonadotrophin 
releasing hormone (GnRH) (100 nM) on the release of luteinising hormone (LH), follicle stimulating hormone 
(FSH), thyroid stimulating hormone (TSH) and prolactin (PRL) from anterior pituitary explants from adult male 
rats (n = 30 per group for LH, n = 10-12 per group for FSH, TSH and PRL). *, P<0.05; **, P<0.01; ***, 
P<0.001 vs. basal release. Results are mean ± SEM. 
 
 
3.4.5 EFFECT OF ALARIN AND GALP ON LH RELEASE FROM LβT2 CELLS 
There were no significant changes in LH release from LβT2 cells after 240 minute incubation with 
alarin compared to basal. GALP at doses of 100 nM and 1000 nM significantly stimulated LH release 
from LβT2 cells after a 240 minute incubation compared to basal (LH ng/ml: basal 12.0 ± 0.9, 100 
nM GALP 22.7 ± 3.1 P<0.05 vs. basal,  1000 nM GALP 29.7 ± 4.8 P< 0.001 vs. basal, n = 8 per 
group) (Figure 3.3C).  
GnRH 100 nM, the positive control, significantly stimulated LH release from LβT2 cells (LH ng/ml: 
basal 12.0 ± 0.9, 100 nM GnRH 36.5 ± 4.3 P<0.001 vs. basal, n = 8 per group).  
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FIGURE 3.3 The effect of artificial cerebrospinal fluid (aCSF) (basal), or aCSF containing alarin (10, 100 or 
1000 nM) on luteinising hormone (LH) (A) and follicle stimulating hormone (FSH) (B) release from anterior 
pituitary explants from adult male rats (n = 10-12 per group). C) The effect on LH release from LβT2 cells of a 
240 minute incubation with serum-free medium (basal), serum-free medium containing alarin (1, 10, 100, 1000, 
10000 nM), serum-free medium containing galanin-like peptide (GALP) (0.1, 1, 10, 100, 1000 nM) or serum-
free medium containing gonadotrophin releasing hormone (GnRH) (100 nM) (positive control) (n = 8 per 
group). *, P<0.05; ***, P<0.001 vs. basal release. Results are mean ± SEM.  
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3.4.6 EFFECT OF ICV ALARIN ON PLASMA HORMONES IN MALE RATS AFTER 
PRETREATMENT WITH CETRORELIX 
ICV administration of 30 nmol alarin significantly increased plasma LH by 70% in ad-libitum fed 
male Wistar rats 30 minutes after ICV injection compared to saline injected controls. This effect was 
blocked by pre-treatment with the GnRH receptor antagonist cetrorelix (200 nmol) (LH ng/ml; SC 
saline/ICV saline 0.6 ± 0.1, SC saline/ICV alarin 1.0 ± 0.2, P<0.05 vs. SC saline/ICV saline; SC 
cetrorelix/ICV alarin 0.4 ± 0.03, P<0.01 vs. SC saline/ICV alarin, n = 9-11 per group). There was a 
significant increase in plasma LH 30 minutes after ICV injection of 2 nmol kisspeptin-10, the positive 
control, compared to saline injected controls. This effect was also blocked by pre-treatment with 
cetrorelix (LH ng/ml; SC saline/ICV saline 0.6 ± 0.1, SC saline/ICV kisspeptin 3.0 ± 0.3, P<0.001 vs. 
SC saline/ICV saline; SC cetrorelix/ICV kisspeptin 0.6 ± 0.1, P<0.001 vs. SC saline/ICV kisspeptin, n 
= 11 saline, n = 5 kisspeptin) (Figure 3.4A). 
ICV administration of 30 nmol alarin had no significant effect on plasma FSH or testosterone 
compared to saline injected controls. Kisspeptin (2 nmol), the positive control, significantly increased 
plasma testosterone, an effect blocked by pretreatment with cetrorelix (testosterone ng/ml; SC 
saline/ICV saline 207.5 ± 46.4, SC saline/ICV kisspeptin 667.2 ± 353.8, P<0.01 vs. SC saline/ICV 
saline; SC cetrorelix/ICV kisspeptin 181.0 ± 66.8, P<0.05 vs. SC saline/ICV kisspeptin, n = 11 saline, 
n = 5 kisspeptin) (Figure 3.4B and C). 
There was no effect of ICV administration of alarin 30 nmol on plasma ATCH, corticosterone, TSH 
or prolactin compared to ICV saline injected controls (Table 3.5). 
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FIGURE 3.4 The effect of ICV administration of saline (S), alarin (A) (30 nmol) or kisspeptin-10 (K) (2 
nmol) 30 minutes after subcutaneous (SC) pre-treatment with 200 nmol cetrorelix (C) or saline (S) in ad-libitum 
fed adult male rats on plasma luteinising hormone (LH) (A), follicle stimulating hormone (FSH) (B) and 
testosterone (C) levels (n = 9-11 alarin and saline, n = 5 kisspeptin) 30 min after ICV injection. *, P<0.05 vs. 
saline/saline. **, P<0.01 vs saline/saline. ***, P<0.001 vs saline/saline. #, P<0.05 vs saline/kisspeptin. ##, P<0.01 
vs saline/alarin. ###, P<0.001 vs. saline/kisspeptin. Results are mean ± SEM.  
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SC Saline 
ICV Saline 
SC Cetrorelix 
ICV Saline 
SC Saline 
ICV Alarin 
SC Cetrorelix 
ICV Alarin 
LH (ng/ml) 0.6 ± 0.1 0.4 ± 0.04 1.0 ± 0.2* 0.4 ± 0.03## 
FSH (ng/ml) 17.7± 2.9 9.9 ± 3.0 13.9 ± 3.0 14.7 ± 2.6 
Testosterone (ng/L) 207.5 ± 46.4 123.5 ± 23.8 190.8 ± 32.1 165.7 ± 25.0 
ACTH (pg/ml) 24.9 ± 3.4 26.9 ± 4.5 40.0 ± 10.8 31.5 ± 6.6 
Corticosterone (ng/ml) 89.7 ± 14.7 161.0 ± 41.2 100.8 ± 25.6 104.5 ± 35.8 
TSH (ng/ml) 4.2 ± 0.4 3.1 ± 0.3 3.6 ± 0.4 3.9 ± 0.5 
PRL (ng/ml) 5.5 ± 0.5 5.4 ± 0.3 5.6 ± 0.8 5.7 ± 0.3 
 
TABLE 3.5 The effect of ICV administration of saline or alarin (30 nmol) 30 min after subcutaneous  
pretreatment with 200 nmol cetrorelix or saline in ad-libitum fed intact adult male rats on plasma luteinising 
hormone (LH), follicle stimulating hormone (FSH), testosterone, adenocorticotrophic hormone (ACTH), 
corticosterone, thyroid stimulating hormone (TSH), and prolactin (PRL)  30 min after ICV injection. *, P<0.05 
vs. saline/saline. **, P<0.01 vs saline/saline. ##, P<0.01 vs saline/alarin. Results are mean ± SEM.  
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3.4.7 REGULATION OF HYPOTHLALAMIC ALARIN BY THE OESTRUS CYCLE  
There was no significant difference in the hypothalamic peptide levels of alarin between female rats at 
different stages of the oestrus cycle as determined by vaginal smearing (alarin fmol/hypothalamus: 
diestrus one 23.4 ± 8.5, diestrus two 16.7 ± 3.4, proestrus 11.1 ± 3.3, oestrus 13.7 ± 2.6, n = 6-18 per 
group). Plasma LH and FSH were significantly increased in rats in the oestrus phase of the cycle (LH 
ng/ml: diestrus one 0.3 ± 0.1, diestrus two 0.3 ± 0.1, proestrus 0.3 ± 0.0, oestrus 0.4 ± 0.0, P<0.01. 
FSH ng/ml: diestrus one 4.8 ± 1.0, diestrus two 7.9 ± 2.5, proestrus 6.9 ± 0.7, oestrus 11.8 ± 1.5, 
P<0.05, n = 6-18 per group) (Figure 3.5). 
 
 
FIGURE 3.5 Hypothalamic alarin-like immunoreactivity (A), plasma luteinising hormone (LH) levels (B), 
and plasma follicle stimulating hormone (FSH) levels (C) from female Sprague Dawley rats at different stages 
of the oestrus cycle; diestrus 1 (D1), diestrus 2 (D2), proestrus (P) and oestrus (O) (n= 6-18 per group). *, 
P<0.05 vs. D1; **, P<0.01 vs. all other groups. Results are mean ± SEM.  
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3.5 DISCUSSION 
The galanin family of peptides are known to play a role in the regulation of the HPG axis 
(Merchenthaler, 2008;Gottsch et al, 2004). I have shown that ICV administration of 6 nmol alarin 
significantly increased plasma LH levels by nearly 50%, 30 minutes after injection. LH levels were 
still elevated 60 minutes after injection of alarin, but this did not achieve statistical significance. 
Plasma LH levels peak at the same time point (30 minutes) after ICV injection of 5 nmol galanin-like 
peptide (Matsumoto et al, 2001). The time course of alarin’s actions on plasma LH suggests that 
alarin may be having a direct effect on hypothalamic GnRH neurons rather than diffusing to a more 
distant site such as the pituitary to elicit this effect. My data suggest that ICV alarin administration has 
no effect on FSH or testosterone release. Similarly, ICV GALP administration has no effect on plasma 
FSH concentration in male rats (Matsumoto et al, 2001) but has been shown to increase plasma 
testosterone levels in mice (Krasnow et al, 2003). Exogenous administration of neuropeptides that 
stimulate GnRH release often show a more potent effect on LH release than on FSH release. For 
example,  central administration of kisspeptin appears to have a more potent effect on LH release than 
FSH release (Patterson et al, 2006a;Thompson et al, 2004;Tena-Sempere, 2010). Changes in GnRH 
pulse pattern differentially affect the synthesis and release of LH and FSH. Higher GnRH pulse 
frequencies and amplitude favour LH release, while slower frequencies stimulate FSH release 
(Marshall et al, 1991;Bedecarrats & Kaiser, 2003). Alarin administration studies are unlikely to 
exactly replicate the effects of endogenous alarin at the GnRH neuron, and the physiological role of 
alarin on differential LH and FSH release is therefore currently unknown. It is possible that alarin-
responsive GnRH neurons fire at a higher frequency and so favour release of LH over FSH. In 
addition, other factors such as inhibin and activin, can influence circulating FSH levels (Gregory & 
Kaiser, 2004). These factors may modulate the actions of alarin on circulating FSH concentrations. 
Studies acutely blocking alarin signalling with specific antibodies, or alarin receptor antagonists may 
be useful to investigate these possibilities.  
 
To investigate the mechanism by which alarin stimulates the HPG axis, I examined the effects of 
alarin on hypothalamic explants and an immortalised GnRH releasing GT1-7 cell line in vitro. Alarin 
(100 nM) significantly stimulated GnRH release from hypothalamic explants. Previous studies have 
determined that both GALP and galanin at the same dose of 100 nM also stimulate GnRH release 
from hypothalamic explants (Seth et al, 2004). There was no dose response in the effect of alarin on 
GnRH since alarin 1000 nM did not significantly affect GnRH release from hypothalamic explants. 
This could be due to receptor desensitisation caused by excess ligand, or dimerisation of alarin at this 
high dose. It might also reflect the activation of different receptors with minimal effects at higher 
doses. Alarin, at doses of 1000 and 10000 nM, was able to stimulate GnRH release from GT1-7 cells. 
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There is a ten-fold difference in the effective dose necessary for a GnRH response between the 
hypothalamic explants and the GT1-7 cell line, and this is possibly due to differences in sensitivity 
between these two in vitro systems. Hypothalamic explants contain many different cell types through 
which alarin may act to increase GnRH release either directly or indirectly. There may only be a small 
direct effect of alarin on GnRH releasing neurons themselves. Such in vitro systems are typically less 
sensitive than in vivo responses to the administration of neuropeptides (Wren et al, 2002). Thus 
relatively high concentrations and n numbers are often required to cause a significant effect, even with 
very potent factors (Thompson et al, 2004). 
 
I also incubated pituitary explants and immortalised LH releasing LβT2 cells with alarin to identify 
any direct effect of alarin on gonadotrophin release. However, even very high concentrations of alarin 
had no effect on LH or FSH release from pituitary segments, or LH release from LβT2 cells. These 
results suggest that alarin stimulates the HPG axis via an effect on hypothalamic GnRH.  
The effects of ICV alarin on LH are blocked by pre-treatment with the GnRH antagonist cetrorelix, 
providing further evidence that this effect of alarin is mediated via hypothalamic GnRH.  In this 
study, I used a higher dose of alarin (30 nmol) than in the previous experiment. This was to ensure 
that alarin had a stimulatory effect on LH, as pre-treatment with a SC injection has been reported to 
cause physical stress sufficient to suppress LH secretion (Li et al, 2004). However, the basal LH 
levels observed in this study were similar to those seen in the first ICV study and the stimulatory 
effect of ICV alarin on LH levels was retained in this experiment. The effect of ICV alarin on 
circulating LH is small, and there appears to be little difference between the magnitude of the LH 
response to 6 or 30 nmol alarin, suggesting perhaps a threshold effect of alarin on the HPG axis rather 
than a dose response.  
 
During the course of my studies, a paper investigating the role of alarin on LH release was published. 
Van Der Kolk et al reported no effect of LV administration of alarin (1 nmol) on plasma LH in intact 
male rats. In contrast, LV alarin (1 nmol) stimulated LH release in castrated male rats (Van Der Kolk 
et al, 2010a). It is unusual that alarin stimulates LH levels only when circulating levels are already 
elevated in castrated rats, although these animals may have altered sensitivity to hormones which 
stimulate the reproductive axis.  It is likely that the dose used in intact male rats in these studies, 1 
nmol, was insufficiently high to elicit a detectable LH response. Despite a difference in the strain of 
rats being used between my study and this report, Wistar v Sprague Dawley, there are no notable 
differences in the reproductive function between these two strains (Wilkinson et al, 2000). It is 
possible that the third ventricle is closer then the lateral ventricle to the alarin responsive neurons 
which mediate the effect of alarin on GnRH release.  
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Interestingly, central alarin administration (1 nmol) is not associated with any increase in Fos IR in 
the mPOA, an area rich in GnRH cell bodies (Van Der Kolk et al, 2010a), suggesting that perhaps 
alarin mediates its effect on LH release via other brain regions. However this dose of alarin does not 
increase LH levels in intact male rats (Van Der Kolk et al, 2010a). It would be interesting to 
determine whether a dose of alarin which stimulates LH (6 or 30 nmol) induces Fos in the mPOA.  
 
GALP has been shown to stimulate the HPG axis via hypothalamic GnRH release in vivo (Matsumoto 
et al, 2001), and to stimulate the release of GnRH from hypothalamic explants in vitro (Seth et al, 
2004). The stimulatory effect of GALP on the HPG axis in vivo is observed following the 
administration of relatively low doses: 1-5 nmol (Castellano et al, 2006;Matsumoto et al, 2001). The 
principal galanin receptor expressed in GnRH neurons is the GalR1 (Mitchell et al, 1999b), which 
may mediate the effects of galanin and GALP on the HPG axis. However, I have shown, in agreement 
with a previous study, that GALP also stimulates the release of GnRH from GT1-7 cells which do not 
express GalR1 or the other known galanin receptors (Seth et al, 2004). I compared the effects of 
GALP and alarin on GnRH release from GT1-7 cells, and they appear to have similar potency. Both 
significantly stimulated GnRH release at a dose of 1000 nM while lower doses had no significant 
effect. The difference in potency between alarin and GALP in vivo may be due to their different 
binding affinities at a novel receptor and/or the activation of different receptors. Alarin may be 
specific for only one receptor, whereas GALP is known to bind to at least three receptors (GalR1, 
GalR2 and GalR3) (Lang et al, 2005).  
 
GALP has been reported to have no direct effect on LH release from pituitary explants (Matsumoto et 
al, 2001), and my results confirm this finding. However, I have shown that GALP dose dependently 
stimulates LH release from cultured LH releasing LβT2 cells. It is not known through which receptor 
GALP mediates this effect. LβT2 cells express mRNA for the GalR3 (chapter 4). Messenger RNAs 
for the galanin receptors, GalR2 and GalR3, have been detected in the anterior pituitary (Waters & 
Krause, 2000). However, the identity of the pituitary cells which express these receptors has, to date, 
not been reported. While the LβT2 cell line provides a very useful model of highly differentiated 
gonadotrophs (Thomas et al, 1996), some physiological responses differ from those in pituitary 
gonadotrophs (Eertmans et al, 2007).  
 
My data suggests that hypothalamic alarin is not regulated by sex steroids in rats, since there is no 
difference in alarin peptide levels across the different stages of the oestrus cycle. However, there was 
a trend towards a reduction in hypothalamic alarin-like IR in the oestrus stage of the cycle, when 
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oestrogen levels are highest. The n numbers in this study are relatively small and there was variation 
in the number of rats in each stage of the cycle. It is possible that with increased n numbers, a 
statistically significant effect of sex steroid milieu on hypothalamic alarin-like IR would be observed. 
It would be interesting to compare hypothalamic alarin levels between sexes of the same strain of rat. 
Data comparing hypothalamic alarin-IR in ovariectomised females to intact females would help to 
establish whether or not alarin levels were regulated by sex steroids. The experiment I carried out 
investigated modulations in hypothalamic alarin peptide levels. It would be useful to determine 
whether or not alarin mRNA expression is affected by sex steroid milieu since message and peptide 
expression are not always related (Gygi et al, 1999). The expression of GALP mRNA in the ARC is 
unaffected by sex steroids in both the rat and macaque (Cunningham et al, 2004a;Cunningham et al, 
2004b) and it therefore seems unlikely that either alarin or GALP mediate the effects of gonadal 
steroids on reproductive behaviour.  
 
ICV alarin administration had no effect on circulating prolactin concentrations in rats. However, there 
was a non-significant, dose dependent stimulation of prolactin release following direct administration 
of alarin to anterior pituitary explants. GALP has previously been reported to have no effect on 
pituitary explants (Matsumoto et al, 2001), and therefore this small stimulation of prolactin by alarin 
may be an effect of alarin which is distinct from the actions of GALP. However, I observed a 
significant increase in prolactin release from pituitary explants following treatment with GALP (1000 
nM). The previous study reports no effect of GALP from 1 to 1000 nM doses on the release of 
pituitary hormones from dispersed pituitary cells (Matsumoto et al, 2001). The difference between my 
results and those shown previously may be due to the different experimental models used: anterior 
pituitary explants compared to dispersed pituitary cells. Intercellular communication exists in the 
anterior pituitary such that cells produce substances which can affect the secretory activities of 
neighbouring cells. This natural organisation is disrupted when using a dispersed pituitary cell model 
and this can effect overall pituitary hormone output (Hu & Lawson, 1995). The Matsumoto study also 
had smaller n numbers (n = 4) compared to my study. In vitro systems often require larger n numbers 
to see an effect due to their relative insensitivity compared to in vivo models.  
 
Prolactin is often released from cells other than lactotrophs in the pituitary, including somatotrophs 
and gonadotrophs (Simmons et al, 1990;Losinski et al, 1989). It is therefore possible that alarin and 
GALP stimulate the release of another pituitary hormone which is associated with the co-release of 
prolactin. My studies suggest that alarin has no effect on gonadotrophin release from anterior pituitary 
explants. It would be interesting to determine whether alarin has a direct effect on prolactin release 
from the prolactin-releasing GH3 rat pituitary tumour cell line. This cell line expresses GalR1 and 
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GalR2 mRNA (Fathi et al, 1997), and reportedly releases prolactin in response to galanin (Drouhault 
et al, 1994). It would be useful to examine the direct effect of alarin on GH release from pituitary 
explants. ICV alarin (6 nmol) administration non-significantly increased plasma GH levels in rats. 
GALP has been reported to have no effect on plasma GH concentrations in rats, but increases GH 
levels in monkeys following ICV administration (Matsumoto et al, 2001;Shahab et al, 2005).  
 
Central alarin administration had no effect on plasma TSH levels in rats. However, incubation of 
hypothalamic explants with increasing concentrations of alarin (10 nM to 1000 nM) gave the 
appearance of a dose-dependent suppressive effect on TRH release, although this did not reach 
statistical significance. Interestingly, alarin (1 nmol) administered centrally to rats has been associated 
with a non-significant reduction in oxygen consumption, an indirect measure of metabolic rate 
compared to vehicle treated rats (Van Der Kolk et al, 2010a). Suppression of the thyroid axis at the 
level of the hypothalamus is associated with a decreased basal metabolic rate (Silva, 1995). GALP has 
previously been reported to inhibit TRH release from hypothalamic explants (Seth et al, 2003). In 
addition, iPVN GALP (1 nmol) administration reduces circulating TSH at 10 minutes post-injection 
(Seth et al, 2003), though ICV administration of GALP (5 nmol) has been reported to have no effect 
on plasma TSH in rats (Matsumoto et al, 2001). These data suggest that the effect of GALP on plasma 
TSH is likely to be mediated via receptors in the PVN, an area rich in TRH neurons (Van Der Kolk et 
al, 2010b). Central administration of alarin induces Fos-IR in the PVN, although the exact phenotype 
of the activated cells has not yet been established (Van Der Kolk et al, 2010a). It is possible that ICV 
administration of alarin suppresses circulating TSH levels, but that the thirty minute time point I used 
was not the optimal point at which to detect this change. However, ICV administration of known 
modulators of TRH release such as AgRP and NDP-MSH have a maximal effect on plasma TSH 
levels between 20 and 40 minutes post-injection (Kim et al, 2000b). Alternatively, higher doses of 
alarin administered ICV may be required for sufficient peptide to reach the PVN to elicit an effect at 
receptors located here. Further studies examining direct administration of alarin into the PVN, are 
required to investigate the role of alarin in the regulation of the HPT axis. 
 
ICV administration of alarin (6 nmol) caused a 400% increase in circulating ACTH concentration 
above saline, 30 minutes post-injection, although this effect was not statistically significant. Plasma 
corticosterone levels were also non-significantly elevated at this time point. However, in the second 
ICV alarin administration study, where rats were given a SC injection 30 minutes prior to ICV 
administration of alarin (30 nmol), only a smaller, 150% increase in plasma ACTH was observed. A 
SC injection is likely to activate the HPA axis in a rat irrespective of previous sham injections. 
Therefore, when rats receive an ICV injection of alarin thirty minutes later, rats may be less 
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responsive to a repeated stress inducer. Interestingly, the basal plasma ACTH and corticosterone 
levels do not differ much between studies, though it is possible that the sensitivity of stress hormone 
responsive pathways does vary. My in vitro studies reveal a small, non-significant increase in CRH 
release from hypothalamic explants incubated with alarin. The n number for this study was small with 
only 6-7 in each group. Increasing the n numbers of this study would determine whether alarin does 
stimulate CRH neurons from hypothalamic explants. Since the majority of CRH producing neurons in 
the brain are located in the PVN (Hashimoto et al, 1982), and alarin increases Fos IR in this nucleus 
(Van Der Kolk et al, 2010a), it would be useful to administer alarin directly into the PVN to establish 
any effect of alarin on the HPA axis at the level of the hypothalamus.  
 
Central administration of GALP (1 nmol) has been reported to increase plasma ACTH levels, with a 
maximal effect five minutes post-injection, and ACTH concentrations returning to pre-injection levels 
after thirty minutes (Onaka et al, 2005). However, an earlier study by a separate group suggested that 
ICV injection of 5 nmol GALP had no effect on plasma ACTH at any time point measured, which 
included ten, twenty and thirty minutes post-injection (Matsumoto et al, 2001). The reason for this 
discrepancy is unknown as the methods used by both groups are very similar. 
 
Activation of the HPA axis occurs readily in response to non-specific stressors. It is difficult to 
differentiate a direct effect of ICV administration of a peptide on the HPA axis from a non-specific 
effect of ICV peptide administration which activates the HPA axis e.g. nausea. Central injection of 
alarin might act as a non-specific stressor to secondarily stimulate increases in the stress hormones. 
There is a well-recognized pattern of pituitary hormone secretion in response to stress. Typically, non-
specific stress raises ACTH, corticosterone and PRL. However, ICV alarin does not cause any 
significant behavioural abnormalities, which are often seen in non-specifically stressed animals, and 
alarin caused a small increase in CRH release from hypothalamic explants in vitro.  
 
In summary, these studies demonstrate that ICV alarin stimulates the HPG axis in rats, and the 
stimulatory effect of alarin on circulating LH is likely mediated via GnRH. Other effects of alarin on 
neuroendocrine axes are less definite, and further studies are required to determine whether alarin 
plays a role in the regulation of the HPT and HPA axes. 
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CHAPTER 4 
INVESTIGATING THE RECEPTOR 
MEDIATING THE BIOLOGICAL EFFECTS OF 
ALARIN 
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4.1 INTRODUCTION 
 
4.1.1 GALANIN RECEPTORS 
The first autoradiographic binding profiles derived from I125labelled-galanin suggested the presence of 
multiple galanin receptor subtypes (Bartfai et al, 1993;Wynick et al, 1993b). Subsequently three 
distinct galanin receptors have been cloned and characterised in rats, mice and humans: GalR1, GalR2 
and GalR3 (Burgevin et al, 1995;Fathi et al, 1997;Howard et al, 1997;Smith et al, 1998). All three are 
membrane bound GPCRs. Receptors of each subtype are highly conserved between species, while the 
different receptor subtypes have relatively low sequence similarities (Kolakowski, Jr. et al, 1998b). 
The three subtypes have distinct but overlapping patterns of expression in the CNS and in the 
periphery. GalR1 and GalR3 act via different intracellular signalling pathways to GalR2 (Wang et al, 
1998b;Smith et al, 1998). 
 
GalR1 and GalR2 demonstrate similar affinities for full-length galanin (Wang et al, 1997c;Borowsky 
et al, 1998). However, the affinity of both rat and human GalR3 for galanin is lower (Smith et al, 
1998). In contrast, GALP binds with greatest affinity to GalR3, followed by GalR2, and then GalR1 
(Lang et al, 2005).  
 
 
FIGURE 4.1 Galanin receptor subtypes signalling pathways. Abbreviations: AC, adenylate cyclase; CaCC, 
Ca2+-dependent chloride channel; cAMP, 3′,5′-cyclic adenosine monophosphate; (p)CREB, (phosphorylated) 
cAMP response element binding protein; 3′,5′-cAMP response element-binding protein; DAG, diacylglycerol; 
IP3, inositol triphosphate; MEK, mitogen-induced extracellular kinase; PDK-1, phosphoinosotide-dependent 
protein-kinase 1; PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol trisphosphate; PI3K, 
phosphatidylinositol 3-kinase; PKB, protein kinase B; PLC, phospholipase C. Taken from (Lang et al, 2007).  
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4.1.1.1 GALANIN RECEPTOR 1 
The GalR1 was originally isolated from the human Bowes melanoma cell line  (Habert-Ortoli et al, 
1994) and has subsequently been cloned from human colon (Lorimer & Benya, 1996), rat insulinoma 
cells (Parker et al, 1995), rat brain (Burgevin et al, 1995) and mouse brain (Wang et al, 1997d). 
Human GalR1 cDNA encodes a protein of 349 amino acids (Habert-Ortoli et al, 1994) while the rat 
homologue is a 346 amino acid protein with 92% homology to the human receptor (Parker et al, 
1995). The mouse GalR1 is 348 amino acids in size and shows 91% and 94% homology to the human 
and rat GalR1 receptors respectively (Wang et al, 1997d). 
 
This galanin receptor subtype signals via pertussis-toxin sensitive Gi/o proteins to inhibit adenylate 
cyclase, reduce cAMP-responsive element binding (CREB) protein phosphorylation and 
hyperpolarise cells via opening of ATP-sensitive K+ channels (Wang et al, 1998b). The GalR1 
hyperpolarisation response is consistent with the inhibition of exocytosis and suggests that this 
receptor might act to inhibit release of neurotransmitters or hormones. 
 
The GalR1 mRNA is widely and abundantly expressed in the mammalian CNS (Habert-Ortoli et al, 
1994). The highest levels are observed in the hypothalamus, amygdala, ventral hippocampus, 
thalamus, brain stem (medulla oblongata, locus coruleus and lateral parabrachial nucleus) and spinal 
cord (dorsal horn) (Gustafson et al, 1996;Burgevin et al, 1995;Parker et al, 1995). A detailed study of 
the distribution of GalR1 mRNA in the hypothalamus using cRNA probes has revealed high levels of 
expression in the MPOA, SON, and the posterior magnocellular and medial parvocellular divisions of 
the PVN (Mitchell et al, 1997). The distribution of 125I-galanin binding sites as shown in 
autoradiograph experiments correlates with that of GalR1 mRNA in rat and mouse brain (Jungnickel 
& Gundlach, 2005) suggesting a more limited and lower level of GalR2/3 expression and/or lower 
affinity of galanin for these subtypes. GalR1 expression in the periphery is controversial. While some 
groups report expression of GalR1 throughout the GI tract with greatest expression in the duodenum 
(Lorimer & Benya, 1996;Parker et al, 1995;Habert-Ortoli et al, 1994), other groups report no 
expression of this receptor subtype outside of the CNS (Waters & Krause, 2000). 
 
Expression of GalR1 mRNA is regulated by metabolic signals (Gorbatyuk & Hokfelt, 1998b), 
reproductive hormone levels (Faure-Virelizier et al, 1998), inflammatory mediators (Benya et al, 
1998) and other signals suggestive of the diverse effects of galanin mediated via this receptor subtype. 
 
A GalR1 knockout mouse (GalR1-/-) has been generated and extensive phenotypic analysis 
undertaken (Jacoby et al, 2002). Interestingly, there is no difference in galanin and GalR2 expression 
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in these knockout mice, but there is an slight increase in GalR3 expression in the spinal cord and a 
decrease in GalR3 expression in the brain of GalR1-/- mice compared to wild type littermates (Jacoby 
et al, 2002;Blakeman et al, 2003). The GalR3 also signals via Gi/o proteins. GalR1-/- mice are viable 
and exhibit normal growth, body weight and reproductive capabilities (Jacoby et al, 2002). However, 
they do exhibit a spontaneous seizure phenotype (Jacoby et al, 2002). These seizures occur with 
variable severity in response to stressful environmental triggers and are associated with impaired 
synaptic inhibition in hippocampal neurons (Fetissov et al, 2003;McColl et al, 2006;Mazarati et al, 
2004b). 
 
Initial studies suggested that GalR1-/- mice didn’t display any marked phenotype relating to energy 
homeostasis, and GalR1-/- mice show normal responses to the feeding and reproductive effects of 
GALP administration (Krasnow et al, 2004). However, Zorilla et al propose that GalR1-/- mice have 
an impaired ability to adapt to acute changes in dietary fat content, suggesting a role for the GalR1 in 
maintaining neutral energy balance (Zorrilla et al, 2007). GalR1-/- mice display significantly reduced 
circulating IGF-1 levels, implicating GalR1 in basal regulation mechanisms associated with IGF-1 
synthesis or secretion, either directly or through regulation of GH secretion (Jacoby et al, 2002). 
Whilst there are no differences in basal ACTH and corticosterone levels between GalR1-/- and wild 
type mice (Mitsukawa et al, 2009), GalR1-/- mice show a test-specific increase in anxiety behaviour 
and fail to respond to galanin-induced inhibition of stress-related responses (hyperthermia, 
locomotion, ACTH and corticosterone levels). These data suggest that the GalR1 plays an important 
role in the anxiolytic-like effects of galanin under conditions of relatively high stress (Holmes et al, 
2003;Mitsukawa et al, 2009).  
 
Regarding a role for the GalR1 in the regulation of nociception, GalR1-/- mice exhibit a slight 
hyperalgesia in response to tissue injury and inflammation, but otherwise appear to have unaltered 
pain responses compared to wild type animals (Malkmus et al, 2005;Blakeman et al, 2003). GalR1-/- 
mice are also reported to have only very subtle test-specific alterations in their performances in 
learning and memory tasks, suggesting that galanin’s effects on cognition are mostly mediated via an 
alternative galanin receptor (Badie-Mahdavi et al, 2005;Rustay et al, 2005;Wrenn et al, 2004). 
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4.1.1.2 GALANIN RECEPTOR 2 
The second galanin receptor subtype to be cloned was originally isolated from a rat hypothalamus  
cDNA library simultaneously by several groups, and was revealed as a 372 amino acid protein (Smith 
et al, 1997b;Howard et al, 1997;Wang et al, 1997a;Fathi et al, 1997). The rat GalR2 shares only 38-
40% homology to the rat GalR1 (Howard et al, 1997;Wang et al, 1997a;Smith et al, 1997b) but is 
highly conserved between species, with 85-87% homology to human GalR2, a 387 amino acid protein 
(Borowsky et al, 1998;Fathi et al, 1998), and 94% homology to the mouse GalR2, a 370 amino acid 
protein (Pang et al, 1998). 
 
GalR2 signals through multiple classes of G-proteins and thus stimulates a number of intracellular 
pathways. The most commonly reported pathway involves activation of phospholipase C which 
increases inositol phosphate hydrolysis, mediating the release of intracellular Ca2+ into the cytoplasm 
and the opening of Ca2+-dependent chloride channels (Borowsky et al, 1998;Pang et al, 1998;Smith et 
al, 1997b). This effect of GalR2 activation is pertussis-toxin insensitive, suggesting that GalR2 may 
act through Gq/11-type G proteins. GalR2 is also reported to inhibit cAMP production, an effect 
sensitive to pertussis toxin and suggestive of coupling of GalR2 to the inhibition of adenylate cyclase 
via Gi-type G proteins  (Fathi et al, 1998;Wang et al, 1997a). There is also evidence that GalR2 is 
couples to Go-type G proteins activating MAPK in a pertussis toxin sensitive PKC dependent fashion  
(Hawes et al, 2006). 
 
The GalR2 has a wider distribution in the brain than the GalR1 and is also present in the pituitary 
gland and peripheral tissues (Wang et al, 1997a;Fathi et al, 1997). Within the CNS, in situ 
hybridisation has revealed moderately high GalR2 mRNA expression levels in the hypothalamus, 
hippocampus, entorhinal and piriform cortex, amygdala, dentate gyrus (Fathi et al, 1997;Xu et al, 
1998). Specifically, all major hypothalamic nuclei express GalR2 mRNA, with highest levels 
observed in the lateral mammillary bodies, the TMN, and the magnocellular neurons of the SON, and 
lower levels in the PVN and the ARC (Depczynski et al, 1998). 
 
Peripherally, GalR2 mRNA is expressed in lactotrophs, somatotrophs, gonadotrophs and thyrotrophs 
of the anterior pituitary, suggesting that this receptor may regulate hypothalamic-pituitary secretion 
(Depczynski et al, 1998). GalR2 mRNA is also highly expressed in the GI tract, spleen, lung, skeletal 
muscle, heart, kidney, liver, ovary, uterus, vas deferens, prostate gland and testis (Fathi et al, 
1997;Smith et al, 1997b;Howard et al, 1997). 
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GalR2 signalling has been implicated in the mediation of numerous and diverse effects of galanin, 
including emotion, memory, nociception, cellular growth, pancreatic islet function, cardiovascular 
tone, peripheral metabolism, reproduction, jejunal contraction, stimulation of growth hormone and 
prolactin secretion, myometrial contraction, seizure susceptibility, peripheral nerve regeneration, and 
hippocampal neuroprotection (Lu et al, 2005a;Elliott-Hunt et al, 2007;Liu et al, 2001;Badie-Mahdavi 
et al, 2005;Burazin & Gundlach, 1998;Mazarati et al, 2004a;Wang et al, 1998a;Woll & Rozengurt, 
1989;Ottlecz et al, 1988;Depczynski et al, 1998;Niiro et al, 1998).  
 
Several different methods have been used to generate GalR2 knockout mice (GalR2-/-) (Hobson et al, 
2006;Krasnow et al, 2004;Shi et al, 2006). Despite detailed phenotypic analysis, GalR2-/- mice do not 
appear to differ significantly from their wild-type controls with respect to growth, reproductive and 
metabolic physiology, locomotor activity, seizure susceptibility and basic behaviours (Gottsch et al, 
2005;Bailey et al, 2007). It is possible that either GalR2 plays no role in the physiological functions 
tested, or that adaptation to congenital absence of GalR2 occurs through developmental compensation 
(Gottsch et al, 2005). However, there is no significant alteration in galanin or GalR1 mRNA 
expression in these animals (Hobson et al, 2006). 
 
GalR2-/- mice do have a significant developmental loss of dorsal root ganglion neurons likely to be 
nociceptors (Shi et al, 2006;Hobson et al, 2006). Studies carried out by Shi et al have revealed no 
changes in pain behaviour between GalR2-/- mice and wild type littermates in several models of 
neuropathic pain (Shi et al, 2006), yet Hobson et al propose that their GalR2-/- mouse does have 
deficits in neuropathic and inflammatory pain behaviours (Hobson et al, 2006). A possible 
explanation for these discordant results is that the GalR2-/- mice used in these two studies have been 
generated from different genetic backgrounds and that the model of neuropathic pain used differs 
between studies. GalR2-/- mice are also reported to have an attenuated response to the protective 
effects of exogenous galanin following neuronal injury, implicating the GalR2 in mediating the 
neuroprotective effects of galanin (Elliott-Hunt et al, 2007). Detailed behavioural phenotyping of the 
GalR2-/- mouse revealed a test-specific anxiety-like phenotype of the GalR2-/- mouse in the elevated 
plus maze (EPM) (Bailey et al, 2007). However, this effect is likely to be strain specific as normal 
behaviour in the EPM has been reported in other GalR2-/- mouse models (Lu et al, 2008). This cohort 
of mice also exhibited a more persistent depressive-like phenotype, suggesting an anti-depressant role 
of GalR2 signalling (Lu et al, 2008). These studies indicate that GalR2-/- mice do not show profound 
changes in anxiety-like behaviour.  
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4.1.1.3 GALANIN RECEPTOR 3 
The third galanin receptor subtype was first cloned from rat, and the cDNA encodes a protein of 370 
residues (Wang et al, 1997b;Wang et al, 1997c). Rat GalR3 shows only 36% and 55% sequence 
similarity to rat GalR1 and rat GalR2 respectively (Mennicken et al, 2002). Human GalR3 was cloned 
from a human genomic library based on structural similarity to human GalR1 and GalR2 and is a 368 
amino acid protein with 90% homology to rat GalR3 (Kolakowski, Jr. et al, 1998a;Kolakowski, Jr. et 
al, 1998b). Mouse GalR3 is 370 amino acids (Kolakowski, Jr. et al, 1998b). 
 
Like the GalR1, GalR3 stimulates a pertussis toxins sensitive activation of inward K+ current 
consistent with coupling to Gi/o-type G proteins (Smith, 1998). GalR3 signalling is therefore capable 
of producing a hyperpolarisation response consistent with the inhibition of exocytosis and thus may 
also act to inhibit neurotransmitter or hormone release. 
 
In the CNS, GalR3 transcripts are expressed at a relatively low level, but detected with highest 
abundance in the hypothalamus and at lower levels in discrete regions of the CNS, including the 
olfactory bulb, cerebral cortex, medulla oblongata, caudate putamen, cerebellum and spinal cord 
(Smith, 1998). Within the hypothalamus, GalR3 mRNA is expressed predominantly in the MPOA and 
the DMN, with lower expression in the LHA, VMN and premammillary nuclei (Mennicken et al, 
2002). 
 
Peripherally, GalR3 has been detected with highest levels in the pituitary, but is also expressed in the 
heart, liver, kidney, stomach, testis, adrenal cortex, lung, adrenal medulla, spleen, pancreas and in the 
microvasculature of the skin (Smith et al, 1998;Schmidhuber et al, 2007;Wang et al, 1997c).  
Functionally, the GalR3 has been implicated in depression and anxiety (Barr et al, 2006;Swanson et 
al, 2005), and in mediating the alcohol-related actions of galanin (Belfer et al, 2007) and the effect of 
galanin on inflammatory oedema formation within the microvasculature (Schmidhuber et al, 2008). 
No GalR3 knockout mouse has been developed to date. 
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4.1.2 GALANIN RECEPTOR AGONISTS AND ANTAGONISTS 
 
4.1.2.1 NON-SPECIFIC GALANIN RECEPTOR AGONISTS  
Galnon and Galmic are non-peptide galanin receptor agonists (Saar et al, 2002;Bartfai et al, 2004). 
Whilst both compounds are substantially more resistant to degradation than endogenous galanin, they 
are low affinity, non-receptor subtype selective, and have been shown to interact with other 
pharmacologically important targets. 
 
4.1.2.2 NON-SPECIFIC GALANIN RECEPTOR ANTAGONISTS  
The commonly used high affinity chimeric galanin receptor antagonists C7 (galanin(1-12)-Pro-
spantide-amide) (Xu et al, 1995c), M15 (galantide (galanin(1-12)-Pro-substanceP(5-11)-amide)) 
(Bartfai et al, 1991), M32 (galanin (1-13) NPY (25-36)-amide) (Xu et al, 1995c), M40 (galanin(1–
13)-Pro2-(Ala-Leu)2-Ala- 
amide) (Crawley et al, 1993) and M35 (galanin(1-12)-Pro-bradykinin(2-9)-amide) (Ogren et al, 1992) 
are not receptor subtype selective, and furthermore, can behave as partial agonists at higher 
concentrations (Lu et al, 2005c).  
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4.1.2.3 SUBTYPE SELECTIVE GALANIN RECEPTOR AGONISTS/ANTAGONISTS 
 
4.1.2.3.1 GALR1 
There are currently no known agonists or antagonists which bind with significantly greater affinity to 
the GalR1 than to either of the other galanin receptors and which could be utilised to investigate the 
physiological role of the GalR1. 
 
4.1.2.3.2 GALR2  
Modifications and truncations to the N-terminus of galanin have been reported to confer specificity to 
the GalR2. [D-Trp2] galanin exhibits significant selectivity for GalR2 over GalR1 and GalR3, and acts 
as an agonist at this receptor (Smith et al, 1997b;Smith, 1998). Galanin (2-29) binds with greater 
affinity to the GalR2 than the other galanin receptors (Wang et al, 1997c). Galanin (2-11) (or AR-
M1896) has been used extensively as a GalR2 selective agonist (Liu et al, 2001), but has recently 
been reported to bind to the GalR3 and has subsequently been termed a non-GalR1 ligand (Lu et al, 
2005b). No specific GalR2 antagonists have been reported to date. 
 
4.1.2.3.3 GALR3 
There have been recent advances in the development of GalR3 specific agonists and antagonists. A 
non-peptide 3-arylimino-2-indolone known as compound 9 has been reported to be a potent and 
selective GalR3 ligand (IC50 = 15 nM) with no detectable binding to the GalR1 or GalR2 when used 
in in vitro receptor binding assays. In vitro functional assays have demonstrated that it acts as an 
antagonist at the GalR3 (Konkel et al, 2006). Two small molecule GalR3 antagonists, SNAP 37889 
and SNAP 398299, have also been reported to exhibit high affinity at the GalR3 in receptor binding 
studies and no binding to the GalR1 or GalR2 subtypes. These molecules antagonise galanin in 
functional assays in vitro and in vivo (Swanson et al, 2005).  
Peripheral administration of either SNAP 37889 or the 3-arylimino-2-indolone has antidepressant-like 
effects in rats and mice. Administration of SNAP 37889 also has anxiolytic properties in rats 
(Swanson et al, 2005;Barr et al, 2006).  
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4.1.3 A GALP SPECIFIC RECEPTOR? 
There is evidence to suggest that galanin and GALP activate different receptor systems. GALP and 
galanin induce different patterns of Fos expression in the rat forebrain following central injection, 
suggesting that the two peptides activate different neuronal populations (Fraley et al, 2003;Lawrence 
et al, 2003). GALP, but not galanin, stimulates GnRH secretion from GT1-7 cells, which do not 
appear to express any of the known galanin receptor subtypes (Seth et al, 2004). Pretreatment with 
M15, a nonspecific galanin receptor antagonist that displays activity at all three identified galanin 
receptor subtypes, does not block GALP's ability to stimulate GnRH release from GT1-7 cells, and 
only partially attenuates GALP's stimulatory effect on GnRH secretion from hypothalamic explants 
(Seth et al, 2004). Fraley et al. have documented a pronounced stimulatory effect of central GALP 
treatment on sexual behavior in male rats (Fraley et al, 2004b). In contrast, ICV galanin suppresses 
sexual behavior in male rats (Fraley et al, 2004b). Although both galanin and GALP have an acute 
stimulatory effect on food intake in the rat, only GALP has a suppressive effect on feeding and body 
weight after 24 h (Lawrence et al, 2002). These observations collectively point toward galanin and 
GALP signalling through different receptors. 
 
There is also evidence to suggest that GALP does signal through galanin receptors in vivo. In addition 
to the structural and pharmacological similarities between galanin and GALP, the two neuropeptides 
have several biological effects in common, which may indicate a shared receptor mechanism. These 
include stimulation of food intake acutely following ICV injection, inhibition of the secretion of 
thyroid-stimulating hormone after iPVN injection (Seth et al, 2003), and stimulation of GnRH 
secretion from hypothalamic explants, amongst others (Seth et al, 2004). These observations suggest 
that the similar actions of galanin and GALP may be mediated by galanin receptor signalling and are 
consistent with GALP interacting with galanin receptors in vivo. 
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4.2 AIMS 
There is evidence to suggest that alarin does not bind to membrane preparations expressing GalR1 or 
GalR2. The receptor through which alarin mediates its effects has not yet been determined. I aim to: 
1) Determine whether alarin binds to the three known galanin receptors 
2) Investigate whether alarin and galanin share a common receptor 
3) Investigate the effect of truncated forms of alarin on bioactivity in vitro and in vivo  
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4.3 MATERIALS AND METHODS 
 
4.3.1 MATERIALS 
Alarin 1-25 and alarin 3-25 were synthesised by BioMol International LP (Exeter, UK) as described 
previously (section 2.3.1). Alarin 6-25 was purchased from Phoenix pharmaceuticals. All other 
peptides were purchased from Bachem UK Ltd. (Merseyside, UK). GalR3 expressing membrane was 
purchased from BioXtal (Mundolsheim, France). 
 
4.3.2 CELL CULTURE OF GALANIN RECEPTOR EXPRESSING CELLS 
Chinese Hamster Ovary (CHO)-GalR1 and CHO-GalR2 expressing cells were maintained in F12 
nutrient mixture containing 1 mM L-glutamine (Invitrogen Ltd.) and supplemented with 10% (v/v) 
fetal bovine serum (Invitrogen), penicillin (100 IU/ml) and streptomycin (100 µg/ml) (Invitrogen) 
under the same conditions as GT1-7 cells described in section 3.3.4.3.  
 
4.3.3 CONFIRMATION OF GALANIN RECEPTOR EXPRESSION BY REVERSE 
TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR) 
 
4.3.3.1 TOTAL RNA EXTRACTION – THE TRI REAGENT METHOD 
Materials 
Tri-Reagent (Helena Biosciences, Sunderland UK) 
1-Bromo-Chloro-Propane (Sigma-Aldrich) 
Propan-2-ol (VWR) 
Ethanol (VWR) 
 
Method 
Total RNA was extracted using Tri-reagent according to the manufacturer’s protocol. Cells cultured 
in T175 flasks had the medium removed and 10ml Tri-reagent was added to the flask. Following 2 
minutes incubation, the mixture was transferred to silanised Corex tubes and incubated for a further 5 
minutes at room temperature.  
To separate the mixture into aqueous and organic phases, 0.1 volumes of 1-bromo-chloro-propane 
was added and mixed vigorously. The mixture was incubated for 5 minutes at room temperature 
before being centrifuged at 12000g for 15 minutes at 4°C (centrifuge 5417 C/R, Eppendorf, Hamburg, 
Germany). The upper, aqueous phase containing RNA was then transferred to a new Corex tube, 
precipitated with 0.5 volumes propan-2-ol for 10 minutes at room temperature and then centrifuged at 
12000g for 10 minutes at 4°C. The supernatant was removed and the pellet washed with 75% ethanol 
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before being centrifuged at 12000g for 10 minutes at 4°C. The supernatant was then removed and the 
pellet allowed to air dry before being re-suspended in 400 µl GDW. RNA concentration was 
determined spectrophotometrically. The RNA was diluted 1:100 in GDW and 1ml placed into a quartz 
cuvette. The absorbance was read at 260 and 280nm (UV-160 spectrophotometer, Shimadzu, Kyoto, 
Japan). The reading at 280nm gives an indication of the purity of the sample as phenol absorbs more 
strongly at 280nm than RNA. The concentration of RNA was calculated using the following formula: 
Concentration (µg/ml) = Abosrbance260 x dilution factor) x 40.  
The viability of the RNA was checked by running it on a denaturing 1% formaldehyde gel. 
 
4.3.3.2 DENATURING FORMALDEHYDE GEL TO CHECK VIABILITY OF TOTAL RNA 
Materials 
Agarose, type II-A medium EEO (Sigma-Aldrich) 
Formaldehyde (VWR) 
20 x MOPS pH7 (appendix) 
Ethidium bromide (VWR) 
DENAT (appendix) 
Gel loading buffer (appendix) 
100 x Tirs-EDTA (TE) pH7.5 (appendix) 
2M Sodium Acetate (NaAc) pH5.2 (appendix) 
Ethanol (VWR)  
Method 
A 1% agarose denaturing gel was prepared in 1 x MOPS buffer with 7.5% formaldehyde (v/v). 
Following quantification of RNA in the spectrophotometer, the RNA samples were ethanol 
precipitated with 0.1 volumes 2M NaAc pH 5.2 and 2.5 volumes ice cold ethanol. The samples were 
precipitated at -20°C for a minimum of 1 hour and centrifuged at 12000g for 7 minutes. The 
supernatant was removed and the pellet vacuum dried for 10 minutes to ensure all ethanol was 
removed. The pellet was re-suspended in an appropriate volume of PCR GDW to give a 5 mg/ml 
solution. One microlitre of this solution was added to 12 µl DENAT and the samples were denatured 
at 65°C for 5 minutes and 3 µl gel loading buffer added. The samples were then loaded onto the gel 
and run in 1 x MOPS buffer with 7.5% formaldehyde (v/v) at 150 volts for approximately 40 minutes 
until the gel front had run 10cm. The gel was then stained in 1 x TE with 0.01% ethidium bromide 
(v/v) on a shaking platform for 30 minutes. The gel was then de-stained overnight in 1 x TE to allow 
visualization under ultraviolet light of the 18s and 28s ribosomal bands and to ensure that the RNA 
had not degraded. 
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4.3.3.3 REVERSE TRANSCRIPTION (RT) 
Materials 
RNA (5 mg/ml) – CHO-GalR1, CHO-GalR2, GT1-7 or LβT2  
10 mM dNTPs (Amersham Biosciences, Little Chalfont, UK) 
5 x reverse transcriptase buffer (Promega, Madison WI) 
Avian myoblastoma virus reverse transcriptase (RT) 10 U/µl (Promega) 
Oligo dT (12-18) 200 ng/µl (Amersham Biosciences) 
 
Method 
The reaction was set up in a final volume of 20 µl containing the following: 1 mg/ml RNA, 1 x RT 
buffer, 1 mM dNTPs and 10 mg/ml oligo dT. The solution was heated to 65°C for 5 minutes and 
allowed to cool to room temperature for 30 minutes. 10 U RT was added and the reaction incubated at 
42°C for 60 minutes. The reaction was then used in polymerase chain reaction. 
 
4.3.3.4 POLYMERASE CHAIN REACTION (PCR) 
Materials  
10 x Taq buffer (Sigma-Aldrich) 
20 µM oligonucleotide primers (Eurogentec) 
Taq DNA polymerase (5U/µl) (Sigma-Aldrich) 
10 mM dNTPs (Amersham Biosciences) 
 
Method 
Riboprobe cDNA fragments were amplified using primers corresponding to sequences published in 
Nucleotide (http://www.ncbi.nlm.nih.gov/nuccore). Half of the RT reaction generated in 4.3.2.3 was 
added to a tube containing 1 x Taq buffer, 0.2 mM dNTPs, 200 nM oligonucleotide primers. The 
reaction was heated to 95°C for 5 minutes and then 5 U Taq DNA polymerase added. The reaction 
was cycled 25 times through the following temperatures: 95°C for 30s, 55°C for 30s and 72°C for 
30s. After completion of the reaction, 10 µl of the PCR products were visualized by gel 
electrophoresis on a 1% TAE/agarose gel. 
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 5' PRIMER 3' PRIMER BP 
ACCESSION 
NUMBER 
GalR1 CCAAGGTTCTCAATCATCTGC AGAACCGAATAGATACCCCG 357 NM 012958.2 
GalR2 CACACCTCGAAACGCGCTGGC CCCGCACTTCCCAACTGCAC 673 NM 019172.4 
GalR3 CTCATCTTCCTGTTGGGCATG CGGTACATCTGCTCATCTAC 234 NM 019173.1 
LH-R TCACAAGCTTTCAGGGGACT ATCCCTTGGAAAGCATTCCC 390 NM 013582.2 
 
TABLE 4.1 Primer sequences used in polymerase chain reaction (PCR), and the expected size of product in 
base pairs (BP). LH-R, luteinizing hormone receptor. 
 
4.3.3.5 VISUALISATION OF PCR PRODUCTS 
Materials 
Agarose, type II-A medium EEO (Sigma-Aldrich) 
50x Tris-acetate-EDTA buffer (TAE) (appendix) 
Ethidium bromide (10mg/ml) (VWR) 
DNA marker (BRL 1Kb ladder, Invitrogen) 
Gel loading buffer (appendix) 
Method 
A 1% (w/v) agarose gel was prepared by dissolving the agarose in 1 x TAE using a microwave oven 
(Panasonic, NNE205W). The gel was cooled to 45°C and ethidium bromide added to a final 
concentration of 0.5 µg/ml. Once set, the gel was placed into an electrophoresis tank containing 0.5x 
TAE.  
 
 
  
170 
 
4.3.4 MEMBRANE PREPARATIONS 
 
4.3.4.1 PREPARATION OF MEMBRANES FROM GALANIN RECEPTOR EXPRESSING 
CELLS AND GT1-7 CELLS  
Membranes for receptor binding studies were prepared by differential centrifugation as described 
previously (Coppock et al, 1999;Bhogal et al, 1993). At least 40 confluent T175 flasks were used for 
each membrane preparation. Cells were washed with ice-cold PBS and scraped into 1 mM HEPES pH 
7.4 (appendix) containing 30 µg/ml aprotinin, 0.5 µg/ml pepstatin, 0.25 µg/ml leupeptin, 0.25 µg/ml 
antipain, 0.1 mg/ml benzamidine and 10 µg/ml soybean trypsin inhibitor, using an Ultra Turrax T25 
homogeniser (IKA Labortechnik, Staufen, Germany). Homogenates were centrifuged at 1500g for 20 
minutes at 4°C (Beckman J2-21, rotor JS-13.1) and the supernatant centrifuged at 100000g at 4°C for 
60 minutes (Sorvall Ultracentrifuge OTD55B, rotor A-841, Cambridgeshire, UK). Pellets were then 
homogenised using a Potter-Elvehjem tissue grinder (Jencons, East Grinstead, West Sussex, UK) and 
re-suspended in 50 mM HEPES (appendix). The protein concentration in the membrane preparation 
was measured by Biuret assay (Gornall et al., 1949) and the preparations stored at -70°C. 
 
4.3.4.2 PREPARATION OF MEMBRANES FROM RAT HYPOTHALAMIC TISSUE 
Membranes were prepared by homogenisation and differential centrifugation. Twenty four 
hypothalami were collected from rats and stored at -70oC. Hypothalami were homogenised (Ultra-
Turrax T25) in ice cold homogenisation buffer containing sucrose (appendix) at 4oC. The 
homogenates were centrifuged at 1500g (Beckman J2-21, rotor JS-13.1) for 15 minutes at 4°C, and 
supernatants were then centrifuged at 100000g (Sorvall Ultracentrifuge OTD55B, rotor A-841, 
Cambridgeshire, UK) for 60 minutes at 4oC. Pellets were removed and re-suspended in 10 volumes of 
the homogenisation buffer without sucrose using a Potter-Elvehjem tissue grinder (Jencons, East 
Grinstead, West Sussex, UK), and re-centrifuged at 100000g for 60 minutes at 4oC as before. Finally, 
pellets were re-suspended in approximately 15 ml 50 mM homogenisation buffer and stored at -70oC 
in 500 µl aliquots. Protein concentration was measured by Biuret assay and the preparations stored at 
-70°C. 
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4.3.4.3 BIURET ASSAY TO DETERMINE PROTEIN CONCENTRATION OF 
MEMBRANES 
Protein concentrations of membranes were assessed by Biuret assay (Gornall et al., 1949). A standard 
curve was constructed using 10 mg/ml BSA standard, with a 1-5 mg/ml curve, and a zero tube 
containing GDW with no BSA. Membrane was added to tubes at 20 µl or 200 µl, and all tubes made 
up to a volume of 500 µl using GDW.  Biuret reagent (2.5 ml) (Sigma, USA) was added to each tube, 
and all tubes were incubated at room temperature and out of direct sunlight for 30 minutes. The 
absorbance at 540nm was then measured on a spectrophotometer (WPA Ltd, Cambridge, UK), 
zeroing the spectrophotometer reference using the 0 mg/ml standard. Membrane protein content was 
then calculated by linear regression of the absorbance values of the sample membrane, using the 
standard curve (GraphPad Prism 5 program). 
 
4.3.5 IODINATION OF GALANIN AND GLP-1  
Porcine galanin was iodinated using the chloramine-T method as previously described (Wood et al, 
1981). Porcine galanin is labelled with 125I at Tyr26 and is widely used as a radioligand in receptor 
membrane binding studies (Mazarati et al, 2004b;Wang et al, 1997c) and autoradiography (Skofitsch 
et al, 1986). It is preferred to 125I-human galanin, which is labelled at Tyr9, and may have altered 
ligand binding properties (Kolakowski, Jr. et al, 1998b). Galanin (2 µg) in 20 µl of 0.5M phosphate 
buffer was iodinated with 0.5 mCi of Na125I (IMS30 Amersham International) using Chloramine T 
(1.4µg/10µl) (Sigma) and the reaction stopped 15 seconds later with sodium metabisulphite 
(4.8µg/10µl) (VWR).   The iodinated peptide was purified by reversed-phase HPLC using an 
acetonitrile (ACN)/H2O/0.05% trifluoroacetic acid (TFA) gradient. Fractions of 0.5 ml were collected 
and activity tested.   
The direct iodogen method was used to iodinate GLP-1 as described previously (Wynick et al, 
1993c). Three nanomoles of GLP-1 in 10 µl of 0.2 M phosphate buffer pH 7.2 were reacted with 37 
MBq of 125I-Na (Amersham) and 23 nM (10 µg) of 1,3,4,6,-tetrachloro-3α, 6α-diphenylglycoluril 
(Iodogen reagent, Pierce Chemical Co, Perbio Science UK Ltd., Cramlington, UK) for 4 minutes at 
22°C. The radiolabelled 125I-GLP-1 was purified by reversed-phase HPLC using an acetonitrile 
(ACN)/H2O/0.05% trifluoroacetic acid (TFA) gradient.  
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4.3.6 COMPETITIVE RECEPTOR BINDING ASSAYS  
4.3.6.1 GALANIN RECEPTOR EXPRESSING MEMBRANES 
GalR1 and GalR2 expressing membranes (60 µg) were incubated for 45 minutes in siliconised 
polypropylene tubes together with 125I porcine galanin (1000 Bq) and unlabelled competing peptides 
(as specified), at 22°C in binding buffer (20 mM HEPES [pH 7.4], 5 mM MgCl2, 1% BSA) (appendix) 
in a final assay volume of 0.5 ml (Wynick et al, 1993b). The reaction was centrifuged (15,874g, 3 
minutes, 4°C) (Sigma Laboratory Centrifuges 3, rotor K18) to separate bound and free label. The 
pellets were then washed with assay buffer (0.5 ml, ice cold) and centrifuged (15,874g, 3 minutes, 
4°C).  
GalR3 expressing membrane was purchased from BioXtal (Mundolsheim, France), and was incubated 
according to the manufacturer’s instructions. Membrane (1.5 µg) was incubated for 90 minutes in 
siliconised polypropylene tubes together with 125I porcine galanin (1000 Bq) and unlabelled 
competing peptides (as specified), at room temperature in binding buffer (50 mM Tris HCl [pH 7.5], 5 
mM MgSO4, 1mM EDTA and 1% BSA) in a final assay volume of 0.2 ml. 
Bound radioactivity was measured by counting in a -counter for 240 seconds. Specific binding was 
calculated as the difference between the number of radioactive counts in 240 seconds in the absence 
(total binding) and presence (nonspecific binding) of 400 nM (1 mM for GalR3 membrane) unlabelled 
galanin. Equilibrium competition curves were constructed with increasing amounts of unlabelled 
peptide (1 x 10-13 – 10-3 M).  
All curves were performed with points in triplicate. IC50 values were calculated from nonlinear 
regression analysis using the GraphPad Prism 5 program (GraphPad Software Inc., San Diego, CA).  
 
4.3.6.2 HYPOTHALAMIC MEMBRANE 
Hypothalamic membrane (10 µg) was incubated with 125I galanin (1000 Bq) and increasing 
concentrations of unlabelled competing peptide (as specified) in 20 mM HEPES buffer (appendix) 
under the conditions described for GalR1 and GalR2 expressing membranes in section 4.3.6.1. 
 
4.3.6.3 GT1-7 MEMBRANE 
Binding of GLP-1 and galanin at the GT1-7 membrane was carried out under the conditions described 
in section 4.3.6.1. GT1-7 membrane (60 µg) was incubated with either 125I GLP-1 (1000 Bq) and 
increasing concentrations of unlabelled GLP-1, or 125I galanin (1000 Bq) and increasing 
concentrations of unlabelled galanin in 20 mM HEPES binding buffer (appendix).   
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4.3.7 GALANIN RECEPTOR ANTAGONIST STUDIES 
C7 (galanin(1-12)-Pro-spantide-amide) is a high affinity galanin receptor antagonist which has been 
reported to inhibit galanin-induced effects in vivo and in vitro (Crawley et al, 1993;Xu et al, 1995c). 
C7 binds to all three galanin receptors, with greatest affinity for the GalR3 in vitro (Smith et al, 1998). 
 
4.3.7.1 COMPETITIVE RECEPTOR BINDING OF C7 TO MEMBRANES EXPRESSING 
GALR1, GALR2 AND GALR3 
Competition receptor binding assays were carried out as previously described in section 4.3.6.1 for 
each of the galanin receptor expressing membranes. The cold-ligand used in these experiments was 
C7 (500 nM). 
 
4.3.7.2 EFFECT OF GALANIN ON GNRH RELEASE FROM GT1-7 CELLS 
GT1-7 cells were maintained and plated as described in section 3.3.4.3. Cells were incubated for 240 
minutes in 0.5 ml serum-free medium (basal), serum-free medium containing galanin (10, 100, or 
1000 nM), or serum-free medium containing GLP-1 (100 nM) (positive control) (n = 9-10 per group).  
 
4.3.7.3 EFFECT OF C7 ON ALARIN INDUCED GNRH RELEASE FROM GT1-7 CELLS 
GT1-7 cells were maintained and plated as described in section 3.3.4.3. Cells were incubated for 240 
minutes in 0.5 ml serum-free medium (basal), serum-free medium containing alarin (1000 nM), 
serum-free medium containing C7 (100 nM), serum-free medium containing alarin (1000 nM) and C7 
(100nM) or serum-free medium containing GLP-1 (100 nM) (positive control) (n = 10-12 per group).  
 
4.3.7.4 EFFECT OF GALANIN AND C7 ON LH RELEASE FROM LβT2 CELLS 
LβT2 cells were maintained and plated as described in section 3.3.4.5. Cells were incubated for 240 
minutes in 0.5 ml serum-free medium (basal), serum-free medium containing galanin (10, 100 or 1000 
nM), or serum-free medium containing GnRH (100 nM) (positive control) (n = 10-14 per group). 
 
In a separate experiment, cells were incubated in 0.5 ml serum-free medium (basal), serum-free 
medium containing C7 (100 nM), serum-free medium containing galanin (1000 nM), serum-free 
medium containing galanin (1000 nM) and C7 (100 nM), or serum-free medium containing GnRH 
(100 nM) (positive control) (n = 7-8 per group).  
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4.3.7.5 EFFECT OF C7 ON GALP INDUCED LH RELEASE FROM LβT2 CELLS 
LβT2 cells were maintained and plated as described in sections 3.3.4.5. Cells were incubated for 240 
minutes in 0.5 ml serum-free medium (basal), serum-free medium containing GALP (1000 nM), 
serum-free medium containing C7 (100 nM), serum-free medium containing GALP (1000 nM) and 
C7 (100nM) or serum-free medium containing GnRH (100 nM) (positive control) (n = 7-8 per group).  
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4.3.8 THE EFFECT OF N TERMINAL TRUNCATION ON ALARIN BIOACTIVITY  
 
4.3.8.1 IN VIVO STUDIES 
 
ALARIN 3-25 
There is a putative enzymatic cleavage site between amino acids two and three of alarin (Pro-Ala). Di-
peptidyl peptidase IV (DPP-IV) selectively cleaves two amino acids from peptides which have proline 
or alanine in the second position. The second amino acid of alarin is proline, making it susceptible to 
DPP-IV degradation (Baum et al, 2003). To determine whether alarin peptide fragments lacking N-
terminal amino acids have altered bioactivity in vivo, alarin 3-25 was administered ICV to rats and 
food intake and plasma hormone levels measured. 
 
4.3.8.1.1 ICV CANNULATION AND ICV INJECTION 
Male Wistar rats were ICV cannulated as described in section 2.3.3.1 and injections carried out as 
described in section 2.3.3.2. 
 
4.3.8.1.2 EFFECT OF ICV ADMINISTRATION OF ALARIN 3-25 ON FOOD INTAKE IN 
AD-LIBITUM FED RATS IN THE EARLY LIGHT PHASE 
Groups of ad-libitum fed male Wistar rats received a single ICV injection of either 0.9% saline, alarin 
3-25 (30 nmol), or 2.4 nmol NPY (positive control) during the early light phase between 0900 and 
1000h (n = 10-11 saline or alarin, n = 5 NPY).  Following injection, animals were returned to their 
home cages with a pre-weighed amount of chow and free access to water.  The remaining food was 
reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body-weight was measured at 0 and 24 hours 
post-injection.  
 
4.3.8.1.3 EFFECT OF ICV ADMINISTRATION OF ALARIN 3-25 ON PLASMA LH AND 
CORTICOSTERONE IN INTACT MALE RATS 
Groups of intact male Wistar rats were ICV injected with either 0.9% saline, alarin 3-25 (30 nmol), or 
1 nmol kisspeptin-10 (positive control) during the early light phase between 0900 and 1000h (n = 10 
saline, n = 4-5 alarin 3-25 and kisspeptin). Rats were decapitated 30 minutes after injection. Trunk 
blood was collected in both lithium heparin tubes containing 4200 kallikrein inhibitor units aprotinin 
(Bayer Corp., Haywards Heath, UK), and tubes containing potassium EDTA (final concentration of 
1.2-2mg EDTA/ml blood) (Starstedt). Plasma was separated by centrifugation, frozen on dry ice, and 
stored at -20°C until measurement of LH and corticosterone by RIA. 
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4.3.8.2 IN VITRO STUDIES 
 
ALARIN 6-25 
The first 5 amino acids of alarin are identical to the first five amino acids of GALP. These residues 
may therefore be important in mediating the common effects of alarin and GALP. To determine 
whether this sequence is critical to biological activity, I looked at the effect of alarin 6-25 on GT1-7 
cells in vitro. 
 
4.3.8.2.1 EFFECT OF ALARIN 3-25 AND ALARIN 6-25 ON GNRH RELEASE FROM GT1-7 
CELLS 
GT1-7 cells were maintained as described previously and secretion experiments performed as 
described in section 3.3.4.3. Cells were incubated in 0.5 ml serum-free medium (basal), serum-free 
medium containing alarin 1-25 (10, 100, or 1000 nM), serum-free medium containing alarin 3-25 (10, 
100 or 1000 nM) or serum-free medium containing GLP-1 (100 nM) (positive control) (n = 14-19 per 
group).  
In a separate experiment, GT1-7 cells were incubated in 0.5 ml serum-free medium (basal), serum-
free medium containing alarin 6-25 (10, 100 or 1000 nM) or serum-free medium containing GLP-1 
(100 nM) (positive control) (n = 21-23 per group).  
 
4.3.8.2.2 COMPETITIVE RECEPTOR BINDING OF ALARIN 3-25 AND ALARIN 6-25 TO 
MEMBRANES EXPRESSING GALR1, GALR2 AND GALR3 
Competitive receptor binding assays for galanin receptor expressing membranes were carried out with 
alarin 3-25 and alarin 6-25 as the cold ligands under the conditions described in section 4.3.5.1.  
 
4.3.9 STATISTICS 
All data is presented as mean ± SEM. Data from in vivo HPG axis studies were analysed using a one-
way ANOVA with post-hoc Tukey’s multiple comparison test. Data from the feeding study and cell 
release studies were analysed using a one-way ANOVA with post-hoc Dunnett’s multiple comparison 
test (GraphPad Prism 5). In all cases, P<0.05 was considered to be statistically significant. 
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4.4 RESULTS 
 
4.4.1 CONFIRMATION OF GALANIN RECEPTOR EXPRESSION BY RT-PCR  
CHO-GalR1 expressing cells expressed GalR1 mRNA as shown by RT-PCR. A band of 
approximately 357 base pairs was seen when compared to a 1Kb ladder (Figure 4.2A).  
CHO-GalR2 expressing cells expressed GalR2 mRNA as shown by RT-PCR. A band of 
approximately 673 base pairs was seen when compared to a 1Kb ladder (Figure 4.2B).  
 
 
FIGURE 4.2 A) Galanin receptor 1 (GalR1) mRNA expression in CHO-GalR1 cell line as determined by 
reverse transcription-polymerase chain reaction (RT-PCR). R1-, CHO GalR1 RNA without reverse transcriptase 
enzyme (RT); R1+, CHO-GalR1 RNA with RT; L, 1-Kb ladder. The size of the expected PCR product for 
GalR1 was 357 base pairs. B) Galanin receptor 2 (GalR2) mRNA expression in CHO-GalR2 cell line as 
determined by RT-PCR. R2-, CHO GalR2 RNA without RT; R2+, CHO-GalR2 RNA with RT; L, 1-Kb ladder. 
The size of the expected PCR product for GalR2 was 673 BP.  
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4.4.2 COMPETITIVE RECEPTOR BINDING ASSAYS  
 
4.4.2.1 GALANIN RECEPTOR EXPRESSING MEMBRANES 
Alarin was unable to displace I125 galanin binding at the GalR1, GalR2, or GalR3 (IC50 values: alarin, 
> 1000 nM for all membranes). Galanin and GALP, the positive controls, were able to displace I125 
galanin binding at the GalR1 (specific binding 91.6 ± 1.5%)  (IC50 values: galanin, 1.4 ± 0.0 nM; 
GALP, 45.0 ± 0.1 nM), GalR2 (specific binding 63.0 ± 2.7%) (IC50 values: galanin 1.9 ± 0.1 nM: 
GALP, 18.7 ± 0.2 nM), and GalR3 (specific binding 47.1 ± 1.8%) (IC50 values: galanin, 108.4 ± 0.3 
µM; GALP, 1.5 ± 0.2 µM; alarin >1000 µM).  Results are pooled from two independent experiments 
performed in triplicate (n = 4–6 per point) (Figure 4.3A, B and C). 
 
4.4.2.2 HYPOTHALAMIC MEMBRANE 
Alarin was unable to displace I125 galanin binding at hypothalamic membrane (IC50 value: alarin > 
1000 nM). Galanin and GALP, the positive controls, were able to displace I125 galanin binding at the 
hypothalamic membrane (specific binding 75.8 ± 2.1%)  (IC50 values: galanin, 0.1 ± 0.1 nM; GALP, 
36.9 ± 0.1 nM). Results are from two independent experiments performed in triplicate (n = 4–6 per 
point) (Figure 4.3D).  
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FIGURE 4.3 Competitive receptor binding of I125 radiolabelled galanin binding with increasing concentrations 
of unlabelled galanin (○), GALP (□) and alarin (∆) to membranes prepared from A) CHO cells transfected with 
GalR1 (IC50 values: galanin, 1.4 ± 0.0; GALP, 45.0 ± 0.1; alarin >1000 nM), B) CHO cells transfected with 
GalR2 (IC50 values: galanin, 1.9 ± 0.1; GALP, 18.7 ± 0.2; alarin >1000 nM), C) GalR3 expressing membrane 
(IC50 values: galanin, 108.4 ± 0.3; GALP, 1.5 ± 0.2; alarin >1000 µM), D) male rat hypothalamus (IC50 values: 
galanin, 0.06 ± 0.1; GALP, 36.9 ± 0.1; alarin >1000 nM). Results are mean ± SEM from two independent 
experiments performed in triplicate (n = 4–6 per point).  
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4.4.3 DETERMINING GALANIN RECEPTOR EXPRESSION IN GT1-7 AND LβT2 CELLS 
GT1-7 cells do not express detectable levels of mRNA for any of the galanin receptors (Figure 4.4A). 
GT1-7 cells do express mRNA for the LH receptor confirming the viability of the RNA (Lei & Rao, 
1994) (Figure 4.4B). LβT2 cells express mRNA for the GalR3 receptor, but not for the GalR1 or 
GalR2 receptors (Figure 4.4A). 
 
 
FIGURE 4.4 A) Galanin receptor mRNA expression in LβT2 and GT1-7 cell lines as determined by reverse 
transcription-polymerase chain reaction (RT-PCR). R1, GalR1 specific primers; R2, GalR2 specific primers; 
R3, GalR3 specific primers; + reverse transcriptase (RT) enzyme; - RT enzyme; L, 1-Kb+ ladder. The size of 
the expected PCR product for GalR1 was 357 base pairs (BP), GalR2 was 673BP and GalR3 was 234BP. B) 
Luteinising hormone receptor (LH-R) mRNA expression in the GT1-7 cell line as determined by RT-PCR. LH-
R, LH-R specific primers; L, 1-Kb+ ladder. The size of the expected PCR product for LH-R was 390BP. 
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4.4.4 COMPETITIVE RECEPTOR BINDING ASSAYS AT GT1-7 MEMBRANE 
I125 labelled GLP-1 was able to bind to GT1-7 membrane, and was displaced with increasing 
concentrations of unlabelled GLP-1 (specific binding 30.0 ± 2.4%) (IC50 value 1.7 ± 0.1 nM), 
confirming the receptor bioactivity of the membrane prep (n = 3 per point) (Figure 4.5A). I125 labelled 
galanin was unable to bind to GT1-7 membrane (specific binding less than 3%) (n = 3 per point) 
(Figure 4.5B). 
 
 
FIGURE 4.5 A) Competitive receptor binding of I125 radiolabelled glucagon-like peptide (GLP-1) binding 
with increasing concentrations of unlabelled GLP-1 to membrane prepared from GT1-7 cells (IC50 value 1.7 ± 
0.1 nM) (n = 3 per point). B) Competitive receptor binding of I125 radiolabelled galanin binding with increasing 
concentrations of unlabelled galanin to membrane prepared from GT1-7 cells (specific binding <3%) (n = 3 per 
point). Results are mean ± SEM.  
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4.4.5 GALANIN RECEPTOR ANTAGONIST STUDIES 
 
4.4.5.1 COMPETITIVE RECEPTOR BINDING OF C7 AT MEMBRANES EXPRESSING 
GALR1, GALR2 AND GALR3 
The non-specific galanin receptor antagonist C7 (500 nM) was able to displace I125 labelled galanin 
binding to membranes expressing GalR1, GalR2 and GalR3.  
 
Cold peptide 
GalR1 
(% of total) 
GalR2 
(% of total) 
GalR3 
(% of total) 
Total 100.0 ± 3.0 100.0 ± 0.4 100.0 ± 4.0 
C7 500 nM 19.7 ± 0.4 56.4 ± 2.1 32.2 ± 0.6 
 
TABLE 4.2 Competitive receptor binding of I125 radiolabelled galanin binding with no cold peptide (total), or 
galanin receptor antagonist, C7 (500 nM), to membranes prepared from GalR1, GalR2 and GalR3 expressing 
cells (n = 3 per group). Results are mean ± SEM. 
 
 
4.4.5.2 EFFECT OF GALANIN ON GNRH RELEASE FROM GT1-7 CELLS 
Incubation of GT1-7 cells with galanin (10, 100 or 1000 nM) had no effect on GnRH release 
compared to basal. Incubation with GLP-1 (100 nM) significantly stimulated GnRH release; P<0.001 
vs. basal (n = 9-10 per group).  
 
Treatment and dose GnRH release (% of basal) 
Basal 100.0 ± 6.3 
Galanin 10 nM 89.8 ± 3.4 
Galanin 100 nM 95.0 ± 4.5 
Galanin 1000 nM 110.8 ± 9.3 
GLP-1 100 nM 168.2 ± 8.4*** 
 
TABLE 4.3 The effect on GnRH release from GT1-7 cells of a 240 minute incubation with serum-free 
medium (basal), serum-free medium containing galanin (10, 100, 1000 nM), or serum-free medium containing 
glucagon-like peptide 1 (GLP-1) (100 nM) (positive control) (n = 9-10 per group). ***, P<0.001 vs. basal 
release. Results are mean ± SEM. 
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4.4.5.3 EFFECT OF C7 ON ALARIN INDUCED GNRH RELEASE FROM GT1-7 CELLS 
Treatment with alarin (1000 nM) significantly stimulated GnRH release from GT1-7 cells compared 
to basal; P<0.01, n = 10-12). Treatment with C7 (100 nM) alone had no effect on GnRH release from 
GT1-7 cells, and had no effect on the alarin-induced increase in GnRH. Incubation with GLP-1 (100 
nM) significantly stimulated GnRH release; P<0.001 vs. basal, n = 10-12 per group).  
 
Treatment and dose GnRH release (% of basal) 
Basal 100.0 ± 7.0 
C7 100 nM 100.2 ± 8.5 
Alarin 1-25 1000 nM 132.2 ± 9.3** 
Alarin 1-25 1000 nM + C7 1000 nM 131.2 ± 8.9** 
GLP-1 100 nM 153.4 ± 7.2*** 
 
TABLE 4.4 The effect on GnRH release from GT1-7 cells of a 240 minute incubation with serum-free 
medium (basal), serum-free medium containing C7 (100 nM), serum-free medium containing alarin (1000 nM), 
serum-free medium containing C7 (100 nM) and alarin (1000 nM) or serum-free medium containing glucagon-
like peptide 1 (GLP-1) (100 nM) (positive control) (n = 10-12 per group). **, P<0.01 vs. basal release ***, 
P<0.001 vs. basal release. Results are mean ± SEM. 
4.4.5.4 EFFECT OF GALANIN AND C7 ON LH RELEASE FROM LβT2 CELLS 
Treatment with 1000 nM galanin significantly increased LH release from LβT2 cells compared to 
basal. GnRH 100 nM, the positive control, significantly stimulated LH release from LβT2 cells (LH 
ng/ml: basal 6.1 ± 0.4, 1000 nM galanin 11.4 ± 1.1 P<0.001 vs. basal, 100 nM GnRH 11.0 ± 1.1 
P<0.001 vs. basal, n = 10-14 per group) (Figure 4.6A). 
 
Incubation of LβT2 cells with C7 alone had no effect on LH release compared to basal.  When LβT2 
cells were incubated with both C7 and galanin together, the galanin-induced increase in LH release 
was attenuated (LH ng/ml: basal 6.2 ± 0.7, 1000 nM galanin 14.4 ± 1.2 P< 0.001 vs. basal, 100 nM C7 
and 1000nM galanin 9.6 ± 1.3 P< 0.05 vs. 1000 nM galanin, 100 nM GnRH 14.7 ± 1.3 P<0.001 vs. 
basal, n = 7-8 per group) (Figure 4.6B). 
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4.4.5.5 EFFECT OF C7 ON GALP INDUCED LH RELEASE FROM LβT2 CELLS 
Treatment with 1000 nM GALP significantly increased LH release from LβT2 cells compared to 
basal. GnRH 100 nM, the positive control, significantly stimulated LH release from LβT2 cells. 
Incubation with C7 alone had no significant effect on LH release from LβT2 cells compared to basal. 
The GALP-induced increase in LH release was attenuated by co-incubation with C7 (LH ng/ml: basal 
4.2 ± 0.4, 1000 nM GALP 7.1 ± 1.3 P< 0.05 vs. basal, 100 nM C7 and 1000nM galanin 4.4 ± 0.5 P< 
0.05 vs. 1000 nM GALP, 100 nM GnRH 7.7 ± 1.2 P<0.01 vs. basal, n = 7-8 per group) (Figure 4.6B). 
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FIGURE 4.6 A) The effect on luteinising hormone (LH) release from LβT2 cells of a 240 minute incubation 
with serum-free medium (basal), serum-free medium containing galanin (10, 100, 1000 nM), or serum-free 
medium containing gonadotrophin releasing hormone (GnRH) (100 nM) (positive control) (n = 10-14 per 
group). B) The effect on LH release from LβT2 cells of a 240 minute incubation with serum-free medium 
(basal), serum-free medium containing C7 (100 nM), serum-free medium containing galanin (1000 nM), serum-
free medium containing C7 (100 nM) and galanin (1000 nM), or serum-free medium containing GnRH (100 
nM) (n = 7-8 per group). C) The effect on LH release from LβT2 cells of a 240 minute incubation with serum-
free medium (basal), serum-free medium containing C7 (100 nM), serum-free medium containing galanin-like 
peptide (GALP) (1000 nM), serum-free medium containing C7 (100 nM) and GALP (1000 nM), or serum-free 
medium containing GnRH (100 nM) (n = 7-8 per group). *, P<0.05 vs. basal release **, P<0.01 vs. basal release 
***, P<0.001 vs. basal release. #, P<0.05 vs. galanin/GALP release. Results are mean ± SEM.  
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4.4.6 THE EFFECT OF N TERMINAL TRUNCATION ON ALARIN BIOACTIVITY  
 
4.4.6.1 IN VIVO STUDIES 
 
4.4.6.1.1 EFFECT OF ICV ADMINISTRATION OF ALARIN 3-25 ON FOOD INTAKE IN 
AD-LIBITUM FED RATS IN THE EARLY LIGHT PHASE 
ICV alarin 3-25 (30 nmol) administration and ICV NPY 2.4 nmol administration (positive control) 
significantly increased food intake between 0-2h post-injection compared to saline injected controls 
(0-2h food intake/g: saline 1.1 ± 0.4, alarin 3-25 30 nmol 2.6 ± 0.4 P<0.05, NPY 2.4 nmol 7.6 ± 1.8 
P<0.001, n = 10-11 saline and alarin 3-25, n = 5 NPY). There was no significant effect of alarin 3-25 
on food intake at any other time point studied. There was no significant effect of alarin 3-25 on body 
weight at 24h (Figure 4.7). 
 
 
FIGURE 4.7 The effect of ICV injection of saline, alarin 3-25 (30 nmol) (n = 10-11) or neuropeptide Y (NPY) 
(2.4 nmol) (positive control) (n = 5) on 0-1h (A), 1-2h (B), and 0-2h (C) food intake in ad-libitum fed male rats 
in the early light phase. *, P<0.05; ***, P<0.001 vs. saline. Results are mean ± SEM.  
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4.4.6.1.2 EFFECT OF ICV ADMINISTRATION OF ALARIN 3-25 ON PLASMA LH IN 
INTACT MALE RATS 
ICV administration of alarin 3-25 (30 nmol) had no significant effect on plasma LH concentration 30 
minutes after injection in intact male rats. ICV kisspeptin-10 (1 nmol), the positive control, 
significantly stimulated plasma LH compared to saline injected controls (plasma LH ng/ml; saline 0.7 
± 0.1, 30 nmol alarin 3-25 0.7 ± 0.2, 1 nmol kisspeptin 5.3 ± 0.7 P<0.001, n = 10 saline, n = 4-5 alarin 
3-25 and kisspeptin) (Figure 4.8A). 
 
4.4.6.1.3 EFFECT OF ICV ADMINISTRATION OF ALARIN 3-25 ON PLASMA 
CORTICOSTERONE IN INTACT MALE RATS 
ICV alarin 3-25 administration significantly increased plasma corticosterone at 30 minutes post 
injection (plasma corticosterone ng/ml; saline 178.6 ± 37.9, 30 nmol alarin 3-25 323.7 ± 127.0 
P<0.05, n = 9 saline, n = 5 alarin 3-25) (Figure 4.8B). 
 
 
FIGURE 4.8 A) The effect of ICV injection of saline, alarin 3-25 (30 nmol) or kisspeptin-10 (1 nmol) (n = 10 
saline, n = 4-5 alarin 3-25 and kisspeptin) on plasma luteinising hormone (LH) levels 30 minutes after 
administration in ad-libitum fed intact male rats. ***, P<0.001 vs. saline. B) The effect of ICV injection of 
saline or alarin 3-25 (30 nmol) (n = 9 saline, n= 5 alarin) on plasma corticosterone levels 30 minutes after 
administration in ad-libitum fed intact male rats. *, P<0.05 vs. saline. Results are mean ± SEM. 
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4.4.6.2 IN VITRO STUDIES 
 
4.4.6.2.1 EFFECT OF ALARIN 3-25 AND ALARIN 6-25 ON GNRH RELEASE FROM GT1-7 
CELLS 
Treatment with 1000 nM alarin 3-25 significantly increased GnRH release from GT1-7 cells 
compared to basal after 240 minute incubation (P<0.05, n = 14-19 per group). Treatment with 1000 
nM alarin 1-25 significantly increased GnRH release from GT1-7 cells compared to basal after 240 
minute incubation (P<0.01, n = 14-19 per group). There was no significant effect of any lower doses 
of alarin 1-25 or alarin 3-25 on GnRH release, and there was no significant difference in GnRH 
release following treatment between treatment with alarin 1-25 (1000 nM) and alarin 3-25 (1000 nM). 
Incubation with GLP-1 (100 nM) significantly stimulated GnRH release; P<0.001 vs. basal, n = 14-19 
per group). 
 
Treatment and dose GnRH release (% of basal) 
Basal 100 ± 12.8 
Alarin 1-25 10 nM 118.1 ± 10.4 
Alarin 1-25 100 nM 115.3 ± 9.3 
Alarin 1-25 1000 nM 157.5 ± 11.6** 
Alarin 3-25 10 nM 120.3 ± 11.5 
Alarin 3-25 100 nM 141.2 ± 11.1 
Alarin 3-25 1000 nM 149.4 ± 7.3* 
GLP-1 100 nM 168.6 ± 14.1*** 
 
TABLE 4.5 The effect on GnRH release from GT1-7 cells of a 240 minute incubation with serum-free 
medium (basal), serum-free medium containing alarin 1-25 (10, 100, 1000 nM), serum-free medium containing 
alarin 3-25 (10, 100, 1000 nM), or serum-free medium containing glucagon-like peptide 1 (GLP-1) (100 nM) 
(positive control) (n = 14-19 per group). *, P<0.05 vs. basal release; **, P<0.01 vs. basal release; ***, P<0.001 
vs. basal release. Results are mean ± SEM.  
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Incubation with alarin 6-25 had no significant effect on GnRH release from GT1-7 cells compared to 
basal.  
Treatment and dose GnRH release (% of basal) 
Basal 100 ± 12.2 
Alarin 6-25 10 nM 129.5 ± 12.2 
Alarin 6-25 100 nM 103.8 ± 9.7 
Alarin 6-25 1000 nM 105.4 ± 10.7 
Glucagon-like peptide-1 100 nM 172.5 ± 12.0** 
 
TABLE 4.6 The effect on GnRH release from GT1-7 cells of a 240 minute incubation with serum-free 
medium (basal), serum-free medium containing alarin 6-25 (10, 100, 1000 nM), or serum-free medium 
containing glucagon-like peptide 1 (GLP-1) (100 nM) (positive control) (n = 21-23 per group). **, P<0.01 vs. 
basal release. Results are mean ± SEM.  
 
4.4.6.2.2 COMPETITVE RECEPTOR BINDING OF ALARIN 3-25 AND ALARIN 6-25 AT 
GALANIN RECEPTOR EXPRESSING MEMBRANES 
Alarin 3-25 and alarin 6-25 were unable to displace radiolabelled galanin from binding to any of the 
three galanin receptor expressing membranes. 
 
 
Cold peptide 
GalR1 
(% of total) 
GalR2 
(% of total) 
GalR3 
(% of total) 
Total 100.0 ± 1.4 100.0 ± 1.0 100.0 ± 0.8 
Galanin 400 nM 13.3 ± 0.7 53.3 ± 1.4 50.5 ± 2.7 
Alarin 3-25 1000 nM 105.1 ± 1.5 101.6 ± 2.3 96.4 ± 2.0 
Alarin 6-25 1000 nM 103.1 ± 0.5 101.8 ± 2.2 98.4 ± 1.4 
 
TABLE 4.7 Competitive receptor binding of I125 radiolabelled galanin binding with no cold peptide (total), 
galanin (400 nM), alarin 3-25 (1000 nM) or alarin 6-25 (1000 nM), to membranes prepared from GalR1, GalR2 
and GalR3 expressing cells (n = 3 per group). Results are mean ± SEM. 
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4.5 DISCUSSION 
Alarin lacks the galanin receptor binding domain which is thought to be responsible for the binding of 
galanin and GALP to the three known galanin receptors (Bloomquist et al, 1998;Land et al, 
1991;Lang et al, 2005;Smith et al, 1998). It has previously been reported that alarin is unable to bind 
to membrane preparations of human GalR1- or GalR2-expressing neuroblastoma cells (Santic et al, 
2007). My results support this finding, demonstrating that alarin is unable to compete with the binding 
of radiolabelled galanin to membranes from CHO cells expressing the GalR1 or GalR2, and I have 
also shown that alarin is unable to compete with the binding of radiolabelled galanin to membranes 
expressing GalR3. Galanin and GALP were able to dose dependently displace galanin binding at all 
three receptors, confirming the viability of the membranes.  
 
The IC50 values I obtained for my receptor binding studies using the GalR1 and GalR2 expressing 
membranes are in keeping with those reported previously (Lang et al, 2005;Ohtaki et al, 1999). 
Galanin binds with the greatest affinity to the GalR1, then the GalR2, and with much weaker affinity 
to the GalR3. GALP binds preferentially to the GalR2, over the GalR1. The GalR3 showed a much 
greater preference for GALP binding compared to galanin, although the IC50 values I recorded suggest 
much weaker binding of both galanin and GALP to the GalR3 than those documented in previous 
studies (Lang et al, 2005;Smith et al, 1998). This may be due to differences in receptor density within 
membrane preparations, or differences in the conditions used for the receptor binding studies resulting 
in poorer sensitivity. Transfection of cell lines with GalR3 has been reported to yield very low 
receptor expression, which may account for the variability between recorded IC50 values (Lang et al, 
2005;Ohtaki et al, 1999). 
 
The hypothalamus expresses all three galanin receptors (Seth et al, 2004). My data suggests that alarin 
does not compete with radiolabelled galanin binding to male rat hypothalamic membranes. Again, 
GALP was able to compete with radiolabelled galanin in this experiment. This suggests that it is 
unlikely that the hypothalamus expresses a receptor to which both alarin and galanin bind. 
Previous studies suggest that none of the known galanin receptors are expressed in GT1-7 cells (Seth 
et al, 2004) and galanin has no effect on GnRH release from GT1-7 cells (Seth et al, 2004). I have 
repeated these findings, and demonstrated using receptor binding studies that radiolabelled galanin is 
unable to bind to GT1-7 cell membranes. GLP-1 was able to bind to GT1-7 membrane and was 
displaced by increasing concentrations of unlabelled GLP-1, confirming the viability of this 
membrane. The release of GnRH from GT1-7 cells in response to alarin and GALP therefore strongly 
suggests that an as yet unidentified receptor mediates this effect, and that this unidentified receptor is 
unable to bind galanin.  
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There is evidence to suggest that GALP mediates some of its biological effects in vivo via a receptor 
or receptors distinct from the three known galanin receptors (Krasnow et al, 2004;Lawrence et al, 
2003;Matsumoto et al, 2001;Seth et al, 2004). It is possible that alarin may act as a ligand for the 
same unidentified receptor or receptors. It is difficult to determine whether GALP and alarin bind to 
the same receptors. GALP has been reported to be very adhesive (Lang et al, 2005) and I125 labelled 
GALP shows high non-specific binding to receptor membranes. Radiolabelling alarin would be useful 
to determine whether alarin binds to GT1-7 membrane, and whether it could be displaced by GALP, 
suggesting a common alarin/GALP receptor.  
 
GT1-7 cells express mRNA for receptors of peptides involved in the regulation of the HPG axis and 
energy homeostasis (Yang et al, 2005b). It is possible that GALP, instead of binding to an as yet 
unknown receptor, acts as a ligand at a characterised receptor. This receptor, expressed by GT1-7 
cells, may already be implicated in the regulation of GnRH release and/or energy homeostasis. 
GPR54 is the kisspeptin receptor, which is structurally similar to the galanin receptors, sharing 45% 
homology with the GalR1 and GalR3, and 44% homology with the GalR2 (Lee et al, 1999). Despite 
this similarity in structure, galanin does not bind to GPR54 (Ohtaki et al, 2001). It would be 
interesting to investigate whether GALP or alarin binds to this receptor. Acting as a ligand at the 
GPR54, kisspeptin potently stimulates the HPG axis by increasing GnRH release (Thompson et al, 
2004). GPR54 mRNA is expressed in GT1-7 cells (Quaynor et al, 2007) and it is possible that GALP 
and/or alarin binds to this receptor to stimulate the HPG axis.  
 
I have shown that galanin and GALP, but not alarin, stimulate LH release from LβT2 cells, a cell line 
resembling mature gonadotrophs. LβT2 cells express the GalR3, but not GalR1 or GalR2. There are 
contradictory reports on the role of galanin in the direct regulation of pituitary LH release. Galanin 
has been reported to stimulate LH release and potentiate GnRH-induced LH release from male and 
proestrus female rat pituitary cells in vitro (Lopez et al, 1991;Leiva & Croxatto, 1994;Peters et al, 
2009). However, a study using very similar methods observed a suppression of GnRH-induced LH 
release from proestrus female rat pituitaries, following incubation with galanin (Todd et al, 1998). 
There was no effect of galanin alone on LH release, or on GnRH-induced LH release from pituitaries 
harvested at any other stage of the oestrus cycle (Todd et al, 1998). Galanin has also been reported to 
have no effect on LH release from male rat isolated anterior pituitary cells (Billiard, 1996). These 
studies suggest that the modulatory effects of galanin on pituitary LH release may be oestrous cycle- 
dependent and sex specific. 
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GALP also stimulates LH release from LβT2 cells, and this is the first time that a biological effect of 
GALP, likely mediated via the GalR3, has been reported. GALP binds to the GalR3 in binding assays, 
but has not been shown to activate any intracellular signalling pathways in functional assays in vitro 
(Lang et al, 2005). The stimulatory effects of GALP and galanin on LH release were blocked by co-
incubation with the non-specific galanin receptor antagonist, C7. It is possible that GalR1 and GalR2 
transcripts are expressed in LβT2 cells, although at very low levels. It would be useful to directly 
compare the potency of galanin and GALP on LH release from LβT2 cells, as GALP binds with 
higher affinity than galanin at the GalR3 (Lang et al, 2005;Smith et al, 1998). The presence of a novel 
galanin receptor in the anterior pituitary has been suggested based on the ability of galanin(3–29), a 
peptide which does not show high-affinity binding to either GalR1, GalR2 or GalR3 (Smith et al, 
1998), to increase prolactin (Wynick et al, 1993b) and decrease gonadotrophin (Todd et al, 1998) 
release in dispersed pituitary cells.  
 
The first two amino acids of alarin (pro-ala) may be cleaved by the proteolytic enzyme DPP-IV, 
resulting in a receptor agonist with different receptor affinities and biological functions, as observed 
for other neuropeptides like NPY (Ghersi et al, 2001). To test this hypothesis, I used alarin 3-25 in 
both in vivo and in vitro experimental paradigms where I have observed a biological effect of full-
length alarin. Alarin 3-25 (30 nmol) displayed some biological effects similar to those seen with alarin 
1-25: ICV administration of alarin 3-25 (30 nmol) significantly stimulated food intake between 0-2 
hours post-injection and also increased plasma corticosterone levels in vivo. Unlike ICV 
administration of full-length alarin, alarin 3-25 (30 nmol) had no effect on plasma LH levels. The 
effect of alarin 3-25 on food intake appears less potent than that seen with full-length alarin, but a 
dose comparison of their effects is required to determine their relative potencies. It is interesting that 
alarin 3-25 had no effect on plasma LH. This could suggest that multiple receptors mediate the effects 
of alarin, and that alarin 3-25 is unable to bind to the receptor responsible for its effect on the 
reproductive axis. However, alarin 3-25 stimulates GnRH release from GT1-7 cells in vitro with a 
similar potency to alarin 1-25. Alternatively, given that alarin significantly increased stress hormones 
in this study, and that basal corticosterone levels were relatively high, this may have been sufficient to 
mask any effect of alarin 3-25 on LH release. In addition, the effect of full-length alarin on LH is not 
powerful, and this lack of effect may reflect a lower potency of alarin 3-25. I have confirmed that 
alarin 3-25, like full-length alarin, does not bind to any of the three known galanin receptors. 
 
Since alarin and GALP have the first five amino acids in common, GALP may also be susceptible to 
enzymatic cleavage by DPP-IV. GALP (3-60) has been described as more potent than GALP (1-60) at 
stimulating LH release and at reducing 24 hour food intake and body weight in mice, although this 
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difference is not statistically significant (Krasnow et al, 2004). Data from receptor binding studies 
demonstrates that removal of the first two amino acids from GALP (1-32) generates a GALP variant 
(3-32) which has a higher affinity for GalR1 and GalR2 than full-length GALP (1-60) or GALP (1-
32). This suggests that removal of the first two amino acids via post-translational processing may be 
important for the biological activity and receptor interaction of GALP (Lang et al, 2005). 
 
If alarin and GALP do bind to a common receptor, it is likely that the first five amino acids are 
important in activating this receptor. I have observed that alarin (6-25) has no effect on GnRH release 
from GT1-7 cells, which suggests that the first five amino acids of alarin are essential for the 
stimulation of GnRH from GT1-7 cells in vitro. There are no published studies investigating the 
biological effects of GALP (6-60), although ICV GALP (22-60) administration has no effect on food 
intake or LH release in mice (Krasnow et al, 2004) and GALP (19–37), unlike full-length GALP, does 
not effect oedema formation following intradermal administration to mice (Schmidhuber et al, 2007). 
However, both these forms of GALP also lack the galanin receptor binding domain.  
 
Further studies are now required to determine whether GALP and alarin mediate any of their 
biological effects through a shared receptor, and therefore whether alarin has utility as a specific 
ligand at a novel receptor. 
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CHAPTER 5 
THE ROLE OF THE VENTRAL TEGMENTAL 
AREA IN THE REGULATION OF FEEDING 
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5.1 INTRODUCTION 
 
5.1.1 THE VENTRAL TEGMENTAL AREA (VTA) 
The VTA is part of the mesencephalon (midbrain). Anatomically, the VTA lies adjacent to the floor 
of the midbrain close to the midline. It is located caudal to the posterior hypothalamus and 
mammillary bodies, medial to the red nucleus and rostral to the pons and the hindbrain. The substantia 
nigra lies laterally to the VTA. 
 
5.1.1.1 VTA STRUCTURE 
The VTA is difficult to distinguish from the substantia nigra, which is why it was first identified by 
Tsai in 1925 in animals with a less developed substantia nigra. It was designated as an area rather than 
a single nucleus due to the heterogeneous nature of its cytoarchitecture and the lack of clear borders 
from other structures. There is great similarity between VTA nuclei across many mammalian species 
(Oades & Halliday, 1987). 
 
The VTA has been defined in several different ways. Most commonly, it is divided into four major 
zones: the paranigral nucleus (PN), the parabrachial pigmented area (PBP), the parafasciculus 
retroflexus area (PFR) and the ventral tegmental tail (VTT) (Swanson, 1982). Some definitions of the 
VTA include the midline nuclei (the interfascicular nucleus, rostral linear nucleus and central linear 
nucleus) (Oades & Halliday, 1987). The PN and PBP are dopaminergic cell-body rich zones which 
make up the middle two-thirds of the VTA, while the PFR and VTT have only a low density of 
tyrosine hydroxylase (TH) positive cell bodies (Hokfelt et al, 1984;Swanson, 1982).  
 
The PN contains TH positive cells which are relatively homogeneous, medium in size and medium to 
dark in staining (Halliday & Tork, 1986). The PBP comprises the rest of the dopamine rich zone. The 
PBP has undefined borders and lies dorsolateral to the PN. The TH positive cells in this nucleus are 
heterogeneous, large or medium sized and intensely stained (Halliday & Tork, 1986). The VTT is 
found posterior to the PN and its few TH-positive cells are small and moderately stained. The PFR 
lies anterior to the PN and its TH-positive cells are small or medium sized and moderate in staining, 
and are continuous with TH-positive cells in the posterior hypothalamic area. Studies suggest that 50-
60% of all neurons in the VTA are dopaminergic (Swanson, 1982). There is also a large population of 
GABAergic neurons and a smaller population of glutamatergic neurons (Ikemoto, 2007;Pierce & 
Kumaresan, 2006). 
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FIGURE 5.1 Schematic coronal section of the rat brain highlighting ventral tegmental area nuclei and the 
substantia nigra. Abbreviations: PN, paranigral nucleus; PIF, parafasciculus nucleus, PBP, parabrachial 
pigmented nucleus; SNCM, substantia nigra, compacta part medial tier; SNCV, substantia nigra compacta part, 
ventral tier; SNCD, substantia nigra, compacta part, dorsal tier; SNR, substantia nigra, reticular part; SNL, 
substantia nigra lateral part. This section is 6.0mm posterior from the bregma. Adapted from (Paxinos & 
Watson, 2007). 
 
5.1.1.2 VTA PROJECTIONS 
Five VTA systems of efferent fibres have been described. The two primary efferent fibre projections 
of the VTA are the mesocortical and the mesolimbic pathways. In addition, the mesostriatal pathway 
projects to the anteromedial striatum, the mesodiencephalic pathway projects to several thalamic and 
hypothalamic nuclei, and the mesorhombencephalic pathway projects to the superior colliculus, 
reticular formation and the periaqueductal grey. The mesocortical pathway projects to the prefrontal 
and insular cortices, while the mesolimbic pathway projects to the limbic cortex, the septo-
hippocampal complex, the nucleus accumbens (NAc) and the amygdala (Van den Heuvel, 2008) 
(Figure 5.2). A large proportion of the mesolimbic projections from the VTA are to the NAc, and 
lesions of the VTA result in an 85-95% decrease in NAc DA content (Simon et al, 1980). The cell 
bodies from which these projections originate are widely distributed throughout the VTA (Swanson, 
1982), although VTA neurons projecting to lateral parts of the NAc originate predominantly from the 
PBP, and medial regions receive abundant projections from the PIF and the PN (Phillipson & 
Griffiths, 1985). 
 
Almost all areas receiving efferent projections from the VTA are the origin of afferent projections 
back to the VTA (Phillipson, 1979). Excitatory glutamatergic afferents arising from all of these areas, 
except the NAc and the lateral septum, project to the VTA, and regulate VTA cell firing. When 
glutamatergic neurons are activated, the firing rate of the DA neurons in the VTA increases and burst 
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firing is induced. Burst firing by DA neurons results in release of DA into synapses within target 
regions (Zweifel et al, 2009). Subpallidal inputs to the VTA are predominantly GABAergic and thus 
inhibitory. There are also abundant intrinsic connections between, and within, nuclei of the VTA 
(Phillipson, 1979). 
 
 
 
 
FIGURE 5.2 Schematic diagram of the circuitry of the mesolimbic dopamine system in the rat brain 
highlighting the major inputs to the nucleus accumbens (NAc) and ventral tegmental area (VTA). Glutamatergic 
projections, blue; dopaminergic projections, red; GABAergic projections, orange; orexinergic projections, 
green. Abbreviations: AMG, amygdala; BNST, bed nucleus of the stria terminalis; LDTg, laterodorsal tegmental 
nucleus; LH, lateral hypothalamus; PFC, prefrontal cortex; VP, ventral pallidum. Taken from (Kauer & 
Malenka, 2007). 
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5.1.2 DOPAMINE  
The most studied of all brain substrates for mediating reward are the DA projections from the 
substantia nigra and VTA to forebrain structures. Mesolimbic DA has been suggested to serve as a 
critical neurotransmitter for reward of most kinds sought by animals and humans (Berridge & 
Robinson, 1998). 
 
5.1.2.1 DA SYNTHESIS AND RELEASE 
DA is synthesized from the amino acid tyrosine, which is taken up into the brain and subsequently 
into dopaminergic neurons by amino acid transporters. Tyrosine is intracellularly converted to L-
dihydroxyphenylalanine (L-DOPA) by the cytosolic enzyme tyrosine hydroxylase (TH). TH 
conversion of tyrosine to L-DOPA is the rate limiting step in DA biosynthesis. Dopamine 
decarboxylase enzyme in the cytosol then converts L-DOPA to DA (Elsworth & Roth, 1997).   
 
DA is sequestered from the cytoplasm into storage vesicles where it is concentrated to levels 10-1000 
times higher than the levels found in the cytoplasm. Following arrival of an action potential, calcium 
ions enter the neuron, stimulating the fusion of DA-containing vesicles with the neuronal membrane. 
Vesicles discharge their DA content into the synapse (Kelly, 1993), an event dependent on the rate 
and pattern of neuronal firing, with increased release in response to burst firing (Grace & Bunney, 
1995).  
 
5.1.2.2 DA SIGNALLING  
DA can be released from a neuron in a tonic or phasic manner. Tonic release is when neurons fire a 
slow irregular spike mode and low levels of DA are released into the synapse. Phasic release is when 
neurons fire action potentials in bursts giving rise to elevated DA levels in the synapse. These 
different patterns of DA release are thought to activate distinct signal transduction cascades through 
the activation of postsynaptic inhibitory and excitatory GPCRs (Elsworth & Roth, 1997). Phasic DA 
is proposed to activate excitatory, low-affinity DA D1-like receptors post-synaptically, stimulating 
adenyl cyclase activity to mediate its downstream effects. Conversely, tonic DA release is proposed to 
act on high-affinity DA D2 receptors to modulate post-synaptic DA signalling via interaction with the 
D1 receptor (Zweifel et al, 2009;Usiello et al, 2000). 
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5.1.2.3 DA METABOLISM 
Dopaminergic nerve terminals contain transporters critical in terminating transmitter action and 
maintaining transmitter homeostasis. Uptake of DA from the synapse is carried out by a high affinity 
membrane carrier protein, dopamine active transporter (DAT), capable of transporting DA in either 
direction depending on concentration gradients (Giros et al, 1996). Following DA release into the 
synaptic cleft, transporters actively pump extracellular DA back into the nerve terminal. In addition to 
the uptake of DA into DA neurons, there is evidence that glia and non-dopaminergic neurons may 
also, to a limited extent, take up and metabolise extracellular DA (Youdim et al, 2006). 
 
As a result of alternative splicing, the D2 gene of the DA receptor family exists in two isoforms, a 
short form and a long form. Activation of autoreceptors (the short isoform D2-like receptors) on the 
DA neuron itself is considered the principal mechanism responsible for the regulation of 
dopaminergic neuronal function (Khan et al, 1998). Terminals of all DA neurons possess DA-release 
modulating autoreceptors. Autoreceptors are present on most parts of a DA neuron and so are 
responsive to both terminal and dendritic DA release. Stimulation of DA autoreceptors on nerve 
terminals results in an inhibition of DA synthesis and/or release (Carlsson, 1975).   
 
The main enzymes responsible for the metabolism of DA include the monamine oxidases A and B 
(MAOA and MAOB), and catechol-O-methyltransferase (COMT). The relative abundance and 
activity of these enzymes varies between cell type, brain region and species (Karoum et al, 1977). The 
monoamine oxidases catalyse the conversion of DA to 3,4-dihydroxyphenylacetic acid (DOPAC), and 
COMT catalyses the conversion of DA to 3-methoxy-4-hydroxyphenylacetic acid (HVA). The major 
end point of DA metabolism in the rat brain is DOPAC, which is generated from the conversion of 
DA in a reaction catalysed by the monoamine oxidase enzyme MAOA (Youdim et al, 
2006;Waldmeier, 1987).  
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FIGURE 5.3 The pathway of dopamine synthesis proceeds from tyrosine via tyrosine hydroxylase (TH) 
catalysis to levodopa (L-DOPA), and subsequent decarboxylation by dopa decarboxylase (DDC) to dopamine. 
Dopamine is metabolized by intraneuronal monoamine oxidase A (MAOA), and by glial and astrocyte MAOA 
and MAOB. Dopamine is also metabolised extraneuronally by catechol-O-methyltransferase (COMT). D1, D2, 
dopamine receptors. Adapted from (Youdim et al, 2006).  
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5.1.3 ROLE OF VTA DOPAMINERGIC NEURONS IN DRUG ADDICTION 
Dopaminergic neurons of the VTA are important for the rewarding and reinforcing properties of 
numerous drugs of abuse (Wise, 1996). All drugs of abuse have been shown to increase DA 
neurotransmission (Kauer & Malenka, 2007). Most studies have examined DA release in the major 
terminal target regions of the VTA dopaminergic neurons - the NAc and the prefrontal cortex - and 
have revealed that drugs of abuse increase the DA concentrations in these regions (Di Chiara & 
Imperato, 1988;Di Chiara & Imperato, 1986). Drugs of abuse increase dopaminergic 
neurotransmission by increasing the firing rate of VTA DA neurons, by blocking DA reuptake, or by 
reversing DAT activity in terminal regions (Pierce & Kumaresan, 2006).  
 
The opioid system is one of the best characterised systems involved in modulating the mesolimbic 
dopaminergic system at the level of the VTA to mediate its rewarding effects. Mu-opioids have been 
shown to disinhibit the firing of VTA DA neurons by inhibiting VTA GABAergic neurons. These 
GABAergic neurons normally inhibit local DA neurons (Johnson & North, 1992), thus the overall 
result is an increase in DA release in the NAc (Leone et al, 1991). The habit forming properties of 
nicotine are also thought to be mediated via the VTA. Nicotine receptors are present on VTA DA 
neurons themselves (Clarke & Pert, 1985) and systemic nicotine increases NAc DA levels by directly 
stimulating dopaminergic cell firing in rats (Mereu et al, 1987). Other drugs of abuse, including the 
stimulants amphetamine and cocaine, are thought to mediate their rewarding properties at the level of 
the NAc. Both drugs increase extracellular DA concentration in the NAc of rats (Di Chiara & 
Imperato, 1988) and their habit forming properties can be blocked by DA antagonists or a depletion of 
DA levels in the NAc (Koob & Swerdlow, 1988). 
 
Food restriction and fasting enhance the addictive or reinforcing properties of drugs of abuse (Carroll 
et al, 1979;Carroll & Meisch, 1984), suggesting that the neural circuits regulating food intake are 
linked to the circuits underlying the rewarding effects of drugs of abuse. However, there is also strong 
evidence that the VTA is involved in the normal regulation of food intake by mediating the rewarding 
properties of foods. 
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5.1.4 ROLE OF THE VTA IN FEEDING 
The neural mechanisms mediating food reward are believed to be similar, if not identical, to those 
driving drug reward (Carelli, 2002;Kelley & Berridge, 2002). Food intake is at least partly driven by 
its rewarding properties, which involve activation of the mesolimbic DA pathway. The repeated 
stimulation of DA reward pathways is thought to result in neurobiological adaptation of the neuronal 
mechanisms that mediate reward, including DA neurotransmission and downstream circuits. This can 
result in increasingly compulsive behaviour and the loss of control over food intake (Blumenthal & 
Gold, 2010). This neurobiological adaptation has been hypothesised to be due to either counter 
adaptation and/or sensitisation of reward (Koob & Le Moal, 1997). Counter adaptation is the 
development of hedonic tolerance, where there is a decrease in dopaminergic neurotransmission in the 
NAc in the absence of rewarding stimulus i.e. food (Weiss et al, 1992). Sensitisation is the 
progressive increase in the effect of a rewarding stimulus with repeated exposure (Robinson & 
Berridge, 2001). 
 
The reward circuits can promote food intake unconnected to hunger, but may also be used to drive the 
hunger felt after food restriction. Chronic, but not acute, food restriction increases mRNA levels of 
TH and DAT in the VTA, effects not observed after acute food deprivation (Lindblom et al, 2006). 
Food restriction has also been reported to reduce levels of extracellular DA in the rat NAc (Pothos et 
al, 1995), which may reflect the upregulated DAT in the VTA. It is possible that this reduction in 
NAc DA stimulates the increased VTA TH mRNA in a feedback loop. Postsynaptic DA receptor 
signalling in the NAc is increased by food restriction in rats (Carr et al, 2003). It has been suggested 
that depletion of long-term energy stores activates neuronal circuitry which upregulates the DAT in 
mesolimbic DA neurons, leading to accumulation of presynaptic DA in the NAc and an increased 
clearance of DA in the NAc. This in turn leads to a sensitization of postsynaptic DA receptors (Carr et 
al, 2003). 
 
Current research into the role of the reward circuitry in feeding focuses on alterations in the 
mesolimbic pathway at the level of the terminal DA projections in the NAc and PFC. Studies using 
positron-emission-tomography (PET) scans have demonstrated a reduction in striatal D2 DA receptor 
(D2R) availability in severely obese humans compared to normal weight controls. The level of D2R 
availability negatively correlates with BMI, suggesting an association between low D2R levels in 
obese individuals and higher BMI. (Wang et al, 2001). However, this study does not reveal whether 
reduced D2R levels are the cause or the effect of obesity; i.e. whether lower levels of striatal D2R 
predispose an individual to addictive behaviours, or alternatively whether the reduction in D2R levels 
represents a compensation for constant overstimulation of the reward system caused by excessive 
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food intake. A recent study revealed that D2R availability is increased in female patients with weight 
loss following Roux-en-Y gastric bypass surgery, and that this increase in receptor availability is 
approximately proportional to the amount of weight lost (Steele et al, 2010). This suggests that D2R 
levels may be reduced in response to overeating and can be normalised by a chronic reduction in food 
intake.  
 
The receptors for many neuropeptides and hormones known to be involved in the regulation of 
appetite are expressed in the VTA (Figlewicz et al, 2003;Hommel et al, 2006;Mountjoy et al, 
1994;Naleid et al, 2005). It is therefore possible that in addition to regulating the homeostatic control 
of food intake in the hypothalamus, these factors also have a role in the regulation of the mesolimbic 
dopaminergic reward pathway. Cell bodies of VTA neurons are in close contact with the BBB, 
suggesting that peripheral factors may be able to affect VTA neurons (Halliday & Tork, 1986). 
However there have been no reports confirming that circulating factors directly access VTA neurons 
without crossing the BBB.  
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5.1.4.1 FOOD REWARD IN FED/FASTED STATES 
Early studies investigating motivation and reward used an experimental setting where rats have to 
press a lever for the delivery of a food pellet. The task requires that rats increase, within each session, 
the amount of effort (lever presses) expended for subsequent food reinforcers. Food deprived rats will 
expend greater effort to secure food than ad-libitum fed rats (Hull, 1952). It is thought that measures 
of performance in this task provide an index of ‘motivation' to work for food, and thus, food deprived 
rats have increased motivation to work for food compared to ad-libitum fed rats.  
 
Negative energy balance is associated with low levels of leptin and insulin and it has been suggested 
that low levels of these hormones may be associated with an increased drive to obtain rewards and a 
heightened reward response. Conversely, increased leptin and insulin may be sufficient to attenuate 
the drive for reward and reduce the reward response. Self-administration of rewarding electrical 
stimulation to specific brain regions including the LHA can be used to assess the state of brain reward 
circuitry (Olds & Milner, 1954). Chronic food restriction enhances self-stimulation in rats (Blundell & 
Herberg, 1968) and this rewarding effect can be blocked with ICV leptin or insulin administration 
(Fulton et al, 2000;Carr et al, 2000;Figlewicz et al, 2006). Food restriction also modifies performance 
in a conditioned place preference (CPP) paradigm in rats. Chronic SC leptin administration or ICV 
insulin administration to food restricted rats attenuates the expression of a CPP to high fat diet, 
suggesting that low leptin and/or insulin levels during states of negative energy balance cause 
behavioural adaptation to food reward (Figlewicz et al, 2001;Figlewicz et al, 2004). ICV 
administration of leptin or insulin reduces motivation for sucrose in rats, a behavioural task dependent 
on intact DA signalling (Figlewicz et al, 2006;Sipols et al, 2000). Interestingly, this effect was not 
observed in rats fed a high fat diet for five weeks, which exhibit a degree of leptin and insulin 
resistance, suggesting that the reward circuitry in the CNS may be affected by insulin/leptin resistance 
(Figlewicz et al, 2006).  
 
These data suggest that leptin and insulin, in addition to their role in promoting satiety as part of a 
homeostatic circuit, also suppress the incentive value of food and other rewards. The effects of leptin 
and insulin on the rewarding value of food are thought to be mediated via modulation of components 
of the mesolimbic DA system. 
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5.1.5 PERIPHERAL HORMONES AND FOOD REWARD 
 
5.1.5.1 LEPTIN  
The leptin receptor is expressed by more than half of the DA-containing neurons in the VTA of the rat 
(Figlewicz et al, 2003;Hommel et al, 2006;Hay-Schmidt et al, 2001) and peripheral, ICV or intraVTA 
(iVTA) leptin administration activates the JAK-STAT signalling pathway in midbrain DA neurons in 
rats (Hommel et al, 2006;Morton et al, 2009;Fulton et al, 2006). Peripheral leptin injection also 
induces pSTAT3 expression in a smaller population of VTA GABAergic neurons (Fulton et al, 2006). 
A population of VTA pSTAT3-positive neurons project to the NAc, suggesting that VTA leptin-
regulated neurons innervate the NAc and these neurons may mediate the effect of leptin on reward 
(Fulton et al, 2006). However, a recent study in mice reports that leptin receptor expressing VTA 
neurons project solely to the central amygdala, an area implicated in anxiety and the behavioural 
response to aversive stimuli, where they innervate CART expressing neurons and regulate expression 
of CART mRNA. This study found no leptin receptor expressing neurons projecting from the VTA to 
the NAc, although this may be due to the different species used in these studies (Leshan et al, 2010). 
 
Direct administration of leptin into the VTA acutely reduces food intake for up to 24 hours in rats 
(Hommel et al, 2006;Morton et al, 2009). RNAi-mediated knockdown of the leptin receptor in the 
VTA resulted in increased food intake, although it did not increase body weight (Hommel et al, 
2006). Rats with VTA leptin receptor knockdown exhibited an increase in sensitivity to highly 
palatable food; they consumed more sucrose than control animals, and their food intake was acutely 
increased following presentation of a high-fat diet compared to controls.  
 
IntraVTA pre-administration with a JAK-2 inhibitor blocks the anorectic effect of iVTA leptin in rats 
(Morton et al, 2009). However, ICV or iVTA leptin administration does not activate the IRS-PI3 
kinase or mTOR signal transduction pathways in the VTA suggesting that different intracellular 
signalling systems may relate the anorectic effects of hypothalamic and VTA leptin-sensitive 
pathways (Morton et al, 2009).  
 
Electrophysiological studies suggest that IV administration of leptin decreases the firing rate of rat 
VTA DA neurons in vivo. This may be a secondary effect of direct action at the hypothalamus. 
However, leptin also directly reduced the frequency of DA neuron action potentials from VTA slices 
in vitro (Hommel et al, 2006). These data support the hypothesis that leptin inhibits the firing of VTA 
DA neurons leading to a decrease in NAc DA release and a reduction in the rewarding value of food. 
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Leptin deficient ob/ob mice have reduced TH protein levels in the VTA and NAc, and reduced DA 
signalling in the NAc compared to wild type mice. Peripheral leptin infusion increases levels of TH in 
these regions (Fulton et al, 2006). This suggests leptin may have a physiological role in the regulation 
of the mesolimbic dopaminergic system. Hyperleptinaemic mice fed on a high fat diet have reduced 
leptin receptor mRNA expression in the VTA (Blendy et al, 2005). 
 
A recent paper has also reported that leptin can act in the LHA to modulate the mesolimbic 
dopaminergic system to suppress feeding (Leinninger et al, 2009).  
 
5.1.5.2 INSULIN  
Insulin has been implicated as an endogenous regulator of DA synthesis and reuptake. DAT is the  
protein responsible for the active uptake of DA from synapses (Giros et al, 1996). Streptozotocin-
induced diabetic rats, which exhibit hypoinsulinaemia, have reduced levels of DAT mRNA in the 
VTA (Figlewicz et al, 1996), while conversely, obese Zucker fa/fa rats, characterised by 
hyperinsulinaemia, have increased VTA DAT mRNA expression (Figlewicz et al, 1998). ICV 
administration of insulin to normal rats increases DAT mRNA levels in the VTA (Figlewicz et al, 
1994). Fasted rats, which have low circulating insulin, also have reduced DAT mRNA expression in 
the VTA and reduced activity of DAT in the striatum (Patterson et al, 1998).  
 
Anatomical evidence supports a role for insulin in modulating the DA reward circuitry. The insulin 
receptor is extensively co-expressed with TH in VTA neurons (Figlewicz et al, 2003;Werther et al, 
1987). Insulin receptor substrate 2 (IRS-2), a key component of the insulin signal transduction 
mechanism, has also been detected in DA VTA neurons (Pardini et al, 2006).  
 
Despite all the evidence suggesting that alterations in insulin levels can modulate food reward 
behaviours and influence the function of the mesolimbic DA pathway, the effect of direct VTA 
insulin administration on food intake has not previously been reported. 
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5.1.5.3 GHRELIN  
The VTA expresses the GHS-R in relatively large concentrations, suggesting that ghrelin may 
modulate the reward circuitry (Zigman et al, 2006;Guan et al, 1997). Specifically, the GHS-R is 
expressed by approximately 50-60% of TH-IR cells, and 30% of GABAergic cells in the VTA of rats 
and mice (Zigman et al, 2006;Abizaid et al, 2006). 
 
Ghrelin binds to rat brain slices containing the VTA in a distribution pattern similar to that of the 
expression of GHS-R (Abizaid et al, 2006), and electrophysiological studies have demonstrated that 
ghrelin acts directly on VTA DA containing neurons and increases the firing rate of these neurons in 
rodents. Ghrelin does not effect the firing rate of DA neurons from GHS-R knockout mice (Abizaid et 
al, 2006). 
 
Ghrelin administered directly into the VTA stimulates feeding in rats (Abizaid et al, 2006;Naleid et 
al, 2005), while pharmacological blockade of the GHS-R in the VTA reduces fasting-induced re-
feeding in mice and blocks the feeding response elicited by peripheral injection of ghrelin in rats 
(Abizaid et al, 2006). The latter experiment suggests that circulating ghrelin can reach the VTA to 
stimulate food intake, although there is no evidence to confirm this. The VTA is thought to be 
protected by the BBB, and thus relatively inaccessible to circulating hormones. It is possible that the 
VTA is primarily targeted by central ghrelin signals, or that there are specific transport mechanisms 
allowing ghrelin to access the VTA. Ghrelin may also stimulate VTA DA neuron activity via an 
indirect method e.g. via lateral hypothalamic neurons. 
 
It is proposed that ghrelin acts at the VTA to stimulate food intake by modulating DA release in the 
NAc. Peripheral, ICV and iVTA administration of ghrelin increases extracellular DA concentration in 
the NAc of rodents (Jerlhag et al, 2006;Jerlhag et al, 2007;Quarta et al, 2009). This effect is 
exaggerated in ghrelin knockout mice and absent in GHS-R knockout mice (Abizaid et al, 2006). 
Peripheral ghrelin infusion in humans is associated with increased hunger and an increased feeding 
response (Wren et al, 2001a), and enhances the activity in regions downstream of the VTA including 
the amygdala and NAc as measured by functional magnetic resonance imaging (fMRI) (Malik et al, 
2008b). These studies suggest that ghrelin may be increasing food intake by increasing activity of the 
mesolimbic dopaminergic system and enhancing the incentive value of food. 
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5.1.6 HYPOTHALAMIC PEPTIDES AND FOOD REWARD 
The homeostatic control system for the regulation of adiposity and body weight impinges on most of 
the brain through widely projecting neurons originating from hypothalamic nuclei including the ARC, 
PVN and LHA (Berthoud, 2002). The VTA DA system has been shown to play a role in the effects of 
peripheral hormones such as leptin and ghrelin on food intake. As some of the appetite related effects 
of leptin and ghrelin are mediated through secondary hypothalamic peptide effector systems, 
including the melanocortins and orexin, it is possible that these factors themselves may regulate the 
DA reward system. Pharmacological studies have outlined functional roles for some of these 
hypothalamic factors in the modulation of drug-taking behaviour. However it is not known whether 
VTA DA neurons are a target for many of the neural or endocrine factors that are implicated in energy 
homeostasis. 
 
5.1.6.1 LATERAL HYPOTHALAMIC NEUROPEPTIDES AND FOOD REWARD 
The LHA is well positioned to integrate homeostatic satiety and reward related feeding in the 
regulation of appetite. The LHA has long been recognised as a common region implicated in both 
reward and food intake. This nucleus contains neurons that potently stimulate food intake and is 
supplied by fibres from the ARC and other crucial hypothalamic areas for energy homeostasis. The 
VTA receives abundant neuronal inputs from the LHA, including projections from orexin A and B-
containing neurons, and MCH-containing neurons (Bittencourt et al, 1992;Fadel & Deutch, 2002). 
 
5.1.6.1.1 OREXIN 
Orexin receptor 1 and 2 are expressed by both dopaminergic and GABAergic VTA neurons in 
rodents, and electrophysiology studies have determined that orexins directly excite dopaminergic 
neurons in the VTA of the rat (Korotkova et al, 2003;Narita et al, 2006;Uramura et al, 2001;Marcus 
et al, 2001). Orexin A increases the intracellular Ca2+ concentration in rat VTA DA neurons in vitro 
via phosphatidylcholine-specific phospholipase C (PLC) (Uramura et al, 2001). Administration of 
orexin A or B directly into the VTA of rats increases levels of DA and the major DA metabolite, 
DOPAC in the NAc (Narita et al, 2006). Interestingly, iVTA administration of orexin has been shown 
to have no effect on food intake in rats (Sweet et al, 1999). 
 
The orexins are implicated in morphine induced reward. Morphine induced physical dependence and 
withdrawal are thought to be, at least in part, regulated by orexin neurons as these behaviours are 
attenuated in prepro-orexin knockout mice (Georgescu et al, 2003). Prepro-orexin knockout mice also 
exhibit a lack of place preference following morphine administration, and a suppression of the 
morphine-induced increase in DA levels in the NAc. Furthermore, morphine-induced place preference 
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is suppressed by iVTA administration of an orexin receptor antagonist in rats (Narita et al, 2006). 
Administration of µ-opioid receptor agonists into the NAc is known to profoundly stimulate high fat 
diet intake in satiated rats (Will et al, 2003). Pre-treatment with an iVTA orexin receptor antagonist 
almost completely abolishes the orexigenic effect the µ-opioid receptor agonist (Zheng et al, 2007). 
These data suggest that activation of the mesolimbic DA system by µ-opioid receptor agonists may be 
regulated by the orexin system.  
 
5.1.6.1.2 MELANIN CONCENTRATING HORMONE (MCH)  
There is little data available regarding the role of MCH in food reward despite the anatomical 
connection between MCH neurons in the LHA and their projections to the VTA (Bittencourt et al, 
1992). MCH1 receptor (MCHR1) mRNA is expressed at a low level in the VTA but is much more 
strongly expressed in the ventral striatum, the terminal field of the mesolimbic dopaminergic neurons 
(Hervieu et al, 2000;Pissios et al, 2008). MCH failed to have any effect on the firing pattern of 
dopaminergic and non-dopaminergic VTA neurons in brain slice recordings, suggesting that MCH 
does not modulate the reward pathway at the level of the VTA (Korotkova et al, 2003).  
 
Several studies have investigated the role of the MCH system in modulating the mesolimbic DA 
pathway. One reports dysregulation of the mesolimbic dopaminergic system in MCH-R1 knockout 
mice. These mice exhibit an upregulation of mesolimbic DA receptors, and heightened sensitivity to 
the effects of amphetamine and a D1 receptor agonist (Smith et al, 2005).  
 
Mice lacking MCH also have enhanced sensitivity to amphetamine injections. These mice have 
increased expression of DAT in the NAc, but DAT mRNA expression is unaltered in the VTA. There 
is evidence that the increased DAT-mediated reuptake of DA in MCH knockout mice is compensation 
for increased DA release in the NAc. Interestingly, MCH knockout mice did not display acute 
hyperphagia, as seen in wild type mice, when presented with a high fat, palatable diet (Pissios et al, 
2008). 
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5.1.6.2 ARCUATE NEUROPEPTIDES AND FOOD REWARD 
 
5.1.6.2.1 NPY  
Central NPY administration to satiated rats increases the amount of work (lever presses) expended to 
obtain a food pellet compared to saline injected rats in a test where increasing lever presses are 
required for each subsequent pellet of food. This implies that NPY increases motivation for food 
(Jewett et al, 1995). Y1, Y2 and Y5 receptors, which mediate the effects of NPY, are expressed in the 
VTA (Parker & Herzog, 1999). Electrophysiological studies report that NPY inhibits both 
dopaminergic and GABAergic VTA cells, reducing firing rate and inducing hyperpolarisation. These 
effects of NPY were preserved in the presence of the voltage-gated sodium channel blocker 
tetrodotoxin (TTX), suggesting a direct post-synaptic effect of NPY on these neurons (Korotkova et 
al, 2003). 
 
Most reports on the rewarding properties of NPY focus on its action in the NAc. The NAc contains 
the highest levels of NPY-IR in the mammalian brain after the hypothalamus, and the greatest density 
of neurons containing NPY mRNA in the human brain (Hendry, 1993). NPY administration into the 
NAc can induce a CPP to a previously neutral environmental cue and this effect can be blocked by 
iNAc injection of the DA receptor antagonist α-flupenthixol (Josselyn & Beninger, 1993), suggesting 
that NPY mediates its effects on reward behaviours via dopaminergic mechanisms. 
 
A recent study has implicated the Y1R in regulating NAc-induced food intake. Injection of the µ 
opioid receptor agonist DAMGO into the NAc stimulates high fat intake (Will et al, 2003). This effect 
is completely abolished by lateral ventricular pretreatment with a specific Y1R antagonist, suggesting 
that downstream Y1R-signaling in areas accessible to lateral ventricular diffusion of the drug is 
necessary for the orexigenic effect of DAMGO (Zheng et al, 2010).  
 
ICV NPY injection increases on-going heroin self-administration, and induces a reinstatement of 
extinguished heroin-seeking behaviour in rats, suggesting that NPY can modulate the rewarding and 
conditioned reinforcing effects of drugs of abuse (Maric et al, 2008). 
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5.1.6.2.2 CART  
CART was originally discovered as an mRNA transcript upregulated in the rodent brain following 
psychostimulant exposure (Douglass et al, 1995), and thus the role of CART in modulating the reward 
and reinforcing effects of psychostimulants has been extensively investigated. Studies report that 
CART mRNA expression is also upregulated in the NAc by other drugs of abuse such as 
methamphetamine (MDMA) and ethanol (Salinas et al, 2006;Jean et al, 2007). Post-mortem tissues 
from humans victims of cocaine overdose reveal an increase in NAc, and a decrease in VTA, CART 
mRNA expression (Albertson et al, 2004;Tang et al, 2003). 
 
Administration of CART peptide into the NAc reduces cocaine self-administration (Jaworski et al, 
2003b) and blocks the locomotor effects associated with cocaine and amphetamine administration in 
rats (Kim et al, 2003;Jaworski et al, 2003a). These studies suggest that CART in the NAc may act to 
blunt the effects of increased DA activity. CART-containing cell bodies in the NAc express DA 
receptors and receive TH-immunoreactive nerve terminals, implying direct dopaminergic input to 
CART containing neurons (Hunter et al, 2006;Hubert & Kuhar, 2006). These CART containing 
neurons have been reported to project to the substantia nigra rather than to the VTA (Dalllvechia-
Adams & Smith, 2001). 
 
The VTA contains no CART mRNA-containing cell bodies or CART peptide-IR cell bodies, but 
nerve terminals containing CART peptide have been detected and are associated with both DA- and 
GABA-synthesizing neurons (Dalllvechia-Adams et al, 2002b;Dalllvechia-Adams et al, 2002a). 
CART may therefore modulate DA activity in the VTA through either a direct effect on dopaminergic 
neurons or an indirect effect on DA neurons via CART-mediated alterations in GABA release. The 
latter appears more likely, but this hypothesis is challenged by a study reporting no effect of CART on 
the firing rate of dopaminergic or GABAergic neurons in vitro (Korotkova et al, 2003). 
Retrograde tracing studies show that many CART containing neurons in the LHA project to the VTA, 
suggesting an anatomical CART circuit may link the effects of CART on feeding and drug-related 
reward. 
 
Interestingly, ICV and iVTA injection of CART peptide increases DA and DOPAC in the NAc (Yang 
et al, 2004;Shieh, 2003;Kuhar et al, 2005). Intra-VTA injection of CART peptide causes 
psychostimulant-like effects: increased locomotor activity and promotion of CPP in rats. This CART-
induced increase in activity can be blocked in a dose-dependent manner by the DA receptor antagonist 
haloperidol, supporting a dopaminergic-mediated mechanism (Kimmel et al, 2000a). 
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There is far less data concerning the role of CART in the rewarding effects of food intake. 
Administration of CART peptide into the NAc reduces feeding (Yang et al, 2005a), suggesting that 
this region may be part of the anorectic CART circuitry. There are no reports to date of the effect of 
iVTA administration of CART peptide on food intake. 
 
 
5.1.6.2.3 MELANOCORTINS  
There is substantial anatomical overlap between components of the melanocortin system and the 
mesolimbic dopaminergic system. Melanocortin receptors 3 and 4 are expressed in the VTA 
(Mountjoy et al, 1994;Roselli-Rehfuss et al, 1993;Kishi et al, 2003). The VTA receives projections 
from POMC-IR neurons originating from both the ARC and the NTS (Joseph & Michael, 
1988;Haskell-Luevano et al, 1999;Bagnol et al, 1999), and AgRP-IR and αMSH-IR have been 
detected in the VTA (Jacobowitz & O'Donohue, 1978;Broberger et al, 1998b;Bagnol et al, 1999). 
 
MC4 receptor expression in the VTA, as measured by autoradiographic binding,  is down-regulated in 
genetically obese OLETF rats compared to controls (Lindblom et al, 2000), suggesting that the MC4 
receptor in the VTA may have a physiological role in appetite regulation. 
 
Electrophysiology studies measuring whole-cell current-clamp recordings in VTA slices reported no 
effect of AgRP on the firing rate or membrane potential of either dopaminergic or GABAergic 
neurons. Similarly, αMSH had no effect on the activity of dopaminergic neurons, but was reported to 
excite a small proportion of VTA GABAergic neurons in single cell recordings (Korotkova et al, 
2003). 
 
There is evidence to suggest that the melanocortin system is able to interact with the mesolimbic DA 
system. Chronic ICV infusion of the melanocortin receptor agonist MTII causes an up-regulation of 
D2-like receptors in the VTA, and an up-regulation of D1-like receptors in the NAc. (Lindblom et al, 
2002). IntraVTA administration of melanocortin receptor agonists increases the levels of DA and the 
DA metabolite, DOPAC, in the NAc of rats (Torre & Celis, 1988;Lindblom et al, 2001). Pre-
treatment with the MC4 receptor antagonist HS131 blocked this effect, suggesting that αMSH 
mediates its effect on NAc DA by activating the MC4 receptor (Lindblom et al, 2001). 
 
A recent paper highlights the involvement of the melanocortin receptors in food reward (Atalayer et 
al, 2010). In a food demand protocol, MC4R knockout mice were hyperphagic at low unit costs for 
food (2-10 nose pushes for a pellet of food), due primarily to increased meal size. However, at higher 
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costs (50 nose pushes for a pellet of food) their intake dropped to below that of WT and MC3R 
knockout mice. This effect has been shown to be an effect of genotypic origin, using DIO mice with 
body weights similar to MC4R knockout mice as controls. These data suggest that MC4R signaling 
plays a role in the motivation for food reward in rats.  
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5.2 AIMS 
The VTA is a major centre for the brain’s reward circuitry. The links between the hypothalamic 
systems and peripheral hormones regulating energy homeostasis and the reward circuitry are unclear. 
I aim to 
1. Investigate the effect on food intake of iVTA administration of neuropeptides and hormones 
known to be involved in energy homeostasis in rats.  
2. Characterise the neurons expressing melanocortin receptors in the VTA 
3. Investigate the mechanisms by which the melanocortin system acts in the VTA to influence 
food intake. 
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5.3 MATERIALS AND METHODS 
 
5.3.1 MATERIALS 
AgRP (86-132) used in study 5.3.6.3.4 was supplied by Peptide Institute (Japan), and AgRP (83-132) 
used in studies in section 5.3.8 was supplied by R&D Systems (Minneapolis, USA). Cis-(Z)-
Flupenthixol dihydrochloride, a D2 receptor antagonist, and bicuculline methiodide, a GABAA 
receptor antagonist, were supplied by Sigma-Aldrich. All other peptides used were supplied by 
Bachem (St Helens, UK). 
 
5.3.2 ANIMALS 
Adult male Wistar rats (Charles River) were maintained in individual cages as described in section 
2.3.2. 
 
5.3.3 VTA CANNULATION  
Animals were either anaesthetised by injectable anaesthetic or by inhalation anaesthesia. Anaesthesia 
induced by injectable anaesthetic drugs was carried out as described in section 2.3.3.1. For 
inhalational anaesthesia, animals were placed in an induction chamber with an inflow of 2 L/min 
oxygen and 4% isofluorane until they lost the pedal reflex. Animals were then maintained on 2% 
isofluorane with an inflow of 2 L/min oxygen throughout the surgery. Cannulation surgery for studies 
in section 5.3.6 was carried out using injectable anaesthetics, but this protocol was superseded by the 
use of inhalational anaesthetics to reduce anaesthetic mortality in animals cannulated for studies in 
section 5.3.8. All animals in each individual study were anaesthetised using the same method.   
Cannulation surgery was carried out as described in section 2.3.3.2 except that for VTA cannulation, a 
26 gauge stainless steel cannula (PlasticsOne) and different cannulation co-ordinates were used. The 
cannula was directed to the DA-rich PBP nucleus of the VTA and was therefore implanted 6mm 
posterior from bregma, 0.5 mm lateral to bregma and projecting 9.5 mm below the surface of the 
skull. These co-ordinates were generated from the rat brain atlas (Paxinos & Watson, 2007). 
 
5.3.4 INTRA-VTA ADMINISTRATION OF FACTORS INVOLVED IN ENERGY 
HOMEOSTASIS 
Peptides were administered in a volume of 1 µl to conscious freely moving animals via a stainless 
steel, 28 gauge injector projecting 1 mm below the tip of the cannula at a rat of 120 µl/hour. 
Otherwise, injections were carried out as described in section 2.3.3.2. 
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5.3.5 VERIFICATION OF INTRA-VTA CANNULA LOCATION 
 
5.3.5.1 INDIA INK INJECTION AND TISSUE PROCESSING  
Animals were killed by decapitation and 1 µl India ink was immediately injected into the iVTA 
cannula, using the injection procedure described in section 2.3.3.2. Brains were then removed, 
immediately stored in 25 ml 4% formaldehyde (appendix) and kept at 4°C. Twenty-four hours later, 
brains were transferred into 30% sucrose solution (appendix) and stored at room temperature for 
several days until dehydrated. Brains were then removed, frozen in isopentane and stored at -80°C 
until they were sliced on a freezing sled microtome (Shandon Southern Products Ltd, Runcorm, 
Cheshire, UK) into 20 µm coronal sections. The location of ink was verified by comparing to The Rat 
Brain Atlas (Paxinos and Watson 1998).  
 
5.3.5.2 HAEMOTOXYLIN STAINING 
Materials 
Poly-l-lysine coated slides (VWR) 
Xylene (VWR) 
Ethanol (VWR) 
Haematoxylin (Vector Labs) 
DPX (Thermo Fisher Scientific) 
 
Method 
Brain sections containing India ink were placed on poly-l-lysine coated slides and allowed to dry for 
at least four hours. Slides were dehydrated from 50% through to 100% ethanol for 2 minutes each, 
and then delipidated in xylene overnight. Slides were then rehydrated from 100% ethanol through to 
GDW for 2 minutes each, before staining for 4 minutes in haemotoxylin. Slides were briefly rinsed in 
GDW, and then dehydrated through ascending ethanol concentrations (50 through to 100%). Brain 
sections were then delipidated in xylene for 5 minutes before mounting with DPX and coverslips. 
Animals with ink more than 0.2 mm outside the VTA when viewed under the microscope (Nikon, 
Eclipse 50i) were not included in analysis of results. 
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5.3.6 INTRA-VTA FEEDING STUDIES 
 
5.3.6.1 THE EFFECT OF iVTA ADMINISTRATION OF PERIPHERAL FACTORS ON 
FOOD INTAKE 
IntraVTA administration of leptin has previously been reported to reduce food intake in rats (Hommel 
et al, 2006;Morton et al, 2009) and iVTA administration of ghrelin has been reported to increase food 
intake in rats (Abizaid et al, 2006;Naleid et al, 2005). No studies have described an effect of iVTA 
insulin administration on food intake in rats. Since there is substantial evidence supporting a role for 
insulin in modulating the VTA DA circuitry, the effect of iVTA insulin administration on food intake 
was examined in rats at the onset of the dark phase, the natural feeding period of the rat, and also in 
the early light phase to investigate any differences in sensitivity to insulin in different nutritional 
states. 
Studies investigating the effect of insulin administration on reward related behaviours elicit an effect 
using 5mU of insulin (Figlewicz et al, 2008;Figlewicz et al, 2006). Administration of 0.1, 1, 10 or 40 
mU insulin reduces food intake following iPVN administration (Menêndez, 1991).  
 
5.3.6.1.1 EFFECT OF iVTA ADMINISTRATION OF INSULIN ON FOOD INTAKE IN AD 
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA at the onset of the dark phase 
with either 0.9% saline, insulin (0.1, 1 or 10 mU) or ghrelin (0.3 nmol) (positive control) (Naleid et al, 
2005) (n = 5-10 per group, n = 5 ghrelin). Rats were immediately returned to their home cages and 
food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was measured at 0 and 24 
hours post-injection.  
 
5.3.6.1.2 EFFECT OF iVTA ADMINISTRATION OF INSULIN ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA during the early light phase 
with either 0.9% saline, insulin (0.1, 1 or 10 mU) or ghrelin (0.3 nmol) (positive control) (n = 7-10 for 
each group, n = 5 ghrelin). Rats were immediately returned to their home cages and food was 
reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was measured at 0 and 24 hours post-
injection.  
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5.3.6.2 THE EFFECT OF IVTA ADMINISTRATION OF LHA NEUROPEPTIDES ON FOOD 
INTAKE 
 
5.3.6.2.1 EFFECT OF iVTA ADMINISTRATION OF OREXIN AND MCH ON FOOD 
INTAKE IN AD LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA during the early light phase 
with either 0.9% saline, orexin (1 nmol), MCH (1 nmol) or ghrelin (0.3 nmol) (positive control) (n = 
8-11 per group, n = 4 ghrelin). Rats were immediately returned to their home cages and food was 
reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was measured at 0 and 24 hours post-
injection.  
 
5.3.6.3 THE EFFECT OF IVTA ADMINISTRATION OF ARC NEUROPEPTIDES ON FOOD 
INTAKE 
Evidence suggests that CART is an ARC neuropeptide likely to be involved in the VTA DA pathway 
regulating food intake due to its well-characterised role in modulating the dopaminergic effects of 
drugs of abuse. ICV CART (55-102) administration has an anorectic effect in rats (Kristensen et al, 
1998), while direct intranuclear injection of CART into the SON, PVN, VMN, DMN, ARC or LHA 
of the hypothalamus stimulates food intake (Abbott et al, 2001). The effect of iVTA administration of 
CART was therefore examined in fasted rats, where any anorectic effect of CART would be 
detectable, and in ad-libitum fed rats, where any orexigenic effect of CART could be identified. ICV 
administration of 0.2 nmol CART is associated with locomotor abnormalities and tremor (Kristensen 
et al, 1998). In contrast, iARC administration of 0.4 nmol CART is not associated with any 
behavioural abnormalities (Abbott et al, 2001). Since the sensitivity of the VTA to any appetite 
related effects of CART is unknown, several doses of CART (55-102) were administered in these 
studies to allow any specific effects of iVTA CART on food intake to be established. 
 
5.3.6.3.1 EFFECT OF iVTA ADMINISTRATION OF CART (55-102) ON FOOD INTAKE IN 
FASTED MALE RATS DURING THE EARLY LIGHT PHASE 
Groups of overnight fasted male Wistar rats were injected into the VTA during the early light phase 
with either 0.9% saline, CART (55-102) (0.04, 0.2 or 0.6 nmol) or ghrelin (0.3 nmol) (positive 
control) (n = 6-10 saline and CART, n = 4 ghrelin). Rats were immediately returned to their home 
cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was measured at 
0 and 24 hours post-injection.  
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5.3.6.3.2 EFFECT OF iVTA ADMINISTRATION OF CART (55-102) ON FOOD INTAKE IN 
AD-LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA during the early light phase 
with either 0.9% saline, CART (55-102) (0.04, 0.2 or 0.6 nmol) or ghrelin (0.3 nmol) (positive 
control) (n = 7-9 saline and CART, n = 5 ghrelin). Rats were immediately returned to their home 
cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was measured at 
0 and 24 hours post-injection.  
 
5.3.6.3.3 EFFECT OF iVTA ADMINISTRATION OF NDP-MSH ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA at the onset of the dark phase 
with either 0.9% saline, NDP-MSH (1 nmol) or leptin (0.06 nmol) (positive control) (Hommel et al, 
2006) (n = 8-10 saline and NDP-MSH, n = 6 leptin). Rats were immediately returned to their home 
cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was measured at 
0 and 24 hours post-injection.  
 
5.3.6.3.4 EFFECT OF iVTA ADMINISTRATION OF NPY AND AGRP ON FOOD INTAKE 
IN AD-LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA during the early light phase 
with either 0.9% saline, NPY (1 nmol), AgRP (1 nmol) or ghrelin (0.3 nmol) (positive control) (n = 8-
10 per group, n = 7 ghrelin). Rats were immediately returned to their home cages and food was 
reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was measured at 0 and 24 hours post-
injection.  
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5.3.7 CHARACTERISATION OF MELANOCORTIN RECEPTOR-EXPRESSING NEURONS 
IN THE VTA 
Melanocortin receptor 3 and 4 mRNA have been detected in the VTA (Mountjoy et al, 1994;Roselli-
Rehfuss et al, 1993;Bagnol et al, 1999). The identity of the neurons expressing these receptors is 
unknown. The VTA contains large populations of dopaminergic and GABAergic neurons, and a much 
smaller population of glutamatergic neurons (Ikemoto, 2007). 
GABA is synthesised in the brain from glutamate by the glutamic acid decarboxylase (GAD) enzymes 
and requires pyridoxal pyruvate as a cofactor. The brain contains at least two forms of GAD which 
differ in molecular size, amino acid sequence, antigenicity, cellular and subcellular location. These 
forms, GAD65 and GAD67, derive from two separate genes (Martin, 1993). 
In situ hybridisation was used to detect tyrosine hydroxylase and GAD65/67 mRNA expression and 
immunocytochemistry (ICC) to detect the MC3R and MC4R in the rat VTA. There are currently no 
reports of the presence of the MC3R and MC4R in the VTA using ICC. 
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5.3.7.1 PRODUCTION OF GAD65 AND TYROSINE HYDROXYLASE PROBES 
The GAD67 probe was generated by Dr T. Ambepitiya using the methods described below. 
 
5.3.7.1.1 REVERSE TRANSCRIPTION AND PCR 
Reverse transcription, PCR and agarose gel electrophoresis were carried as described in section 
4.3.3.3 - 4.3.3.5. Rat hypothalamic RNA was used in all RT reactions. The primers used for the PCR 
are described in the table below. 
 
 
5' PRIMER 3' PRIMER BP 
ACCESSION 
NUMBER 
RESTRICTION 
ENZYMES 
GAD65 GCAGCTTGCCACAGCCACTT 
ACCACCACCCC
ACTGGTTTT 310 NM008078 
EcoR1 and 
BamHI 
GAD67 TTGAACCGTAGAGACCCCAA 
CTTCAGTGAGA
TGGCCTAGA 1917 NM008077 NotI and Hind 
TH TGCTGTTCTCAACCTGCTCT 
CTTCAGCTCCCC
ATTCTGTT 910 NM012740 
EcoR1 and 
BamH1 
 
TABLE 5.1 Primer sequences used in polymerase chain reaction (PCR) to detect gluatamic acid decarboxylase 
65 and 67 (GAD65 and GAD67), and tyrosine hydroxylase (TH). The expected size of the product is in base 
pairs (BP). Accession numbers refer to those published in the Nucleotide Sequence Database. 
 
5.3.7.1.2 PURIFICATION OF PCR PRODUCTS 
Materials  
Phenol chloroform (VWR) 
 Ethanol (VWR) 
 2M sodium acetate (NaAc) pH5.2 (appendix) 
 
Method 
PCR products were phenol chloroform extracted by addition of an equal volume of phenol 
chloroform. Solutions were thoroughly mixed before centrifugation at 12300g for 3 minutes. The 
supernatant was carefully removed and precipitated with the addition of 1/10 volume of NaAC and 
2.5 volumes of ice-cold ethanol for more than an hour at -20°C. Following precipitation, suspensions 
were centrifuged at 12300g for 7 minutes and the supernatant decanted. Pellets were re-suspended in 
100 µl PCR GDW (appendix). 
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5.3.7.1.3 RESTRICTION ENDONUCLEASE DIGESTION OF PCR PRODUCTS AND 
PLASMIDS 
Purified PCR products and the plasmid into which they were inserted were cut with the same 
restriction endonucleases in order for the plasmid and the PCR fragment to be joined in a ligation 
reaction. Restriction endonucleases were originally isolated from bacteria and recognise and cleave 
specific target sequences within target DNA (Roberts, 2005).  
 
Materials 
 Purified PCR products 
 Plasmid DNA (pBluescript) 
Restriction endonucleases: BamHI and EcoR1 (New England Biolabs, Herts. UK) 
 10x restriction buffer (New England Biolabs) 
 100x bovine specific albumin (BSA) (New England Biolabs) 
 Shrimp alkaline phosphatase (for plasmid digestion only) (New England Biolabs) 
 
Method 
Reactions were set up in a total volume of 100 µl containing the following: 10 µg DNA (either PCR 
product or plasmid), restriction endonucleases in equal proportion to make up to 8% of total volume, 
restriction buffer and BSA were added to a final concentration of 1x by diluting with PCR GDW.  The 
reaction was placed in a water bath at 37°C for 1.5-2 hours. Digested DNA was then purified by 
phenol chloroform extraction followed by ethanol precipitation as described in section 5.3.8.1.2 and 
re-suspended in 20 µl PCR GDW.  
 
5.3.7.1.4 ELECTROELUTION OF DNA FRAGMENTS 
This procedure was used to purify the fragment of interest and remove any contaminating fragments. 
Purification of plasmids following restriction endonuclease digestion is particularly important as any 
closed circular DNA remaining can affect the efficiency of transformation.  The DNA was separated 
on an agarose gel and the appropriate fragments electroeluted.  
 
Materials 
 1% TAE (tris, acetic acid and EDTA) agarose gel (appendix) 
Dialysis tubing 
DNA marker (Invitrogen) 
50x TAE (appendix) 
 Gel loading buffer (appendix) 
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Methods 
A 1% TAE (tris, acetic acid and EDTA)/agarose gel was prepared as described in section 4.3.2.5. 
Precipitated DNA was added to 0.3 volumes gel loading buffer. DNA marker was dissolved 1:10 in 
PCR GDW and added to 0.3 volumes gel loading buffer. Samples were loaded onto the gel and 
electrophoresed at 120 volts.  DNA was visualised by ultraviolet illumination and the band of interest 
excised from the gel and placed in dialysis tubing with 400 µl 0.5x TAE. This was sealed with clips 
and electrophoresed at 200 volts for 20 minutes, the current was then reversed and the gel fragment 
electrophoresed for another 40 seconds. The TAE in the tubing was removed and DNA purified by 
ethanol precipitation. The DNA pellet was re-suspended in 20 µl PCR GDW.  
 
5.3.7.1.5 LIGATION OF PCR PRODUCTS INTO PLASMIDS 
Ligation of DNA fragment requires DNA ligase, a virus-derived enzyme which catalyses the 
formation of covalent phosphodiester bonds between the 3’ hydroxyl end of one nucleotide and the 5’ 
phosphate end of another.  
 
Materials 
 T4 DNA ligase, 6U/µl (New England Biolabs) 
 10x ligase buffer (New England Biolabs) 
 
Methods 
Twenty nanograms of plasmid were added to a fourfold molar excess of insert. Ligase buffer was 
added to a final concentration of 1x, 6 U ligase enzyme was added and the final volume made up to 10 
µl with PCR GDW. This was incubated at 16°C overnight.  
 
 
5.3.7.1.6 PREPARATION OF PLASMIDS 
 
5.3.7.1.6.1 PRODUCTION OF COMPETENT BACTERIA 
In order to allow entry of plasmids, gram negative bacteria such as E. Coli must be rendered 
competent to take up DNA. Although several methods exist to produce competent bacteria, treatment 
with cations was used for the studies in this thesis. This method was originally described by Hanahan 
et al. in 1983 (Wilkinson, 2010a), although several adaptations have been made since.   
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Materials 
 Lysogeny Broth (LB) (appendix)  
Tetracycline (Sigma-Aldrich) 
 Transformation Buffer I (TFB I) (appendix) 
Transformation Buffer II (TFB II) (appendix) 
XL1B cells (ATCC, Middlesex, UK)  
 
Method 
One hundred millilitres of LB supplemented with 5 mg/ml tetracycline (LBtet) was inoculated with a 
colony of XL1B cells and incubated overnight at 37°C with vigorous shaking. One millilitre of this 
culture was taken and incubated in LBtet at 37°C with vigorous shaking, until the bacteria were in log 
phase growth (OD550 = 0.4-0.5). The bacteria were recovered by centrifugation for 15 minutes at 
800g. Bacteria were resuspended in 40 ml ice cold TFBI and incubated on ice for 40 minutes. The 
bacteria were then recovered by centrifugation, as above, and resuspended in 4 ml TFBII, then 
incubated on ice for 4 minutes. Aliquots (50 µl) were prepared, frozen on ethanol in dry ice and stored 
at -70°C until use.  
 
5.3.7.1.6.2 TRANSFORMATION OF COMPETENT BACTERIA 
Once treated with cations, bacteria are able to take up DNA. However, further steps are required to 
optimise entry of DNA into the cells. Methods for transformation of cells include heat shock and 
electroporation. Heat shock transformation was used for preparation of these probes. Incubation on ice 
allows attachment of the plasmid to the bacterial cell membrane. The heat shock step allows efficient 
transport of the plasmid into the bacteria and the incubation following the heat shock promotes 
expression of the resistance genes before exposure to the antibiotic.  
Materials 
LB (appendix) 
LB ampicillin plates 
Competent bacteria (XL1B cells) 
 
Method 
An aliquot of competent bacteria was thawed on ice, 10 ng of plasmid added and the mixture 
incubated on ice for 20 minutes. The reaction was then incubated at 42˚C for 2 minutes, followed by 
incubation on ice for 2 minutes. LB was added (200 µl) and the reaction incubated at 37˚C for thirty 
minutes. Agar plates supplemented with ampicillin were dried and 100 µl of the transformed bacteria 
was added to the plate and incubated at 37˚C overnight. 
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5.3.7.1.6.3 SMALL SCALE PREPARATION OF PLASMID DNA 
Plasmids were initially grown using small scale culture to allow analysis of several clones 
simultaneously. In order to isolate plasmids from within bacterial cells the cell wall must be disrupted 
to release intracellular contents and plasmid DNA separated from other unwanted components such as 
genomic DNA, protein and RNA. The method described in this thesis involves lysis of the cell with 
alkaline sodium dodecyl sulphate (SDS) and precipitation of cellular debris using NaAc. This 
removes protein and genomic DNA components which are anchored to the cell wall. Removal of 
RNA is carried out by treatment with RNase at a later stage. The correct clones were selected for large 
scale amplification by digestion with restriction enzymes. Digestion with EcoR1 and BamHI allows 
the size of the gene of interest to be confirmed.   
 
Materials 
LB (appendix) 
Ampicillin (Sigma-Aldrich) 
Glucose-tris-EDTA (GTE): (appendix) 
25mM Tris-HCl, pH8 
10mM EDTA 
50mM glucose  
Alkaline SDS (appendix)  
5M potassium acetate (KAc) (appendix) 
Phenol/chloroform (VWR) 
Propan-2-ol (VWR) 
RNase A (GE Healthcare) 
 
Methods 
A single bacterial colony was picked from the agar plate using sterile technique. This was placed in 2 
ml LB supplemented with 0.5 mg/ml ampicillin and was incubated overnight at 37°C with vigorous 
shaking. From this, 1.5 ml was removed and centrifuged at 12,300g for 3 minutes to pellet the 
bacterial cells and the remainder stored at 4°C for future use. The supernatant was removed and the 
bacterial pellet resuspended in 100 µl GTE. Alkaline SDS (200 µl) was added to the resuspended 
bacteria and the mixture left on ice for 5 minutes, before 150 µl KAc was then added and the mixture 
left on ice for a further 5 minutes. The mixture was centrifuged at 12,300g for 5 minutes and 350 µl 
supernatant was removed to a fresh tube separate from the remaining bacterial debris. Phenol 
chloroform extraction was carried out and the DNA precipitated by adding 0.6 volumes propan-2-ol 
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and incubating at room temperature for 10 minutes. This was centrifuged at 12,300g for 7 minutes to 
pellet the DNA. Following removal of the supernatant, DNA was resuspended in 100 µl GDW. 
Ethanol precipitation was carried out to further purify the DNA.  Restriction endonuclease digestion 
was carried out to verify which clones contained the correct plasmid insert. Purified DNA was 
resuspended in 10 µl GDW. From this 1 µl was digested with EcoR1 and BamHI with the addition of 
0.5 µg/µl RNaseA, and visualised by agarose gel electrophoresis. Clones containing the correct insert 
were selected for large scale purification. 
 
5.3.7.1.6.4 LARGE SCALE PRODUCTION OF PLASMID DNA 
Materials 
LB (appendix) 
Ampicillin (Sigma-Aldrich) 
GTE (appendix) 
Alkaline SDS (appendix) 
5M KAc (appendix) 
Lysozyme (Sigma-Aldrich) 
Propan-2-ol (VWR) 
RNase A (GE Healthcare) 
Tris-EDTA (TE) (appendix) 
Phenol chloroform (VWR) 
Methods 
Using sterile techniques, 50 µl LB containing the clone of interest was added to 500 ml warmed LB 
containing 0.5 mg/ml ampicillin. This was incubated overnight at 37°C with vigorous shaking. The 
mixture was centrifuged for 8 minutes at 2500g, the supernatant removed and each bacterial pellet 
resuspended in 12.5 ml GTE supplemented with 2 mg/ml lysozyme. The resuspended bacterial pellets 
were incubated at room temperature for 5 minutes before the addition of 25 ml alkaline SDS to each. 
Tubes were mixed and incubated on ice for 5 minutes. To neutralise the alkalinity, 19 ml 5M KAc 
was added to each tube. Tubes were then incubated on ice for 10 minutes before being centrifuged at 
8000g for 10 minutes. The supernatant was filtered through nylon gauze into separate tubes to remove 
remaining cell debris and 36 ml propan-2-ol added to each. Tubes were incubated on ice for 15 
minutes before being centrifuged at 8000g for 15 minutes. Supernatant was removed and pellets 
resuspended in 5 ml 1x TE and united in one tube. To remove any remaining RNA, 100 µl 10 mg/ml 
RNaseA was added and samples were incubated at 37°C for one hour.  Phenol chloroform extraction 
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followed by propan-2-ol precipitation using 5M NaAc was carried out to purify and precipitate the 
DNA. 
 
5.3.7.1.6.5 CAESIUM CHLORIDE GRADIENT PURIFICATION OF PLASMID DNA 
This technique was used to purify plasmid DNA from other DNA components. The buoyancy of 
different types of DNA varies depending on their binding to ethidium bromide. Ethidium bromide 
binds less effectively to closed circular DNA than to linear (genomic) DNA or nicked plasmids;, 
consequently, intact plasmid DNA has a lower buoyant density. This allows separation of plasmids on 
a caesium chloride density gradient.  
 
Materials 
N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonicd acid (TES) (appendix) 
Caesium Chloride (CsCl2) 
CsCl2 /isopropanol (appendix) 
Ethidium bromide (VWR) 
 
Methods 
The DNA obtained from large scale plasmid production of plasmid DNA was recovered by 
centrifugation for 20 minutes at 24,000g at 4°C and dissolved in 8.25 ml TES. Then 8.4 g CsCl2 and 
150 µl ethidium bromide was added and the solution mixed. This mixture was transferred to two poly-
alumina centrifuge tubes and centrifuged overnight at 50,000g. DNA was collected immediately after 
the centrifuge stopped and the correct band was removed using a hypodermic needle under ultraviolet 
light. Removal of ethidium bromide was carried out by adding equal volumes of CsCl2/isopropanol 
and removing the upper phase. Ethanol was used to precipitate the DNA and the pellet resuspended in 
1 ml PCR GDW. Concentration was verified using a spectrophotometer.  
 
5.3.7.1.6.6 DETERMINATION OF DNA CONCENTRATION BY SPECTROPHOTOMETRY 
The DNA was diluted 1:100 in PCR GDW and 1 ml transferred to a quartz cuvette. The absorbance 
was read at 260 and 280 nm (UV-160 Spectrophotometer, Shimadzu, Kyoto, Japan). The reading at 
280 is used to give an indication of the purity of the sample because phenol absorbs more strongly 
than DNA at this wavelength. The concentration of DNA was calculated using the following formula: 
Concentration (µg/ml) = (Absorbance260 x Dilution Factor) x 50 
Sequencing of DNA was carried out by Imperial College sequencing service, Genomics Core 
Laboratory, MRC Clinical Sciences Centre to confirm the correct nucleotide sequence was present in 
each probe produced. 
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5.3.7.2 IN SITU HYBRIDISATION FOR GAD65, GAD67 AND TH 
In situ hybridisation is a technique which allows detection of mRNA within a tissue whilst 
maintaining structural integrity. In situ hybridisation takes advantage of the specific annealing of 
complementary nucleic acids which can be DNA and/or RNA, through hydrogen bonds formed 
between bases attached to a sugar-phosphate backbone: adenine (A) anneals with thymine (T in DNA) 
or uracil (U in RNA), and cytosine (C) anneals with guanine (G). This base pairing underlies the 
formation of a double stranded complex. Any nucleic acid sequence can therefore be specifically 
detected by use of a probe that is the ‘antisense’ reverse complementary sequence. The 
complementary probe is hybridised to sectioned tissue mounted on poly-lysine coated slides. Probes 
can be labelled with radioactive labels which are detected by autoradiography, or non-radioactive 
antigen labels e.g. digoxygenin (DIG) which are detected by ICC. Non-radioactive labelling has 
several assets including safety, high stability, rapid results and a single cell resolution (Wilkinson, 
2010b). 
To determine the localisation of TH mRNA expressing neurons and GAD65/67 mRNA expressing 
neurons in the rat midbrain, in situ hybridisation was carried out using a DIG labelled riboprobe 
specific for TH or GAD65/67. A combined GAD65/67 probe has been used previously to identify 
GABAergic neurons in the brain (Wang & Morales, 2008). Each GAD probe is produced separately 
before sections are hybridised with both probes simultaneously.  
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5.3.7.2.1 PRODUCTION OF DIG-LABELLED RNA PROBE FOR IN SITU 
HYBRIDISATION – GAD65, GAD67 AND TH  
Materials 
Template plasmid (200 µg/µl) linearised by digestion with restriction enzymes (BamHI (NotI 
for GAD67) for antisense riboprobe or EcoRI (Hind for GAD67) for sense riboprobe)  
100mM dithiothreitol (DTT) (Promega) 
30U/µl RNase inhibitor (Invitrogen) 
T3 or T7 RNA polymerase (Promega)  
10x DIG RNA labelling mix (Roche) 
5x polymerase buffer (Promega) 
DNase I (Invitrogen) 
10x DNase buffer (appendix) 
Ammonium acetate (NH4Ac) (appendix) 
Ethanol (VWR) 
100xTE (appendix) 
  
Methods 
The DIG-labelled template probe was produced using an in vitro transcription reaction. Two hundred 
nanograms of template (TH-PBluescript, GAD65-PBluescript or GAD67-PBluescript) was added to a 
reaction containing 5 mM DTT, 1x polymerase buffer, 30 U RNase inhibitor and 1x DIG labelling 
mix in a total volume of 19 µl. Finally, 20 U RNA polymerase was added (T3 to the anti-sense 
reaction and T7 to the sense reaction) and this was incubated at 37°C for 2 hours. After incubation, 3 
µl DNase buffer and 7.5 U DNaseI were added and the reaction incubated for a further 15 minutes at 
37°C. The reaction was precipitated by adding 12 µl NH4Ac and 80 µl ice cold ethanol. After one 
hour at -20°C the reaction was centrifuged at 8000g, the supernatant removed and the pellet 
resuspended in 100 µl 1 x TE. The concentration of DIG-labelled probe was determined 
spectrophotometrically (UV-160 spectrophotometer, Shimadzu, Kyoto, Japan). 
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5.3.7.2.2 IN SITU HYBRIDISATION FOR TH AND GAD 65/67 ON FRESH FROZEN RAT 
BRAIN SECTIONS 
Initial in situ hybridisation was carried out on fresh frozen sections. Cryostat-cut sections are more 
sensitive to detection as these sections are relatively thick and thus have greater mRNA signal. In 
addition, paraffin embedding is thought to reduce signal as the mRNA is less accessible due to the 
wax.  
Materials 
Optimum Cutting Temperature (OCT) embedding compound (Bright Instruments, 
Huntingdon, UK) 
Poly-lysine coated slides (VWR) 
40% (v/v) Formaldehyde (VWR) 
0.01M phosphate buffered saline (PBS) (appendix) 
0.1M triethanolamine pH8.0 (TEA) (appendix) 
100% acetic anhydride (VWR) 
Ethanol (VWR) 
Chloroform (VWR) 
Hybridisation buffer (appendix):  
Formamide (FMM) (Sigma) 
5M sodium chloride (NaCl) (appendix) 
100x Denhardts solution (appendix) 
1M Tris/HCl pH8 
0.5M EDTA pH8 
50% (w/v) dextran sulphate (Sigma-Aldrich) 
100mM DTT 
10mg/ml yeast tRNA (Sigma-Aldrich) 
20x salt sodium citrate (SSC) (appendix) 
1x RNase buffer (Promega) 
RNaseA (Promega) (appendix) 
 Blocking solution: (appendix) 
  0.1M Tris 
0.15M NaCl 
Fetal bovine serum (FBS) (Invitrogen) 
1:10 Triton X (VWR) 
Anti-DIG-AP, Fab fragments (Roche) 
 Tris-NaCl buffer (appendix) 
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4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-phosphate, 4-toluidine salt kit 
(BCIP/NBT alkaline phosphatase substrate kit) (Vector Labs) 
 Xylene (VWR) 
Wax pen (Vector Labs) 
DPX mountant (Thermo Fisher Scientific) 
 
Methods 
Rats were killed by CO2 asphyxiation. Brains were removed immediately, mounted onto cork discs 
with OCT embedding compound and rapidly frozen in isopentane at -150°C. They were stored at -
80°C until use. Rat brains were sliced on a cryostat (Bright Instruments) at -25°C into 12 µm sections. 
The sections were mounted onto poly-lysine coated slides and stored at -80°C until use.  
Sections were fixed in 0.01 M PBS containing 4% formaldehyde on ice for 20 minutes. Slides were 
washed twice in 0.01 M PBS for 5 minutes each, in 0.1 M TEA for 2 minutes and then acetylated in 
0.25% (v/v) acetic anhydride in 0.1 M TEA for 10 minutes. Slides were washed twice for 2 minutes in 
0.01 M PBS before dehydration through 50%, 70%, 95% and 100% ethanol for 3 minutes each. 
Finally, slides were delipidated in chloroform for 5 minutes and allowed to air dry for several hours.  
Hybridisation buffer was supplemented with 2.5ng/µl DIG labelled TH, or 1ng/µl of each DIG-
labelled GAD65 and DIG-labelled GAD67, and 80 µl added to each slide. Slides were coverslipped 
and hybridised overnight at 60°C in a humid environment.  
Slides were washed in a series of washes with decreasing salt content to remove non-specifically 
bound probe. Slides were washed in 4x SSC at room temperature and the cover slips removed. Slides 
were then washed a further four times in 4x SSC at room temperature for 5 minutes each, before 
RNase treatment by incubation in 1x RNase buffer containing 100µg/ml RNaseA for 30 minutes at 
37°C. Slides were washed twice in 10 mM DTT/2x SSC for 5 minutes, once in each of 10 mM 
DTT/1x SSC and 10 mM DTT/0.5x SSC for 10 minutes each, and once for 30 minutes in 10 mM 
DTT/0.1M SSC at 60°C, before rinsing in room temperature 10 mM DTT/0.1x SSC. Sections were 
then subjected to two hours of blocking with FBS before incubation for two hours in a humidified 
chamber with blocking solution containing anti-DIG-AP, Fab fragments at a 1:2000 concentration. 
Individual sections were isolated using a hydrophobic wax pen prior to incubation with anti-DIG-AP. 
Slides were then washed in Tri-NaCl buffer pH7.5 and Tris-NaCl buffer pH9.5 for five minutes each, 
before immersion into  development solution containing 2 drops of reagents 1,2 and 3 per 5 ml Tris-
NaCl buffer pH9.5. Slides were incubated in this solution in the dark and development was monitored 
microscopically over the following 1-2 hours. Following sufficient development, slides were washed 
in Tris-NaCl buffer pH9.5 before dehydration through 50%, 70%, 95% and 100% ethanol each for 3 
minutes. Finally slides were immersed in xylene for 2 x 5 minutes and mounted using DPX.  
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Sections were observed under the microscope (Nikon, Eclipse 50i) and photographs taken using a 
GXCAM camera (GX Optical, Haverhill, UK) and Tsview software (Tsview 6.0). 
 
5.3.7.2.3 IN SITU HYBRIDISATION FOR TH AND GAD65/67 ON PARAFFIN EMBEDDED 
RAT BRAIN SECTIONS 
The use of paraffin embedded tissue for in situ hybridisation has several advantages including the 
better preservation of tissue morphology and the ability to cut thinner sections. For dual ISH/ICC, 
paraffin sections are much more resilient than frozen sections. However an effective fixation protocol 
is essential for detection of mRNA. 
 
5.3.7.2.3.1 BRAIN TISSUE FIXATION AND PROCESSING 
Materials 
 Pentobarbitone (Merial) 
 0.01M PBS (appendix) 
Formaldehyde (VWR)  
Poly-lysine coated slides (VWR) 
 
Methods 
Adult female Wistar rats were terminally anaesthetised with an IP injection of a lethal dose of 
pentobarbitone (Merial Animal Health Ltd, UK). Once the withdrawal reflex was no longer present, 
the heart of the rat was exposed. A 21 gauge needle was inserted into the apex of the left ventricle and 
slightly advanced towards the aorta. A small nick was made in the right atrium and the animal was 
perfused with 0.01 M PBS pH7.4 (see appendix) from a 1m height under gravitational pressure until 
body fluid was running clear (approximately 100 ml). The rat was then perfusion fixed with 
approximately 500 ml 4% formaldehyde in phosphate buffered hypertonic (1.5%) saline solution pH 
6.5 (appendix) from a 1m height under gravitational pressure. After 2 hours, the brain was dissected 
out and divided coronally into four sections, before immersion in the same fixative solution for 24h at 
4°C.  
Following transfer of sections into 70% ethanol, each coronal segment of the brain was then paraffin 
embedded, and 3 µm sections were sectioned using a rotary microtome (Leitz, Wetzlar, Germany), 
and mounted on polylysine-coated slides.  
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5.3.7.2.3.2 IN SITU HYBRIDISATION 
Due to the differences in tissue processing for paraffin embedded sections, the protocol for in situ 
hybridisation is slightly different to that described for frozen tissue in section 5.3.7.2.2. 
Materials 
0.01M PBS (appendix) 
0.01 M citrate buffer (appendix) 
Ethanol (VWR) 
Hybridisation buffer (appendix):  
Deionised FMM (Sigma-Aldrich) 
20 x SSC (appendix) 
100 x Denhardts solution (Sigma-Aldrich) 
1M Tris/HCl pH7.5 
0.5M EDTA pH8 
10% (w/v) dextran sulphate (Sigma-Aldrich) 
10mg/ml yeast tRNA (Sigma-Aldrich) 
10% SDS 
Maleic buffer (Roche) 
 Blocking solution: (appendix) 
  Maleic buffer (appendix) 
1x commercial block (Roche) 
10% FBS (Invitrogen) 
Anti-DIG-AP, Fab fragments (Roche) 
DIG wash (Roche) 
 Detection buffer: (appendix) 
  0.1M NaCl 
  0.05MTris-HCl, pH9.8 
  0.05M MgCl2 
4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-phosphate, 4-toluidine salt kit 
(BCIP/NBT alkaline phosphatase substrate kit) (Vector Laboratories, Burlingame, CA) 
 Xylene (VWR) 
DPX mountant (Thermo Fisher Scientific) 
Wax pen (Vector Labs) 
 
Methods 
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Paraffin sections were dewaxed in two changes of xylene (5 minutes each) and rehydrated through 
graduated ethanol washes (2 x 100%, 1 x 70%, 1 x 50%) for 3 minutes each before rinsing in distilled 
water and then 0.01 M PBS. Antigen retrieval was carried out on the sections by boiling for 20 
minutes in a microwave oven in pre-boiled 0.01 M citrate buffer pH6 (appendix), after which, 
sections were allowed to cool for a further 15 minutes before rinsing in PCR GDW. Slides were then 
dehydrated through 50%, 70%, and 100% ethanol for 3 minutes each, and individual sections were 
isolated using a hydrophobic wax pen, before slides were allowed to air dry. Pre-hybridisation of 
sections was carried out using hybridisation buffer not containing any DIG-labelled probe. Slides 
were incubated in this solution for 1 hour at 57°C in a humidified chamber. Fifteen minutes before 
hybridisation, probes were added to hybridisation buffer and denatured at 75°C for 15 minutes, before 
cooling on ice for 5 minutes. Hybridisation buffer containing 2.5ng/µl DIG labelled TH, or 1ng/µl of 
each DIG-labelled GAD65 and DIG-labelled GAD67 (80 µl) was added to each slide, and sections 
were hybridised overnight at 57°C in a humid environment.  
Slides were washed in a series of washes with decreasing salt content to remove non-specifically 
bound probe. Slides were washed in 5x SSC at 60°C for 10 minutes, before a series of increasing 
stringency washes at 60°C in 50% FMM/2 x SSC for 30 minutes, 2 x SSC for 30 minutes, and twice 
in 0.2x SSC for 30 minutes each. Slides were then incubated in maleic buffer at room temperature for 
5 minutes before undergoing blocking in a blocking solution containing FBS for 30 minutes at room 
temperature. Sections were then subjected to two hours incubation in a humidified chamber with 
blocking solution containing anti-DIG-AP, Fab fragments at a 1:2000 concentration.  
Slides were then washed in DIG wash twice for 15 minutes each at room temperature. Sections were 
briefly rinsed in detection buffer for 5 minutes before incubation in detection buffer, an equal volume 
of 10% polyvinyl acetate, and 2 drops of reagents 1, 2 and 3 (BCIP-NBT kit) per 5 ml detection 
buffer. Slides were incubated in this solution in the dark and development was monitored 
microscopically over the following 1-2 hours. Following sufficient development, slides were washed 
in water three times for 5 minutes each, before dehydration through 50%, 70% and 100% ethanol each 
for 15 seconds. Finally slides were immersed in xylene for 30 seconds and mounted using DPX.  
Sections were observed under the microscope (Nikon, Eclipse 50i) and photographs taken using a 
GXCAM-3 camera (GX Optical, Haverhill, UK) and Tsview software (Tsview 6.0). 
 
5.3.7.3 IMMUNOCYTOCHEMISTRY FOR MELANOCORTIN RECEPTORS IN THE VTA 
The MC3R antibody used was an affinity purified goat polyclonal antibody raised against a peptide 
mapping at the C-terminus of MC3-R of human origin (MC3R (C20) sc-6878 Santa Cruz 
Biotechnology,Inc.). The MC4R antibody used was an affinity purified goat polyclonal antibody 
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raised against a peptide mapping at the C-terminus of MC4-R of rat origin (MC4R (R-19) sc-6880 
Santa Cruz Biotechnology,Inc.).  
 
5.3.7.3.1 BRAIN TISSUE FIXATION AND PROCESSING Adult female Wistar rats were 
terminally anaesthetised with pentobarbitone. Animals were fixed, and brain tissue was processed as 
described in section 5.3.7.2.3.1.  
 
5.3.7.3.2 MELANOCORTIN RECEPTOR ICC 
Materials 
Polylysine coated slides (VWR) 
Ethanol (VWR) 
Xylene (VWR) 
0.01M PBS/PBST (appendix) 
0.01M citrate buffer pH6 (appendix) 
 Fetal calf serum (FCS) (Invitrogen) 
Antibody diluent: (appendix) 
 Tris buffered saline (appendix) 
 Bovine serum albumin (BSA) 
 Sodium azide (VWR) 
Biotinylated donkey anti-goat (Jackson Labs) 
Avidin Biotin Complex (ABC) (Vector Labs) 
Imidazole (Sigma-Aldrich) 
Diaminobenzidinetetrahydrochloride hydrate (DAB) (Sigma-Aldrich) 
Copper sulphate solution (appendix) 
DPX mountant (Thermo Fisher Scientific) 
 Wax pen (Vector Labs) 
 
Methods 
Paraffin sections were dewaxed in two changes of xylene (5 minutes each) and rehydrated through 
graduated ethanol washes (2 x 100%, 1 x 70%, 1 x 50%) for 3 minutes each before rinsing in distilled 
water and then 0.01M PBS. Antigen retrieval was carried out on the sections by boiling for 20 
minutes in a microwave oven in pre-boiled 0.01 M citrate buffer pH6, after which, sections were 
allowed to cool for a further 15 minutes before rinsing in 0.01 M PBS. Endogenous peroxidase 
activity was blocked by incubation in 0.01 M PBS containing 1.6% hydrogen peroxide for 10 
minutes. Following a 5 minute wash in water, sections were incubated for 30 minutes at room 
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temperature with 10% fetal calf serum in antibody diluent. The MC3R antibody was diluted 1:100 in 
antibody diluent and incubated on the sections overnight at room temperature. The MC4R antibody 
was diluted 1:100 in antibody diluent and incubated on the sections overnight at room temperature. 
Control sections were routinely processed by omitting the primary antiserum. Sections were then 
washed in 0.01 M PBS containing 0.05% Tween-20 (PBST), incubated in biotinylated donkey anti-
goat (1:400 dilution) for 30 minute at room temperature before being washed in PBST, and incubated 
with avidin-biotin complex horseradish peroxidase at room temperature for 30 minutes. After a final 
wash in 0.01 M PBS, the antigen-antibody complex was visualised by incubation in PBS 
containing imidazole (final concentration 0.1 M), 0.04% 3,3'-diaminobenzidine (DAB), and  0.015% 
hydrogen peroxide. The pH of the chromogenic solution was adjusted to 7.4 with HCl. Following 
DAB staining for 5-10 minutes, sections were rinsed in PBS and then water. DAB staining was 
enhanced by incubation in copper sulphate for 4 minutes. Sections were then rinsed in water before 
being dehydrated though ascending ethanol concentrations (50-100%) for 3 minutes each and 2 x 5 
minutes in xylene. Slides were mounted using DPX and coverslips. Sections were visualised under the 
microscope (Nikon, Eclipse 50i) and photographs taken using a GXCAM-3 camera (GX Optical, 
Haverhill, UK) and Tsview software (Tsview 6.0). 
As no immunostaining was observed at 1:100 dilution, the MC4R antibody was diluted to a range of 
concentrations (1:10, 1:25, 1:50, 1:100, 1:200, 1:400, 1:800, 1:1600, 1:4000, 1:8000, 1:16000 and 
1:32000) in antibody diluent and incubated on the sections overnight at room temperature. Control 
sections were processed by omitting the primary antiserum.  
 
5.3.7.4 DUAL IN SITU HYBRIDISATION/IMMUNOCYTOCHEMISTRY FOR GAD65/67 OR 
TH MRNA AND MC3R-IR 
In situ hybridation for TH and GAD65/67 was carried out on paraffin sections as described in section 
5.3.7.2.3.  Following development in chromagen containing detection solution, slides were rinsed in 
PCR GDW for 5 minutes and then washed in 0.01 M PBS for 2 x 5 minutes. Sections were then 
incubated overnight at room temperature in antibody diluent containing 1:100 MC3R antibody. The 
ICC protocol was then carried out as described in section 5.3.7.3.2. 
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5.3.8 STUDIES INVESTIGATING THE MECHANISMS BY WHICH iVTA 
MELANOCORTINS MEDIATE THEIR EFFECTS ON FOOD INTAKE 
IntraVTA administration of the melanocortin receptor agonist NDP-MSH reduced food intake to 10% 
of saline injected controls in the first hour following injection in study 5.3.6.3.3, while iVTA AgRP 
profoundly increased food intake over 24 hours and resulted in a body weight gain of approximately 
15g at 24h post-injection compared to the 2g gain of saline injected controls in study 5.3.6.3.4. These 
studies suggest the presence of a melanocortin tone in the VTA. However, the 1 nmol doses of NDP-
MSH and AgRP used in the previous studies are relatively high for an intranuclear injection. Further 
studies were carried out to investigate the role of the melanocortin system in the regulation of VTA 
mediated food intake. 
To determine the sensitivity of the VTA to the anorectic effect of melanocortin receptor agonists, 
lower doses of NDP-MSH were administered. 
 
5.3.8.1 EFFECT OF iVTA ADMINISTRATION OF NDP-MSH ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA at the onset of the dark phase 
with either 0.9% saline or NDP-MSH (0.1, 0.3 or 1 nmol) (n = 6). Rats were immediately returned to 
their home cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was 
measured at 0 and 24 hours post-injection.  
 
5.3.8.2 EFFECT OF iVTA ADMINISTRATION OF LOWER DOSES OF NDP-MSH ON 
FOOD INTAKE IN AD-LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA at the onset of the dark phase 
with either 0.9% saline or NDP-MSH (0.01, 0.03 or 0.1 nmol) (n = 6-7 per group). Rats were 
immediately returned to their home cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-
injection. Body weight was measured at 0 and 24 hours post-injection.  
 
5.3.8.3 EFFECT OF iVTA ADMINISTRATION OF NDP-MSH ON FOOD INTAKE IN 
FASTED MALE RATS DURING THE EARLY LIGHT PHASE 
The effect of NDP-MSH was investigated in fasted rats to determine whether the melanocortin tone in 
the VTA is affected by alterations in energy states. 
Groups of overnight fasted male Wistar rats were injected into the VTA at the onset of the dark phase 
with either 0.9% saline or NDP-MSH (0.03, 0.1 or 1 nmol) (n = 6-7 per group). Rats were 
immediately returned to their home cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-
injection. Body weight was measured at 0 and 24 hours post-injection.  
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IntraVTA administration of AgRP at low doses was carried out to investigate the sensitivity of the 
VTA to the orexigenic effects of melanocortin receptor blockade. The doses of AgRP used in this 
study were the same as the lowest doses of NDP-MSH which had an anorectic effect in study 5.3.8.2. 
 
5.3.8.4 EFFECT OF iVTA ADMINISTRATION OF LOW DOSES OF AGRP ON FOOD 
INTAKE IN AD-LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Groups of ad-libitum fed male Wistar rats were injected into the VTA during the early light phase 
with either 0.9% saline or AgRP (0.01, 0.03 or 0.1 nmol) (n = 5-7 per group). Rats were immediately 
returned to their home cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured at 0 and 24 hours post-injection.  
 
5.3.8.5 EFFECT OF iVTA ADMINISTRATION OF AGRP ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Higher doses of AgRP were used in this study to determine the lowest dose of AgRP with a 
significant effect on food intake. Groups of ad-libitum fed male Wistar rats were injected into the 
VTA during the early light phase with either 0.9% saline or AgRP (0.3 or 1 nmol) (n = 7-9 per group). 
Rats were immediately returned to their home cages and food was reweighed at 1, 2, 4, 8 and 24 hours 
post-injection. Body weight was measured at 0 and 24 hours post-injection.  
 
 
5.3.8.6 EFFECT OF iVTA ADMINISTRATION OF γ-MSH ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
NDP-MSH binds with high affinity to both the MC3R and the MC4R (Adan et al, 1999). To 
determine whether the MC3R plays a role in the anorectic effect of iVTA NDP-MSH, the relatively 
selective MC3R antagonist, γ-MSH, was used (Oosterom et al, 1999). 
 
Groups of ad-libitum fed male Wistar rats were injected into the VTA at the onset of the dark phase 
with either 0.9% saline or γ-MSH (0.03, 0.1 or 1 nmol) (n = 6-7 per group). Rats were immediately 
returned to their home cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured at 0 and 24 hours post-injection. Behaviour was observed between 0-1 and 1-2 
hours post-injection by an observer blinded to the experimental treatments. This was carried out as 
described in section 2.4.3.6.  
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5.3.8.7 EFFECT OF IP PRETREATMENT WITH THE GABA RECEPTOR ANTAGONIST 
BICUCULLINE-METHIODIDE BEFORE iVTA ADMINISTRATION OF NDP-MSH ON 
FOOD INTAKE IN AD-LIBITUM FED MALE RATS BEFORE THE EARLY DARK PHASE 
The VTA contains large populations of both dopaminergic and GABAergic neurons (Oades & 
Halliday, 1987;Ikemoto, 2007). The melanocortin receptors identified in the VTA co-localise with 
GABAergic neurons. To investigate whether the mechanism by which iVTA melanocortin 
administration mediates its anorectic effect is dependent on GABA signalling, a GABA receptor 
antagonist was administered before iVTA injection of NDP-MSH. 
 
Bicuculline-methiodide is a more stable and soluble salt of bicuculline, a potent GABAA receptor 
antagonist (Olsen et al, 1976). The dose of bicuculline methiodide used in this study (3 mg/kg) has 
previously been shown to have no effect on food intake (Zarrindast et al, 1989). The dose of NDP-
MSH used in this study has been shown in earlier studies to significantly reduce food intake.  
Groups of ad-libitum fed male Wistar rats were IP injected 15 minutes before the onset of the dark 
phase with either 0.9% saline or bicuculline-methiodide (3 mg/kg). Fifteen minutes later, rats were 
injected iVTA with either 0.9% saline or NDP-MSH (0.03 nmol) (n = 6-7 per group). Rats were 
immediately returned to their home cages and food was reweighed at 1, 2, 4, 8 and 24 hours post-
injection. Body weight was measured at 0 and 24 hours post-injection. 
 
5.3.9 STATISTICS 
All data from iVTA feeding studies were analysed using one-way ANOVA and Dunnett’s post hoc 
test with all groups compared to saline (GraphPad Prism 5). Data points more than two standard 
deviations above or below the group mean were removed as outliers. This removed animals with low 
food intake due to sickness and normalised the data for analysis. In all cases P<0.05 was considered 
statistically significant. 
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5.4 RESULTS 
5.4.1 CONFIRMATION OF CANNULA PLACEMENT 
Eighty-four percent of cannulae in studies described in section 5.3.6 were directed within or less than 
0.2mm outside the VTA. A representative ink injection in the parabrachial pigmented nucleus of the 
VTA is shown in Figure 5.4. 
 
 
 
FIGURE 5.4 A) A representative coronal section of a rat brain following 1 µl India Ink injection into the 
parabrachial pigmented nucleus (PBP) of the ventral tegmental area. B) A corresponding coronal section of a rat 
brain atlas diagram. Abbreviations: AQ, aqueduct; cp, cerebral peduncle; IPL, interpeduncular nucleus, lateral 
subnucleus; IPR, interpenduncular nucleus, rostral subnucleus; PBP, parabrachial pigmented nucleus; PIF, 
parafasciculus nucleus, PN, paranigral nucleus; SNC/M, substantia nigra, compacta part medial tier. This 
section is 6.0mm posterior from the bregma. Adapted from (Paxinos & Watson, 2007). 
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5.4.2 INTRA-VTA ADMINISTRATION OF FACTORS INVOLVED IN ENERGY 
HOMEOSTASIS 
 
5.4.2.1 THE EFFECT OF IVTA ADMINISTRATION OF PERIPHERAL FACTORS ON 
FOOD INTAKE 
 
5.4.2.1.1 EFFECT OF iVTA ADMINISTRATION OF INSULIN ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
There was no significant effect of iVTA insulin administration on food intake at any dose or time 
point studied. Ghrelin (0.3 nmol) the positive control significantly stimulated food intake one hour 
post-injection (P<0.01) and increased 0-24h body weight (P<0.05) compared to saline, n = 7-10 saline 
and insulin, n = 5 ghrelin (Table 5.2). 
 
Time period saline 0.1 mU insulin 1 mU insulin 10 mU insulin ghrelin (0.3nmol) 
0-1 (g) 0.9 ± 0.2 1.4 ± 0.5 1.8 ± 0.7 1.5 ± 0.7 4.5 ± 0.4** 
1-2 (g) 1.5 ± 0.6 1.3 ± 0.5 1.3 ± 0.5 0.7 ± 0.5 3.0 ± 0.5 
2-4 (g) 0.2 ± 0.1 0.5 ± 0.3 0.2 ± 0.0 0.1 ± 0.0 1.0 ± 0.8 
4-8 (g) 0.7 ± 0.3 0.5 ± 0.2 0.3 ± 0.1 1.4 ± 0.7 0.2 ± 0.0 
8-24 (g) 26.7 ± 1.4 26.7 ± 1.1 27.4 ± 1.0 25.9 ± 1.0 25.1 ± 2.4 
0-24 (g) 30.0 ± 1.0 30.4 ± 1.0 30.9 ± 1.5 29.7 ± 1.6 33.9 ± 1.4 
BW change (g) -5.1 ± 1.9 -5.1 ± 1.5 -0.8 ± 1.1 -2.5 ± 1.0 -1.0 ± 2.3* 
 
TABLE 5.2 The effect of intra-VTA injection of saline, insulin (0.1, 1 and 10 mU) or ghrelin (0.3 nmol) 
(positive control) (n = 7-10 saline and insulin, n= 5 ghrelin) on food intake and 24h body weight (BW) change 
in ad-libitum fed male rats in the early light phase. *, P<0.05 vs. saline; **, P<0.01 vs. saline. Results are mean 
± SEM.  
 
 
5.4.2.1.2 EFFECT OF iVTA ADMINISTRATION OF INSULIN ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
There was no significant effect of iVTA insulin administration at any dose or time point studied (n = 
5-10 saline and insulin, n = 5 leptin). IntraVTA leptin administration had no significant effect on food 
intake, although there was a trend towards a reduction in food intake between 8-24 h post-injection 
(P=0.06), and cumulative 0-24 h food intake (P= 0.08) compared to saline injected controls (Table 
5.3). 
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Time Period saline 0.1 mU insulin 1 mU insulin 10 mU insulin leptin (0.06 nmol) 
0-1 (g) 3.5 ± 0.4 2.8 ± 0.5 3.0 ± 0.5 3.2 ± 0.4 4.1 ± 0.6 
1-2 (g) 2.3 ± 0.4 2.4 ± 3.0 1.9 ± 0.4 2.0 ± 0.3 2.2 ± 0.3 
2-4 (g) 5.0 ± 0.7 5.2 ± 3.3 5.9 ± 0.6 4.5 ± 0.5 4.2 ± 0.8 
4-8 (g) 5.2 ± 1.0 6.2 ± 3.9 7.3 ± 0.8 7.6 ± 0.8 4.3 ± 0.8 
8-24 (g) 11.7 ± 0.7 10.8 ± 4.5 11.0 ± 0.8 11.7 ± 0.9 8.5 ± 1.1 
0-24 (g) 27.7 ±1.4 27.4 ± 3.9 29.1 ± 0.9 29.1 ± 0.8 23.3 ± 1.8 
BW change (g) -9.3 ± 1.7 -10.8 ± 10.8 -7.8 ± 0.9 -4.8 ± 1.7 -13.6 ± 1.4 
 
TABLE 5.3 The effect of intra-VTA injection of saline, insulin (0.1, 1 and 10 mU) or leptin (0.06 nmol) 
(positive control) (n = 5-10 saline and insulin, n = 5 leptin) on food intake and 24h body weight (BW) change in 
ad-libitum fed male rats in the early dark phase. Results are mean ± SEM.  
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5.4.2.2 THE EFFECT OF IVTA ADMINISTRATION OF LHA NEUROPEPTIDES ON FOOD 
INTAKE 
 
5.4.2.2.1 EFFECT OF iVTA ADMINISTRATION OF OREXIN AND MCH ON FOOD 
INTAKE IN AD-LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
There was no significant effect of iVTA administration of either orexin or MCH on food intake at any 
time point measured or on body weight at 24 h. IntraVTA ghrelin (0.3 nmol), the positive control, 
significantly stimulated food intake between 0-1h (P<0.01) compared to saline (n = 8-11 for each 
group, n = 4 for ghrelin) (Table 5.4).  
 
Time Period saline orexin (1 nmol) MCH (1 nmol) ghrelin (0.3 nmol) 
0-1 (g) 1.0 ± 0.3 1.0 ± 0.3 1.2 ± 0.4 3.4 ± 1.3** 
1-2 (g) 0.6 ± 0.3 1.3 ± 0.4 0.5 ± 0.2 1.4 ± 0.8 
2-4 (g) 0.5 ± 0.2 0.6 ± 0.2 0.5 ± 0.2 0.3 ± 0.0 
4-8 (g) 0.5 ± 0.1 1.1 ± 0.3 0.6 ± 0.2 0.4 ± 0.0 
8-24 (g) 28.9 ± 1.0 27.5 ± 1.2 26.9 ± 0.9 27.1 ± 2.7 
0-24 (g) 31.7 ±1.2 31.5 ± 1.5 29.7 ± 1.0 32.7 ± 1.9 
BW change (g) +1.6 ± 1.0 +2.4 ± 0.7 +0.1 ± 1.2 +2.3 ± 3.2 
 
TABLE 5.4 The effect of intra-VTA injection of saline, orexin A (1 nmol), melanin concentrating hormone 
(MCH) (1 nmol) or ghrelin (0.3 nmol) (positive control) (n = 8-11 for each group, n = 4 ghrelin) on food intake 
and 24h body weight (BW) change in ad-libitum fed male rats in the early light phase. **, P<0.01 vs. saline. 
Results are mean ± SEM.  
 
 
5.4.2.3 THE EFFECT OF IVTA ADMINISTRATION OF ARC NEUROPEPTIDES ON FOOD 
INTAKE 
 
5.4.2.3.1 EFFECT OF iVTA ADMINISTRATION OF CART ON FOOD INTAKE IN FASTED 
MALE RATS DURING THE EARLY LIGHT PHASE 
Administration of 0.6 nmol CART (55-102) into the VTA of overnight fasted rats significantly 
reduced food intake between 0-1h, and 0-24 hours post-injection (0-1h food intake/g: saline 7.1 ± 
1.1, CART (55-102) 0.6 nmol 3.2 ± 0.8 P<0.001. 0-24h food intake/g: saline 41.7 ± 1.0, CART (55-
102) 0.6 nmol 33.3 ± 1.5 P<0.01, n = 6-10 saline and CART). Food intake was significantly increased 
between 2-4 hours post-injection following administration of 0.6nmol CART (55-102) (2-4h food 
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intake/g: saline 0.8 ± 0.5, CART (55-102) 0.6nmol 4.4 ± 0.7 P<0.001, n = 6-10 saline and CART). 
(Figure 5.5) Administration of 0.6nmol CART (55-102) caused tremors in a few animals.  No 
significant differences in food intake were detected at any other time points measured. No significant 
differences in body-weight change were detected between any groups at 24 hours post-injection.   
 
5.4.2.3.2 EFFECT OF iVTA ADMINISTRATION OF CART ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Administration of 0.6nmol CART (55-102) into the VTA of ad-libitum fed rats significantly reduced 
food intake between 8-24h and 0-24 hours post-injection (8-24h food intake/g: saline 30.5 ± 0.8, 
CART (55-102) 0.6nmol 20.7 ± 1.6 P<0.001. 0-24h food intake/g: saline 32.7 ± 1.1, CART (55-102) 
0.6nmol 23.7 ± 1.5 P<0.001, n = 7-9 saline and CART). (Figure 5.6) Administration of 0.6nmol 
CART (55-102) caused tremors in a few animals.  No significant differences in food intake were 
detected at any other time points measured. CART (55-102) There was a significant reduction in 
body-weight at 24 hours post-injection following administration of 0.6nmol CART (55-102) (BW 
change/g: saline 1.4 ± 1.5, CART (55-102) 0.6nmol -9.8 ± 2.4 P<0.01, n = 7-9 saline and CART). 
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FIGURE 5.5 The effect of intra-ventral tegmental area injection of saline, cocaine- and amphetamine- 
regulated transcript (CART 55-102) (0.04, 0.2 and 0.6 nmol), or ghrelin (0.3 nmol) (positive control) (n = 6-10 
saline and CART, n = 4 ghrelin) on (A) 0-1h, (B) 2-4h, and (C) 0-24h food intake in fasted male rats in the early 
light phase. **, P<0.01 vs. saline; ***, P<0.001 vs. saline. Results are mean ± SEM.  
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FIGURE 5.6 The effect of intra-ventral tegmental area injection of saline, cocaine and amphetamine regulated 
transcript (CART 55-102) (0.04, 0.2 and 0.6 nmol), or ghrelin (0.3 nmol) (positive control) (n = 7-9 saline and 
CART, n= 5 ghrelin) on (A) 0-1h and (B) 8-24h food intake in ad-libitum fed male rats in the early light phase. 
***, P<0.001 vs. saline. Results are mean ± SEM.  
 
  
247 
 
5.4.2.3.3 EFFECT OF iVTA ADMINISTRATION OF NDP-MSH ON FOOD INTAKE IN AD 
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE  
Administration of NDP-MSH (1 nmol) into the VTA of rats at the onset of the dark phase 
significantly inhibited food intake between 0-1h and 1-2h compared to saline injected animals and 
increased food intake between 8-24h (0-1h food intake/g: saline 4.0 ± 0.5, NDP-MSH 1 nmol 0.4 ± 
0.1 P<0.001, leptin 0.06 nmol 4.3 ± 0.7. 1-2h food intake/g: saline 3.1 ± 0.5, NDP-MSH 1 nmol 0.3 
± 1.1 P<0.001, leptin 0.06 nmol 3.3 ± 0.4. 8-24h food intake/g: saline 9.2 ± 0.6, NDP-MSH 1 nmol 
12.2 ± 2.1 P<0.05, leptin 0.06 nmol 7.3 ± 1.3, n= 8-10 saline and NDP-MSH, n= 6 positive control) 
(Figure 5.7).  
Leptin (0.06 nmol), the positive control, inhibited food intake at 4-8h and cumulatively at 0-24h post-
injection (4-8h food intake/g: saline 8.5 ± 0.8, NDP-MSH 1 nmol 9.1 ± 1.7, leptin 0.06 nmol 3.0 ± 
1.1 P<0.001. 0-24h food intake/g: saline 28.9 ± 1.1, NDP-MSH 1 nmol 26.2 ± 1.3, leptin 0.06 nmol 
21.9 ± 2.6 P<0.05, n= 8-10 saline and NDP-MSH, n= 6 positive control). 
 
5.4.2.3.4 EFFECT OF iVTA ADMINISTRATION OF NPY AND AGRP ON FOOD INTAKE 
IN AD LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
IntraVTA NPY administration (1 nmol) significantly stimulated food intake between 0-1h and 1-2h 
post injection (0-1h food intake/g: saline 0.6 ± 0.2, NPY 1 nmol 4.9 ± 0.8 P<0.001, AgRP 1 nmol 
0.7 ± 0.3, ghrelin 0.3 nmol 2.6 ± 0.5. 1-2h food intake/g: saline 0.3 ± 0.1, NPY 1 nmol 2.0 ± 0.5 
P<0.05, AgRP 1 nmol 1.2 ± 0.5, ghrelin 0.3 nmol 1.9 ± 0.5 n= 8-10 per group, n= 7 positive control) 
(Figure 5.8). 
Administration of AgRP (1 nmol) significantly increased food intake between 4-8h post injection 
compared to saline injected controls (4-8h food intake/g: saline 1.4 ± 0.3, NPY 1 nmol 0.4 ± 0.1, 
AgRP 1 nmol 3.6 ± 0.7 P<0.01, ghrelin 0.3 nmol 0.3 ± 0.02). AgRP also significantly increased 
cumulative 24h food intake and body weight compared to saline injected control animals (0-24h food 
intake/g: saline 30.9 ± 0.8, NPY 1 nmol 33.7 ± 0.9, AgRP 1 nmol 37.6 ± 1.8 P<0.01, ghrelin 0.3 
nmol 31.0 ± 1.6. 24h body weight gain/g: saline 1.3 ± 1.5, NPY 1 nmol 2.4 ± 1.4, AgRP 1 nmol 15.1 
± 2.1 P<0.001, ghrelin 0.3 nmol 0.5 ± 5.0 n= 8-10 per group, n= 7 positive control) (Figure 5.8). 
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FIGURE 5.7 The effect of intra-ventral tegmental area injection of saline, [Nle4,D-Phe7]-α-melanocyte 
stimulating hormone (NDP-MSH) (1 nmol), or leptin (0.06 nmol) (positive control) (n = 8-10 saline and NDP-
MSH, n = 6 leptin) on (A) 0-1h, (B) 1-2h, (C) 4-8h, (D) 8-24h and (E) 0-24h food intake in ad-libitum fed male 
rats in the early dark phase. *, P<0.05 vs. saline; **, P<0.01 vs. saline; ***, P<0.001 vs. saline. Results are mean 
± SEM. 
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FIGURE 5.8 The effect of intra-ventral tegmental area injection of saline, agouti-related peptide (AgRP) (1 
nmol), neuropeptide Y (NPY) (1 nmol) or ghrelin (0.3 nmol) (positive control) (n = 8-10 per group, n = 7 
ghrelin) on (A) 0-1h, (B) 1-2h, (C) 4-8h, and (D) 0-24h food intake and (E) 0-24h body weight  change in ad-
libitum fed male rats in the early light phase. *, P<0.05 vs. saline; **, P<0.01 vs. saline; ***, P<0.001 vs. saline. 
Results are mean ± SEM.  
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5.4.3 CHARACTERISATION OF MELANOCORTIN RECEPTOR-EXPRESSING NEURONS 
IN THE VTA  
 
5.4.3.1 EXPRESSION OF TH AND GAD65/67 MRNA IN THE RAT VTA 
 
5.4.3.1.1 PRODUCTION OF GAD65 AND TYROSINE HYDROXYLASE PROBES 
Rat brain tissue expressed TH mRNA as shown by RT-PCR. A band of approximately 910 base pairs 
was observed when compared to a 1Kb ladder (Figure 5.9A). TH was cloned into P.Bluescript 
plasmid using the enzymes BamH1 and EcoR1 (Figure 5.9B). Sequencing of DNA following large 
scale preparation of the plasmid confirmed correct probe generation. 
 
 
 
 
FIGURE 5.9 A) Tyrosine hydroxylase (TH) mRNA expression in rat hypothalmus as determined by reverse 
transcription-polymerase chain reaction (RT-PCR); L, 1-Kb ladder. The size of the expected PCR product for 
TH was 910 base pairs. B) Tyrosine hydroxylase following large scale preparation of plasmid DNA in 
P.Bluescript and digestion with EcoR1 and BamHI restriction enzymes; L, 1-Kb ladder.  
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Rat brain tissue expressed GAD65 mRNA as shown by RT-PCR. A band of approximately 310 base 
pairs was observed when compared to a 1Kb ladder (Figure 5.10A). TH was cloned into P.Bluescript 
plasmid using the enzymes BamH1 and EcoR1 (Figure 5.10B). Sequencing of DNA following large 
scale preparation of the plasmid confirmed correct probe generation. 
 
 
 
 
FIGURE 5.10 A) Glutamic acid decarboxylase (GAD) 65 mRNA expression in rat hypothalamus as 
determined by reverse transcription-polymerase chain reaction (RT-PCR); L, 1-Kb ladder. The size of the 
expected PCR product for GAD65 was 310 base pairs. B) GAD65 after large scale preparation of plasmid DNA 
in P.Bluescript following digestion with EcoR1 and BamHI restriction enzymes; L, 1-Kb ladder.  
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5.4.3.1.2 EXPRESSION OF TYROSINE HYDROXYLASE MRNA IN FROZEN RAT BRAIN 
SECTIONS 
Using a DIG-labelled TH antisense probe, TH mRNA expression was detected in the VTA and 
substantia nigra in the midbrain sections used (Figure 5.11). The signal for TH mRNA was not 
detected when brains sections were hybridised with the corresponding DIG-labelled sense probe. 
 
 
 
 
FIGURE 5.11 Expression of tyrosine hydroxylase (TH) mRNA in a coronal rat midbrain frozen section (12 
µm thickness) hybridized with antisense dixogigenin TH riboprobe seen under 20x magnification. Expression of 
TH (blue dots) is seen in the ventral tegmental area (VTA) and substantia nigra (SN). Bregma -6 mm.  
 
 
 
 
 
 
253 
 
5.4.3.1.3 EXPRESSION OF TYROSINE HYDROXYLASE MRNA IN FIXED PARAFFIN 
EMBEDDED RAT BRAIN SECTIONS 
The pattern of TH mRNA expression detected using paraffin sections was very similar to the pattern 
seen in frozen midbrain sections (Figure 5.12A). TH mRNA was detected in the VTA and substantia 
nigra and no expression was detected when sections were hybridised with a DIG labelled TH sense 
probe (Figure 5.12B). 
 
 
 
 
FIGURE 5.12 A) Expression of tyrosine hydroxylase (TH) mRNA in a coronal rat midbrain paraffin 
embedded section (3 µm thickness) hybridized with antisense digoxigenin TH riboprobe seen under 20x 
magnification. Expression is seen in the ventral tegmental area (VTA) and substantia nigra (SN). B) No 
expression of tyrosine hydroxylase mRNA is observed in sections hybridized with sense dixogigenin TH 
riboprobe seen under 20x magnification. This section is counterstained with haematoxylin to allow the brain 
section to be visualised. AQ, aqueduct. Bregma -6 mm.  
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5.4.3.1.4 EXPRESSION OF GAD65/67 MRNA IN FROZEN RAT BRAIN SECTIONS 
Using a DIG-labelled GAD65/67 antisense probe, GAD65/67 mRNA expression was abundant 
throughout the midbrain sections used, including the VTA (Figure 5.13). Signal for GAD65/67 
mRNA was not detected when brains sections were hybridised with the corresponding DIG-labelled 
sense probe.  
 
 
 
 
FIGURE 5.13 Expression of glutamic acid decarboxylase 65 and glutamic acid decarboxylase 67 (GAD65/67) 
mRNA in a coronal rat midbrain frozen section (12 µm thickness) hybridized with antisense digoxigenin 
GAD65/67 riboprobe seen under 20x magnification. Expression is widespread throughout the brain section. 
Abbreviations: AQ, aqueduct ; VTA, ventral tegmental area. Bregma -6 mm.  
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5.4.3.1.5 EXPRESSION OF GAD65/67 MRNA IN FIXED PARAFFIN EMBEDDED RAT 
BRAIN SECTIONS 
The pattern of GAD65/67 mRNA expression detected using paraffin sections was comparable to 
expression observed in frozen midbrain sections (Figure 5.14A). GAD65/67 mRNA was widespread 
throughout the brain and no expression was detected when sections were hybridised with a DIG 
labelled GAD65/67 sense probe (Figure 5.14B). 
 
 
 
 
FIGURE 5.14 A) Expression of glutamic acid decarboxylase 65 and glutamic acid decarboxylase 67 
(GAD65/67) mRNA in a coronal rat midbrain paraffin embedded section (3 µm thickness) hybridized with 
antisense digoxigenin GAD65/67 riboprobe seen under 50x magnification. Expression is widespread throughout 
the brain section. B) No expression of GAD65/67 mRNA is observed in sections hybridized with sense 
dixogigenin GAD65/67 riboprobe seen under 20x magnification. This section is counterstained with 
haematoxylin to allow the brain section to be visualised. Abbreviations: AQ, aqueduct; VTA, ventral tegmental 
area. Bregma -6 mm.  
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5.4.3.2 LOCALISATION OF MELANOCORTIN RECEPTORS IN THE RAT BRAIN 
 
5.4.3.2.1 LOCALISATION OF MELANOCORTIN RECEPTOR 3 IMMUNOREACTIVITY IN 
THE RAT BRAIN 
Staining of coronal sections of the rat midbrain with an affinity purified anti-MC3R antibody revealed 
MC3R-IR in the VTA (Figure 5.15A). MC3R–IR was also observed in cortical regions (Figure 
5.15B). The MC3R-IR was localised around the periphery of cell bodies and extending up the axon in 
a pattern in agreement with a previous study (Nyan et al, 2008). 
 
 
FIGURE 5.15 Melanocortin 3 receptor (MC3R) immunoreactive (IR) neurons in coronal rat midbrain paraffin 
embedded sections (3 µm thickness) seen under 50x magnification. MC3R-IR (brown) is detected in the ventral 
tegmental area (A) and in the cortex (B). MC3R-IR is localised to the periphery of cell bodies and along axon 
processes. Sections are counterstained with haematoxylin (blue).  Bregma -6 mm.  
 
5.4.3.2.2 LOCALISATION OF MELANOCORTIN RECEPTOR 4 IMMUNOREACTIVITY IN 
THE RAT BRAIN 
Staining of coronal sections of the rat midbrain with an affinity purified anti-MC4R antibody was 
unable to detect specific MC4R-IR in any brain region examined at any dilution of primary and 
secondary antibody tested. 
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5.4.3.3 DUAL IN SITU HYBRIDISATION/IMMUNOCYTOCHEMISTRY FOR GAD65/67 OR 
TH MRNA AND MC3R-IR 
Dual-labelling ISH/ICC revealed co-expression of MC3R-IR with GAD65/67 mRNA expressing 
neurons in the VTA (Figure 5.16A, B and C) and in the cortex (Figure 5.16D and E).  
 
There was no co-expression of MC3R-IR with TH mRNA expressing neurons in the VTA. 
 
 
 
 
FIGURE 5.16 Melanocortin 3 receptor (MC3R) immunoreactive (IR) neurons and GAD65/67 mRNA 
expressing neurons in coronal rat midbrain paraffin embedded sections (3 µm thickness). A) MC3R-IR (brown) 
is found solely on GABAergic cells (blue) in the ventral tegmental area (VTA) as seen under 50x magnification. 
B) and C) Higher magnification (100x magnification) images of VTA neurons co-expressing GAD65/67 
mRNA and MC3R-IR. D) Higher magnification (100x magnification) image of cortical neurons co-expressing 
GAD65/67 mRNA and MC3R-IR. E) Non-GABAergic MC3R-IR cortical neurons and GABAergic MC3R-IR 
cortical neurons seen under 100x magnification.  Bregma -6 mm.  
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5.4.4 STUDIES INVESTIGATING THE MECHANISMS BY WHICH iVTA 
MELANOCORTINS MEDIATE THEIR EFFECTS ON FOOD INTAKE 
 
5.4.4.1 EFFECT OF iVTA ADMINISTRATION OF NDP-MSH ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
Administration of all doses of NDP-MSH (0.1, 0.3 or 1 nmol) iVTA significantly reduced food intake 
between 0-1h, 1-2h and 2-4h post-injection. (0-1h food intake/g: saline 2.3 ± 0.3, NDP-MSH (0.1 
nmol) 0.4 ± 0.1 P<0.001, NDP-MSH (0.3 nmol) 0.4 ± 0.1 P<0.001, NDP-MSH (1 nmol) 0.2 ± 0.0 
P<0.001. 1-2h food intake/g: saline 2.8 ± 0.3, NDP-MSH (0.1 nmol) 1.0 ± 0.3 P<0.001, NDP-MSH 
(0.3 nmol) 0.4 ± 0.1 P<0.001, NDP-MSH (1 nmol) 0.8 ± 0.3 P<0.001. 2-4h food intake/g: saline 4.6 
± 0.7, NDP-MSH (0.1 nmol) 0.9 ± 0.3 P<0.001, NDP-MSH (0.3 nmol) 0.8 ± 0.3 P<0.001, NDP-MSH 
(1 nmol) 2.0 ± 0.7 P<0.01, n = 6 per group) (Figure 5.17). No significant differences in food intake 
were detected at any other time points measured. No significant differences in body-weight change 
were detected between any groups at 24 hours post-injection.   
 
5.4.4.2 EFFECT OF iVTA ADMINISTRATION OF LOWER DOSES OF NDP-MSH ON 
FOOD INTAKE IN AD-LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
Administration of NDP-MSH (0.03 and 0.1 nmol) iVTA significantly reduced food intake between 0-
1h and 2-4h post-injection. (0-1h food intake/g: saline 2.2 ± 0.2, NDP-MSH (0.03 nmol) 0.9 ± 0.4 
P<0.05, NDP-MSH (0.1 nmol) 0.5 ± 0.2 P<0.01. 2-4h food intake/g: saline 4.0 ± 0.8, NDP-MSH 
(0.03 nmol) 1.5 ± 0.9 P<0.05, NDP-MSH (0.1 nmol) 1.3 ± 0.8 P<0.05, n = 6-7 per group). 
Administration of NDP-MSH (0.03 nmol) significantly reduced food intake between 4-8h and caused 
a significant reduction in cumulative 0-24h food intake (4-8h food intake/g: saline 8.2 ± 0.8, NDP-
MSH (0.03 nmol) 3.4 ± 1.2 P<0.05. 0-24h food intake/g: saline 27.4 ± 0.8, NDP-MSH (0.03 nmol) 
18.2 ± 2.7 P<0.05, n = 6-7 per group) (Figure 5.18). No significant differences in food intake were 
detected at any other time points measured. No significant differences in body-weight change were 
detected between any groups at 24 hours post-injection.   
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FIGURE 5.17 The effect of intra-ventral tegmental area injection of saline, or [Nle4,D-Phe7]-α-melanocyte 
stimulating hormone (NDP-MSH) (0.1, 0.3 or 1 nmol), (n = 6-7 per group) on (A) 0-1h, (B) 1-2h, and (C) 2-4h 
food intake in ad-libitum fed male rats in the early dark phase. **, P<0.01 vs. saline; ***, P<0.001 vs. saline. 
Results are mean ± SEM.  
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FIGURE 5.18 The effect of intra-ventral tegmental area injection of saline, or [Nle4,D-Phe7]-α-melanocyte 
stimulating hormone (NDP-MSH) (0.01, 0.03 or 0.1 nmol), (n = 6-7 per group) on (A) 0-1h and (B) 2-4h on 
food intake in ad-libitum fed male rats in the early dark phase. *, P<0.05 vs. saline; **, P<0.01 vs. saline. 
Results are mean ± SEM.  
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5.4.4.3 EFFECT OF iVTA ADMINISTRATION OF NDP-MSH ON FOOD INTAKE IN 
FASTED MALE RATS DURING THE EARLY LIGHT PHASE 
Administration of NDP-MSH iVTA had no significant effect on 0-1h or 1-2h food intake compared to 
saline. All doses of NDP-MSH significantly reduced food intake between 2-4h post-injection. (2-4h 
food intake/g: saline 3.8 ± 1.1, NDP-MSH (0.03 nmol) 1.2 ± 0.5 P<0.05, NDP-MSH (0.1 nmol) 0.6 ± 
0.5 P<0.05, NDP-MSH (1 nmol) 0.8 ± 0.4 P<0.05, n = 6-7 per group) (Figure 5.19). No significant 
differences in food intake were detected at any other time points measured. No significant differences 
in body-weight change were detected between any groups at 24 hours post-injection.   
 
 
FIGURE 5.19 The effect of intra-ventral tegmental area injection of saline, or [Nle4,D-Phe7]-α-melanocyte 
stimulating hormone (NDP-MSH) (0.03, 0.1 or 1 nmol) (n = 6-7 per group) on (A) 0-1h, (B) 1-2h and (C) 2-4h 
food intake in fasted male rats in the early light phase. *, P<0.05 vs. saline. Results are mean ± SEM. 
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5.4.4.4 EFFECT OF iVTA ADMINISTRATION OF LOW DOSES OF AGRP ON FOOD 
INTAKE IN AD-LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Intra VTA administration of low doses of AgRP had no significant effect on food intake at any dose 
or time point measured. There was a trend toward increased food intake between 1-2h, 2-4h and 4-8h 
post-injection compared to saline injected rats (1-2h food intake/g: saline 0.9 ± 0.5, AgRP (0.01 
nmol) 1.8 ± 0.6, AgRP (0.03 nmol) 2.3 ± 0.3, AgRP (0.1 nmol) 1.6 ± 0.7. 2-4h food intake/g: saline 
0.2 ± 0.1, AgRP (0.01 nmol) 0.5 ± 0.4, AgRP (0.03 nmol) 1.3 ± 0.7, AgRP (0.1 nmol) 0.6 ± 0.3. 4-8h 
food intake/g: saline 1.2 ± 0.4, AgRP (0.01 nmol) 0.7 ± 0.5, AgRP (0.03 nmol) 1.2 ± 0.4, AgRP (0.1 
nmol) 1.8 ± 0.5, n = 5-6 per group) (Figure 5.20). No significant differences in body-weight change 
were detected between any groups at 24 hours post-injection.   
 
 
FIGURE 5.20 The effect of intra-ventral tegmental area injection of saline, or agouti-related peptide (AgRP) 
(0.01, 0.03 or 0.1 nmol), (n = 5-6 per group) on (A) 1-2h, (B) 2-4h and (C) 4-8h food intake in ad-libitum fed 
male rats in the early light phase. Results are mean ± SEM. 
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5.4.4.5 EFFECT OF iVTA ADMINISTRATION OF AGRP ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY LIGHT PHASE 
Administration of the top dose of AgRP (1 nmol) significantly stimulated food intake between 0-1h 
compared to saline. Administration of 0.3 nmol AgRP iVTA significantly stimulated food intake 
between 0-2h and 0-24h (0-1h food intake/g: saline 1.2 ± 0.4, AgRP (0.3 nmol) 1.9 ± 0.5, AgRP (1 
nmol) 2.7 ± 0.3, P<0.05 vs. saline. 0-2h food intake/g: saline 2.8 ± 0.5, AgRP (0.3 nmol) 5.0 ± 0.9, 
P<0.05 vs. saline, AgRP (1 nmol) 4.7 ± 0.4. 0-24h food intake/g: saline 29.4 ± 0.7, AgRP (0.3 nmol) 
33.6 ± 1.5, P<0.05 vs. saline, AgRP (1 nmol) 30.8 ± 1.1, n = 7-9 per group) (Figure 5.21A,B and C). 
Administration of 0.3 nmol AgRP iVTA also significantly increased body weight at 24h post-
injection (BW change/g: saline 7.2 ± 1.8, AgRP (0.3 nmol) 18.1 ± 1.8, P<0.001 vs. saline, AgRP (1 
nmol) 11.3 ± 1.2, n = 7-9 per group) (Figure 5.21D). 
 
 
FIGURE 5.21 The effect of intra-ventral tegmental area injection of saline, or agouti-related peptide (AgRP) 
(0.3 or 1 nmol) (n = 7-9 per group) on (A) 0-1h, (B) 0-2h, (C) 0-24h food intake, and (D) 0-24h body weight 
change in ad-libitum fed male rats in the early light phase. *, P<0.05 vs. saline. ***, P<0.001 vs. saline. Results 
are mean ± SEM. 
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5.4.4.6 EFFECT OF iVTA ADMINISTRATION OF γ-MSH ON FOOD INTAKE IN AD-
LIBITUM FED MALE RATS DURING THE EARLY DARK PHASE 
 Administration of γ-MSH iVTA had no significant effect on 0-1h or 1-2h food intake compared to 
saline, although there was a trend towards a reduction in food intake 0-1 h post injection with all 
doses administered (Figure 5.22A). Gamma-MSH (0.03 nmol) significantly reduced cumulative food 
intake between 0-2h post-injection. (0-2h food intake/g: saline 5.5 ± 0.6, γ-MSH (0.03 nmol) 3.4 ± 
0.6 P<0.05, n = 6-7 per group) (Figure 5.22B). No significant differences in food intake were detected 
at any other time points measured. No significant differences in body-weight change were detected 
between any groups at 24 hours post-injection. There was no effect of iVTA γ-MSH administration on 
any observed behaviour compared to iVTA saline injected animals. 
 
 
FIGURE 5.22 The effect of intra-ventral tegmental area injection of saline, or gamma-melanocyte stimulating 
hormone (gamma-MSH) (0.03, 0.1 or 1 nmol), (n = 6-7 per group) on (A) 0-1h and (B) 0-2h food intake in ad-
libitum fed male rats during the early dark phase. *, P<0.05 vs. saline. Results are mean ± SEM. 
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5.4.4.7 EFFECT OF IP PRETREATMENT WITH THE GABA RECEPTOR ANTAGONIST 
BICUCULLINE-METHIODIDE BEFORE iVTA ADMINISTRATION OF NDP-MSH ON 
FOOD INTAKE IN AD-LIBITUM FED MALE RATS BEFORE THE EARLY DARK PHASE 
IntraVTA NDP-MSH significantly reduced food intake between 0-2h post-injection. Pretreatment 
with an IP injection of the GABAA receptor antagonist bicuculline (3 mg/kg) blocked this effect (0-2h 
food intake/g: saline/saline 4.2 ± 0.6, saline/NDP-MSH (0.03 nmol) 1.9 ± 0.6 P<0.05 vs. saline, 
bicuculline/NDP-MSH 3.3 ± 0.6 n = 6-7 per group) (Figure 5.23). No significant differences in food 
intake were detected at any other time points measured. No significant differences in body-weight 
change were detected between any groups at 24 hours post-injection.   
 
 
FIGURE 5.23 The effect of intra-ventral tegmental area injection of saline (SAL), or [Nle4,D-Phe7]-α-
melanocyte stimulating hormone (NDP) (0.03 nmol) 15 minutes after an intraperitoneal injection with either 
saline (SAL) or the γ-aminobutyric acid (GABA) receptor antagonist bicuculline (BIC) (3 mg/kg) (n = 6-7 per 
group) on food intake in ad-libitum fed male rats in the early dark phase. *, P<0.05 vs. saline/saline. Results are 
mean ± SEM 
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5.5 DISCUSSION 
 
Factors known to regulate energy homeostasis at the level of the hypothalamus may also modulate the 
mesolimbic DA reward pathway. Direct administration of some, but not all, appetite related peptides 
into the VTA of rats significantly influences food intake, suggesting that reward circuits may 
contribute to the effects of neuropeptides and hormones on feeding. The melanocortin system is likely 
involved in the regulation of VTA output: the MC3R is found on GABAergic neurons in the VTA and 
administration of melanocortin receptor agonists and antagonists into the VTA profoundly affects 
feeding in rats.  
 
Recent studies have recognised that peripheral factors involved in appetite regulation, such as leptin 
and ghrelin, directly modulate the activity of VTA neurons, altering downstream DA release in the 
NAc and influencing feeding (Abizaid et al, 2006;Hommel et al, 2006). There is convincing evidence 
implicating insulin in food reward via modulation of the mesolimbic DA pathway too. Central 
administration of insulin suppresses several different DA dependent aspects of reward or motivation, 
such as acute sucrose licking (Sipols et al, 2000), conditioning of a place preference relating to food 
(Figlewicz et al, 2004), and sucrose self-administration  (Figlewicz et al, 2006) in rats fed ad libitum 
chow. Functional insulin receptors are expressed on TH-containing neurons in the rat VTA (Figlewicz 
et al, 2003;Figlewicz et al, 2007), suggesting that insulin may modulate DA activity at the level of the 
VTA. However, my data suggests that iVTA administration of insulin has no significant effect on 
food intake in ad-libitum fed rats in either the early light phase or at the onset of the dark phase. It has 
previously been reported that iVTA insulin administration has no effect on basal sucrose intake 
(Figlewicz et al, 2007). Feeding can be stimulated by iVTA administration of the µ-opioid agonist 
DAMGO, and this feeding is DA-dependent (MacDonald et al, 2004). IntraVTA administration of 
insulin has been shown to block this iVTA DAMGO induced feeding (Figlewicz et al, 2008). It is 
possible that the effect of insulin on food reward may only be relevant when there is adequate 
stimulation or drive within the VTA. 
 
The lateral hypothalamus has long been recognised as an important region in both food intake and 
reward processing. My studies suggest that iVTA administration of orexin (1 nmol) has no significant 
effect on food intake in rats. This is in agreement with a previous study which also reports no effect of 
iVTA orexin (500 pmol) administration on food intake in rats (Sweet et al, 1999). This study used 
different co-ordinates for their VTA injections, targeting the rostral VTA, while my cannulations 
targeted the parabrachial pigmented nucleus of the VTA. Both areas are rich in DA neurons but VTA 
DA neurons exhibit considerable heterogeneity regarding projection targets and pharmacological 
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properties (Bolaos et al, 2003;Ikemoto, 2007). It is interesting that despite anatomical evidence to 
suggest a role for orexin in VTA mediated food reward (Fadel & Deutch, 2002;Korotkova et al, 
2003;Marcus et al, 2001;Narita et al, 2006;Uramura et al, 2001), there is no detectable effect of iVTA 
orexin administration on food intake. Intra-VTA infusion of orexin A increases the time that rats 
spend awake and grooming, and these behaviours may mask any specific effects of orexin on food 
intake (Vittoz & Berridge, 2006). 
 
There is evidence to suggest that orexin is activated by reward-associated stimuli such as morphine 
and cocaine administration, and that orexin drives reward-seeking behaviour (such as reinstatement of 
an extinguished place preference) when activated by these stimuli (Harris et al, 2005). However, not 
all reward cues activate LHA orexin neurons (Harris et al, 2005). It is likely that orexin modulates the 
rewarding response to specific stimuli such as morphine, cocaine and fasting, but has no effect on 
reward seeking behaviour in the absence of an appropriate stimulus. In both my study and the study 
carried out by Sweet et al, the rats were ad-libitum fed. It would be interesting to investigate whether 
iVTA administration of an orexin receptor antagonist suppresses re-feeding in fasted rats. 
 
My data also suggest that iVTA administration of MCH has no significant effect on food intake in 
rats. This is in keeping with a lack of effect of MCH on the firing rate of VTA neurons (Korotkova et 
al, 2003), and the very low level of MCH1R expression in the VTA (Hervieu et al, 2000;Pissios et al, 
2008). It is likely that the documented effects of the MCH system on reward behaviour (Pissios et al, 
2008;Smith et al, 2005;Chung et al, 2009) are mediated by a direct action at the level of the NAc or 
other regions of the mesolimbic system.  
 
Neuropeptides of the ARC have a well-characterised role in the regulation of energy homeostasis. 
These neuropeptides have projections to many extra-hypothalamic brain regions, but studies 
investigating their roles in appetite regulation have tended to focus on hypothalamic circuitry. CART 
is perhaps the best candidate ARC neuropeptide to regulate VTA neurons and modulate food intake 
via the reward pathway. There is substantial evidence that CART is involved in reward and 
reinforcement systems (Rogge et al, 2008;Kimmel et al, 2000b). However, there has been little work 
carried out investigating the involvement of CART in these systems in relation to the control of food 
intake.  
 
Intra-VTA administration of 0.6 nmol CART (55-102) in satiated animals significantly reduced food 
intake between 8 and 24 hours post-injection, resulting in significantly reduced food intake over 24 
hours. In fasted animals, iVTA administration of 0.6 nmol CART (55-102) significantly reduced food 
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intake in the first hour post-injection, followed by a significant increase in food intake between 2 and 
4 hours post-injection. In both fed and fasted studies, administration of this dose of CART (55-102) 
was associated with some behavioural abnormalities, mainly tremors, in a number of animals. 
Tremors and seizure like activity have been previously reported following intra-VTA administration 
of higher doses of CART (55-102) (Kimmel et al, 2000a). Significant increases in locomotor activity 
have also been reported following intra-VTA administration of CART (55-102) at doses similar to 
those shown to influence food intake in my studies (Kimmel et al, 2002). It is difficult to determine 
whether CART injection into the VTA specifically influences food intake, or whether the anorectic 
effects of CART are secondary to alterations in locomotor activity and tremors. If injection of CART 
antiserum into the VTA increased food intake, this would provide evidence that the VTA CART 
system has a physiological role in the regulation of food intake. 
 
My studies suggest that iVTA administration of NPY significantly stimulates food intake in ad-
libitum fed rats. Y1 and Y5 receptors, which mediate the orexigenic effects of NPY, are expressed in 
the VTA providing a possible mechanism mediating this effect (Parker & Herzog, 1999). The dose 
used in this study is relatively high for intranuclear injection; a dose of 100 pmol NPY is sufficient to 
stimulate food intake when administered into the PVN (Stanley & Leibowitz, 1985). It is possible that 
NPY may have diffused to, and mediated its orexigenic effect via, neighbouring brain regions rather 
than having a specific orexigenic effect in the VTA. Further studies using lower doses of NPY and Y 
receptor antagonists are required to establish whether NPY signalling in the VTA has a physiological 
role in food intake. It is possible that NPY mediates at least a part of its potent orexigenic effect via 
the dopaminergic reward pathway as iNAc NPY administration can produce a CPP to a previously 
neutral environmental cue and this effect can be blocked by a DA receptor antagonist (Josselyn & 
Beninger, 1993).  
 
IntraVTA administration of NDP-MSH (1 nmol) to ad-libitum fed rats profoundly reduced 0-1h food 
intake to 10% of that of saline injected control rats, while iVTA administration of the melanocortin 
receptor antagonist AgRP significantly increased food intake and caused a large increase in body 
weight. These studies suggest the presence of endogenous melanocortin tone in the VTA, disruption 
of which affects food intake. Doses of NDP-MSH as low as 0.03 nmol significantly reduced food 
intake following iVTA administration in ad-libitum fed rats. It would be interesting to compare the 
sensitivity of the VTA to the anorectic effect of NDP-MSH with the sensitivity of the hypothalamus. 
However, a previous study investigating the effect of intranuclear NDP-MSH administration on food 
intake has only looked in fasted rats (Kim et al, 2000a). In this study, intranuclear NDP-MSH (0.1 
nmol) administration into the PVN, DMN and mPOA of fasted rats significantly reduced food intake 
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to 50% of saline injected controls between 0-1h post-injection (Kim et al, 2000a). My studies show 
that in ad-libitum fed rats in the dark phase 0.03 nmol NDP-MSH suppressed 0-1h food intake to 
approximately 40% of that of saline injected animals, while the comparable dose of 0.1 nmol NDP-
MSH reduced food intake to 20% of that of saline injected animals. These data suggest that perhaps 
the VTA is more sensitive than the hypothalamus to the effects of melanocortin administration. 
There was no reduction in 24 hour body weight following administration of even the highest dose of 
NDP-MSH into the VTA in these studies. This is in contrast to reports of a reduction in body weight 
following ICV injection of the melanocortin receptor agonist MTII (0.01 nmol) in rats (Thiele et al, 
1998), and following ICV injection of NDP-MSH (10 nmol) in mice (Kim et al, 2005). It is possible 
that VTA melanocortin circuits exert only a short term suppression of food intake before 
hypothalamic circuits are activated and override manipulations of the reward pathway, stimulating 
rebound feeding and thus maintaining body weight.  
 
My studies found that administration of NDP-MSH into the VTA of fasted rats had no significant 
effect on food intake for the first two hours post injection. There was a reduction in food intake 
between 2-4 hours post-injection but no effects at any other time point measured. This delay in the 
anorectic effect of melanocortin receptor agonists has not previously been reported. The time at which 
ICV α-MSH administration is suggested to mediate its effects on feeding is between 30 minutes and 6 
hours post-injection (Semjonous et al, 2009). The reduction in food intake observed with iVTA NDP-
MSH administration after an overnight fast was less significant than the iVTA NDP-MSH induced 
suppression of night-time feeding, although rats tend to eat more in the first few hours of re-feeding 
following a fast than in the first few hours of the dark phase. These data suggest that there are 
differential effects of melanocortin signalling in the VTA between fed and fasted states. 
 
It is tempting to speculate that the importance of the reward circuitry differs under different 
physiological conditions. In the fasted state, the melanocortin tone in the VTA hedonic circuitry may 
be less responsive to administration of melanocortins because it is overridden by the homeostatic 
drive to eat. In freely feeding rats, it is possible that the hedonic VTA circuitry is more sensitive to the 
anorectic effect of melanocortin administration as the homeostatic feeding pathways are not activated. 
In support of this hypothesis, iVTA administration of ghrelin to fasted rats had no effect on food 
intake. The orexigenic effect of a peptide is often less pronounced in fasting induced re-feeding 
settings, but ICV ghrelin injection has been reported to have a more enhanced orexigenic effect in 
fasted rats than in ad-libitum fed rats (Bagnasco et al, 2003;Tung et al, 2005). This is proposed to be 
due to a lack of inhibition by leptin and insulin, levels of which are reduced in fasting (Tung et al, 
2001). 
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IntraVTA administration of AgRP stimulates food intake in ad-libitum fed rats. However, the pattern 
of the orexigenic effect of AgRP is inconsistent in my studies. In the early feeding study, 1 nmol 
AgRP had no significant effect on food intake up to 4 hours post-injection, after which it dramatically 
increased food intake, lasting up to 24 hours and resulted in a large gain in body weight at 24 hours 
post-injection. In the later studies, iVTA AgRP injection (0.3 and 1 nmol) mediated its orexigenic 
effect between 0-4 hours post-injection, with no significant effect at later time points. The effect of 
AgRP on cumulative 24h food intake and 24h body weight was retained in this study, although only 
significantly at the lower (0.3 nmol) dose. The reason for these discordant results is not known. The 
AgRP used in these two studies was supplied by different manufacturers and differed by three amino 
acids in length. The AgRP used in the earlier study was 86-132, and the AgRP used in the later study 
was AgRP83-132. Both forms should similarly antagonise the MC3R and MC4R (Joseph et al, 
2003;Kim et al, 2002), so it is possible, but unlikely that these differences in the peptide may account 
for these different timing of the orexigenic effect of iVTA AgRP. It is also possible that the effects 
seen in the second study reflect the greater susceptibility to spurious effects of experiments using 
lower n numbers, and that larger groups would result in similar outcomes. 
 
The increase in body weight observed following iVTA AgRP administration is profound, with an 
increase of 15-18g across studies. This is not accountable solely by the increase in food intake over 
the same period and is more likely due to an increase in water intake or retention. Previous studies 
report an increase in body weight, independent of food intake of approximately 5-10g 24 hours 
following ICV administration of AgRP (Small et al, 2001;Small et al, 2003), and an even greater 
increase (20g) following administration of the long-acting AgRP analogue, SHU9119 (Grill et al, 
1998). ICV administration of SHU9119 stimulates water intake in rats (Grill et al, 1998). However, 
the increase in body weight has also been attributed to reduced energy expenditure (Small et al, 
2003). The exact mechanisms mediating the increased body weight following VTA melanocortin 
receptor blockade remain to be elucidated. 
 
Alpha-MSH mediates its central biological effects via the MC3R and the MC4R. MC3R and MC4R 
are both expressed in the VTA (Mountjoy et al, 1994;Roselli-Rehfuss et al, 1993). The effect of iVTA 
administration of γ-MSH was carried out to attempt to elucidate which melanocortin receptor 
mediates the anorectic effect of iVTA NDP-MSH administration. Gamma-MSH is an endogenous 
agonist of the MC3R, with 50 fold higher affinity for the MC3R over the MC4R (Oosterom et al, 
1999). IntraVTA γ-MSH administration caused a less potent suppression of food intake compared to 
iVTA administration of NDP-MSH. While all doses reduced food intake, only the lowest dose (0.03 
nmol) resulted in a statistically significant reduction in food intake between 0-2h post-injection. This 
271 
 
study suggests that activation of the MC3R in the VTA can have anorectic effects. It is important to 
note that the synthetic melanocortin receptor antagonist NDP-MSH is structurally engineered to bind 
the melanocortin receptors with higher affinity and may be cleared less readily than endogenous 
melanocortin peptides, including γ-MSH (Sawyer et al, 1980). It is possible that following a higher 
dose of γ-MSH administered into the VTA, a more significant anorectic effect would be observed. 
Additionally, the γ-MSH used in this study was γ2-MSH,, a non-amidated form of γ-MSH with weaker 
affinity for the MC3R compared to amidated γ1-MSH (Oosterom et al, 1999). IntraVTA 
administration of a specific MC4R agonist would help to clarify whether the VTA mediated anorectic 
effect of the melanocortins is via this receptor. 
 
Interestingly, it has previously been reported that ICV administration of γ1-MSH or γ2-MSH has no 
effect on fasting-induced re-feeding in rats (Abbott et al, 2000;Kask et al, 2000), although other 
studies observe a small reduction in food intake following ICV γ2-MSH administration to fasted rats 
(Millington et al, 2001). 
 
IntraVTA administration of the melanocortins αMSH and γ-MSH has previously been associated with 
an increase in grooming behaviour, an effect mediated by alterations in VTA DA neuronal activity 
(Klusa et al, 1999;Torre & Celis, 1988). There was no effect of iVTA γ-MSH administration on 
grooming, or any other observed behaviour in my studies. The reason for this discrepancy may be that 
the dose of γ-MSH used in the previous study was much higher (3 nmol) than the dose used in my 
study (1 nmol). It is possible that the anorectic effect of iVTA MSH administration is secondary to 
alterations in other behaviours. However, no significant behavioural effects were observed following 
iVTA administration of γ-MSH in these studies, and iVTA administration of the melanocortin 
receptor antagonist AgRP stimulates food intake, suggesting a physiological role for the VTA 
melanocortin system in the regulation of food intake. 
   
Expression of MC3R mRNA is more abundant in the VTA than in most other brain regions, including 
some hypothalamic nuclei (ARC and LHA) (Roselli-Rehfuss et al, 1993). The phenotype of the 
neurons on which the MC3R is expressed has not previously been reported. My studies suggest that 
the MC3R co-localises with GAD65/67 in the VTA but is not expressed by any VTA TH-containing 
neurons. All MC3R-IR neurons in the VTA were GABAergic. These neurons were located primarily 
in the lateral part of the PBP nucleus, with little MC3R-IR observed in other VTA nuclei. 
 
Unfortunately I was unable to detect MC4R in any brain region using ICC.  Receptor ICC can be 
difficult as receptor levels are often much lower than the levels of neuropeptides. Further studies 
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examining the co-localisation of MC4R mRNA, which has been previously detected in the VTA, with 
TH and GAD expressing neurons, are essential to further characterise the VTA melanocortin system. 
The downstream mediators of melanocortin receptor signalling in the VTA are currently unknown. 
The VTA contains large populations of dopaminergic and GABAergic neurons and a much smaller 
population of glutamatergic neurons. The majority of the GABAergic neurons in the VTA are 
interneurons which synapse onto local dopamine neurons, modulating their function (Steffensen et al, 
1998). There are also populations of GABAergic neurons which project to the nucleus accumbens and 
the cortex (Steffensen et al, 1998). Pre-administration with a GABA receptor antagonist partially 
blocked the anorectic effect of iVTA NDPMSH, suggesting that GABA signalling is an important 
mediator of the effects of NDP-MSH on food intake. It is possible that melanocortin receptor 
signalling in the VTA activates GABAergic neurons which act locally to suppress the firing of VTA 
DA neurons, resulting in a reduction in NAc DA release. Alternatively GABAergic neurons 
expressing melanocortin receptors may project to the NAc and inhibit DA release from VTA nerve 
terminals. Pre-administration of bicuculline directly into the VTA or the NAc, before iVTA NDP-
MSH would provide more precise information of the downstream pathways mediating the anorectic 
effect of iVTA melanocortin administration. In addition, it would be useful to determine where 
MC3R-IR GABAergic VTA neurons project to.  
 
It would be interesting to pre-administer a DA receptor antagonist prior to iVTA AgRP injection. If a 
DA receptor antagonist were to block the orexigenic effect of iVTA AgRP, this would provide 
convincing evidence that the endogenous melanocortin tone in the VTA directly interacts with the 
mesolimbic DA circuitry. Furthermore, activation of c-fos in downstream targets of the reward 
pathway, including the NAc and the prefrontal cortex, following AgRP injection into the VTA would 
strongly suggest enrolment of the reward circuitry in the mediation of AgRP’s orexigenic effect. 
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CHAPTER 6  
GENERAL DISCUSSION 
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6.1 INTRODUCTION  
 
Neuropeptides play an important role in the regulation of food intake and reproduction. Food intake is 
regulated by homeostatic systems designed to maintain a constant body weight, and also by the 
brain’s reward circuitry. The regulation of energy homeostasis is closely linked to the HPG axis to 
ensure that sufficient energy reserves are available for reproduction. The studies described in this 
thesis have investigated the effects of the novel hypothalamic neuropeptide alarin on food intake and 
the HPG axis, and the role of the melanocortin system in the mesolimbic reward system. 
 
6.2 THE ROLE OF ALARIN IN THE REGULATION OF ENERGY HOMEOSTASIS AND 
REPRODUCTION 
Alarin is a recently discovered splice variant of the galanin-like peptide (GALP) gene (Santic et al, 
2006). GALP has a well-characterised hypothalamic role in the integration of energy and reproductive 
homeostasis (Matsumoto et al, 2001;Matsumoto et al, 2002). Alarin is a highly conserved 25 amino 
acid peptide which shares its first 5 amino acids with GALP, but lacks the galanin receptor binding 
domain, suggesting that it mediates its biological effects through alternative receptors. Alarin mRNA 
has been detected in the brain and within specific nuclei of the hypothalamus (Eberhard et al, 
2007;Santic et al, 2007).  
 
My studies suggest that alarin is an orexigenic neuropeptide, in agreement with a recent paper 
published after the completion of my studies (Van Der Kolk et al, 2010a). ICV administration of 
alarin to rats stimulated food intake acutely. Alarin stimulated the release of the orexigenic NPY from 
hypothalamic explants, suggesting that the orexigenic effect of alarin may be mediated by increased 
hypothalamic NPY release. However, hypothalamic alarin levels do not appear to be altered between 
fed and fasted states, suggesting that alarin may not be an endogenous regulator of energy 
homeostasis. As the receptor through which alarin mediates its orexigenic effect is currently 
unknown, it is not possible to investigate whether the expression of this putative receptor is altered by 
changes in nutritional status.  
 
The orexigenic effect of alarin appears to be relatively weak compared to well characterised 
hypothalamic orexigenic neuropeptides such as NPY and GALP (Levine & Morley, 1984;Matsumoto 
et al, 2002). Alarin did not stimulate food intake following ICV administration to rats in fasted or 
early dark phase experimental paradigms, and a relatively high dose (30 nmol) of alarin was required 
to significantly increase food intake in satiated rats. It has been reported that administration of doses 
as low as 1 nmol of c-terminally amidated alarin into the LV were sufficient to elicit an orexigenic 
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response in rats (Van Der Kolk et al, 2010a). It is important to determine whether the endogenous 
form of alarin is amidated, and thus whether this endogenous alarin has more potent effects in vivo 
than my studies have revealed. However, there is no reason that endogenous alarin would be amidated 
as the C-terminal residue of alarin is a serine. Endogenous amidation is catalysed by the enzyme 
PAM, which converts peptides with the structure -X-Gly to the form -X-NH2 (Eipper & Mains, 
1988;Bradbury et al, 1982). It is possible that the orexigenic effect of alarin is a pharmacological 
effect only stimulated by exogenous alarin administration. However, alarin-IR has been detected in 
hypothalamic nuclei known to be involved in the regulation of energy homeostasis (Eberhard et al, 
2007), and central alarin administration to rats induces fos activity in hypothalamic nuclei implicated 
in the control of food intake, including the PVN, DMN and LHA (Van Der Kolk et al, 2010a).  
 
My in vivo studies have shown that ICV alarin stimulates plasma LH levels in intact male rats in vivo. 
My in vitro studies demonstrate that alarin stimulates gonadotrophin releasing hormone (GnRH) 
release from hypothalamic explants from male rats and from an immortalised GnRH releasing cell 
line. Pre-treatment with a GnRH antagonist, cetrorelix, blocked the increase in plasma LH levels 
following central administration of alarin in vivo, providing further evidence that ICV alarin activates 
the HPG axis via GnRH. 
 
Though the role of GnRH is well-characterised, the endogenous neuropeptides operating upstream of 
GnRH to regulate the HPG axis are less well characterised. Numerous peptides are known to 
influence hypothalamic GnRH release, including several also involved in energy homeostasis such as 
NPY and GALP (Kalra & Kalra, 1996;Matsumoto et al, 2001). The focus of much current research is 
to tease out the precise physiological functions of the neuronal circuits upstream of the GnRH neuron. 
The sheer number of neurotransmitters known to regulate GnRH release suggests that there is 
redundancy built into the system, which makes sense from an evolutionary perspective, but can make 
it more difficult to demonstrate the physiological role of a single signal. However, with the genetic 
and pharmacological tools currently available, biology is beginning to establish the anatomical 
circuits and the hierarchy of signals responsible for regulating reproduction under different 
physiological conditions. The activity of the reproductive axis is sensitive to the adequacy of nutrition 
and the stores of metabolic reserves. Circulating levels of adipocyte-derived hormone leptin are 
thought to reflect the state of nutrition and energy reserves, and thus to serve as a metabolic signal to 
the reproductive system (Barash et al, 1996). However, the leptin receptor has not been identified on 
GnRH neurons in vivo (Hakansson et al, 1998), and the intermediaries in the signal transduction 
pathway between leptin and GnRH are yet to be conclusively established. There is evidence that the 
potent GnRH-releasing neuropeptide kisspeptin may play a role in mediating this link between energy 
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homeostasis and reproduction (Fernandez-Fernandez et al, 2006). In addition, galanin family peptides 
may be involved. Hypothalamic GALP peptide and mRNA expression are up-regulated by leptin 
(Jureus et al, 2001), and GALP antiserum blocks leptin-induced GnRH release from hypothalamic 
explants (Seth et al, 2004), supporting the hypothesis that GALP may mediate the actions of leptin on 
the HPG axis. Alarin may also play a role in integrating metabolic state with HPG axis function, 
although further studies are required to confirm this hypothesis.  
 
Alarin lacks the galanin receptor binding domain which is thought to be responsible for the binding of 
galanin and GALP to the three known galanin receptors (Bloomquist et al, 1998;Land et al, 
1991;Lang et al, 2005;Smith et al, 1998). My results confirm that alarin is unable to bind to the GalR1 
or GalR2 in agreement with a previous study (Santic et al, 2007), and demonstrate for the first time 
that alarin is also unable to bind to the GalR3. My data also suggests that alarin does not bind to any 
receptor at which galanin is also able to bind, and that this receptor is expressed by GT1-7 cells, 
supporting previous evidence that there are as yet uncharacterised galanin peptide family receptors 
(Fraley et al, 2003;Fraley et al, 2004b;Lawrence et al, 2002;Lawrence et al, 2003;Seth et al, 2004). 
GALP is thought to mediate some of its biological effects via a receptor or receptors distinct from the 
three known galanin receptors (Krasnow et al, 2004;Lawrence et al, 2003;Matsumoto et al, 2001;Seth 
et al, 2004). It is possible that alarin may act as a ligand for the same unidentified receptor or 
receptors. Alarin and GALP have similar biological effects in vivo and in vitro, and alarin (6-25), 
which lacks the five amino acids which it has in common with GALP, is unable to elicit a biological 
effect in vitro. 
 
There is interest in the development of GALP as a therapy in the treatment of obesity or reproductive 
disorders (Nonaka et al, 2008;Gundlach, 2002). However, due to the promiscuity of GALP binding to 
all of the galanin receptors, concerns regarding side-effects have hampered progress in its 
development. Although the in vivo potency of alarin appears to be relatively low compared to GALP, 
if alarin is a specific ligand for a particular novel receptor, it may provide a tool to investigate and 
manipulate the specific neural pathways mediating the different actions of the galanin peptide family. 
Further work is thus required to identify and characterise the receptor or receptors through which 
alarin mediates its biological effects, and to establish the potential of alarin as a pharmacological 
and/or medicinal tool. 
 
The studies described in this thesis demonstrate the pharmacological effects of alarin in vitro and in 
vivo. There is still much to be determined regarding the physiology of galanin peptide family. There 
has been a sustained interest in this family of peptides for the past thirty years, but as yet no drugs 
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targeting this system have been developed. My research has focussed on the central role of alarin in 
the regulation of energy homeostasis and reproduction. I have demonstrated that alarin has orexigenic 
effects and regulates the HPG axis via hypothalamic GnRH. However there are other important areas 
in which alarin may have effects. In particular, roles for alarin in the skin and in tumourigenesis have 
been suggested but not fully investigated (Santic et al, 2006). The most important discovery regarding 
alarin, however, will likely be the identification of an alarin receptor. This will allow a better 
understanding of the alarin system and potentially allow us to elucidate the receptors mediating 
specific GALP effects. It may even provide a therapeutic target.  
 
6.3 THE ROLE OF THE VTA MELANOCORTIN SYSTEM IN THE REGULATION OF 
FEEDING 
The VTA is the origin of DA neurons which project to the NAc and mediate the rewarding properties 
of palatable food. Recent work suggests that this reward pathway is regulated by appetite regulating 
signals such as leptin and ghrelin (Abizaid et al, 2006;Hommel et al, 2006). My data suggest that 
some, but not all, factors with known roles in energy homeostasis are able to affect food intake 
following iVTA administration.  
 
Despite evidence of anatomical interactions between insulin signalling and the VTA DA circuitry 
(Figlewicz et al, 2003;Pardini et al, 2006), and reports of regulation of DA-related behaviours by 
insulin (Figlewicz et al, 2004;Figlewicz et al, 2008;Figlewicz et al, 2006), there was no significant 
effect of iVTA insulin on food intake. The orexigenic LHA peptides, orexin A and MCH, were also 
unable to affect food intake following iVTA administration. These studies were carried out in the 
absence of any reward related stimulus. It is possible that these factors play a role in modifying VTA 
neuronal activity when the reward pathway is already activated by an appropriate stimulus. 
Alternatively, these factors may affect the mesolimbic VTA DA pathway without influencing food 
intake.   
 
All ARC neuropeptides tested altered food intake when administered iVTA. The anorectic effect of 
iVTA CART may be due to increases in locomotor activity and tremors observed post-injection rather 
than a direct effect on food intake. IntraVTA administration of NPY at a relatively high dose 
stimulated food intake and it is likely that NPY mediates its orexigenic effect, at least in part, by 
increasing the rewarding value of food (Jewett et al, 1995). Further studies are required to investigate 
physiological importance of the VTA NPY system, and the downstream signalling mediating the 
orexigenic effect of iVTA NPY. 
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The data in this thesis suggest that the melanocortin system may be involved in the hedonic regulation 
of appetite in addition to its well characterised role in homeostatic regulation of appetite. 
Administration of NDP-MSH into the VTA reduced food intake, and iVTA administration of the 
melanocortin receptor antagonist AgRP increased food intake, suggesting the presence of an 
endogenous VTA melanocortin tone. IntraVTA administration of NDP-MSH at doses as low as 0.03 
nmol significantly reduced food intake, suggesting that the VTA may be more sensitive to the 
anorectic effects of melanocortins than the hypothalamus. However the sensitivity of the VTA to 
melanocortins appears to vary with altered nutritional status; iVTA administration of NDP-MSH to 
fasted animals resulted in a delayed and less significant reduction in food intake than that following 
iVTA injection in ad-libitum fed rats. These data support the hypothesis that in the fasted state, the 
melanocortin tone in the VTA hedonic circuitry may be less responsive to administration of 
melanocortins due to an overriding homeostatic drive to eat, while in ad-libitum fed rats, the hedonic 
VTA circuitry is more sensitive to the anorectic effect of melanocortin administration as homeostatic 
feeding pathways are not activated.  
 
The downstream pathways mediating the anorectic effect of iVTA melanocortin administration may 
involve the MC3R. This receptor co-localises exclusively with GABAergic neurons in the VTA and 
administration of a GABA receptor antagonist attenuates the anorectic effect of iVTA NDP-MSH. It 
is not yet known whether the GABAergic neurons expressing MC3R-IR are local interneurons 
modulating VTA DA neuron activity, or whether these GABAergic neurons project to other brain 
regions such as the NAc. Administration of a DA receptor antagonist prior to iVTA AgRP injection 
would be a useful study to determine whether the melanocortins influence mesolimbic DA release to 
mediate their effects on feeding. The MC4R may also play a role in mediating the anorectic effects of 
iVTA NDP-MSH.  Further studies which successfully localise the MC4R in the VTA and identify the 
phenotype of these neurons are essential to characterise the VTA melanocortin system.   
 
The studies in this thesis have identified an endogenous melanocortin tone in the VTA and 
characterised, in part, the mechanisms by which VTA melanocortins mediate their effects on food 
intake. The importance of hedonistic control of eating from an evolutionary perspective is clear. In a 
society like ours, with plentiful food, hedonistic drives to eat may play a more important role in over-
consumption than homeostatic drives. There is a large body of evidence focussing on the mechanisms 
underlying homeostatic appetite regulation, yet there is currently little information available regarding 
how reward pathways interact with appetite. Recent studies have used functional neuroimaging such 
as fMRI to provide insights into food-reward regulation by allowing the simultaneous assessment of 
brain activity concurrent with external stimuli, appetitive ratings, physiological and metabolic changes 
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and eating itself. These studies can evaluate the brain specific effects of appetite regulating factors 
and illustrate changes in the reward system in obese humans compared to normal weight controls 
(Neary & Batterham, 2010).  
 
Neural responses to food images have been assessed using fMRI in human subjects before and after 
weight loss, with and without leptin replacement (Rosenbaum et al, 2008), and in leptin deficient 
subjects before and after leptin replacement (Farooqi et al, 2007). Following weight loss, brain 
activity was altered in areas implicated in reward processing such as the NAc, the amygdala and the 
frontal cortex. Many of these changes in activity were reversed by leptin replacement. These results 
may provide an explanation as to why maintaining weight loss is difficult; decreased leptin levels 
result in enhanced activation of reward circuits, driving behaviour towards consumption of highly 
palatable foods. 
 
Administration of the anorectic gut hormone PYY3-36 to fasted human volunteers has been reported 
to modulate brain activity in both homeostatic (hypothalamic and brainstem) and non-homeostatic 
regions including the amygdala, orbitofrontal cortex (OFC), VTA and the ventral striatum (Batterham 
et al, 2007). This study also observed that following saline infusion, when endogenous PYY3-36 
levels are low, activity in the hypothalamus predicted subsequent caloric intake, whereas in the 
presence of high PYY3-36 levels, activity in the OFC predicted subsequent caloric intake. There was 
also a negative correlation between OFC activation and meal pleasantness ratings. These findings 
suggest that PYY enhances discrimination of rewarding foods and reduces reward-motivated drives to 
eat in the fed state. 
 
Ghrelin infusion to satiated humans alters neural response to images of food in regions such as the 
amygdala, VTA, and OFC (Malik et al, 2008a). The effects of ghrelin on the amygdala and OFC 
response were correlated with self-rated hunger ratings, demonstrating that metabolic signals such as 
ghrelin may increase food consumption by enhancing the hedonic and incentive responses to food-
related cues. 
 
It is important to note that much of the in vivo data obtained is open to ambiguous interpretation. A 
reduction in the responsiveness of reward circuits can be used as evidence that obese individuals will 
need to eat more to obtain reward, and an over-responsive reward pathway can be used to support the 
case that obese individuals obtain increased reward from eating and therefore eat more. However, it 
seems unlikely that both paradigms are correct. More precise mechanistic data is required to delineate 
280 
 
the precise circuits underlying the reward system before it can be effectively targeted as a therapy for 
obesity. 
 
The cannabinoid receptor inverse agonist Rimonabant has previously been used as a therapy for 
obesity. Rimonabant is thought to act at least in part by targeting the reward system. Despite reducing 
body weight in obese patients, Rimonabant has been withdrawn due to its side effects of severe 
depression and suicidal thoughts. As CB1 receptors are found throughout the CNS, it is not currently 
understood where exactly Rimonabant is acting to cause these side-effects. However, it certainly 
seems possible that it may be the effects of this drug on the reward system that drive them. This 
highlights that while targeting the reward system can be effective in the treatment of obesity, it may 
also result in unwanted side-effects. It is possible that with a better understanding of the neural 
circuitry regulating food reward, we will be able to manipulate very specific components of the 
reward system, and that this may prove an effective therapy for the treatment of obesity. 
 
In support of my hypothesis, I have provided evidence that the alarin system regulates appetite and 
reproductive function. Alarin has been shown to fulfil some of the criteria expected of a neurotransmitter. 
It is found in synapses in dense core vesicles (Santic et al, 2006). Electrophysiological studies are 
required to determine whether alarin is released from nerve terminals in response to calcium dependent 
presynaptic depolarisation. Alarin likely operates through a specific receptor system, most likely a GPCR-
based system, like other galanin family peptides. However, no receptor for alarin has yet been identified. 
My studies suggest that GT1-7 cells express an alarin receptor. If the receptor could be isolated from this 
cell line, it would provide further evidence that alarin operates as a neurotransmitter. My studies have 
mainly concerned the functions of alarin in the hypothalamus and pituitary gland, particularly with 
regards to the regulation of appetite and the hypothalamo-pituitary axes. I have demonstrated that ICV 
administration of alarin stimulates food intake and the HPG axis.  
 
VTA administration of specific appetite regulating factors influenced food intake, supporting my 
hypothesis, though not all factors investigated had an effect on feeding. My data suggests that the 
ARC neuropeptides, and in particular the melanocortin system, modulate the mesolimbic 
dopaminergic reward pathway to regulate food intake. My studies have widened the known roles of 
the melanocortins from the relatively well-characterised homeostatic regulation of feeding to 
encompass a novel role in the modulation of food-related reward. 
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APPENDIX I –SOLUTIONS USED IN THIS THESIS 
 
0.5M acetic acid  
Add 15ml of glacial acetic acid (98%) to 500ml GDW 
 
5M ammonium acetate 
Dissolve 385g CH3.COONH4 in 600ml GDW and make up to 1L 
 
100mg/ml ampicillin 
Dissolve 1g in 10ml GDW, sterilise by passage through a 0.2µm filter and distribute in 1ml aliquots 
 
Artificial cerebrospinal fluid (aCSF) 
Make aCSF immediately before use. To make 500 ml aCSF mix 100ml 0.1M NaHCO
3
, 100ml 0.63M 
NaCl, 5ml 0.09M Na2HPO4.2H2O, 5ml 0.59M KCl, 5ml 0.09M MgSO4
.
7H2O, 450 mg glucose, 88 mg 
ascorbic acid, 5ml aprotinin (Trasylol, Bayer Corp) and 270ml GDW. Saturate with 95% O2
 
and 5% 
CO2. Add 10ml 0.07M CaCl2.2H2O after gassing.  
 
56mM KCl (stimulatory) aCSF 
Make aCSF immediately before use. To make 100ml 56mM KCl aCSF, mix 20ml 0.1M NaHCO3, 
11.6ml 0.63M NaCl, 1ml 0.09M Na2HPO4.2H2O, 10ml 0.59M KCl, 1ml 0.09M MgSO4
.
7H2O, 90 mg 
glucose, 17.6mg ascorbic acid, 1ml aprotinin (Bayer Corp) and 53.4ml GDW. Saturate with 95% O2
 
and 5% CO2. Add 2ml 0.07M CaCl2.2H2O after gassing.  
 
aCSF stock solutions:  
0.09M disodium hydrogen orthophosphate dehydrate: Dissolve 1.56g Na2HPO4.2H2O in 
100ml GDW  
0.07M calcium chloride dehydrate: Dissolve 1.04g CaCl2.2H2O in 100ml GDW 	  
0.09M magnesium sulphate heptahydrate: Dissolve 2.2g MgSO4
.
7H2O in 100ml GDW  
0.59M potassium chloride: Dissolve 4.42g KCl in 100ml GDW  
0.1M sodium bicarbonate: Dissolve 4.62g NaHCO3 in 500ml GDW  
0.63M sodium chloride: Dissolve 18.43g NaCl in 500ml GDW 
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Blocking solution (ISH) 
Dissolve 18.21g Trizma base and 13.14g NaCl in 440ml GDW. Add 30ml FBS and 7.5ml 1:10 Triton 
X and pH to 7.5 
 
Caesium chloride saturated isopropanol 
Mix 100g CsCl2, 100ml GDW and 100ml isopropanol and leave to settle  
 
0.01M citrate buffer 
Dissolve 19.2g citric acid in 900ml GDW. pH to 6 and make up to 1L with GDW 
 
1% Copper sulphate solution 
Dissolve 1g of copper sulphate in 100ml GDW 
 
Deionised formamide 
Add 1g of amberlite MB6113 (indicator) mixed resin per 10ml formamide. Incubate for 1 hour in the 
37°C shaker until indicator turns yellow. Pass through a sterile filter before use. 
 
Denaturing solution (DENAT) 
Mix 1ml formamide, 300µl formaldehyde and 100µl 20 x MOPS 
 
Denhart’s solution 
Dissolve 10g of each of ficoll, polyvinyl-pyrrolidone and BSA in 500ml GDW. Store in aliquots at -
20°C 
 
Detection buffer 
Mix 0.8ml 5M NaCl, 1.6ml MgCl2, 8ml 0.5M Tris-HCl pH9.8 and add 20mg levamisol. Make up to 
20ml with GDW and add 20ml of 10% polyvinyl acetate. For development, omit the MgCl2 and add 2 
drops of reagent 1, 2, and 3 per 5 ml detection buffer. 
 
Dextran coated charcoal 
Add 2.4g charcoal and 0.24g dextran to 100ml phosphate buffer with gelatine and mix for 20 mins at 
20°C 
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Dextran sulphate 
Dissolve 1g dextran sulphate on 1.5ml GDW. Warm at 60°C for 2-3 hours to dissolve and vortex 
before use 
 
DNA loading buffer 
Mix 3.125ml 80% glycerol, 50µl 0.5M CH14H2O8Na2.2H2O (EDTA) and 6.075ml GDW, add 10mg 
orange G 
 
10 x DNAse buffer 
Add 0.8 ml 1M tris/HCl, pH7.4, 120 µl 1M MgCl2 and 40 µl of CsCls2 to 99ml PCR GDW  
 
dNTP mix for PCR and reverse transcription 
Mix 20µl each of 100mM dGTP, dCTP,dATP and dTTP in 120µl filtered GDW. 
 
0.5M ethylenediaminetetra-acetic acid (EDTA) 
Dissolve 186.1g CH14H2O8Na2.2H2O (EDTA) in 800ml GDW and adjust pH to 8.0. Make up to 1L 
with GDW 
 
4% formaldehyde solution 
Dissolve 100mls 40% formaldehyde in 1L GDW 
 
4% formaldehyde in phosphate buffered 1.5% saline 
15g of NaCl, 28.2g Na2HPO4.2H20 and 5.44g KH2PO4 were dissolved in 800mls H20. 100mls of 40% 
formaldehyde were added and the solution made up to 1L. Adjust to pH 6.5 using HCl.  
 
Glucose-Tris-EDTA buffer (GTE) 
Mix 2.5ml 1M Tris HCl pH8, 2ml 0.5M CH14H2O8Na2.2H2O (EDTA) and 5ml 18% glucose and make 
up to 100ml with GDW. Sterilise by passing through a 0.2µm filter 
 
1M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
Add 238.3g HEPES to 450ml GDW. Adjust to pH 7.4 or 7.6 using HCl, and make up to 1L with 
GDW. 
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1mM HEPES pH 7.4 buffer (cell membrane preparation) 
Add 100µl 1M HEPES pH 7.4 and 1ml aprotinin to 99ml GDW. Add 100µl pepstatin (Sigma, USA), 
100µl leupeptin (Sigma, USA), 100µl benzamidine (Sigma, USA), 100µl antipain (Sigma, USA) and 
200µl soya bean trypsin inhibitor (SBTI) (Sigma, USA), and store on ice. 
 
20mM HEPES binding buffer 
Dissolve 0.74g MgCl2 and 0.204g of CaCl2 into 980ml GDW. Add 20ml 1M HEPES and adjust to pH 
7.4. Add BSA as required at 3.3% v/v. 
 
50mM HEPES pH 7.4 buffer (cell membrane preparation) 
Add 5ml 1M HEPES pH 7.4 and 1ml aprotinin to 94ml GDW. Add 100µl pepstatin, 100µl leupeptin, 
100µl benzamidine, 100µl antipain and 200µl soya bean trypsin inhibitor (SBTI), and store on ice. 
 
Homogenisation buffer (tissue membrane preparation) 
Add 5ml 1M HEPES pH 7.6, 100ul pepstatin, 100ul leupeptin, 100ul benzamidine, 100ul antipain and 
200ul soya bean trypsin inhibitor (SBTI) to 95ml water. To 50ml buffer, add 8.55g sucrose. Put both 
the sucrose and non sucrose containing buffers on ice. 
 
Hybridisation buffer (frozen sections) 
Add 1.25ml formamide, 300µl 5M NaCl, 50µl 100 x Denhardts Solution, 50µl 1M Tris pH8, 10µl 
0.5M EDTA pH8, 1.34ml DEPC water and 1ml 50% dextran sulphate together and mix well.  To 
800µl hybridisation buffer, add 200µl probe mixture: 50µl 10mg/ml tRNA and 10µl 100mM DTT 
made up to 200µl with DEPC water, and mix well. 
 
Hybridisation buffer (paraffin sections) 
Add 5ml deionised formamide, 2.5ml 20x SSC, 200µl 100 x Denhardts Solution, 100µl 1M Tris 
pH7.5, 250µl 10% SDS, 20µl 0.5M EDTA pH8, 1.25ml 10mg/ml tRNA, 680µl DEPC GDW, 1g 
dextran sulphate together and mix well.   
 
Kemteck buffer (0.05M) (RIA buffer)  
Dissolve 22.4g NaH2PO4.2H2O, 9.96g Na2HPO4.2H2O, 14.8g C10H14H2O8Na2.2H2O, 1g 
C9H9HgNaO2S, 26.6ml of 30% BSA in 5L of glass distilled water (GDW) that has been boiled and 
allowed to cool. Adjust to pH 7.4 with sodium hydroxide. Store at 4°C. 
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Lysogeny broth (LB) 
Dissolve 10g NaCl, 10g tryptone and 5g yeast extract. Adjust pH to 7.5 and sterilise by autoclaving 
 
LB agar 
Add 7g agar to 500ml LB and melt by autoclaving 
 
1M magnesium chloride 
Dissolve 203.3g MgCl2 in 1L GDW 
 
Maleic buffer 
Dissolve 116g maleic acid and 88g NaCl into 800ml GDW. pH to 7.5 with NaOH and make up to 1L 
with GDW 
 
20x MOPS 
Dissolve 83.6g 3-(N-Morpholino)propanesulphonic acid (MOPS), 8.1g sodium acetate, 7.4g 
C10H14H2O8Na2.2H2O and 2.5ml formaldehyde to 800ml GDW.  Adjust to pH 7.0 with 10M sodium 
hydroxide and make up to 1L. 
 
PCR GDW 
PCR GDW is sterile. Autoclave 100ml ultrapure GDW in small aliquots. Keep sterile until use. 
 
Phosphate buffer (0.06M) (RIA buffer) 
Dissolve 48 g of Na2HPO4.2H2O, 4.13 g KHPO4, 18.61 g C10H14H2O8Na2.2H2O, 2.5 g NaN3
 
in 5 L of 
GDW that has been boiled and allowed to cool. Measure the pH to confirm it is 7.4±0.1. Store at 4°C.  
 
Phosphate buffer (0.06M) with gelatin 
The buffer is produced as above with 12.5 g of gelatin dissolved in the boiling GDW then cooled 
before the addition of the other ingredients.  
 
Phosphate buffered saline (PBS) 
10x PBS (0.1M) 
Add 80g of NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 to 800ml GDW. Adjust volume to 1L with 
GDW, adjust pH to 7.4 and sterilise by autoclaving. 
1x PBS (0.01M) 
Add 100ml 10x PBS to 900ml GDW. Sterilise by autoclaving. 
360 
 
 
Phosphate buffered saline containing Tween 0.05% (PBST) 
Add 1ml Tween 20 (VWR) to every 2L 0.01M PBS 
 
10% Polyethylene glycol (RIA) 
Dissolve 100g of polyethylene glycol into 1L GDW 
 
3M potassium acetate 
Dissolve 294.4g CH3COOK in 500ml GDW and add 115ml glacial acetic acid. Make up to 1L with 
GDW 
 
10mg/ml RNase A 
Add 100mg RNAse A, 50µl 2M Tris and 30µl 5M NaCl to 9.92ml GDW, and boil for 15 minutes. 
Allow to cool and aliquot. 
 
20 x salt sodium citrate (SSC) 
Add 1.753g NaCl and 882g Na3C6H5O7.2H2O to 8L GDW, adjust to pH 7.0 and make up to 10L. 
 
Sephadex G
50
for iodination of pituitary hormones 
Add 8g Sephadex G50 beads (Sigma) to 200ml GDW. Soak for 1 hour at room temperature. Heat for 
20 minutes in a boiling water bath, and allow to cool overnight. To make columns, plug a 10ml 
pipette with glass wool, and slowly fill with cooled Sephadex gel. Allow gel to settle, and seal 
columns with parafilm to prevent drying out. 
 
2M sodium acetate pH5.2 
Dissolve 164.1g CH3CooNa in 800 ml GDW, adjust to pH 5.2 with glacial acetic acid and make up to 
1L with GDW 
 
5M sodium chloride 
Dissolve 292.2g NaCl in 1L GDW 
 
20% sodium dodecyl sulphate (SDS) 
Add 200g SDS to 800 ml autoclaved water, heat to 60°C while stirring. Allow to cool and make up to 
1L with water. To make 1% SDS, dilute 5ml 20% SDS into 95ml water. 
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10M sodium hydroxide 
Dissolve 400g of NaOH in 500ml GDW. Once dissolved, make up to 1L with GDW 
 
0.2M sodium hydroxide/1%SDS 
Mix 2ml 10M sodium hydroxide, 5ml 20% SDS and 93ml autoclaved water  
 
0.5M sodium phosphate pH6.8 
Dissolve 71g Na2HPO4.2H20 in 1L GDW and 41.4g NaH2PO4.H20 in 600ml gdw and mix 
 
30% sucrose solution  
Dissolve 300g of sucrose in 1L GDW 
 
50 x Tris-acetate-EDTA (TAE) buffer  
Dissolve 242g Trizma base in 843ml GDW and mix in 57ml glacial acetic acid and 100ml 0.5M 
C10H14H2O8Na2.2H2O. 
 
TAE running buffer 
To 1L GDW, add 75µl ethidium bromide and 10ml 50 x TAE. 
 
100 x TE 
Dissolve 121.1g Trizma base and 3.7g C10H14H2O8Na2.2H2O in 800ml GDW and adjust to pH 7.5 
with HCl. Make up to 1L. 
 
1M TEA 
Dissolve 7.42g C6H15NO3.HCl (triethanolamine-hydrochloride) in 30ml GDW, adjust to pH 8.0 with 
conc. NaOH and adjust the volume to 400ml with GDW. 
Tris-EDTA-Sodium chloride (TES) Buffer 
Mix 25ml 1M Tris-HCl pH8, 5ml 5M NaCl and 5ml C10H14H2O8Na2.2H2O, make up to 500ml with 
distilled water. 
 
Transformation buffer I (TFBI) 
Dissolve 589g CH3.COOK, 2.4g RbCl, 1.979g CaCl2.2H2O and 438mg MnCl2.4H20 in GDW. Add 
37.5ml 80% glycerol and make up to 200ml with GDW. Sterilise by passing through a 0.2µm filter.  
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Transformation buffer II (TFBII) 
Dissolve 418g MOPS, 3.28g CaCl2.2H2O and 242mg RbCl in GDW. Add 37.5ml 80% glycerol and 
make up to 200ml with GDW. Sterilise by passing through a 0.2µm filter.  
 
1M Tris-HCl pH7.5 
Dissolve 121.1g Trizma base in 800ml GDW and adjust to pH 7.5 with HCl. Make up to 1L 
 
2M Tris-HCl pH 8.0 
Dissolve 121.1g Trizma base in 450ml GDW and adjust to pH 8.0 with HCl. Make up to 500ml. 
 
0.1M Tris-NaCl buffer (ISH) 
Dissolve 12.14g Trizma base and 8.76g NaCl in 995ml GDW. Add 5ml Triton X 1;10 and pH to 9.5 
or 7.5 as required. 
 
Versene 
Dissolve 16g  NaCl,  0.4g KCl,  2.88g Na2HPO4.2H2O (di-sodium hydrogen orthophosphate),  1.2g 
C10H14N2O8Na2.2H2O (EDTA) and 0.4g KH2PO4 (potassium dihydrogen orthophosphate) in 1l GDW, 
add 3ml phenol red (Sigma) and make up to 2L with GDW. Sterilise by autoclaving.  
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APPENDIX II – SUPPLIERS OF REAGENTS AND EQUIPMENT USED IN THIS THESIS 
 
Amersham International plc, Little Chalfont, Buckinghamshire, UK. 
Associated Dental Products Ltd, Kemdent Works, Purton, Swindon, UK 
ATCC, Middlesex, UK 
Bachem St. Helens, UK 
Bayer UK, Bury St. Edmonds, UK 
BioXtal, Mundelsohm, France 
Bright Instruments, Huntingdon, UK 
Campden Instruments, Loughborough, UK  
Charles River, Bicester, UK. 
Clark Electromedial Instruments, Pangbourne, Reading, UK 
Fisher Scientific, Leicestershire, UK 
Gibco BRL (Life Technologies Ltd.), Paisley, Renfrewshire, UK. 
GraphPad, La Jolla, CA, USA 
Harvard Apparatus, Massachusetts, USA 
Helena Biosciences, Sunderland, UK 
Invitrogen, Paisley, UK 
Life Sciences Technology, Eggenstein, Germany 
New England Bioloabs, Hitchin, Herts, UK 
Parke-Davis, Pontypool, Gwent, UK. 
Peptide Institute, Kyoto, Japan. 
Perkin Elmer, Massachusetts, USA 
Pharmacia Biotechnology Ltd., St. Albans, Hertsfordshire, UK. 
Phoenix Pharmaceuticals Belmont, CA, USA  
Plastics One Inc, Roanoke, VA, USA. 
Promega, Southampton, UK 
Research Diets Inc, New Brunswick, NJ, USA 
Schering-Plough Corporation, Welwyn Garden City, Herts, UK 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK. 
Systat Ltd., Evanston, Illinois, USA. 
VWR, Poole, UK 
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